| Entries |
| Document | Title | Date |
|---|
| 20080199972 | Spectroscopic Method For the Detection of Analytes - The present invention relates to methods for the detection of one or more analytes, in particular pathogens, viruses, prions, bacteria, parasites, pharmaceuticals, antibiotics, cytostatics, psychoactive substances, narcotics, analgesics, cardiac drugs, metabolites, coagulation inhibitors, hormones, interleukins and cytokines, performance-enhancing drugs, drugs, toxins, noxious substances, pesticides, insecticides, wood preservatives, herbicides, fungicides, explosives, vitamins and flavors by providing a conjugate of the analyte and an europium cryptate fluorophore or respectively a terbium cryptate fluorophore together with an antibody which is specific for the analyte and an antibody which is specific for the europium cryptate fluorophore or respectively the terbium cryptate fluorophore and by spectroscopically determining the fluorescence quenching which occurs when the analyte is added. Furthermore the present invention relates to conjugates of the analyte and the europium cryptate fluorophore or respectively terbium cryptate fluorophore as well as to a kit for the detection of analytes. | 08-21-2008 |
| 20080206888 | Screening using polarization anisotropy in FRET emissions - Methods and apparatus are described for detecting specific binding between first and second chemical entities. The first chemical entity in association with a first fluorophore is immobilized. The second chemical entity is allowed to bind with the immobilized first chemical entity. The second chemical entity is or becomes coupled to a second fluorophore, which forms a FRET pair with the first fluorophore. The bound chemical entities are exposed to radiation at an excitation frequency for either the first or the second fluorophore, and polarization anisotropy of a FRET fluorescent signal from the bound chemical entities is measured to detect specific binding between the first and second chemical entities. Techniques are also disclosed for detecting whether a FRET interaction is occurring between a first chemical entity including a donor fluorophore and a second chemical entity including an acceptor fluorophore, using simultaneous anisotropy measurements at the wavelengths of the donor and acceptor fluorophores. | 08-28-2008 |
| 20080213916 | Allosterically Catalyzed Signal Amplification in Chemical and Biological Sensing - Coordination complexes having at least two structural conformations are disclosed. The coordination complexes contain at least one metal center and at least one hemi-labile ligand, and change structural conformations due to the presence or absence of allosteric effectors. Methods of detecting an analyte using the coordination complexes are also disclosed. | 09-04-2008 |
| 20080213917 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands. | 09-04-2008 |
| 20080213918 | Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof - The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 09-04-2008 |
| 20080220536 | Methods for Identifying Compounds that Modulate Enzymatic Activities by Employing Covalently Bonded Target-Extender Complexes with Ligand Candidates - The present invention relates to the use of “tethering” to identify compounds that modulate enzymatic activity. | 09-11-2008 |
| 20080227218 | TARGET SUBSTANCE DETECTION METHOD AND TARGET SUBSTANCE DETECTION KIT - A target substance detection method for detecting a target substance in a specimen, comprises the steps of contacting with a specimen a target substance detecting element comprised of a base, a metal structure and a first capturing body for capturing a target substance; contacting with the target substance detecting element a labeling material comprised of a labeling substance and a second capturing body for capturing a target substance; and acquiring an absorption spectrum (A) of the target substance detecting element contacted with the specimen and the labeling material, wherein the employed labeling substance is a substance that a slope of a tangent of an absorption spectrum (C) of the labeling substance at a peak wavelength (λ | 09-18-2008 |
| 20080233659 | PROCESS OF SCREENING FOR ALPHA-THALASSEMIA CARRIER USING IMMUNOCHROMATOGRAPHIC STRIP TEST - The invention provides a device and method for the rapid identification of patients suspected of having thalassemia. The invention provides a test strip for the aqueous detection of thalassemia related proteins in whole blood. The test strip includes antibodies specific to the gamma 4, (γ4) protein and provides easy visual discrimination between a positive result and a negative result. The invention can be used in remote or clinical settings. | 09-25-2008 |
| 20080241958 | Method for Determining HCG Levels in Fluid Samples - The subject invention is an immunoassay for the semi-quantitative test kit for determination of human chrionic gonadtropin (hCG) in fluid sample (such as urine) as an aid in the diagnosis of a certain stage of pregnancy. The test device includes five strips having each having a dipping end or sample ends where sample can be applied. Results are indicated by coloration of two bands across a clear area of the strips, one band being coated with a reagent such as hCG antigens and the other with a reagent such as goat/rabbit polyclonal antibody gold conjugate. The combination of color indications on the bands provides the test results. | 10-02-2008 |
| 20080241959 | Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification - The present invention relates to new macrolide compounds represented by the general structure I, | 10-02-2008 |
| 20080241960 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN - Using the proteins of the present invention, DNAs encoding the proteins, and antibodies recognizing the proteins, detection methods for diseases relating to the novel insulin-like growth factor binding proteins of the present invention, as well as diagnostic agents, preventive agents, and therapeutic agents for diseases relating to the proteins of the present invention can be provided. | 10-02-2008 |
| 20080241961 | DROSOPHILA G PROTEIN COUPLED RECEPTORS, NUCLEIC ACIDS, AND MEHTODS RELATED TO THE SAME - The present invention provides a | 10-02-2008 |
| 20080248588 | SHRIMP ALLERGEN, ANTI-SHRIMP ALLERGEN ANTIBODY, AND USE THEREOF - Provided is a novel shrimp allergen. The shrimp allergen of the present invention includes an isolated shrimp collagen or a polypeptide fragment thereof. According to the present invention, there is provided the novel shrimp allergen, and there are provided, using the allergen, an anti-shrimp allergen antibody, a method of detecting contamination of a shrimp allergen, an agent for detecting contamination of a shrimp allergen, a method of measuring sensitivity to a shrimp allergen, and an agent for measuring sensitivity to a shrimp allergen. | 10-09-2008 |
| 20080261327 | Cell Free Assay for Determining a Substance of Interest and Molecular Complexes Used Therefore - The invention involves receptor complexes which include, inter alia, a receptor protein, and a reporter molecule. There is at least one unnatural, or non-naturally occurring amino acid in the receptor molecule. When a ligand interacts with the receptor, the interaction causes the reporter to generate a detectable signal. The complexes are useful in cell free, assay systems and may be used as part of micelles. | 10-23-2008 |
| 20080280376 | Method of Evaluation of the Relative Risk of Developing Atherosclerosis in Patients - The present invention relates to a method for determining the amount of circulating CD36 protein or a fraction thereof which is present in cell-free plasma, preferably in a high molecular weight plasma fraction, such as a lipoprotein fraction selected from Low Density Lipoprotein, Intermediate Density Lipoprotein, and Very Low Density Lipoprotein using an immunological method which comprises the steps of (i) providing a plasma sample to be investigated, (ii) providing an anti-CD36 antibody, (iii) exposing the sample to be investigated to the antibody, and (iv) detecting and quantifying the amount of CD36 which binds to the antibody. | 11-13-2008 |
| 20080280377 | HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure provides among other things assays, methods and kits for assessing the presence or amount of human B-type natriuretic peptide in a test sample wherein the assay exhibits reduced cross-reactivity with other forms of the peptide. | 11-13-2008 |
| 20080293159 | Validation Process - The present invention provides a process for validating the efficacy of a sample having a known activity determined using a biological assay. The process includes subjecting the sample to a biological assay capable of testing for the activity. The process may optionally include an initial step of determining a biological assay for the desired activity. The present invention is particularly applicable to samples from milk. | 11-27-2008 |
| 20080293160 | DNA AND RNA CONFORMATIONAL SWITCHES AS SENSITIVE ELECTRONIC SENSORS OF ANALYTES - The electrical conductivity of DNA and other oligonucleotide constructs is dependent on its conformational state. Such a dependence may be harnessed for the electronic sensing of external analytes, for instance, adenosine or thrombin. Such a DNA sensor incorporates an analyte receptor, whose altered conformation in the presence of bound analyte switches the conformation, and hence, the conductive path between two oligonucleotide stems, such as double-helical DNA. Two distinct designs for such sensors are described that permit significant electrical conduction through a first or “detector” double-helical stem only in the presence of the bound analyte. In the first design, current flows through the analyte receptor itself whereas, in the second, current flows in a path adjacent to the receptor. The former design may be especially suitable for certain categories of analytes, including heterocycle-containing compounds such as adenosine, whereas the latter design should be generally applicable to the detection of any molecular analyte, large or small, such as the protein thrombin. Since analyte detection in these DNA sensors is electronic, the sensors may be used in rapid and automated chip-based detection of small molecules as well as of proteins and other macromolecules. | 11-27-2008 |
| 20080293161 | Detection of Carbohydrate Biomarkers - The present invention generally relates to detection of carbohydrate biomarkers in nipple aspirate fluid samples. One aspect of the invention is a method for assaying a nipple aspirate fluid for the presence of TF or Tn carbohydrate biomarker. The assay generally employs an immobilized capture agent specific for TF or Tn and can be further coupled to either direct or indirect detection of bound TF or Tn carbohydrate biomarker through the use of a labeled binding agent. | 11-27-2008 |
| 20080293162 | Methods and compositions for diagnosing neoplastic disease - Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods. | 11-27-2008 |
| 20080299676 | METHODS FOR DIAGNOSING ENDOMETRIOSIS - Provided herein is a method for diagnosing and monitoring endometriosis in a subject by measuring levels of the 13-subunit of fibrinogen. | 12-04-2008 |
| 20080305557 | Novel Applications of Acridinium Compounds and Derivatives in Homogeneous Assays - Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus. | 12-11-2008 |
| 20080311673 | Biomarkers for Breast Cancer - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry. | 12-18-2008 |
| 20080311674 | METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS - Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags. | 12-18-2008 |
| 20080311675 | DYES HAVING RATIOMETRIC FLUORESCENCE RESPONSE FOR DETECTING METABOLITES - The presently disclosed subject matter provides thiol-reactive, environmentally sensitive fluorescent dyes, or fluorophores, which have an emission wavelength in the visible spectral region. When conjugated with a binding protein, the fluorophores exhibit a ratiometric response to one or more ligands or target analytes. The presently disclosed fluorophore-binding protein conjugates can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples. | 12-18-2008 |
| 20080311676 | IMMUNOASSAYS EXHIBITING REDUCED CROSS-REACTIVITY WITH HYDROPHOBIC DRUG ANALYTE METABOLITES - The present disclosure provides among other things immunoassays exhibiting reduced cross-reactivity with analyte metabolites. Additionally, the present disclosure provides diagnostic immunoassays to determine the concentration or level in a test sample of a hydrophobic drug that metabolizes in vivo or in vitro to form cross-reacting metabolites wherein cross-reactivity with such metabolites of the drug analyte is reduced. In particular, the disclosure provides such immunoassays where the hydrophobic drug is an immunosuppressant drug such as cyclosporine A. | 12-18-2008 |
| 20080318337 | Method for Determining a Tissue Degradation Process by Detection of Comp Neoepitopes - The present invention relates to a method for determining a tissue degradation process by detection on COMP (Cartilage Oligomeric Matrix Protein) neoepitopes, where said COMP neoepitopes appear after cleavage of COMP at one or more site between position 530 and 660 of the amino acid sequence of COMP. Such as between position 550 (N | 12-25-2008 |
| 20080318338 | Assays and Implements for Determining and Modulating HSP90 Binding Activity - Ligand binding assays as applied to HSP90s as receptors or ligands, and reagents useful therefore, are described and claimed, as are methods of assaying for HSP90 modulators and methods of using the resulting products identified thereby. | 12-25-2008 |
| 20080318339 | Sensing Device and Method For Determination of Teh Amount of Target Molecule in an Analyte - A sensing device is provided which has a universal sensor surface. This allows easy modification of the detection properties without the need for investigation of the binding properties of a new target to the sensor surface. The device comprises a sensor surface, which has attached thereto a primary capture molecule. The invention further relates to a method for measurement of a target wherein this device is used. | 12-25-2008 |
| 20090004755 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND/OR PROGNOSIS IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES - The present invention relates to methods and compositions for diagnosing SIRS, sepsis, severe sepsis, septic shock, or MODS in a subject, or assigning a prognostic risk for one or more clinical outcomes for a subject suffering from SIRS, sepsis, severe sepsis, septic shock, or MODS, the method comprising performing an immunoassay for CCL23 splice variant. | 01-01-2009 |
| 20090004756 | METHODS FOR IDENTIFYING AGENTS THAT TARGET LEAKS IN RYANODINE RECEPTORS - The present invention provides screening methods for identifying agents that enhance binding of a ryanodine receptor and its corresponding FKBP protein, such agents to be used in treating diseases associated with ryanodine receptors. | 01-01-2009 |
| 20090004757 | Analyte Assay Using Particulate Labels - Method for specific detection of one or more analytes in a sample. The method includes specifically associating any one or more analytes in the sample with a scattered-light detectable particle, illuminating any particle associated with the analytes with light under conditions which produce scattered light from the particle and in which light scattered from one or more particles can be detected by a human eye with less than 500 times magnification and without electronic amplification. The method also includes detecting the light scattered by any such particles under those conditions as a measure of the presence of the analytes. | 01-01-2009 |
| 20090011520 | Stable D-dimer liquid preparation - The invention is in the field of coagulation diagnosis and relates to a liquid, buffer-based D-dimer composition, which additionally contains fibrinogen and which is suitable as a standard material for control or calibration purposes for D-dimer test procedures. | 01-08-2009 |
| 20090011521 | Streptavidin surface acoustic wave immunosensor apparatus - The invention, the manufacturing process and operation method for forming the streptavidin surface acoustic wave (SAW) immunosensor apparatus is disclosed. Firstly, the PZT film is formed on silicon substrate by using the micro-powder-sol-gel method. Then, the metal transducer electrodes are coated on the PZT film using semiconductor process technology to produce the SAW. Finally, the sensing area of the SAW element is modified by streptavidin to form the streptavidin SAW immunosensor. The invention could be used for examining the ligand decorated by biotin, also for examining antibody. | 01-08-2009 |
| 20090017555 | DELTA-9-TETRAHYDROCANNABINOL DETECTION METHOD - The invention provides competitive immunoassay techniques for high sensitivity detection of delta-9-tetrahydro-cannabinol ( | 01-15-2009 |
| 20090017556 | METHODS AND COMPLEXES INVOLVING IMMUNOGLOBULIN MOLECULE - A device that includes a proteinaceous factor is disclosed. The proteinaceous factor is encoded by the nucleotide sequence of any one of SEQ ID NO.: 1, a degenerate variant of SEQ ID NO.: 1, and a complement of SEQ ID NO.: 1. The proteinaceous factor may be a recombinant. In addition, the device may include any one of (i) Immunoglobulin G (IgG) bound non-specifically to the proteinaceous factor, (ii) at least one diagnostic label bound to the proteinaceous factor, (iii) Immunoglobulin G bound non-specifically to the proteinaceous factor and at least one diagnostic label bound to the proteinaceous factor, and (iv) at least one base supporting the proteinaceous factor. | 01-15-2009 |
| 20090017557 | FVII Specific Antibodies and Use Thereof - The present invention relates to novel antibodies against FVII, use for determining amount of correctly folded and intact FVII in a sample, as well as for purification and process optimization. | 01-15-2009 |
| 20090017558 | APOLIPOPROTEIN E STABLE FOLDING INTERMEDIATE AND METHODS OF USE THEREOF - The present invention provides isolated apolipoprotein E (apoE) stable folding intermediates. The invention further provides methods for identifying compounds that alter the structure or level or activity of an apoE stable folding intermediate, as well as methods of inhibiting the formation or activity of stable folding intermediates of apoE. The invention further provides methods for reducing the level and/or activity of an apoE stable folding intermediate, and methods for treating disorders relating to apoE4 in a subject. | 01-15-2009 |
| 20090017559 | Methods for diagnosing renal disorders - The present invention relates to methods for diagnosing the presence and progress of pathologies characterized by an accumulation of the extracellular matrix components by measuring the level of Connective Tissue Growth Factor (CTGF) in a sample. The method of the present invention is directed to diagnosing kidney fibrosis and associated renal disorders, in particular, complications associated with diabetes, hyperglycemia, and hypertension. | 01-15-2009 |
| 20090023224 | Vascular endothelial growth factor 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof. | 01-22-2009 |
| 20090023225 | Methods and devices for analyte detection - Methods for detecting one or more analytes, such as a protein, in a fluid path are provided. The methods include resolving, immobilizing and detecting one or more analytes in a fluid path, such as a capillary. Also included are devices and kits for performing such assays. | 01-22-2009 |
| 20090023226 | Variant Integrin Polypeptides and Uses Thereof - Polypeptides comprising all or part of a variant integrin α subunit A domain and its flanking region are described. In solution or in membrane-associated form, the A domain polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine or glutamic acid residue is altered. For example, the glutamic acid can be either deleted or replaced with different amino acids residue, e.g., glutamine, aspartic acid, or alanine The variant integrin polypeptides of the invention selectively impair binding of activation-dependent ligands, but not independent ligands. They are useful in screening assays for the identification of molecules that enhance binding of variant polypeptides with impaired binding. In addition, they are useful in distinguishing between activation-dependent ligands and activation-independent ligands. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the impaired form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in the high affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin α subunit that could be used therapeutically. | 01-22-2009 |
| 20090023227 | METHOD - The invention provides a method of measuring the affinity of first and second biomolecules in which a first biomolecule is tethered by a first tether portion having a first tether portion length and a second biomolecule is tethered by a second tether portion having a second tether portion length, the method comprising determining binding of adjacent first and second biomolecules to each other, varying at least one of the first and second tether lengths and determining binding of the first and second biomolecules. The invention also provides apparatus suitable for use in the method of the invention. | 01-22-2009 |
| 20090023228 | Dual-acting Imidazole antihypertensive agents - The invention is directed to compounds having the formula: | 01-22-2009 |
| 20090029481 | Method for separating target component using magnetic nanoparticles - An object to be achieved by the present invention is to provide a method for determining the amount of a component contained in a specific lipoprotein fraction in a biological sample using an automatic analyzer, without the requirement of a step of fractionating a sample by centrifugation. The present invention provides a method for separating a target component in a biological sample, which comprises the steps of: (1) causing a biological sample to come into contact with independently dispersed magnetic nanoparticles having a particle size of 50 nm or less, which have anionic functional groups on their surfaces, so as to form an agglutinate of the magnetic nanoparticles and biomolecules capable of interacting with the magnetic nanoparticles; and (2) collecting the agglutinate by an external magnetic field. | 01-29-2009 |
| 20090035874 | THERAPEUTIC AGENTS AND METHODS FOR CARDIOVASCULAR DISEASE - The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding. | 02-05-2009 |
| 20090035875 | Cytochrome C And Leucine-Rich Alpha-2-Glycoprotein-1 Assays, Methods, And Antibodies - The present invention relates generally to assays and methods involving Cytochrome c (Cyt c) and leucine-rich alpha-2-glycoprotein-1 (LRG), and related antibodies. In an embodiment, the invention includes an isolated antibody produced by a hybridoma cell line having ATCC Accession Number PTA-8131, or antibody fragment thereof that specifically binds to leucine-rich alpha-2-glycoprotein-1. In an embodiment, the invention includes a hybridoma cell line producing such an antibody or antibody fragment. In an embodiment, the invention includes a kit including such an antibody. Other embodiments are included herein. | 02-05-2009 |
| 20090042314 | LANTHANIDE-DOPED NAYF4 NANOCRYSTALS, METHOD OF PREPARING AND USES THEREOF - The present invention relates to a method of preparing lanthanide-doped NaYF | 02-12-2009 |
| 20090042315 | COMPOSITIONS OF SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR - Compositions comprising nonpolar amino acids and specific binding agents to hepatocyte growth factor (HGF) are provided. Methods of making and using such compositions are also provided. | 02-12-2009 |
| 20090042316 | USE OF PERFLUOROPOLYMERS IN THE DETERMINATION OF THE RECEPTOR-LIGAND BINDING CONSTANT - Use of flat surfaces comprising perfluorinated polymers in the determination of the binding constant of two interacting molecular species by using measurements of reflected light intensity, said surface comprising at least one molecule with the receptor function adsorbed or immobilized on said surface, and at least one ligand which interacts with the receptor. | 02-12-2009 |
| 20090053825 | MOLECULAR RECOGNITION POLYMER ENABLING RECONSTRUCTION OF RECOGNITION FIELD FOR TARGET MOLECULE AND METHOD OF PRODUCING THE SAME - A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which is produced by applying the molecular imprinting method is disclosed. A molecular recognition polymer enabling the reconstruction of the recognition field for a target molecule which has a molecule interacting with the target molecule in the polymer and in which the recognition field for a target molecule has been constructed and the above-described molecule interacting with the target molecule is detachable and replaceable. This molecular recognition polymer can be produced by synthesizing a complex of the target molecule with a molecule capable of specifically and reversibly binding to the target molecule, copolymerizing this complex with a molecule interacting with the target molecule and a crosslinking agent to give a polymer, and then detaching the target molecule and the molecule interacting with the target molecule from the polymer thus obtained. | 02-26-2009 |
| 20090053826 | Electropolymerisable monomers that are soluble in aqueous solution and electroactive probes that can be obtained with such monomers - The invention relates to an electropolymerizable monomer, intended to be polymerized in aqueous solution, comprising a single electropolymerizable unit and an electron-donating group, characterized in that it also comprises at least one arm ionizable in aqueous solution. The invention also relates to the polymerization process, to the electroactive probe thus obtained and to the method for the detection of a target ligand in a biological sample. | 02-26-2009 |
| 20090053827 | Assay device and method - An assay device includes a first reagent including a magnetic particle and a second reagent including detectable component. The first and second reagent can each independently bind to an analyte in a sample. A time-varying magnetic field can be used to distinguish detectable components that are associated with analyte from detectable components not associated with analyte. | 02-26-2009 |
| 20090053828 | DETECTION OF GLYCOPEPTIDES AND GLYCOPROTEINS FOR MEDICAL DIAGNOSTICS - A diagnostic method for determining the absence or presence of a disease is provided. The method includes assaying the amount and/or types of glycopeptides in a sample from a subject, and comparing these to the amount and types of reference glycopeptides. The method may include the use of a stable isotope label, affinity selection, immunoaffinity chromatography, and glycoproteomics techniques, to identify and quantify changes in glycosylated peptides or glycosylated proteins associated with cancers such as malignant lymphoma or breast cancer, to monitor patient's response to therapy, and to monitor disease recurrence. | 02-26-2009 |
| 20090053829 | ABSORPTION PAD FOR IMMUNOASSAY, STRIP FOR IMMUNOASSAY AND IMMUNOASSAY APPARATUS - Providing an absorption pad which shows remarkable water absorptivity and can shorten a detection time when employed for an immunoassay apparatus. A water absorption pad for the immunoassay apparatus, containing 50% by weight or more of silicon-containing particles wherein a moisture absorptivity is 30% or less at a humidity of 60% or less and a moisture absorptivity is 40% or more at a humidity of 90% or more, a strip for an immunoassay using said absorption pad as a suction part, and an immunoassay apparatus including said strip for the immunoassay. | 02-26-2009 |
| 20090053830 | Blood Test Kit - A blood crossmatching apparatus, kit and methods for testing the compatibility of mammals for blood transfusion. Particulate layers in the apparatus allow nonagglutinated red blood cells to permeate through, while agglutinated red blood cells cannot. The apparatus also has a density solution. The density solution separates white blood cells from red blood cells in the whole blood when centrifuged, without lysing the red blood cells. Thus, the apparatus can be used to test whole blood. | 02-26-2009 |
| 20090061531 | DNA BINDING PROTEIN - Methods of screening for compounds which are, for example, capable of modulating amino acid-DNA interaction, modulating DNA replication, modulating cell proliferation, and for identifying compounds which inhibit cellular proliferation caused by cancer, are provided. | 03-05-2009 |
| 20090061532 | FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION WITH NANOPARTICLES FOR IN VITRO AND IN VIVO APPLICATIONS - A combination of nanoparticles is disclosed comprised of amine functionalized polyethylene glycol in which one particle with a fluorescent donor dye having one wavelength excitation maximum and at least one additional particle with a second fluorescent dye having a second, higher wavelength excitation maximum, the particles having the same or different biomolecule targeting moieties bound to their external surfaces. | 03-05-2009 |
| 20090068758 | SYNTHETIC RECEPTOR - A polymer capable of selectively binding alfentanil is prepared from one or more suitable monomers (e.g. ethylene glycol methacrylate phosphate) and a cross-linker. It may be a molecularly imprinted polymer. An element ( | 03-12-2009 |
| 20090075392 | AGENTS FOR AND METHOD OF QUANITIFYING MULTIPLE RELATED COMPONENTS IN A BIOLOGICAL SYSTEM - The present invention relates to agents comprising non-natural protein sequences with at least two protein or polypeptide epitopes that are relationally linked by a common or shared functional relationship such as being components in a series of components of the same metabolic or signal transduction pathway or a pathway associated with interaction between two systems such as host-parasite or host-pathogen. The invention further includes a method of simultaneously calibrating and investigating the quantitative relationships between the at least two protein or polypeptide epitopes. | 03-19-2009 |
| 20090075393 | Integrated Affinity Microcolumns and Affinity Capillary Electrophoresis - Device and method for detecting the presence of known or unknown toxic agents in a fluid sample. Targets in the sample are bound to releasable receptors immobilized in a reaction region of a micro- or nano-fluidic device. The receptors are selected based on their affinity for classes of known toxic agents. The receptors are freed and the bound and unbound receptors separated based on differential electrokinetic mobilities while they travel to a detection device. | 03-19-2009 |
| 20090075394 | Voltage Sensor Domains of Voltage-Dependent Ion Channel Proteins and Uses Thereof - A composition of matter suitable for use in identifying chemical compounds that bind to voltage-dependent ion channel proteins, the composition comprising a screening protein that comprises an ion channel voltage sensor domain of the ion channel protein immobilized on a solid support. | 03-19-2009 |
| 20090081808 | DEVICE AND METHOD FOR IDENTIFYING MYCOTOXINS - The invention relates to an apparatus and a process for detection of mycotoxins and to kits suitable for carrying out said process. | 03-26-2009 |
| 20090081809 | Monoclonal antibody specific to dentin-derived heparan sulfate - The present invention provides a monoclonal antibody displaying excellent specificity against heparan sulfate saccharide chains for the analysis of heparan sulfate saccharide chains specific to dentin. The invention also provides a method of evaluating reproductive dentin using the monoclonal antibody. The anti-heparan sulfate monoclonal antibody reacts against dentin-derived heparan sulfate and in particular the anti-heparan sulfate monoclonal antibody reacts strongly and specifically with uncalcified predentin regions. In the method of evaluating dentin, the antibody is reacted against an isolated dentin-derived sample and the reaction is used in order to evaluate the development of dentin. | 03-26-2009 |
| 20090087922 | SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS OF HIGHLY POLYMORPHIC TARGET SEQUENCES - Methods and probes are provided for the analysis of target sequences having two or more polymorphisms wherein one of the polymorphisms is to be distinguished and another polymorphism is to be masked. | 04-02-2009 |
| 20090087923 | METHOD OF HIGH SENSITIVE IMMUNOASSAY - An object of the present invention is to provide a method of high sensitive immunoassay using immunoagglutination reaction by antigen-antibody reaction for quantification of thyroid stimulating hormone (TSH). The present invention provides a method of assaying a thyroid stimulating hormone (TSH) comprising assaying agglutination which is generated by contacting TSH with a carrier to which an anti-TSH antibody has been bound, wherein a plurality of types of anti-TSH antibodies that recognize different epitopes of TSH are independently supported on separate carriers, and each carrier on which a TSH antibody has been supported is brought into contact with a TSH-containing analyte with time intervals. | 04-02-2009 |
| 20090093066 | GLYCATED PEPTIDES AND METHODS OF USE - The invention provides glycated peptides and glycated fragments and glycated variants thereof, antibodies and aptamers which bind thereto, compositions and kits comprising the same, related conjugates, and a database comprising data indicating the concentration of glycated peptides present in diabetic and non-diabetic persons. The invention also provides a method of monitoring glycemic control, a method of treating or preventing diabetes, a method of preventing a complication of diabetes, a method of monitoring the status of diabetes, a method of determining the efficacy of a diabetes treatment, as well as methods of detecting diabetes or a predisposition thereto. | 04-09-2009 |
| 20090093067 | METHODS FOR MAKING AND USING SPR MICROARRAYS - An article, process, and method for surface plasmon resonance plates are described. A substrate is covered with a thin metal film onto which a second thin metal film is deposited. The surface of the second thin metal film is converted to the metal oxide which is used to covalently bond organosilanes to the surface. Reactive organosilanes containing terminal bonding groups are arranged in a plurality of spots that are surrounded by inert organosilanes. Biomolecule attachment to the binding group is detected or measured from surface plasmon signals from the first thin metal film. | 04-09-2009 |
| 20090093068 | IMMUNOSENSOR AND MEASURING METHOD USING THE SAME - An immunosensor includes a base body ( | 04-09-2009 |
| 20090098660 | Method for the Purification of Antibodies - A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described. | 04-16-2009 |
| 20090098661 | Method for Determination of Sample Using Agglutination Reaction of Immunological Microparticle, and Kit for the Determination - A method for determining an analyte in a sample, includes the steps of: (a) mixing the analyte and a first specific binding substance, the first specific binding substance being a substance that can specifically bind to the analyte; (b) adding microparticles having a second specific binding substance bound thereto to a mixture obtained in the step (a) and mixing therewith, the second specific binding substance being a substance that can specifically bind to the first specific binding substance; and (c) determining an agglutination reaction of the microparticles in a mixture obtained in the step (b). | 04-16-2009 |
| 20090104712 | HEPATITIS B PRE-S2 NUCLEIC ACID - This invention relates to a nucleic acid molecule encoding a middle Hepatitis B virus (HBV) surface protein, a vector comprising the nucleic acid molecule, a host cell comprising the vector, and a composition comprising the expression products of this vector, which may comprise middle HBV surface protein, or a mixture of middle HBV surface protein and small HBV surface protein. The compositions of the invention may be useful for expressing a middle HBV surface protein, or a mixture of small and middle HBV surface proteins in defined ratios, determining the binding of an antibody to a middle or small HBV surface protein, determining the quality of an anti-middle or an anti-small HBV surface protein antibody, or determining the quality of a kit containing anti-middle or anti-small HBV surface protein antibodies. | 04-23-2009 |
| 20090104713 | Phenobarbital derivatives useful in immunoassay - Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (“an antibody specific for phenobarbital”). | 04-23-2009 |
| 20090104714 | VISUAL GLUCOSE SENSOR AND METHODS OF USE THEREOF - A method for determining the presence or amount of one or more ligands or analytes in a sample including contacting the sample with a biosensor having an environmentally-sensitive dye conjugated to a binding member, wherein the biosensor compound exhibits a detectable color change as a result of binding to the ligand or analyte or as a result of a change in concentration of the ligand or analyte in the sample. The presently disclosed biosensors can be used to detect the presence of or amount of physiologically-important metabolites, such as glucose, fatty acids, and lactate, in biological samples. | 04-23-2009 |
| 20090111194 | Methods and device for the detection of occult blood - The present invention relates generally to detection of occult blood. In particular, the present invention provides a device and methods for the simultaneous detection of hemoglobin and transferrin in fecal samples, which permit a more sensitive diagnosis of occult blood in fecal sample and a differential diagnosis of bleeding of the upper GI tract versus the lower GI tract. | 04-30-2009 |
| 20090111195 | CHEMICAL REAGENTS AND METHODS FOR DETECTION AND QUANTIFICATION OF PROTEINS IN COMPLEX MIXTURES - The invention provides a reagent comprising an affinity tag, a detectable moiety, a linker, an isotope tag and a reactive group. The invention also provides methods of using a reagent of the invention. The methods can be used to label a polypeptide in a sample by contacting a sample with a reagent of the invention under conditions allowing the reactive group to bind to one or more polypeptides in the sample. The invention additionally provides methods of isolating, identifying and quantifying a polypeptide in a sample. The invention further provides methods of diagnosing a disease using a reagent of the invention. | 04-30-2009 |
| 20090117665 | Rapid sample collection and analysis device and methods of use - The present invention is directed to devices and methods for determining the presence of analyte in a fluid sample. The devices utilize a sample collection well, an expression plate for expressing sample into the sample collection well, a plunger that drives a lance, and a test compartment containing test elements. The devices also preserve an aliquot of fluid sample in a reservoir for later confirmation testing. When the plunger is lowered into the sample collection well, a lance on the device punctures a frangible material that covers a sample outlet. When the sample outlet is thus opened, fluid sample flows from the sample collection cup to the test compartment. In one embodiment the plunger is lowered as a cap is applied to the device. The devices are useful for detecting the presence of analyte in a wide variety of fluid samples, such as saliva, oral fluids, and more. The invention also provides methods of using the devices, and kits containing the devices. | 05-07-2009 |
| 20090117666 | System and Method for Quantifying Analytes in Immuno or Enzymatic Assays - The present invention provides apparatus and methods for performing assays for determining the presence of and/or quantifying an analyte in a sample. The analyte and a label preferably immobilized on a particle are mixed to provide a homogenous solution. The homogeneous solution can be optionally made to flow through a filter. The homogenous solution or the filtrate can be metered through the read zone at a controlled flow rate and the presence of the label or the presence of the particle can be detected. The methods and apparatus of the invention do not require the use of a capture zone. | 05-07-2009 |
| 20090117667 | METHODS FOR MEASURING AFFINITY SUBSTANCES IN SAMPLES COMPRISING STEP OF DISRUPTING BLOOD CELL COMPONENTS - The present invention provides methods for measuring an affinity substance using pearl chain formation of carrier particles, in which the methods include the step of electrically disrupting blood cell components. Blood cell components which interfere with the counting of carrier particles are electrically disrupted. Furthermore, blood cell components can be disrupted without addition of hemolytic agents which interfere with immunological reactions. Whole blood samples can be directly used as measurement samples without separating serum or plasma. Therefore, it is unnecessary to separate serum or plasma when analyzing blood components. | 05-07-2009 |
| 20090117668 | Immune Agglutination Reagent Kit and Method of Measuring Antigen - In cases of poor reaction efficiency with the antibody due to inadequate number of epitopes or steric hindrance caused by epitopes being close to each other, this invention provides a direct method of efficiently measuring antigen in a given specimen without the need of pretreating it. Two types of monoclonal antibodies that recognize different epitopes are individually sensitized on separate latex. The specimen and one latex sensitized monoclonal antibody reagent are reacted to produce a reaction solution which is then reacted with the other latex sensitized monoclonal antibody reagent. The antigen can thus be directly measured in an efficient and highly sensitive way without pretreating it. | 05-07-2009 |
| 20090124022 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 05-14-2009 |
| 20090124023 | Reagens for the Detection of Protein Acetylation Signaling Pathways - The invention discloses 432 novel acetylation sites identified in signal transduction proteins and pathways underlying human protein acetylation signaling pathways, and provides acetylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these acetylated sites/proteins, as well as methods of using the reagents for such purpose. Among the acetylation sites identified are sites occurring in the following protein types: Acetyltransferases, Adaptor/Scaffold proteins, Actin binding proteins, Adhesion proteins, Apoptosis proteins, Calcium-binding proteins, Cell Cycle Regulation proteins, Cell Surface proteins, DNA binding proteins, DNA replication proteins, Channel proteins, Chaperone proteins, Cellular Metabolism enzymes, Cytoskeletal proteins, DNA repair proteins, Endoplasmic reticulum proteins, Enzyme proteins, G protein and GTPase Activating proteins, Guanine Nucleotide Exchange Factors, Helicase proteins, Isomerase proteins, Extracelluar matrix proteins, Hydrolases, Ligase proteins, Lipid kinases, Inhibtor proteins, Lipid Binding proteins and Lyases. | 05-14-2009 |
| 20090130774 | Elisa assays using prion-specific peptide reagents - Peptide reagents that interact preferentially with the PrPsc form of the prion protein are described for use in detecting PrPsc in biological samples. In particular, ELISA assays are described. | 05-21-2009 |
| 20090130775 | METHOD FOR CLINICAL STAGING OF ULCERATIVE COLITIS OR INTERSTITIAL PNEUMONIA AND REAGENT KIT FOR THE SAME - The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. | 05-21-2009 |
| 20090137063 | METHOD FOR DETERMINING THE QUALITY OF A BIOLOGICAL SAMPLE - The present invention relates to a method of determining the quality of a biological sample. A method according to the invention may be used to determine if a biological sample is suitable to use in a further biological assay demanding samples of good quality to render an accurate result. The method comprises detecting the presence of protein fragments in the biological sample by using appropriate means. The invention also relates to a kit for determining the quality of a biological sample. | 05-28-2009 |
| 20090142854 | SILANIZING AGENTS COMPRISING A SACCHARIDE END GROUP AND USES THEREOF, IN PARTICULAR FOR THE FUNCTIONALIZATION OF SOLID SUPPORTS - The invention relates to silanizing agents comprising a saccharide end group and to the use thereof for the functionalization of solid supports. The invention also relates to solid supports that have been functionalized by said silanizing agents (glycochips) and to the use of same, such for biological analysis and, in particular, for screening saccharide molecules or proteinaceous ligands of interest. | 06-04-2009 |
| 20090142855 | Polynucleotides and Polypeptides of the IL-12 Family of Cytokines - The present invention relates to the primate family of cytokines. Provided herein are polynucleotides encoding such polypeptides, and reagents useful for producing the encoded polypeptides in a host source, and for identifying compounds which bind and modulate the activity of the encoded polypeptides. Also provided are reagents useful for the diagnosis or treatment of inflammatory and/or autoimmune related diseases in primates. | 06-04-2009 |
| 20090148958 | NUCLEOTIDE-TRANSITION METAL COMPLEX CATALYST - This invention is to provide a catalyst (an artificial enzyme) which can be used as an alternative to a protein enzyme in the field relating to medicine, pharmaceuticals, biochemistry or chemical engineering. Such a catalyst comprises a complex of a transition metal and a monomeric or polymeric nucleotide or an analogue thereof. | 06-11-2009 |
| 20090148959 | METHOD OF QUANTITATIVELY MEASURING SMALL PARTICLE LOW DENSITY LIPOPROTEINS - The object of the present invention is to provide a fast and simple method for fractional measurement of a small particle LDL. | 06-11-2009 |
| 20090155928 | Modulating robo: ligand interactions - Disclosed are methods and compositions for identifying agents which modulate the interaction of Robo and a Robo ligand and for modulating the interaction of Robo and a Robo ligand. The methods for identifying Robo:ligand modulators find particular application in commercial drug screens. These methods generally comprise (1) combining a Robo polypeptide, a Slit polypeptide and a candidate agent under conditions whereby, but for the presence of the agent, the Robo and Slit polypeptides engage in a first interaction, and (2) determining a second interaction of the Robo and Slit polypeptides in the presence of the agent, wherein a difference between the first and second interactions indicates that the aget modulates the interaction of the Robo and Slit polypeptides. The subject methods of modulating the interaction of Robo and a Robo ligand involve combining a Robo polypeptide, a Slit polypeptide and a modulator under conditions whereby, but for the presence of the modulator, the Robo and Slit polypeptides engage in a first interaction, whereby the Robo and Slit polypeptides engage in a second interaction different from the first interaction. In a particular embodiment, the modulator is dominant negative form of the Robo or Slit polypeptide. | 06-18-2009 |
| 20090155929 | METHODS FOR DETECTION OF HYDROPHOBIC DRUGS - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. For conducting an assay for the hydrophobic drug, the above pretreatment is performed and to the medium is added reagents for determining the presence and/or amount of the hydrophobic drug in the sample wherein the reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug, the presence and/or amount of the complex indicating the presence and/or amount of the hydrophobic drug in the sample. | 06-18-2009 |
| 20090155930 | MONOCLONAL ANTIBODY DS6, TUMOR-ASSOCIATED ANTIGEN CA6, AND METHODS OF USE THEREOF - The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described. | 06-18-2009 |
| 20090162943 | Reagents and Methods for the Detection of Transmissible Spongiform Encephalopathy - This invention relates to the detection of transmissible spongiform encephalopathy (TSE) in samples using agents, such as antibodies, that bind to the extreme N-terminal region of mature full-length PrP. These allow the development of sensitive immunoassays for PrP | 06-25-2009 |
| 20090162944 | Method of Measuring Biomolecular Reaction at Ultrahigh Speed - According to the present invention, a method for ultrafast and precise measurement and analysis of biomolecules using a small sample was established, and moreover, a compact and simple micro fluid device for implementing the method was provided. Using the method and the micro fluid device of the present invention, the ultrafast, instant, and precise analysis of biomolecules is possible, and there is a great deal of potential for application in the research field, manufacturing field or medical field, environmental monitoring and the like. | 06-25-2009 |
| 20090162945 | INHIBITION OF GASC1 - The present invention provides a method of testing the ability of a test compound to bind to and optionally modulate the activity of a protein of the JMJD2 subfamily of Jumonji proteins. The method comprises incubating a test compound with a protein of the JMJD2 subfamily of Jumonji proteins, a co-factor of said protein and, optionally, a substrate for demethylation. The method of the invention can be used for screening large numbers of compounds to identify a group of compounds that are candidate compounds for clinical use for treatment of certain cancers especially prostate cancers. Other compounds that do not have activity in the screening assays can be eliminated from further consideration as candidate compounds. The method of the invention therefore has utility in the pharmaceutical industry. | 06-25-2009 |
| 20090170218 | METHODS FOR DETECTION OF CYCLOSPORIN A - Methods and reagents are disclosed for determining the presence and/or amount of cyclosporin A in a medium suspected of containing cyclosporin A. In the method a combination is provided in a medium. The combination comprises (i) the sample, (ii) a first member of a signal producing system (sps) associated with a first support wherein the first sps member is capable of activating a second member of the sps and wherein the first support is associated with a first member of a specific binding pair, and (iii) the second sps member associated with a second support wherein the second sps member is activatable by the first sps member. The second support comprises either (I) cyclosporin C or cyclosporin A and the combination further comprises a conjugate of an antibody for cyclosporin A and a second member of the specific binding pair or (II) antibody for cyclosporin A and the combination further comprises a conjugate of cyclosporin A and a second member of the specific binding pair. The combination is subjected to conditions for binding of cyclosporin A to the antibody for cyclosporin A. The first sps member is activated and the amount of signal generated by the second sps member is detected. The amount of signal is related to the presence and/or amount of cyclosporin A in the sample. | 07-02-2009 |
| 20090170219 | Nucleic acid capable of binding to immunoglobulin G and use thereof - The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like. | 07-02-2009 |
| 20090176317 | Soluble B7-H1 - This document features methods of evaluating mammals by assessing expression of B7-H4 in the vasculature. | 07-09-2009 |
| 20090176318 | BINARY DNA PROBE FOR FLUORESCENT ANALYSIS OF NUCLEIC ACIDS - The invention is directed to binary oligonucleotide probes for nucleic analysis, which probes can be made of DNA or RNA that recognize nucleic acid analytes (both DNA and RNA) with unprecedented high selectivity under mild conditions and are highly sensitive to single nucleotide mismatches (SNP single nucleotide polymorphisms) without PCR amplification. In one group, the binary probes indicate that they have hybridized to a particular nucleic analyte by binding to a molecular beacon that gives off a fluorescent signal. A second group of binary probes bind to a dye such as malachite green, where upon hybridization to analyte the fluorescence of the dye increases dramatically and is easily detected and measured. The new binary probes require only about five minutes at room temperature to generate a detectable signal. | 07-09-2009 |
| 20090181468 | Methods and compositions for treating cellular proliferative diseases - The present invention relates to compounds and pharmaceutical compositions for treating cellular proliferative disorders, screening assays for identifying such compounds, and methods for treating such disorders. | 07-16-2009 |
| 20090181469 | METHOD OF ENHANCING SIGNAL DETECTION OF CELL-WALL COMPONENTS OF CELLS - The invention relates to methods of enhancing signal detection of components of cell walls, wherein the methods involve lysing cells to form cell-wall fragments and analyzing the cell-wall fragments. | 07-16-2009 |
| 20090186422 | SPECIFIC INHIBITORS OF NFAT ACTIVATION BY CALCINEURIN AND THEIR USE IN TREATING IMMUNE-RELATED DISEASES - Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided. | 07-23-2009 |
| 20090191644 | Imprinted polymer for binding of organic molecules or metal ions - The invention relates to an imprinted polymer imprinted with an organic molecule or a metal ion wherein the matrix of the polymer has been prepared from one or more monomers including bilirubin or an analogue thereof. The imprinted polymers may be prepared by polymerising one or more monomers including bilirubin or an analogue or derivative thereof in the presence of the molecule or metal ion to be imprinted or an analogue or derivative thereof, and subsequently at least partly removing the molecule or ion to be imprinted or its analogue or derivative. The polymers may be used in a method for detection and/or assay of the imprinting molecule or metal ion. | 07-30-2009 |
| 20090191645 | COMPOUNDS AND METHODS FOR MODULATING INTEGRIN ACTIVITY - The present invention provides methods and compositions for modulating integrin activity. In particular, the present invention encompasses methods and compositions for altering the interaction between the α and β chain extracellular clasp regions. | 07-30-2009 |
| 20090191646 | MOLYBDENUM COMPLEX & TEST KIT TO ENHANCE ACCURACY OF ANALYSIS OF ENDOGENOUS ANALYTES IN BIOLOGICAL FLUIDS - Methods for enhancement in accuracy of immunochemical analysis of heterogeneous biological fluids containing exogenous substances that can interfere in immunochemical analysis for endogenous analytes of interest. According to this method a heterogeneous biological fluid sample is pretreated with an interferant suppression effective amount of a molybdenum coordination complex, so as to reduce manifestation of the presence of said exogenous material under immunoassay conditions. This invention is suitable for the suppression of manifestation of exogenous substances, specifically metabolites of drugs of abuse, during the immunoassay of biological fluids of infants for detection of endogenous substances indicative of a wellness or disease state. This invention also has application for similar suppression exogenous substances in the biological fluid of adults that have been inadvertently exposed to such substances (e.g. secondhand smoke). | 07-30-2009 |
| 20090191647 | Antibody Pair Screening Methods - The invention provides methods for identifying antibody preparations that can form a pair of antibodies that optimally detect a target antigen, for example, in a sandwich immunoassay. These methods provide high affinity and epitope-specific antibodies. | 07-30-2009 |
| 20090197347 | IMMUNOASSAY FOR PLASMODIUM FALCIPARUM AND ASSAY DEVICE USED THEREFOR - Disclosed are an immunoassay of | 08-06-2009 |
| 20090197348 | PYROCATECHOL VIOLET-METAL PROTEIN ASSAY - A method for protein determination utilizing a pyrocatechol violet-metal complex, a composition used in the protein determination assay, and a kit. | 08-06-2009 |
| 20090197349 | ELECTROCHEMILUMINESCENCE OF RARE EARTH METAL CHELATES - Luminescent chemical reagents that include complexes of rare earth metals with ligands such as aromatic heterocyclic nitrogen-containing compounds and semi-aromatic oxygen-containing compounds are used to detect small quantities of complex substances such as pharmaceuticals, metabolites, and microorganisms in complex sample mixtures. | 08-06-2009 |
| 20090203149 | ENHANCED METHODS FOR GAS AND/OR VAPOR PHASE ANALYSIS OF BIOLOGICAL ASSAYS - Processes for improved efficiencies as it relates to the analysis of small molecules whose concentration in the analysis solution is dependent upon the concentration of a target as determined through a liquid phase biological assays with vapor and/or gas phase analysis are disclosed. The process generally includes the competitive or non-competitive binding of target substances onto carrier particles functioning as substrates in the biological assay. Employing the carrier particles as substrates provides increased surface area for the reaction to occur; increased ease of washing steps; and allows for concentration of the increased surface area into a smaller reaction volume prior to introduction into the vapor and/or gas phase spectrometer such as an ion mobility spectrometer. | 08-13-2009 |
| 20090203150 | METHODS AND SYSTEMS FOR IDENTIFYING INSULIN MIMETICS - Methods are provided for identifying and selecting candidate molecules that activate glucose transport through binding of the insulin receptor at a site other than the insulin binding site. The methods include analyzing the properties of one or more candidate molecules in terms of the ability to bind the insulin receptor and activate glucose transport. Optionally the methods include, competitive assays in the presence of the glucose receptor, a candidate molecule, and one or more of insulin, alpha PGG and beta PGG. | 08-13-2009 |
| 20090209045 | SCREENING ASSAY - The present invention relates to agents that modulate the interaction of a dopamine receptor interacting polypeptide (DRIP) as represented by FIGS. | 08-20-2009 |
| 20090209046 | Neutral Pharmaceuticals - The invention comprises neutral multi-functionality assemblies of pharmaceuticals comprising an active medicinal functionality, a transition metal functionality, and an ancillary ligand functionality. An exemplary series of mixed-ligand coordination complexes comprised of copper(II), a drug and an ancillary ligand were made and tested. It is demonstrated that the judicious choice of an ancillary ligand affords a large degree of control over die relative lipophilicity/hydrophilicity of the complex in relation to the uncomplexed drug molecule. The important factors to be considered in the design of such complexes, such as the additive-constitutive nature of the partition coefficient of the ancillary ligand and the relative size of the two types of ligands are disclosed, and methods of designing neutral multi-functionality assemblies of pharmaceuticals are disclosed. | 08-20-2009 |
| 20090209047 | BIOMARKERS AND ASSAYS FOR MYOCARDIAL INFARCTION - Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included. | 08-20-2009 |
| 20090209048 | Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same - Disclosed are a luminescence biotin-transition metal complex conjugate and a method of amplifying signals using the same. More particularly, disclosed herein are a luminescence biotin-transition metal complex conjugate comprising an energy acceptor and biotin, and optionally an energy donor and a method of amplifying signals using the biotin-transition metal complex conjugate using intramolecular energy transfer. The luminescence biotin-transition metal complex conjugate using a transition metal probe provides a phosphorescence detection system capable of improved sensitivity. | 08-20-2009 |
| 20090215195 | Set1 proteins and uses thereof - The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5. | 08-27-2009 |
| 20090215196 | Sequential Method - A method for determination of an analyte in an original liquid sample by performing an inhibition affinity assay in a microchannel structure of a microfluidic device. The main characteristic feature is the steps of: (i) providing the microfluidic device in a form where the microchannel structure comprises a reaction microcavity which a) an inlet end, and b) contains a solid phase with binding sites (BS) for an analyte or an analyte-related entity, (ii) providing a liquid sample (1) containing the analyte or the analyte-related entity within the microchannel structure at the inlet end of the reaction microcavity, and flowing sample (1) through the reaction microcavity under conditions such that the analyte or the analyte-related entity is captured by BS leaving a portion of BS unoccupied (free BS), (iii) providing a liquid sample (2) which contains an analytically detectable analogue of the analyte or of the analyte-related entity, and flowing sample (2) through said reaction microcavity to capture the analogue by free BS, and (iv) measuring the amount of analyte analogue captured in step (iii) and relating this amount to the amount of analyte in an original sample. | 08-27-2009 |
| 20090215197 | TARGET SUBSTANCE CAPTURING MOLECULE - A capturing molecule having not less than two domains specifically binding to different sites of a target substance, wherein the not less than two domains comprise (1) a first domain having a hypervariable loop structure at a binding site to the target substance, and (2) a second domain having no hypervariable loop structure at a binding site to the target substance. | 08-27-2009 |
| 20090215198 | Immunological Latex Turbidimetry Method and Reagent Therefor - An immunological latex turbidimetry method for analyzing an antigen or antibody in a sample, comprising steps of:
| 08-27-2009 |
| 20090221094 | Anthrax Polypeptide Binding - Methods are disclosed for detecting anthrax protective antigen polypeptides and inhibiting their binding to β2 integrin α. A domain polypeptides, for example β2 integrin receptors. The disclosed methods are useful, for example, in diagnosing the presence of an anthrax toxin in the environment or in a subject and also for reducing anthrax intoxication in a subject. The methods can also be used to identify compounds that inhibit binding of an anthrax toxin to a β2 integrin. | 09-03-2009 |
| 20090221095 | Colorimetric Screening of DNA Binding/Intercalating Agents with Gold Nanoparticle Probes - Methods are provided to identify and characterize compounds that bind with duplex and triplex polynucleotides. | 09-03-2009 |
| 20090221096 | THIN FILM BIOSENSOR AND METHOD AND DEVICE FOR DETECTION OF ANALYTES - Thin-film biosensor chips for detecting a target analyte in a biological sample are disclosed. The chips include a solid substrate, an antireflective optical layer, an attachment layer using a non-polymeric silane, and an Fc-specific binding molecule coupled to the non-polymeric silane. Kits containing the chips and methods of using and making the chips are also disclosed. | 09-03-2009 |
| 20090221097 | METHOD OR AGENT FOR INHIBITING THE FUNCTION OF EFFLUX PUMP OF PSEUDOMONAS AERUGINOSA - The purpose of the present invention is to provide a method and an agent to efficiently inhibit the function of the drug efflux pump of | 09-03-2009 |
| 20090221098 | METHODS AND COMPOSITIONS FOR OBTAINING AND USING BIOLOGICALLY ACTIVE MULTI-PROTEIN COMPLEXES - Methods for isolating and using multi-protein complexes that are biologically active are provided. The complexes contain one or more proteins of interest (e.g. a receptor, ion channel, etc.) and associated scaffolding proteins such as phosphatases, kinases and post synaptic density components. Buffers that do not contain denaturing agents and which may be used to isolate the multi-protein complexes are also provided, as are protein arrays containing the biologically active multi-protein complexes. The protein arrays may be used, for example, for high throughput screening assays. | 09-03-2009 |
| 20090221099 | Methods and compositions for protein detection using fluorescent polymer sensors - Compositions, methods and related apparatus, as can be used for selective protein detection and identification. | 09-03-2009 |
| 20090221100 | METHODS FOR DIFFERENTIATING PLASMA-DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE - The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein. | 09-03-2009 |
| 20090233379 | Taste Receptors Of The T1R Family From Domestic Dog - The present invention relates to the discovery of several genes of the domestic dog ( | 09-17-2009 |
| 20090239309 | METHOD OF STABILIZING PULMONARY SURFACTANT PROTEIN - The present invention relates to a method for long-term stabilizing a pulmonary surfactant protein, to a stabilized aqueous solution containing a pulmonary surfactant protein, and to a kit for assaying a pulmonary surfactant protein which kit contains, as a component reagent, a stabilized aqueous solution containing a pulmonary surfactant protein. | 09-24-2009 |
| 20090239310 | KOKUMI-IMPARTING AGENT - The present invention encompasses a method for screening for a kokumi-imparting substance by using the calcium receptor activity as an index, a composition containing a kokumi-imparting substance obtained by the screening method, a method for producing food or drink imparted with kokumi, and food or drink imparted with kokumi. | 09-24-2009 |
| 20090239311 | Method of Differentially Diagnosing Dementias - In an ex vivo method of differentially diagnosing dementias selected from a group of demetias, which includes vascular dementias and frontotemporal lobe degenerations, a concentration of at least one carboxy-terminally truncated amyloid β peptide species as a biomarker is determined in a body fluid obtained from a patient, the at least one carboxy-terminally truncated amyloid β peptide species being selected from the group of species consisting of Aβ1-38, Aβ1-37 and Aβ1-39; and the concentration of the at least one carboxy-terminally truncated amyloid β peptide species is compared to a threshold concentration value for the respective one carboxy-terminally truncated amyloid β peptide species. | 09-24-2009 |
| 20090239312 | Chromosome 6 and 9 Genes Involved in Premature Canities - The invention provides a cosmetic or therapeutic method for combating canities and/or stimulating natural pigmentation and/or treating a pigmentation disorder comprising administering at least one polynucleotide fragment comprising 18 consecutive nucleotides, the sequence of which corresponds to all or part of a gene on human chromosome 9 selected from the group consisting of the FREQ, NT_030046.18, NT_030046.17, GTF3C5, CEL, CELL, FS, ABO, BARBLI, DDX31, GTF3C4 and Q96MA6 genes, or the sequence of which corresponds to all or part of a gene on human chromosome 6 selected from the HLAG, NT_007592.445, NT_007592.446, NT_007592.506, NT_007592.507, NT_007592.508, HSPA1 B, G8, NEU1, NG22, BAT8, HLA-DMB, HLA-DMA, BRD2, HLA-DQA1, HLA-DQA2, NT_007592.588, GRM4, RNF23, FLJ22638, NT_007592.459 and NT_007592.457 genes, and diagnostic methods employing same. | 09-24-2009 |
| 20090246884 | Reagent for Assaying Antiphospholipid Antibody and Reagent for Assaying Anti-Treponema Pallidum Antibody - It is an object of the present invention to provide a reagent for assaying anti-phospholipid antibodies, which is excellent in long-term storage stability and enables an accurate diagnosis of syphilitic infection, and a reagent for assaying anti- | 10-01-2009 |
| 20090246885 | Media for affinity chromatography - The invention relates generally to solid supports for chromatography. In specific embodiments the invention provides for solid supports suitable for affinity chromatography along with methods, systems and kits which use the same. | 10-01-2009 |
| 20090246886 | LATERAL FLOW TEST STRIP WITH MIGRATING LABEL - A lateral flow test strip is disclosed that includes a path of flow from a sample receiving zone through a mobilization zone to a primary capture zone and a secondary capture zone. A mobilizable conjugate is present in the mobilization zone, and a mobilizable label is present on the test strip upstream of the conjugate. An immobilized first specific binding partner is present in the primary capture zone and an immobilized second specific binding partner is present in the secondary capture zone. The conjugate includes a primary specific binding partner for the first specific binding partner in the primary capture zone, and a secondary specific binding partner that binds the label and the second specific binding partner. Application of liquid sample to the sample receiving zone results in movement of the liquid sample along the path of flow to move the label and conjugate distally along the test device. The label binds the conjugate after the conjugate binds the analyte, the first specific binding partner or second specific binding partner, so that labeling of the conjugate is delayed. | 10-01-2009 |
| 20090246887 | Diamond Crystallites For Biotechnological Applications - A diamond-based composition that contains (1) a diamond crystallite having chemically derivatized surface groups, and (2) a polymer having functional groups, in which a portion of the functional groups bind to the chemically derivatized surface groups non-covalently. Also disclosed are methods of using such composition for analyzing a biological sample by determining the identity of biomolecules bound to the composition. | 10-01-2009 |
| 20090253217 | Method of Quickly Detecting Antigen Using Fluorescence Correlation Spectroscopy or Fluorescence Cross-Correlation Spectroscopy - The present invention is to provide a method of quickly detecting an antigen at an arbitrary concentration in an antigen sample, without a multi-stage examination of the concentration ratio between a detection reagent and an antigen to be detected, particularly when the concentration of the antigen in the sample is unknown, in the method of detecting an antigen using fluorescence correlation spectroscopy (FCS) or fluorescence cross-correlation spectroscopy (FCCS). By preparing (1) a series to which only a detection reagent is added and (2) a series to which an antigen and the detection reagent are added to achieve a maximum trimer concentration, and by performing a fluorescence spectroscopic analysis, the presence or absence of the antigen in the detection sample is quickly detected by the presence or absence of a trimer detection signal from a detector in the cases of (1) and (2), in a method of detecting an antigen by FCS or FCCS using as a detection reagent a fluorescent-labeled intact antibody or fluorescent-labeled antibody fragment targeted to an epitope of the antigen to be detected, and a non-fluorescent-labeled intact antibody or fluorescent-labeled intact antibody or fluorescent-labeled antibody fragment targeted to another epitope of the antigen. | 10-08-2009 |
| 20090253218 | METHOD FOR SEROLOGIC AGGLUTINATION AND OTHER IMMUNOASSAYS PERFORMED IN A THIN FILM FLUID SAMPLE - A method and system for performing a serological agglutination assay in a liquid sample. The system provides a simple method for creating an in-situ sample/reagent admixture within a sample analysis chamber without the use of any precision fluid-handling components. | 10-08-2009 |
| 20090258434 | FLUORESCENT PROBE FOR PEROXYNITRITE - A compound represented by the following general formula (I): | 10-15-2009 |
| 20090258435 | BIOTIN-RECEPTOR REAGENTS FOR SENSITIVITY MODULATION IN ASSAYS - Methods are disclosed for designing an antibody reagent for use in an assay for the detection of an analyte to obtain an optimum assay sensitivity and/or dynamic range. The antibody reagent is a conjugate of a small molecule attached by a spacer group to an antibody for the analyte. The method comprises controlling, in the preparation of the conjugate, reaction parameters comprising the hydrophobicity or hydrophilicity of the spacer group, the length of the spacer group, the number of molecules of the small molecule attached to the antibody and the point of attachment of the small molecule to the antibody to obtain an optimum assay sensitivity and/or dynamic range. In some embodiments the method comprises preparing two or more conjugates by selecting a set of parameters for each conjugate wherein the set of parameters is different for each conjugate, conducting an assay for the analyte employing each conjugate and selecting for use in the assay the conjugate that provides the optimum assay sensitivity and/or dynamic range. | 10-15-2009 |
| 20090258436 | Reagents for the Detection of Protein Phosphorylation in Signaling Pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, Protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function. | 10-15-2009 |
| 20090258437 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS - The present invention provides compounds and methods for rapid labeling of N-glycans, for example, rapid fluorescent labeling of N-glycans. In one aspect, the present invention provides fluorescent carbamate or thiocarbamate compounds. Upon contacting with N-glycans, the compounds undergo facile reactions with N-glycans to form fluorescent-labeled N-glycans. | 10-15-2009 |
| 20090258438 | Method for universal biodetection of antigens and biomolecules - A universal signal molecule is generated in response to the presence within a biological fluid sample of a target agent. Two probes that bind to the target agent are provided within the sample and the target agent is captured, purified, and concentrated on a bead. One of the probes is attached to a signal nucleic acid that does not bind to the target agent. The signal nucleic acid is caused to be released from the probe, thereby generating a universal signal molecule. The presence of the universal signal molecule in the sample is detected, thereby providing for detection of the target agent within the sample. | 10-15-2009 |
| 20090263914 | BIOANALYTICAL ASSAY - A nanoparticle having a detectible feature and whose diameter is less than 200 nm, and which is coated with multiple specific binding reactants such that the affinity constant of the nanoparticle towards an analyte exceeds that of free binding reactant towards the analyte and/or the association rate constant between the nanoparticle and the analyte exceeds the association rate constant between the free binding reactant and the analyte. Also disclosed is a homogenous assay based on a first group labeled with a luminescent energy donor nanoparticle and a second group labeled with an energy acceptor compound, where the donor has a long excited state lifetime, and the increase or decrease, respectively, in the energy transfer from the donor to the acceptor resulting from shortening or lengthening, respectively, of the distance between these groups, is measured. | 10-22-2009 |
| 20090263915 | AGGLUTINATION INHIBITION ASSAY METHOD AND REAGENT - Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form. | 10-22-2009 |
| 20090263916 | Antagonists of HMG1 for treating inflammatory conditions - There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG 1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment. | 10-22-2009 |
| 20090269856 | METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PROGNOSIS - Methods and compositions for evaluating the prognosis of a breast cancer patient, particularly an early-stage breast cancer patient, are provided. The methods of the invention comprise detecting expression of at least one, more particularly at least two, biomarker(s) in a body sample, wherein overexpression of the biomarker or a combination of biomarkers is indicative of breast cancer prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The biomarkers of the invention are proteins and/or genes whose overexpression is indicative of either a good or bad cancer prognosis. Biomarkers of interest include proteins and genes involved in cell cycle regulation, DNA replication, transcription, signal transduction, cell proliferation, invasion, proteolysis, or metastasis. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. | 10-29-2009 |
| 20090275145 | METAL-ENHANCED FLUORESCENCE FOR POLARIZATION-BASED AFFINITY ASSAYS - A method and kit for determining the quantity of an analyte include providing a functionalized substrate and a reagent. The functionalized substrate includes metallic nanoparticles and a plurality of substantively identical bioactive target molecules affixed to a substrate. The bioactive target molecule binds to a particular analyte. The reagent includes identical detection molecules. Each detection molecule includes a fluorophore, and binds to a particular analyte or competes with a particular analyte for binding to the target molecule. The functionalized substrate is contacted to a test sample and the reagent. The functionalized substrate and a covering solution are exposed to polarized electromagnetic waves that excite the fluorophore. A quantity of the particular analyte in the test sample is determined based on measuring polarization anisotropy of fluorescent emissions from the substrate and the covering solution. | 11-05-2009 |
| 20090286328 | USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER - The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer. | 11-19-2009 |
| 20090286329 | ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES - The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample. | 11-19-2009 |
| 20090291507 | FLUIDICS DEVICES - The invention relates to fluidics as used in medical and diagnostic equipment and relates further to means for purifying, abstracting, filtering, detecting and/or measuring analytes in liquid samples. | 11-26-2009 |
| 20090298195 | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS - Method for engineering an immunoglobulin comprising at least one modification in a structural loop region of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of:—providing a nucleic acid encoding an immunoglobulin comprising at least one structural loop region,—modifying at least one nucleotide residue of at least one of said structural loop regions,—transferring said modified nucleic acid in an expression system,—expressing said modified immunoglobulin,—contacting the expressed modified immunoglobulin with an epitope, and—determining whether said modified immunoglobulin binds to said epitope, as well as modified immunoglobulins. | 12-03-2009 |
| 20090298196 | QUANTITATIVE MEASUREMENT METHOD FOR RECOMBINANT PROTEIN - The present invention is intended to provide a method of rapidly, simply and accurately measuring a recombinant protein. As means for resolution, the protein quantity is measured by causing the expression of a fusion protein with the target protein and epitope tags containing two types of epitopes, bringing them into contact with detection antibodies which specifically recognize each epitope, and detecting a phenomenon caused by both detection antibodies coming close to each other. | 12-03-2009 |
| 20090298197 | SERS-BASED METHODS FOR DETECTION OF BIOAGENTS - An assay and method of assay for optical detection of bioagents, a target nucleic acid or a target protein using a surface enhanced Raman scattering (SERS) active biomolecule molecular beacon. The present invention also provides the assay and method in a multiplexed format. | 12-03-2009 |
| 20090298198 | DIAGNOSING AND MONITORING INFLAMMATORY DISEASES BY MEASURING COMPLEMENT COMPONENTS ON WHITE BLOOD CELLS - The invention is related to methods of diagnosing inflammatory diseases or conditions by determining levels of components of the complement pathway on the surface of white blood cells. | 12-03-2009 |
| 20090305432 | Polypeptide Molecular Switch - A polypeptide can conduct electricity in a closed circuit. Conformational changes in the polypeptide due to posttranslational modifications or ligand binding can effect the conductive properties of the polypeptide which can be measured. In such a closed circuit, a polypeptide having at least one residue capable of reversible modification can be used as a molecular switch. Circuits comprising such molecular switches can be used, for example, in methods for assessing the modification state of a polypeptide, determining the activity of an enzyme of interest, identifying compounds that affect the activity of an enzyme of interest, storing data, detecting the presence of a compound and identifying inhibitors of protein-protein interactions. | 12-10-2009 |
| 20090305433 | Water-Soluble Rhodamine Dye Conjugates - The present invention provides novel, water-soluble, red-emitting fluorescent rhodamine dyes and red-emitting fluorescent energy-transfer dye pairs, as well as labeled conjugates comprising the same and methods for their use. The dyes, energy-transfer dye pairs and labeled conjugates are useful in a variety of aqueous-based applications, particularly in assays involving staining of cells, protein binding, and/or analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing. | 12-10-2009 |
| 20090305434 | METHOD OF DIAGNOSING NEUROPHSYCHIATRIC DISEASES, EATING DISORDERS OR METABOLIC DISEASES - The application relates to a method of diagnosing neuropsychiatric diseases, eating disorders and/or metabolic diseases, which comprises: (i) measuring the affinity and/or the avidity of antibodies, derived from a biological sample, directed against a biological molecule involved in homeostatic regulation and/or in motivational behavior and/or in emotion; (ii) comparing the affinity value obtained with a control value. | 12-10-2009 |
| 20090305435 | METHOD OF CALIBRATING LIGAND SPECIFICITY - A method to determine specificity of ligand binding includes comparing a solid phase carrier first extract obtained by pre-treating a sample with a ligand-immobilized solid phase carrier and a solid phase carrier second extract obtained by treating the pretreated sample again with a ligand-immobilized solid phase carrier in terms of the proteins contained therein, and identifying a protein whose content is remarkably decreased in the second extract compared to the first extract, in order to solve | 12-10-2009 |
| 20090311800 | Ultrasound method - The present invention provides methods and apparatus for detecting the product of a reaction on a particle held at the pressure node of a standing wave. The methods and apparatus are particularly concerned with blood typing and the Coombs method. | 12-17-2009 |
| 20090311801 | Diagnostic Test to Exclude Significant Renal Injury - Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 12-17-2009 |
| 20090311802 | Isolated Soluble IL-TIF/IL-22 Receptor or Binding Protein Which Binds to IL-TIF/IL-22 and Uses Thereof - The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described. | 12-17-2009 |
| 20090311803 | Treatment Of Tumors Expressing Mutant EGF Receptors - The invention discloses methods for identifying antibodies that reduce or prevent signaling by intact epidermal growth factor receptor (EGFR), or mutant EGFRs, such as EGFRvIII. | 12-17-2009 |
| 20090317919 | Method for Assaying Antigens - A method for assaying an antigen adsorbed on a solid support is provided. The method comprises: a) contacting a suspension of the antigen adsorbed on the solid support with a solution or suspension of an optionally detectably-labelled primary antibody to the antigen to form a solid-supported antigen-antibody complex; b) where the primary antibody is detectably labelled, optionally measuring the detectable label thereby to determine the quantity of the antigen; or c) contacting the solid-supported antigen-antibody complex with a detectably-labelled probe for the solid-supported antigen-antibody complex; and d) measuring the detectable label on the probe, thereby to determine the quantity of antigen. The antigen is preferably a component of a sub-unit vaccine, and most preferably anthrax protective antigen. | 12-24-2009 |
| 20090317920 | HAPTEN COMPOUND AND ANTIBODY - The present invention is a compound having a structure represented by the following formula (1): | 12-24-2009 |
| 20090317921 | ANTIBODY TO INHIBIN/ ACTIVIN BETA-B SUBUNIT - The present invention provides an improved antibody specific for the inhibin/activin beta-B subunit polypeptide. The antibody is highly specific for the beta-B subunit in a sample, and does not require processing of the sample with heat or oxidizing agents. Thus, discovery of the new antibody provides for simpler, more accurate immunoassays for a wider range of sample types. | 12-24-2009 |
| 20090325311 | Measurement methods - The invention relates to methods for measuring unconjugated molecules, e.g. antibodies, in a mixture that also includes conjugated molecules, e.g. antibodies. | 12-31-2009 |
| 20090325312 | Reagens for the detection of protein acetylation signaling pathways - The invention discloses | 12-31-2009 |
| 20090325313 | TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of Staphylococcal protein A, comprising a pair of anti-parallel alpha helices that are capable of binding a target, is provided herein. Introduction of an un-natural amino acid in the polypeptide is provided here. Also provided are methods of using the two-helix binders. | 12-31-2009 |
| 20090325314 | N-Methyl Scanning Mutagenesis - The present invention relates to methods and compositions comprising the insertion of a single N-methyl amino acid into functional peptides. More specifically, the invention discloses methods referred to as N-methyl scanning mutagenesis, where one or more N-methyl amino acid substitutions into functional peptides enhances protease resistance while retaining binding affinity. | 12-31-2009 |
| 20090325315 | DETECTION METHOD OF TARGET SUBSTANCE, DETECTION REAGENT USED FOR THE SAME, AND THE USES THEREOF - A new detection method, for detecting a target substance using formation of an aggregate due to binding of a target substance and a binding substance that binds thereto, that is excellent in detection accuracy, and sensitivity, and a new detection reagent used for the same are provided. Modifying substances having a maximum diameter of about 50 nm or less bind to a binding substance that binds to a target substance, and a modified binding substance is prepared as a binding reagent. A target substance in a sample is detected by bringing this modified binding reagent into contact with the sample, and optically detecting an aggregate that is formed by binding of the modified binding substance and the target substance in the sample. Preferably, the modifying substance includes biotin or a biotin derivative and further includes avidin or an avidin derivative, and the avidin or the avidin derivative binds to the biotin or the biotin derivative. Further, preferably, the biotin or the biotin derivative binds to the binding substance via a spacer. | 12-31-2009 |
| 20100003766 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: | 01-07-2010 |
| 20100009461 | Npcil1 (Npc3) And Methods Of Identifying Ligands Thereof - The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject. | 01-14-2010 |
| 20100009462 | Timp-2 as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of TIMP-2 in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes. | 01-14-2010 |
| 20100009463 | Reagents for the detection of protein phosphorylation in signaling pathways - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function. | 01-14-2010 |
| 20100009465 | METHOD FOR THE ANALYSIS OF CIRCULATING ANTIBODIES - There is provided a method for the analysis of circulating antibodies comprising the steps:
| 01-14-2010 |
| 20100015723 | Antagonists of Interleukin-15 - Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the β- or γ-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease. | 01-21-2010 |
| 20100015724 | LYSINE ACETYLATION SITES - The invention discloses 332 novel acetylation sites identified in various cancers, peptides (including AQUA peptides) comprising a acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above. | 01-21-2010 |
| 20100015725 | LUMINESCENT 1-HYDROXY-2-PYRIDINONE CHELATES OF LANTHANIDES - The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention. | 01-21-2010 |
| 20100022024 | Method for testing performance of reagents containing microparticles - The present invention provides: a method of testing the performance of reagents containing microparticles by mixing a standard specimen containing two or more kinds of ligands with two or more kinds of microparticles containing receptors capable of specifically binding to the respective ligands and being optically distinguishable, and detecting the optical characteristics of the aggregates thus formed; a kit for detecting a specimen provided with the standard specimen and the microparticles as described above; a method of quantifying a specimen after testing the performance of reagents containing microparticles as described above, mixing a specimen containing two or more kinds of ligands capable of specifically binding to the respective receptors in the microparticles with the microparticles, detecting the optical characteristics of the aggregates thus formed, and then repeating the testing performance of reagents containing microparticles. Thus the present invention provides a performance test of reagents containing microparticles which is suitable for detecting a biological specimen such as a nucleic acid, a quantification method of a specimen which uses the performance testing method thereof and a specimen detection kit including the reagent. | 01-28-2010 |
| 20100022025 | METHOD OF DETECTING HUMAN BETA-DEFENSINS - A method of detecting β-defensin in a bodily sample from a subject includes reducing the electrostatic interaction between β-defensin and negatively charged moieties in the bodily sample prior to detecting the β-defensin with an antibody or epitope binding fragment thereof. | 01-28-2010 |
| 20100022026 | METHODS, KITS, REAGENTS AND DEVICES FOR DETECTING MESOTHELIN AND/OR MEGAKARYOCYTE POTENTIATING FACTOR IN PERITONEAL FLUIDS - Certain embodiments disclosed herein are directed to methods and kits for detecting and quantifying in patient peritoneal fluid, such as spent peritoneal dialysis buffer, peptides having amino acid sequences related to megakaryocyte potentiating factor. The methods and kits can be used to monitor the biological status of the mesothelial lining of the peritoneal cavity in a patient, to predict development of a pathology of the mesothelium in an otherwise asymptomatic patient, and/or to assess the risk and suitability of a therapeutic method. In particular, the method can be used to assess negative effects of peritoneal dialysis on the biological integrity of the peritoneum, and thus to determine the time point when peritoneal dialysis treatment should be discontinued in favor of hemodialysis in a patient with kidney dysfunction, in order to avoid the development of peritoneal hypertrophy and other progressive mesothelial disorders such as encapsulating peritoneal sclerosis. | 01-28-2010 |
| 20100022027 | GENE 763 OF PHYTOPATHOGENIC FUNGUS MAGNAPORTHE GRISEA AND USE THEREOF FOR IDENTIFYING FUNGICIDAL COMPOUNDS - The invention concerns a novel nucleic acid fragment of the genome of rice pathogenic fungus | 01-28-2010 |
| 20100022028 | HUMAN OX2 RECEPTORS - Isolated receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof. | 01-28-2010 |
| 20100022029 | HOMOCYSTEINE IMMUNOASSAY - In immunoassays such as homocysteine immunoassays, it is known that the measured values can be dispersed due to the influence of inhibiting substances present in a biological sample on the immunoreaction. The present invention provides among other things a method whereby the influence of the immunoreaction inhibiting substances is easily and efficiently suppressed or eliminated, and also provides a kit used for such a method. The influence of the immunoreaction inhibiting substances is suppressed or eliminated when the analyte (e.g., homocysteine) contained in the biological sample is reacted with the antibody in the presence of extrinsic polyanion. | 01-28-2010 |
| 20100029012 | Method for identifying modulators of the NRF2-KEAP1-AREP pathway - A method for identifying modulators of the Keap1-NrG-ARE pathway is described. In particular, an assay is described that identifies molecules that inhibit the binding of a labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Molecules that inhibit the binding are activators of the Keap 1-Nrf2-ARE pathway. Activation of the Keap 1-Nrf2-ARE pathway may result in an increased accumulation of Nrf2 and the subsequent induction of protective enzymes, for example, the phase 2 detoxification enzymes. Activators of the Keap1-NrG-ARE pathway are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke. | 02-04-2010 |
| 20100029013 | Methods for Detecting Asymmetric Dimethylarginine in a Biological Sample - The present invention provides methods of detecting asymmetric dimethylarginine (ADMA) in a sample, particularly a sample that may contain symmetrical dimethylarginine (SDMA) and/or arginine. The methods generally involve modifying any SDMA and arginine in the sample such that SDMA and arginine are readily distinguishable from ADMA; and detecting ADMA. The invention further provides antibodies specific for ADMA; antibodies specific for modified SDMA; and antibodies specific for modified arginine. The invention further provides kits for practicing the subject methods. | 02-04-2010 |
| 20100035360 | REAGENT FOR DETECTION OF AUTOANTIBODY AND KIT FOR DIAGNOSIS OF AUTOIMMUNE DISEASE - This invention is intended to discover a novel autoantibody that can be used as a marker for an autoimmune disease and to provide an effective means for diagnosing an autoimmune disease. Disclosed is a reagent for detecting an autoantibody comprising an inositol 1,4,5-trisphosphate receptor (IP | 02-11-2010 |
| 20100035361 | TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of | 02-11-2010 |
| 20100035362 | BIO-SILICA CHIP COMPRISING SILICA BINDING PROTEIN AND METHOD FOR FABRICATING THE SAME - The present invention relates to a bio-silica chip comprising a silica-binding protein and a fabrication method thereof, and more particularly to a bio-silica chip in which a fusion protein of a silica-binding protein and a probe protein is immobilized on a chip comprising a silica layer, a fabrication method thereof and a method of using the bio-silica chip to detect interactions with biomaterials. The bio-silica chip will be very useful in biosensors, etc., because the bio-silica chip is advantageous in that it does not cause non-specific protein binding in the detection of protein-DNA, protein-ligand, protein-antibody, protein-peptide, protein-carbohydrate, protein-protein and cell-biomaterial interactions. Also, in the method for fabricating the bio-silica chip, a probe chip can be selectively immobilized on a silica device chip, which is widely used in biosensors, without a chemical surface treatment process. Thus, a chip fabricating process is simplified and a complicated process for purifying the probe protein becomes unnecessary, thus providing great improvements in productivity and economic efficiency | 02-11-2010 |
| 20100035363 | Homogeneous Time Resolved Fluorescence Based Test System for Paramyxoviridae - The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the RSV F1 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN57 (SEQ ID NO: 1); a second helical polypeptide consisting essentially of the sequence of C45 (SEQ ID NO: 2) wherein said IQN57 is labeled with a light emitting fluorophore and said C45 is labeled with an ultra-violet excitable fluorophore. | 02-11-2010 |
| 20100035364 | Diagnostic Test for Renal Injury - A method is provided of diagnosing and monitoring acute renal injury leading to acute renal failure in a human or mammalian subject by determining the ratio of the concentration of neutrophil gelatinase-associated lipocalin (NGAL) in urine to that in plasma or serum. | 02-11-2010 |
| 20100035365 | Fluorescent Silica-Based Nanoparticles - The present invention provides nanoparticle compositions comprising, for example, a core comprising a fluorescent silane compound; and a silica shell on the core. Also provided are methods for the preparation of nanoparticle compositions including fluorescent nanoparticles, ligated-fluorescent nanoparticles, ligated-fluorescent nanoparticles having therapeutic agents, and ligated-fluorescent nanoparticles coupled or associated with an analyte. Also provided are methods: for the detection of the ligated-fluorescent nanoparticles; for associating the linked-fluorescent nanoparticles with a cellular component of interest and recording or monitoring the movement of the cellular component; for improving the therapeutic properties of the therapeutic agent by combining the therapeutic agent with linked-fluorescent nanoparticles and contacting or administering the combination to a cell or organism; for making and using the fluorescent nanoparticles in, for example, diagnostic agents for the detection of various analytes, and like applications. | 02-11-2010 |
| 20100041165 | PROBE-IMMOBILIZED CARRIER STORING MANUFACTURING CONDITION DATA AND MANUFACTURING METHOD AND APPARATUS THEREOF, DETECTING METHOD OF TARGET SUBSTANCE BY USE OF THE PROBE-IMMOBILIZED CARRIER, AND MEASURING APPARATUS, RECORDING MEDIUM, KIT AND SYSTEM FOR USE IN THE DETECTING METHOD - A target substance is more accurately detected by recording a manufacturing condition specific to a probe-immobilized carrier that influences a measurement result for the detection of the target substance, and correcting the measurement result obtained from the detection of the target substance by use of the probe-immobilized carrier on the basis of the recorded manufacturing condition. The influence of variations in the immobilization states of the probe onto the solid phase carrier on the measurement result of the target substance can be eliminated. | 02-18-2010 |
| 20100041166 | Method and system for detecting a target within a polupation of molecules | 02-18-2010 |
| 20100047922 | TURBIDIMETRIC IMMUNOASSAY FOR ASSESSING HUMAN CYSTATIN C - There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved. | 02-25-2010 |
| 20100047923 | TWO HELIX BINDERS - An isolated polypeptide, Z domain, derived from B domain of | 02-25-2010 |
| 20100047924 | STABLE NANOREPORTERS - The present invention relates to compositions and methods for detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to improved, stable nanoreporter probes that are capable of binding to and identifying target molecules based on the probes' uniquely detectable signal. Methods for identifying target-specific sequences for inclusion in the probes are also provided, as are methods of making and using such probes. Polynucleotide sequences of certain nanoreporter components are also provided. The probes can be used in diagnostic, prognostic, quality control and screening applications. | 02-25-2010 |
| 20100047925 | SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting multiple targets in a biological sample are provided. The methods includes contacting the sample with a first probe; physically binding the first probe to a first target; observing a first signal from the first probe; applying a chemical agent to modify the first signal; contacting the sample with a second probe; physically binding the second probe to a second target; and observing a second signal from the second probe. The methods disclosed herein also provide for multiple iterations of binding, observing, signal modification for deriving information about multiple targets in a single sample. An associated kit and device are also provided. | 02-25-2010 |
| 20100047926 | HYBRIDIZATION CHAIN REACTION - The present invention relates to the use of nucleic acid probes to identify analytes in a sample. In the preferred embodiments, metastable nucleic acid monomers are provided that associate in the presence of an initiator nucleic acid. Upon exposure to the initiator, the monomers self-assemble in a hybridization chain reaction. The initiator nucleic acid may be, for example, a portion of an analyte to be detected or may be part of an initiation trigger such that it is made available in the presence of a target analyte. | 02-25-2010 |
| 20100062540 | Method for Detecting Aggregate-Forming Circulating Protein Forms Using an Agent for Aggregating Said Forms and an Agent for Capturing Formed Aggregates - The present invention concerns a method for detecting aggregate-forming circulating protein forms in a biological sample of human origin that may contain said aggregate-forming circulating protein forms, characterized in that it uses a non-protein agent I producing aggregation of the circulating forms of the noninfectious proteins involved in pathological aggregation processes of the central nervous system and/or a non-protein agent II for capturing the natural aggregrates of aggregate-forming circulating protein forms or the aggregates induced by said agents I. | 03-11-2010 |
| 20100062541 | Adiponectin receptor and gene encoding the same - The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability. | 03-11-2010 |
| 20100062542 | ANTIBODY AGAINST AFLATOXINS, SUPPORT USING THE ANTIBODY, METHOD OF IMMUNOLOGICALLY DETECTING AFLATOXINS AND METHOD OF CONCENTRATING AND PURIFYING AFLATOXINS - It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties. | 03-11-2010 |
| 20100068823 | Carrier Material, Method for the Production and Use Thereof - An embodiment of the present invention relates to a carrier material which is used in a method of diagnosis and which comprises a base material which is provided with a surface which is equipped with at least two different affinity ligands. | 03-18-2010 |
| 20100068824 | SENSING METHOD, SENSING DEVICE, INSPECTION CHIP, AND INSPECTION KIT - A sensing method comprises the steps of: allowing a liquid sample containing an analyte to flow through a channel, applying a force oriented in a given direction normal to a direction in which the liquid sample flows in the channel upon the analyte in a given position of the channel to move the analyte in the given direction so that the analyte is concentrated, causing the liquid sample to flow to a sensing surface forming a part of a wall surface of the channel located downstream of the given position and in the given direction against the channel, the sensing surface securing thereon a binding substance specifically reacting with the analyte, to allow the concentrated analyte to bind to the binding substance, and detecting a quantity of the analyte bound to the binding substance. | 03-18-2010 |
| 20100075436 | METHODS FOR USE WITH NANOREACTORS - The invention relates to methods of using nanoreactor technology for sample analysis in microfluidic systems. | 03-25-2010 |
| 20100075437 | Synthesis of highly luminescent colloidal particles - The present invention includes compositions and methods for their used wherein the compositions include clusters of coated fluorescent nanocrystals having a select size formed by controlled aggregation of individual coated nanocrystals. | 03-25-2010 |
| 20100075438 | BIOCOMPATIBLE AND PHOTOCURABLE POLYMERS - The present invention relates to substrates for biological testing produced from photo-curable epoxy compositions which further include carboxyl-containing monomers such as acrylic acid, 2-carboxyethyl acrylic acid, 4-vinylbenzoic acid, or 3-Acrylamido-3-methyl-1-butanoic acid, or glycidyl methacrylate, etc. The photo-curable compositions may be used to cast films or fabricate beads, magnetic beads, or magnetic beads containing nickel barcodes. The resulting various kinds of films, beads, magnetic beads, or magnetic beads containing nickel barcodes may find use in clinical or biological applications. | 03-25-2010 |
| 20100081211 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE - The invention relates to a detectable molecule comprising a biospecific binding reactant attached to a luminescent lanthanide chelate comprising a lanthanide ion and a chelating ligand of the formula (I) | 04-01-2010 |
| 20100081212 | ANTIBODIES FOR DETERMINING THE PROTHROMBIN FRAGMENT F2/F1+2 IN A HOMOGENEOUS IMMUNOASSAY - The present invention is in the area of coagulation analysis and relates to antibodies which bind specifically to an immune complex of prothrombin fragment F2/F1+2 and an F2/F1+2 neoepitope-specific antibody fragment, and to the preparation and the use thereof in methods for determining F2/F1+2. | 04-01-2010 |
| 20100087010 | METHOD FOR MEASURING IMMUNOCHROMATO TEST PIECE - After dropping a sample onto an immunochromatographic test strip | 04-08-2010 |
| 20100087011 | Detection and/or Characterisation of Oligomers - Disclosed is a method of detecting the presence of an oligomer analyte in a liquid sample, the method comprising the steps of: (a) contacting a sample comprising the oligomer or aggregate with an oscillating sensor surface, which surface may optionally be coated with a receptor that binds directly or indirectly to at least one component of the oligomer or aggregate, so as to cause direct or indirect binding of the oligomer or aggregate to the surface; (b) using a detection circuit to measure or calculate at least two of the following parameters: series resonance frequency (f | 04-08-2010 |
| 20100093106 | Amine-Reactive Biosensor - Described are methods, articles of manufacture, and kits for coupling an analyte-binding molecule to the surface of a biosensor through formation of amide bonds. One amide bond is formed between a first carboxyl group on a polymer and a first reflecting surface comprising an aminoalkyl moiety. A second amide bond is formed between a second carboxyl group on the polymer and an amine group on an analyte-binding molecule to be coupled. The present invention thus provides for covalent attachment of the analyte-binding molecule to the biosensor, thus providing advantages over non-covalent attachment methods of the prior art. These advantages include the ability to couple without using bio tin (which, in some instances can alter functional properties of a molecule) the ability to improve the fidelity with which a binding or dissociation reaction that takes place on the surface of the biosensor represents a solution phase reaction, and the ability to regenerate the sensor by stripping ligands from the covalently bound analyte-binding molecule. | 04-15-2010 |
| 20100093107 | POLYMER-PROTEIN SUBSTRATES FOR IMMUNOSORBENT FLUORESCENCE ASSAYS - The present invention relates to antigen-capture substrates useful for orienting capture antibodies for immunosorbent antigen determination. | 04-15-2010 |
| 20100099200 | DIRECT MASS SPECTROMETRIC ANALYSIS OF DRUG CANDIDATES TARGETING PROTEIN COMPLEXES - The invention relates to a method of using high mass matrix assisted laser desorption-ionization (MALDI) mass spectrometry for the qualitative and quantitative analysis of the effect of drug candidates on protein complexes such as protein-protein interactions in purified samples or complex biological matrices, as well as to the use of this method for lead compound optimization, drug characterization, drug manufacturing processes, and drug quality control processes, including automated high throughput applications. | 04-22-2010 |
| 20100105150 | ISOLATED HUMAN AUTOANTIBODIES TO NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AND METHODS AND KITS FOR THE DETECTION OF HUMAN AUTOANTIBODIES TO NGAL - A method of determining the presence, amount or concentration of at least one autoantibody that reacts with neutrophil gelatinase-associated lipocalin (NGAL), alone or in further combination with a method of determining the concentration of NGAL, which methods can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of a patient and, optionally, modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy; a kit comprising at least one component for assaying a test sample for at least one autoantibody that reacts with NGAL and instructions for assaying; a method of isolating an autoantibody that reacts with NGAL; an isolated autoantibody that reacts with NGAL; and a method for determining the reliability of an NGAL assay result. | 04-29-2010 |
| 20100105151 | Novel Druggable Regions in the Dengue Virus Envelope Glycoprotein and Methods of Using the Same - The present invention relates to novel druggable regions discovered in dengue virus envelope glycoprotein, or dengue virus E protein, which is a class II viral E protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases caused by viruses having class II E proteins, e.g. viral fusion inhibitors. | 04-29-2010 |
| 20100112719 | ELECTRONIC SIGNAL AMPLIFICATION IN FIELD EFFECT DEVICE BASED CHEMICAL SENSORS - Briefly, disclosed is a method and apparatus for detecting an analyte wherein an enhanced charge marker may enhance steric, electrostatic, optic and/or mechanical changes associated with a recognition event between an analyte and a probe. | 05-06-2010 |
| 20100112720 | CONTINUOUSLY REPEATABLE METHOD OF DETECTING ANTIGENS IN TEST VOLUME - A continuously repeatable method of detecting possible presence of one or several different selected target antigen(s), such as explosives and/or narcotics, in a predetermined test volume with a flow-through analysis device, such as a Piezoelectric Quartz Crystal Microbalance device (QCM), an Ellipsometer device or a Surface Plasmon Resonance biosensor device, is described. The device is equipped with one or several fluidly connected, individually operated, flow-through testing cells, each cell containing a sensing surface, each sensing surface comprising a selected modified target antigen immobilized thereon, which modified antigen has weaker affinity than the target antigen for a selected antibody specific for the selected target antigen. One testing cell is for analyzing a target antigen by the competition mode, whereas optional other testing cells are individually selected for analysis by the competition mode or the displacement mode. | 05-06-2010 |
| 20100112721 | BLOOD BIOMARKERS FOR BONE FRACTURE AND CARTILAGE INJURY - Blood biomarkers are described for use in methods and compositions to determine whether an individual has sustained a bone fracture or a cartilage injury. | 05-06-2010 |
| 20100112722 | Immunoassays and Characterization of Biomolecular Interactions Using Self-Assembled Monolayers - The present disclosure relates to methods of characterizing protein-protein interaction or conducting immunoassays in a biological sample using self-assembled monolayers (SAMs) and matrix-assisted laser desorption/ionization time of flight mass spectrometry (SAMDI). The biological sample may be obtained from a living subject, such as a human or animal clinical sample containing multiple unknown proteins and/or antigens. Label-free methods of identifying protein-protein interactions, antigen-antibody binding and/or diagnosing a medical condition based on analysis of a biological sample using SAMDI are also provided, as well as biochips comprising surface bound proteins and/or antibodies and methods of making these biochips. The methods and biochips are useful, for example, for identifying protein-protein binding interactions and/or conducting immunoassays in samples such as humoral fluids or other clinical samples, cell lysates, tissue lysates, tumor lysates, and samples obtained, isolated or derived from animals or plants. | 05-06-2010 |
| 20100112723 | MICROFLUIDIC APPARATUS AND METHODS FOR PERFORMING BLOOD TYPING AND CROSSMATCHING - Microfluidic cartridges for agglutination reactions are provided. The cartridges include a microfluidic reaction channel with at least two intake channels, one for an antigen-containing fluid and the other for an antibody-containing fluid, conjoined to a reaction channel modified by incorporation of a downstream flow control channel. At low Reynolds Number, the two input streams layer one on top of the other in the reaction channel and form a flowing, unmixed horizontally-stratified laminar fluid diffusion (HLFD) interface for an extended duration of reaction. Surprisingly, the design, surface properties, and flow regime of microfluidic circuits of the present invention potentiate detection of antibody mediated agglutination at the stratified interface. Antigen:antibody reactions involving agglutination potentiated by these devices are useful in blood typing, in crossmatching for blood transfusion, and in immunodiagnostic agglutination assays, for example. | 05-06-2010 |
| 20100112724 | METHOD OF DETERMINATION OF PROTEIN LIGAND BINDING AND OF THE MOST PROBABLE LIGAND POSE IN PROTEIN BINDING SITE - The present invention proposes a method of structural design, search and selection of potential medicinal compounds—ligands, comprising prognostication of the value of the protein ligand binding in terms of the score calculated with the help of the scoring function developed for scoring, and prognostication of the most probable ligand pose in the protein binding site in terms of the score calculated with the help of the scoring function developed for docking (the docking function). It is proposed to use two absolutely different scoring functions for docking and scoring. A special procedure is proposed for the development of docking function. Use of two absolutely different functions in the process of docking and scoring principally distinguishes the proposed method of predicting the binding affinity of ligand-protein interaction from all the known methods and makes it possible to substantially improve the quality of said prediction. | 05-06-2010 |
| 20100120170 | DETECTION AND MEASUREMENT OF THYROID HORMONE AUTOANTIBODIES - A non-radioisotopic method detects T3AA and T4M thyroid autoantibodies in a sample from a non-human species such as the canine species. Antibodies and autoantibodies are bound, and a precipitated or bound antigen-antibody or antigen-autoantibody complex is formed. The supernatant or surrounding fluid of the bound or precipitated antigen-antibody or antigen-autoantibody complex is then removed. The thyroid activity of the bound complex, precipitate, supernatant or surrounding fluid is measured. The thyroid analyte is at least one of T3, Free T3, T4 or Free T4. | 05-13-2010 |
| 20100120171 | CIRCULATING VE-CADHERIN AS A PREDICTIVE MARKER OF SENSITIVITY OR RESISTANCE TO ANTI-TUMORAL TREATMENT AND IMPROVED METHOD FOR THE DETECTION OF SOLUBLE PROTEINS - The application relates to improved means for the detection of soluble protein(s), such as soluble angiogenesis-related protein(s), more particularly circulating VE-cadherin. These means notably comprise the dilution of the fluid sample (e.g., serum or plasma sample), before submitting it to protein detection. Said dilution is advantageously diluted in a surfactant-containing solution. The improved means of the invention enabled to determine that circulating VE-cadherin is a reliable prognostic marker of the sensitivity or resistance to anti-tumoral treatment. It is believed that prior art sVE-cadherin detection means did not enable such determination. | 05-13-2010 |
| 20100120172 | SUBSTANCE WITH ANTITHROMBOTIC ACTIVITY AND METHOD FOR DETECTING GLYCOKALLIDIN - A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding. | 05-13-2010 |
| 20100129927 | Peptides for Use in Diagnosing the Presence of Ruptured Atherosclerotic Lesions in a Individual - The present invention relates to peptides that are able to interact with ruptured atherosclerotic plaque-associated antibodies, which peptides comprise an immunoreactive part of one of the amino acid sequences according to SEQ ID NOS: 1-25. The invention further relates to a diagnostic reagent comprising the peptides, to the use of the method and to a method and test kit for the diagnosis of a sample from an individual for the presence therein of antibodies that are indicative of the presence of ruptured atherosclerotic plaques in the individual. | 05-27-2010 |
| 20100129928 | Tyrosine Phosphorylation Sites - The invention discloses 347 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 05-27-2010 |
| 20100129929 | Tyrosine Phosphorylation Sites - The invention discloses 349 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 05-27-2010 |
| 20100129930 | Tyrosine Phosphorylation Sites - The invention discloses 351 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 05-27-2010 |
| 20100129931 | Anti-Methylation-Controlled J Protein Antibodies and Uses Thereof - This application includes, in part, methods of preparing antibodies that specifically bind to tnethylation-controlling J (MCJ) polypeptide. In some aspects, the application also includes, hybridoma cell lines that produce antibodies that specifically MCJ polypeptide; antibodies and antigen-binding fragments thereof produced with the methods of the application,—and methods of using antibodies and antigen-binding fragments that specifically bind MCJ polypeptide for diagnosis and treatment of cancer. | 05-27-2010 |
| 20100129932 | Determination of Isoerythropoietins - A method for the determination of the occurrence of an analyte subpopulation of isoEPOs in a biological fluid comprising the steps of: i) providing a liquid sample deriving from the biological fluid and containing isoEPOs that are characteristic (=analyte isoEPOs) for said analyte subpopulation together with isoEPOs of other subpopulations, ii) separating the isoEPOs of said liquid sample into two or more fractions so that at least one of these fractions contains analyte isoEPOs which are enriched relative to other isoEPOs, by A) contacting the liquid sample with an isoEPO reactant under conditions allowing affinity complex formation between isoEPOs of the liquid sample and the affinity reactant, and B) fractionating and collecting the isoEPOs of the liquid sample into said two or more fractions, relating the occurrence of analyte isoEPOs in said at least one fraction to the occurrence of said analyte subpopulation in the biological fluid. A flow matrix containing an application zone and downstream thereof a separation zone in which there is an immobilized isoEPO reactant. | 05-27-2010 |
| 20100129933 | METHOD FOR DETECTING THE BINDING BETWEEN MDM2 AND THE PROTEASOME - This invention provides both nucleic acid and amino acid sequences encoding for isolated protein-HDM2 binding sites as well as for isolated protein-proteasome binding sites (the ED(X)Y sequences). In a further aspect this invention also provides related nucleic acids, amino acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with the binding between HDM2 and the proteasome, as well as pharmaceutical compositions comprising said test compound, in particular as anti-cancer agent, even more particular for treating cell proliferative disorders in a subject. | 05-27-2010 |
| 20100129934 | Glycated Insulin as a Biomarker for Diagnosis and Monitoring of Diabetes - One of the major pathophysiological consequences of long term elevation of plasma glucose in diabetes is an increase in the non-enzymatic glycation of proteins. Contrary to expectations the present inventors have determined that individuals with well controlled short duration diabetes have particularly high concentrations of glycated insulin which decrease with increased disease severity and duration of diabetes. Further, a small proportion of apparently normal healthy individuals exhibit high glycated insulin levels in line with expected incidence of diabetes in the population. Methods of predicting the onset of diabetes and for monitoring the progression of diabetes by measuring the concentration of Glycated Insulin and the progression of diabetes are disclosed. | 05-27-2010 |
| 20100136710 | RNA processing protein complexes and uses thereof - The invention provides human protein complexes with endonuclease activity. In particular, the invention provides human protein complexes with tRNA splicing endonuclease activity and/or 3′ end pre-mRNA endonuclease activity. The invention also provides a splice variant of human Sen2, namely human Sen2deltaEx8, and human protein complexes comprising human Sen2deltaEx8. The human Sen2deltaEx8 complexes have pre-tRNA cleavage activity and/or 3′ end pre-mRNA endonuclease activity. The invention also provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and methods of diagnosing, preventing, treating, managing or ameliorating a disorder utilizing such antibodies. The present invention also provides methods utilizing the complexes described herein, inter alia, in screening, diagnosis, and therapy. The invention further provides methods of preparing and purifying the complexes. The present invention further provides methods of identifying a compound that modulates the expression of a component of a complex described herein, the formation of a complex described herein or the activity of a complex described herein, and methods of preventing, treating, managing or ameliorating a disorder, such as a proliferative disorder, or a symptom thereof utilizing a compound identified in accordance with the methods. | 06-03-2010 |
| 20100136711 | IMMUNOASSAY METHOD FOR PRO-GASTRIN-RELEASING PEPTIDE - To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. | 06-03-2010 |
| 20100144055 | Assays For Clinical Assessments of Disease-Associated Autoantibodies - The disclosure provides methods of detecting autoantibodies (AAs) in biological samples. The methods use capture probes that can bind to an disease-associated antigen/AA complex and a detection probe that can bind to the AAs. The presence, absence, and/or amount of the complex may be measured, wherein the presence of the complex may be diagnostic or prognostic of a disease or medical condition. The disclosure also provides methods of simultaneously detecting AAs and antigens in biological samples. The presence, absence, and/or amount of AAs and antigens may be measured, wherein the amount of antigen present and/or the amount of autoantibody present may be diagnostic or prognostic of a particular disease or medical condition. | 06-10-2010 |
| 20100144056 | PARTICLES CONTAINING DETECTABLE ELEMENTAL CODE - The invention relates to a new type of element encoded particles suitable for the attachment of bio molecules to enable massively multiplex bio-analytical methods, and to calibrate and tune the elemental flow cytometer mass spectrometer (FC-MS). | 06-10-2010 |
| 20100144057 | Fluidic Force Discrimination - This invention describes a method of using controlled fluidic forces to improve the performance of a biochemical binding assay where a target molecule is captured by specific molecular recognition onto a substrate surface with an affinity coating, and then labeled with a detectable micrometer-scale particle using a second specific molecular recognition reaction with the target. By using specific ranges of label sizes and laminar flow conditions, controlled fluidic forces can be applied to the label particles in order to selectively remove molecules bound to a surface according to their binding strength, and thereby increase the ratio of specifically bound labels to more weakly attached non-specifically bound labels. This method can be used with a wide variety of label types and associated detection methods, improving the sensitivity and selectivity of a broad range of binding assays. | 06-10-2010 |
| 20100144058 | B-LYMPHOCYTE STIMULATOR BINDING POLYPEPTIDES AND METHODS BASED THEREON - Binding polypeptides that specifically bind B lymphocyte stimulator protein or B lymphocyte stimulator-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate function of B lymphocyte stimulator or B lymphocyte stimulator receptor, comprising B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate B lymphocyte stimulator function or B lymphocyte stimulator receptor function, comprising administering to an animal, preferably a human, an effective amount of one or more B lymphocyte stimulator binding polypeptides or fragments or variants thereof, that specifically bind to B lymphocyte stimulator. | 06-10-2010 |
| 20100151587 | Method of Assaying Antigen and Kit to be Used therein - By using an antibody which is covalently bonded to a water soluble polymer as an antibody to be used in a competitive immunoagglutination assay in a homogeneous system, a protein antigen at a high concentration can be accurately assayed in an undiluted system without resorting to dilution. | 06-17-2010 |
| 20100151588 | MEANS AND METHODS FOR DIAGNOSING AND TREATING CANCER BASED ON THE FRMD3 GENE - The present invention relates to pharmaceutical compositions comprising a FRMD3 polynucleotide or polypeptide as well as diagnostic compositions, devices or kits comprising a FRMD3 polynucleotide or polypeptide as well as antibodies or oligonucleotides derived therefrom. Moreover, the present invention relates to methods and uses for diagnosing or treating a hyperproliferative disorder based on the aforementioned FRMD3 polynucleotides or polypeptides. | 06-17-2010 |
| 20100151589 | Glycoproteins Having Lipid Mobilising Properties and Therapeutic Applications Thereof - A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α | 06-17-2010 |
| 20100151590 | DIAGNOSIS AND TREATMENT OF INFECTIOUS DISEASES THROUGH INDEL-DIFFERENTIATED PROTEINS - A compound capable of specifically binding to pathogen EF-1α but not host EF-1α, wherein the compound binds to any part of an amino acid sequence having at least 70% sequence identity to amino acids 240-230 of SEQ ID NO:22. | 06-17-2010 |
| 20100151591 | RAPID HOMOGENEOUS DIAGNOSTIC TESTING PLATFORM BASED ON LANTHANIDE FLUORESCENT RESONANCE ENERGY TRANSFER - The present invention provides compositions and methods for detecting the presence of an analyte in a sample. Exemplary compositions comprise macrocyclic lanthanide complexes that are useful for transferring energy to an energy transfer acceptor to indicate the presence of the analyte. The compositions and methods are particularly suited for detecting antibodies in a sample. | 06-17-2010 |
| 20100159613 | Method for assaying the antioxidant capacity of a skin care product - A method for assaying the antioxidant capacity of a skin care product, the method including preparing an emulsion base, dissolving a sample of a skin care product into the emulsion base to form a homogeneous emulsion mixture, adding a detection probe to the homogeneous emulsion mixture, adding reactive oxygen species generator and/or reactive nitrogen species generator to the homogeneous emulsion mixture, measuring the fluorescence intensity change of the detection probe in the presence of the sample over time, in the presence of the standard over time, and in the presence of a blank over time, and calculating the initial rate of oxidation of the detection probe to determine the antioxidant capacity of the sample of the skin care product. | 06-24-2010 |
| 20100159614 | BIOCHIP AND APPARATUS FOR DETECTING BIOMATERIAL USING BIOCHIP - Provided is a biochip and an apparatus for detecting a biomaterial. The biochip includes a metal thin film on the surface of a substrate, restraining autofluorescence of the substrate, and a spacer on the metal thin film, having capture molecules immobilized on the surface of the spacer and specifically bound to target molecules. The spacer has a thickness controlled to enhance the strength of a fluorescence signal emitted from a fluorophore labeled with the target molecules and immobilized on the spacer by the specific binding between the capture molecule and the target molecule. | 06-24-2010 |
| 20100159615 | IMMUNOLOGICAL DETECTION METHOD USING AVIAN ANTIBODY - An object of the present invention is to provide an immunological detection method using an avian antibody, comprising suppressing a non-specific reaction caused by using an avian antibody. According to the present invention, there is provided an immunological detection method comprising detecting a target substance in a sample from a mammal using an avian antibody, characterized in that a non-specific reaction induced by the use of the avian antibody is suppressed. | 06-24-2010 |
| 20100167416 | Novel Boronate Complex and Its Use in a Glucose Sensor - A sensor comprises respective acceptor and donor compounds immobilised in or on a matrix including a glucose-binding boronate and a cationic species, whereby the spacing between the acceptor and donor compounds is reduced in the presence of glucose. For example a holographic sensor comprises a glucose-binding boronate and a cationic species held within the sensor. | 07-01-2010 |
| 20100167417 | LONG WAVELENGTH THIOL-REACTIVE FLUOROPHORES - Reactive fluorescent dyes compositions and methods of using same are disclosed. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed having thiol-reactive groups. Squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus dyes are disclosed that exhibit a fluorescence emission of at least about 575 nm. Biosensors are disclosed having a binding protein and a squaraine nucleus, Nile Red nucleus, benzodioxazole nucleus, coumarin nucleus or aza coumarin nucleus. | 07-01-2010 |
| 20100167418 | STABILIZED LOW AFFINITY CONFORMATION OF INTEGRINS FOR DRUG DISCOVERY - The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation. | 07-01-2010 |
| 20100167419 | Capillary Flow Solid Phase Assay - Methods, materials, apparatus and systems are described for performing capillary flow assay. In one aspect, a system includes a sample collection unit to collect a sample liquid and a sample testing and storing unit to interface with the sample collection unit to test and store the collected sample liquid. The sample testing and storing unit includes a sample inlet shaped to receive the collected sample from the sample collection unit, and a sample well positioned below the sample inlet to retain at least a portion of the sample liquid. The sample testing and storing unit includes a sample housing unit to store a remainder of the sample liquid not retained in the sample well, and an analyte testing unit housing shaped to receive an analyte detecting unit to test a presence of a target analyte in the sample liquid. | 07-01-2010 |
| 20100167420 | Micro Mechanical Methods and Systems for Performing Assays - The present invention provides a micro mechanical system for performing assays for determining the presence of one or more selected analytes in a sample. The device comprises of a base and a disposable strip with at least one reaction well and at least one moveable member capable of moving fluids and parts through the fluids in a defined reaction well. Reagents in the reaction chambers and or the moveable members, react with the sample to yield a physically detectable change. The moveable parts are capable of executing motions that either mix, move reaction components, exchange or systematically deliver reagents to targets in the cartridge. Sensors in the base are configured to detect and or quantify the presence of a sample in the reaction well and of analytes in the sample. The signal is converted to an output on a visual display window on the external part of the base. | 07-01-2010 |
| 20100173425 | High Capacity Solid Phase - A high capacity solid phase for bioaffinity assays and other solid phase applications prepared by coating a solid support with an analyte-specific biomolecule in the presence of a zwitterionic additive is described. Structures prepared according to the invention provide high capacity solid phases with enhanced binding properties, which are advantageous for any solid phase based assay. | 07-08-2010 |
| 20100173426 | BIOMAKER IDENTIFYING THE REACTIVATION OF STAT3 AFTER SRC INHIBITION - A method of identifying cancer or an associated disorder comprising identifying and quantifying STAT3 occurring in a biological sample taken from a subject after administering a SFK inhibitor to said subject. | 07-08-2010 |
| 20100173427 | LEVETIRACETAM IMMUNOASSAYS - Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam. | 07-08-2010 |
| 20100173428 | Protein Phosphorylation By Basophillic Serine/Threonine Kinases - The invention discloses 461 novel phosphorylation sites identified in basophilic Ser/Thr kinase signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 07-08-2010 |
| 20100173429 | METHODS USING NOVEL CHEMILUMINESCENT LABELS - Methods using chemiluminescent label compounds and chemiluminescent labeled conjugates are provided. The compounds comprise an acridan ring bearing an exocyclic ketene dithioacetal group and further contain a labeling substituent which permits attachment to compounds of interest. The novel chemiluminescent compounds and labeled conjugates are convenient to prepare, are highly stable, and generate chemiluminescence rapidly on demand. The compounds and conjugates are useful in assays of an analyte in a sample and in assays employing labeled specific binding pairs. | 07-08-2010 |
| 20100184236 | GUANOSINE TRIPHOSPHATE (GTP)-BINDING PROTEIN-COUPLED RECEPTOR PROTEIN, BG37 - The present inventors conducted a similarity search of the amino acid sequence of known G protein-coupled receptor proteins in GenBank, and obtained a novel human GPCR gene “BG37”, cDNA containing the ORF of the gene was cloned and its nucleotide sequence was determined. Moreover, novel GPCR “BG37” genes from mouse and rat were isolated. Use of the novel GPCR of the present invention enables screening of ligands, compounds inhibiting the binding to a ligand, and candidate compounds of pharmaceuticals which can regulate signal transduction from the “BG37” receptor. | 07-22-2010 |
| 20100190264 | Genetic Variants Increase the Risk of Age-Related Macular Degeneration - Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD, but it was not identified. We identified a strongly associated haplotype in two independent data sets. DNA sequencing of the complement factor II gene (CHI) within this haplotype revealed a coding variant, Y402II, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This identifies Complement factor II as involved in pathogenesis of AMD. This single variant alone is so common that it likely explains 43 percent of AMD in older adults. In addition, we have replicated and refined previous reports implicating a coding change in LOC387715 as the second major AMD susceptibility allele. The effect of rs10490924 appears to be completely independent of the Y402II variant in the CFH gene. The joint effect of these two susceptibility genes is consistent with a multiplicative model, and together, they may explain as much as 65% of the PAR of AMD. In contrast, the effect of rs10490924 appears to be strongly modified by cigarette smoking. Smoking and LOC387715 together may explain as much as 34% of AMD. Our data indicate that variant genotypes at rs10490924 confer a substantially larger AMD risk to cigarette smokers than non-smokers. This observation is supported by traditional case-control modeling, by ordered subset linkage analysis (OSA) incorporating pack-years of cigarette smoking as a covariate, and by family-based association analysis using a more homogeneous set of families as defined by OSA. | 07-29-2010 |
| 20100190265 | FLUIDICS DEVICE FOR ASSAY - The present invention relates to a device for use in performing assays on standard laboratory solid supports whereon chemical entities are attached. The invention furthermore relates to the use of such a device and a kit comprising such a device. The device according to the present invention is adapted to receive one or more replaceable solid support(s) (40) onto which chemical entities ( | 07-29-2010 |
| 20100190266 | METHOD FOR MEASURING BONDING ACTIVITY OF ANTIBODY WHICH MIMICS ANTIBODY-DEPENDENT CELL MEDICATED CYTOTOXIC ACTIVIY - The present invention provides a simple method which is capable of evaluating the binding activities of an antibody to both an antigen and an Fc receptor. | 07-29-2010 |
| 20100190267 | Miniature Chemical Analysis System - An apparatus, according to one aspect, may include a chromatograph and a bulk acoustic resonator. The chromatograph may include a channel that is defined at least partially in a monolithic substrate. The channel may have an inlet to receive a sample and an outlet. A chromatography material may be included in the channel. The bulk acoustic resonator may have a first electrode and a second electrode that has a chemically functionalized surface. The chemically functionalized surface may be included in a chamber that is defined at least partially in the monolithic substrate and that is coupled with the outlet of the channel. Methods of making and using such apparatus, and systems including such apparatus, are also disclosed. | 07-29-2010 |
| 20100197040 | ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate. | 08-05-2010 |
| 20100197041 | NUCLEIC ACID BINDING ASSAYS - This invention relates to methods for screening compounds for the ability to interact with a nucleic acid target, assay kits useful thereof and compositions regarding same. In a particular aspect, the invention relates to specific binding assays employing fluorescent label(s). The methods involve assessing the conformation of nuclei acid targets in the presence and absence of test compounds, and identifying as a ligand any test ligand that causes a measurable conformation change in nuclei acid targets. The effect of compounds on target nuclei acids conformation is assessed by measuring the fluorescence changes of a fluorescently label(s) attached hereto. | 08-05-2010 |
| 20100203650 | BIOMOLECULE BINDING LIGANDS - The invention provides biomolecule binding ligands, collections of biomolecule binding ligands, and their use in the purification of biological mixtures and in the identification of ligands having an affinity for a substance. The ligand is a compound of formula (III) or a compound of formula (IV): wherein for compounds of formula (I) one of R | 08-12-2010 |
| 20100210032 | SPECIFICITY AND SENSITIVITY ENHANCEMENT IN CANTILEVER SENSING - The invention is directed to a sensor system including at least one sensor and target specific receptors bound substrates for purposes of enhancing detection sensitivity. Optionally, the sensor system may include quantum dots for independently verifying the presence of a target molecule or compound. The sensor system may be particularly beneficial in the field of medical diagnostics, bio-defense, food safety, water safety and general chemical detection. | 08-19-2010 |
| 20100210033 | PORTABLE DEVICE FOR DETECTING FOOD ALLERGENS - The invention relates to a portable device and method for detecting allergenic substances. | 08-19-2010 |
| 20100210034 | METHODS OF DETERMINING PATIENT RESPONSE BY MEASUREMENT OF HER-3 - The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3. | 08-19-2010 |
| 20100210035 | HUMAN PROTEINS RESPONSIBLE FOR NEDD8 ACTIVATION AND CONJUGATION - The invention relates to covalent modification of proteins through their conjugation with other proteins. More particularly, the invention relates to the modulation of such conjugation involving the protein NEDD8. The invention provides compositions and methods for detecting and/or modulating the activation and/or conjugation of NEDD8, as well as compositions and methods for discovering molecules which are useful in detecting and/or modulating the activation and/or conjugation of NEDD8. The present invention arises from the purification and characterization of novel NEDD8 activating and conjugating enzymes. | 08-19-2010 |
| 20100210036 | PPAR ACTIVE COMPOUNDS - Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile. | 08-19-2010 |
| 20100216253 | Organic Material-Immobiling Structure and Method for Production of the Same, and Peptide and DNA Therefor - The invention provides an organic material-immobilizing structure employing new immobilization means, characterized in that at least a part of the surface of the substrate is comprised of one or more members containing silicon oxide, the organic material is bound to the surface of the substrate through a binding domain bound to the organic material and containing an amino acid sequence capable of binding to silicon oxide, selected from the group consisting of amino acid sequences of SEQ ID NOS: 1 and 2: Val-Ser-Pro-Met-Arg-Ser-Ala-Thr-Thr-His-Thr-Val; and Ile-Pro-Met-His-Val-His-His-Lys-His-Pro-His-Val, and derivatives thereof. | 08-26-2010 |
| 20100216254 | DRUG MONITORING ASSAY - A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided. | 08-26-2010 |
| 20100216255 | METHODS OF DETERMINING ACTIVE LEVELS OF DRUGS IN FLUID SAMPLES - Methods for determining the presence and level of active drugs in fluid samples are provided. Advantageously, entire families or classes of drugs can be tested for in one test by identifying the enzyme or receptor upon which members of that drug family act and measuring enzyme activity levels or binding activity levels of receptors. Methods for establishing standard activity levels of these drugs based upon results from samples having known quantities of drug therein are also provided. | 08-26-2010 |
| 20100221844 | Caustic stable chromatography ligands - The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, | 09-02-2010 |
| 20100221845 | BIOSENSOR - One object of the present invention is to provide a biosensor and a production method therefor, by which hydrogel that enables immobilization of a physiologically active substance can be conveniently produced using safe raw materials. The present invention provides a biosensor which comprises a substrate having a metal layer on its surface, wherein a hydrophilic polymer having a reactive functional group capable of reacting with a hydroxyl group or an amino group of a physiologically active substance is bound to the metal layer directly or indirectly via an intermediate layer. | 09-02-2010 |
| 20100227414 | Affinity capture mass spectroscopy with a porous silicon biosensor - Affinity Capture-Mass Spectroscopy (AC-MS), an analytical technique which couples the sensitivity of a label-free binding detected biosensor, and the information richness of mass spectroscopy is described. A 3-dimensional porous silicon bio-surface is used to capture proteins, DNA, or small molecules while acquiring a label-free, time resolved signal linearly proportional to the amount of binding. A switch to dissociative buffer conditions then frees the captured molecule for analysis by mass spectroscopy. In particular, techniques for use with electrospray mass spectroscopy are described. | 09-09-2010 |
| 20100227415 | METHOD AND MEANS FOR PREDICTION OF SYSTEMIC LUPUS ERYTHEMATOSUS SUSCEPTIBILITY - A method of predicting the risk of a person developing systemic Lupus erythematosus susceptibility comprises the detection of autoantibody to class A scavenger receptors, in particular to MARCO and SR-A autoantibody. Also disclosed is a support coated with the autoantibody and a kit comprising the support and a secondary antibody capable of binding to a serum component bound to the autoantibody on the support. | 09-09-2010 |
| 20100227416 | Nano-Scale Bridge Biosensors - Devices, systems, and methods for detecting nucleic acid hybridization, including single nucleic base mutations at low concentrations, are disclosed, using capture units having nanoparticles with attached single-stranded oligonucleotides that are capable of hybridizing target oligonucleotides and reporter molecules having nanoparticles with attached single-stranded oligonucleotides, without the use of labeling or target modification. | 09-09-2010 |
| 20100227417 | Methods and Kits for Detection of Thromboxane A2 Metabolites - Methods, compositions and kits are provided for measuring aspirin's anti-thrombotic effectiveness on a subject. Included are a novel assay for quickly and specifically measuring TxA2 metabolite levels in urine and correlating the levels with aspirin dose in a subject. The methods, compositions and kits utilize a novel anti TxA2 metabolite antibody. | 09-09-2010 |
| 20100227418 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 09-09-2010 |
| 20100233824 | MICROFLUIDIC METHODS AND SYSTEMS FOR USE IN DETECTING ANALYTES - A microfluidic reactor arrangement ( | 09-16-2010 |
| 20100240145 | Novel hemopoietin receptor protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system. | 09-23-2010 |
| 20100240146 | FLUORESCENT PROTEIN PARTICLES - A fluorescent protein particle comprising: a particle forming component capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; a fluorescent component; and a functional component capable of binding to, or being bound by, a target. | 09-23-2010 |
| 20100240147 | HIGH SENSITIVITY NANOTECHNOLOGY-BASED MULTIPLEXED BIOASSAY METHOD AND DEVICE - In a method and device for high sensitivity analysis of multiple bioassays plurality of nanoparticles (N) is dispersed in a fluid sample, at least one probe (C) of a first type having affinity for at least one analyte being attached to each nanoparticle; a plurality of probes of at least a second type having affinity for the analyte is attached to the internal surface (S) of the container; means are provided for detecting the signal generated by the adhesion of the nanoparticles to the internal surface of the reactor, brought about by the interaction of the analyte with the nanoparticle-bound probes and that of the analyte with the probes attached to the internal surface. The method and the device are particularly effective for detecting different genotypes of human papilloma virus (HPV). | 09-23-2010 |
| 20100240148 | Method and Kit for Measurement of Acrolein Adduct in Sample Utilizing Agglutination Reaction of Immunological Microparticle - A method for measuring an acrolein adduct present in a sample comprising the steps of: (a) mixing a sample containing the acrolein adduct with a solution comprising an immunoglobulin that specifically recognizes the acrolein adduct; (b) adding to the mixture obtained in the step (a), a solution comprising microparticles to which a substance that specifically binds to the immunoglobulin that specifically recognizes the acrolein adduct and a blocking agent have been bound, and mixing them; and (c) measuring an extent of an agglutination reaction of the microparticles in the mixture obtained in the step (b), wherein the extent of the agglutination reaction being decreased relative to an amount of the acrolein adduct in the sample. The method enables a measurement of an acrolein adduct without requiring a complex operation. | 09-23-2010 |
| 20100240149 | ELECTRONIC ANALYTE ASSAYING DEVICE - The invention is an electronically processed single-step test device for detecting the presence of a preselected analyte in a fluid. The device includes a hollow rectangular outer casing, disposed within co-joined upper and lower sections of the casing are assay material, an electronic processing system, and a LCD display. The LCD display is observable through a viewing window. The assay material is a sorptive material including a fluid sample application region in the form of a sample wick in fluid communication with a test strip. The test strip includes an analyte capture region adjacent to a light shield. The electronic processing system includes red and green LEDs which are alternately pulsed or energized over predetermined periods of time to determine if fluid test results show a marker or markers in the capture region indicative of the presence of a preselected analyte in the fluid. If so, Yes+ is displayed on the LCD. If not, No− is displayed on the LCD. | 09-23-2010 |
| 20100248389 | ELECTROCHEMICAL DEPOSITION OF POLYMERS ON METAL SUBSTRATES - Described herein are methods for electrodepositing a variety of different polymers on metal substrates. The polymers are strongly adhered to the substrates. The substrates produced herein can be used in a number of different applications such as, for example, medical devices and biosensors. For example, the biosensors can be composed of one or more electrodes, where the electrodes have the same or different polymers electrochemically deposited on them. Finally, the methods described herein permit the evaluation of the electrodeposition process as well as monitor the ability of biomolecules to bind to the electrodeposited polymers. | 09-30-2010 |
| 20100248390 | COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS - The present invention relates to compositions and methods for identifying odorant-odorant receptor interactions. In particular, the present invention relates to in silico methods for identifying odorant receptor-odorant interactions based on chemical and physical properties of odorant receptors and odorants. | 09-30-2010 |
| 20100248391 | BIOSENSOR DEVICE AND METHOD OF DETECTING BIOLOGICAL PARTICLES - A biosensor device ( | 09-30-2010 |
| 20100248392 | Method of Immunoassaying Specimen Using Aggregation Reaction of Microparticles and Assay Kit - A method of assaying a sample with the use of the aggregation reaction of immunological microparticles and an assay kit. The assay is conducted by using microparticles wherein the same or an analog of the analyte and a substance that specifically binds to a substance that can specifically bind to the analyte are both bound to an insoluble carrier. Thus, it becomes possible to conveniently carry out the assay even in the case where the analyte has only a small number of specific binding sites, without especially adding a competitive substance carrying hapten bonded thereto to the reaction system so as to induce simultaneous competition of the target substance and the competitive substance. | 09-30-2010 |
| 20100261291 | Nucleic acids specifically binding bioactive ghrelin - The present invention is related to a nucleic acid specifically binding bioactive ghrelin, more preferably n-octanoyl ghrelin, and its use for the diagnosis of ghrelin mediated diseases and disorders. | 10-14-2010 |
| 20100267165 | MICROELECTRONIC SENSOR DEVICE FOR THE DETECTION OF TARGET PARTICLES - The invention relates to a microelectronic sensor device for the examination of target particles ( | 10-21-2010 |
| 20100273274 | POLYNUCLEOTIDES ENCODING ACETYLCHOLINE-GATED CHLORIDE CHANNEL SUBUNITS OF CAENORHABDITIS ELEGANS - The invention relates to novel polynucleotides which encode novel polypeptides that are acetylcholine-gated chloride channel subunits and immunogenic or acetylcholine-binding fragments thereof. The novel polypeptides may be used for identifying compounds that modulate the acetylcholine-gated chloride channels, e.g. for use as pesticides and antiparasitic agents. Methods for identifying compounds that modulate the acetylcholine-gated chloride channels are provided. | 10-28-2010 |
| 20100273275 | Methods of determining levels of steroid fractions utilizing SHBG calculations - There are provided methods for assaying biological specimens for steroids (androgens and estrogens), Sex Hormone-Binding Globulin (SHBG) and Albumin in order to calculate the free and bioavailable steroid concentration based on the laws of mass action and association constants predicated on the identification that one molar equivalent of SHBG contains two molar equivalents of steroid binding sites. | 10-28-2010 |
| 20100279431 | USE OF BNP-TYPE PEPTIDES FOR PREDICTING DIALYSIS NEED - The present invention relates to diagnosing the risk of developing a need for dialysis and/or predicting a need for dialysis, particularly in patients suffering from renal disorders, comprising the steps of measuring the level of a BNP-type peptide or a variant thereof in a sample from the patient, diagnosing the risk by comparing the measured level of the BNP-type peptide or a variant thereof to at least one reference level. The BNP-type peptide may, for example, be brain natriuretic peptide (BNP), proBNP, NT-proBNP, a variant of BNP, a variant of proBNP, or a variant of NT-proBNP. | 11-04-2010 |
| 20100279432 | INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided. | 11-04-2010 |
| 20100279433 | ASSAY METHOD FOR ALZHEIMER'S DISEASE - A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of Aβ | 11-04-2010 |
| 20100285605 | Neurofibrillary labels - Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of “blocking ligands” to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors. | 11-11-2010 |
| 20100285606 | DENSITY-BASED METHODS FOR SEPARATION OF MATERIALS, MONITORING OF SOLID SUPPORTED REACTIONS AND MEASURING DENSITIES OF SMALL LIQUID VOLUMES AND SOLIDS - The ability to levitate, to separate, and to detect changes in density using diamagnetic particles suspended in solutions containing paramagnetic cations using an inhomogeneous magnetic field is described. The major advantages of this separation device are that: i) it is a simple apparatus that does not require electric power (a set of permanent magnets and gravity are sufficient for the diamagnetic separation and collection system to work); ii) it is compatible with simple optical detection (provided that transparent materials are used to fabricate the containers/channels where separation occurs; iii) it is simple to collect the separated particles for further processing; iv) it does not require magnetic labeling of the particles/materials; and v) it is small, portable. The method and kits provided provide for separation and collection of materials of different densities, diagnostics for detection of analytes of interest, monitoring of solid-supported chemical reactions and determination of densities of solid and liquid mixtures. | 11-11-2010 |
| 20100285607 | METHOD FOR DETECTING AND QUANTIFYING ANALYTES ON A SOLID SUPPORT WITH LIPOSOME-ENCAPSULATED FLUORESCENT MOLECULES - The present invention relates to an improved method for detecting and quantifying analytes on a solid support, with liposome-encapsulated fluorescent molecules. | 11-11-2010 |
| 20100285608 | CONFORMATIONAL ENTROPY IN MOLECULAR RECOGNITION - The present invention provides methods for the determination of the degree of molecular recognition of a protein with a ligand, including a first protein with a second protein. The methods may comprise determining the squared generalized order parameter (hereinafter, O) for at least one intramolecular bond of the first protein. The protein is then formed into a complex with a ligand. The value or values of O2 for the said at least one bond of the protein is then determined while the protein and the ligand are in the complex. The O value or values determined for the protein while the protein and the ligand are in a complex are compared or related to the O value or values determined for the uncomplexed protein. | 11-11-2010 |
| 20100285609 | SENSOR - This invention relates to a method for detecting an analyte in a sample, comprising the steps of exposing the sample to a transducer which is capable of transducing a change in energy to an electrical signal, the transducer having at least one tethered reagent on or proximal thereto, the at least one tethered reagent having a binding site which is capable of binding the analyte; introducing a labelled reagent into the sample, wherein the labelled reagent contains a binding site for the analyte or the tethered reagent and a label which is capable of absorbing electromagneticradiation generated by a radiation source to generate energy; allowing the labelled reagent to bind to the analyte or tethered reagent in a first period in which the transducer is oriented such that the labelled reagent is caused to settle, at least in part, on the transducer; subsequently, in a second period, causing the labelled reagent to become unsettled; irradiating the sample with electromagnetic radiation during the first and second periods, transducing the energy generated into an electrical signal; detecting the electrical signal. A device for performing the method is also provided. | 11-11-2010 |
| 20100285610 | Lateral Flow Test Kit and Method for Detecting an Analyte - A method and device for detecting analytes in a test sample. Embodiments include methods for quantitatively detecting analytes within a range of concentrations. In an embodiment the method includes a lateral flow test strip with multiple test areas for capturing a labeled receptor to provide a detectable signal. | 11-11-2010 |
| 20100291705 | ANTIGEN EXPOSING MICELLE AND UNORDERED AGGREGATE - An antigen exposing micelle or unordered aggregate comprising at least one carrier, at least one epitope and at least one anchoring molecule, wherein said anchoring molecule comprises at least one anchoring part, intended to anchor the antigen exposing micelle to a surface. | 11-18-2010 |
| 20100291706 | DYE CONJUGATES AND METHODS OF USE - The present invention relates to cyanine compounds, compositions comprising them, articles of manufacture, and methods of making and using them. The cyanines usefully comprise one or more carboxyl groups or derivatives thereof that are indirectly attached to an aryl ring on an alkylaryl cyanine substituent. Also provided are conjugates of the disclosed cyanines and one or more other substances. Solvates, solutions, and derivatized forms of the cyanines are also provided. The cyanines find use in a variety of bioassays, both in direct single-label applications and in energy transfer formats. Methods utilizing the disclosed cyanines for analyzing a sample for a target are provided. Also disclosed are detection complexes comprising the disclosed cyanines, as well as compositions and articles comprising the cyanines in an excited state, for example formed by direct excitation or by energy transfer. The cyanines may be used as alternatives to other known optically active species in a variety of settings. Other embodiments are described further herein. | 11-18-2010 |
| 20100291707 | Multiplexed Scanometric Assay for Target Molecules - The present invention is directed to compositions and methods of use of a functionalized nanoparticle having a catalytic metal deposit. | 11-18-2010 |
| 20100291708 | METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION - Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β | 11-18-2010 |
| 20100297778 | Conjugate Having Cleavable Linking Agent - A method and reagent that can be used to eliminate the signal caused by non-specific binding of a labeled conjugate, e.g., a specific binding member attached to a label, to a solid phase, e.g., a magnetic microparticle. The method and the reagent involve the use of a cleavable linking agent to link the label to the specific binding member that specifically binds to the analyte. The use of a cleavable linking agent would allow the release of the label from the specific binding member from the complex comprising the magnetic microparticle, analyte, and labeled conjugate into solution. After the release of the label, the magnetic microparticles having any label non-specifically bound thereto, are removed from the reaction mixture. Only the label, e.g., acridinium, from the labeled conjugate would remain in the elution well. The conjugate that is non-specifically bound through interaction between the label and the solid phase, e.g., a magnetic particle, would remain bound to the solid phase, and would subsequently be removed from the elution well when the solid phase is removed from the elution well and transferred to another well the introduction of additional reagent(s). | 11-25-2010 |
| 20100304498 | MICROCHIP REACTION DETECTION SYSTEM AND METHOD OF REACTION OF MICROCHIP IN FLOW PATH - Disclosed is a microchip reaction detection system comprising: a microchip comprising a driving liquid injection unit into which a driving liquid for driving a solution is injected and a detection unit on which a substance to be reacted is supported and where the reaction between the substance and the solution is detected; a driving liquid pump for injecting the driving liquid into the driving liquid injection unit; an air pump for injecting a gas into the detection unit; and a control unit for controlling the driving liquid pump so that the driving liquid can be injected into the driving liquid injection unit and also controlling the air pump so that the gas can be injected into the detection unit intermittently in an amount at least effective for pushing away the solution injected in the detection unit while feeding the solution to the detection unit. | 12-02-2010 |
| 20100304499 | METHOD OF EXTRACTING FOOD COMPONENT, FOOD INSPECTION METHOD AND FOOD INSPECTION KIT - Provided is a technique of extracting a component in a food from the food by using a reducing agent that is inexpensive and has a mild reducing action. A component in a food is extracted by mixing the food with an extractant containing a sulfite. In addition, the resultant food extract is brought into contact with a specific antibody that specifically recognizes a substance included in a specified ingredient of interest for inspection, to thereby inspect the presence or absence and/or the amount of a specified ingredient in a food by utilizing an immunological measurement method. Further provided is a food inspection kit for inspection of the presence or absence and/or the amount of a specified ingredient in a food, including: (1) an extractant and a sulfite to be added to the extractant, or an extractant including a sulfite added; and (2) an antibody that specifically recognizes a substance included in a specified ingredient of interest for inspection. | 12-02-2010 |
| 20100304500 | NANO-BIOSENSOR FOR BIOMOLECULAR RECOGNITION AND A METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a nano-biosensor for detecting avidin bio-conjugated antibodies and a method of manufacturing the same. The nano-biosensor comprises a core made up of Zns: Mn nanoparticles. The core is surrounded by mercaptoelthanol molecules. Biotin is attached to the mercaptoethanol molecules surrounding the core. The ZnS:Mn nano particles with a size of 5-10 nm are prepared by quaternary W/O micro-emulsion method. According to one embodiment, a nano-biosensor comprises a nano particle of ZnS:Mn wherein the nano particle of ZnS:Mn includes ZnSO | 12-02-2010 |
| 20100311185 | DETECTION METHODS - The invention relates to a method for quantitatively or qualitatively detecting an analyte in a sample, with the sample being incubated, for the purpose of avoiding, diminishing and/or detecting the high-dose hook effect, with an analyte-specific binding partner R | 12-09-2010 |
| 20100311186 | DEVICES AND METHODS FOR PERFORMING RECEPTOR BINDING ASSAYS USING MAGNETIC PARTICLES - The present invention provides methods, devices, and systems for performing receptor binding assays. In particular, magnetically responsive particles configured to form a complex with a labeled conjugate corresponding to one or more analytes of interest can be moved within an assay device to one or more discrete detection regions through the application of one or more magnetic fields. By positioning the detection region such that the direction of this movement is, for at least a portion of the movement, counter to the direction of fluid flow within the device, detection of assay signals can be performed without the need for separate wash steps. Moreover, contamination of the signals resulting from labeled conjugate being carried in the direction of fluid flow substantially reduced. | 12-09-2010 |
| 20100311187 | ANTIBODY RECOGNIZING C-DOMAIN OF MIDKINE - It is intended to provide an antibody which inhibits the function of midkine. An antibody which recognizes an epitope consisting of amino acid residues 62 to 104 of midkine or a fragment thereof; DNA encoding the antibody or a fragment thereof; a recombinant vector which contains the DNA; a transformant which has the vector or a hybridoma which produces the antibody; a method for producing the antibody by allowing the transformant or hybridoma to produce the antibody or a fragment thereof and collecting the resulting antibody or fragment thereof; a pharmaceutical composition containing the antibody or a fragment thereof as an active ingredient; and a diagnostic agent containing the antibody or a fragment thereof as an active ingredient. | 12-09-2010 |
| 20100311188 | FEMALE FERTILITY TEST - The present invention is related to a diagnostic test kit that assesses ovarian reserve by measuring Follicle Stimulating Hormone (FSH) in a liquid sample. The sample can be deposited on a first portion of the device for transport to a second portion of the device. The device can include a release medium formed of a first material and including a detectable label thereon and a capture medium, including a test site, in fluid communication with the release medium and formed of a second, different material. | 12-09-2010 |
| 20100311189 | Novel Receptor Nucleic Acids and Polypeptides - Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided. | 12-09-2010 |
| 20100311190 | DEVICES AND METHODS FOR DETECTING AMNIOTIC FLUID IN VAGINAL SECRETIONS - The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies. | 12-09-2010 |
| 20100317126 | AGGLUTINATION ASSAY METHOD IN POROUS MEDIUM LAYER - An agglutination assay method for quantitatively determination of an analyte in an aqueous liquid sample using particles bearing an anti-analyte. The agglutination is conducted in the porous medium layer of the analysis element. A speedy quantitative analysis of the analyte can be conveniently attained with high sensitivity. When the particle-labeled anti-analyte is contained in the porous medium layer, the anti-analyte can be stored with higher stability in the dry state. A dry analysis element for enabling such analysis method is also provided. | 12-16-2010 |
| 20100317127 | DIAGNOSIS OF LIVER PATHOLOGY THROUGH ASSESMENT OF PROTEIN GLYCOSYLATION - Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states. | 12-16-2010 |
| 20100317128 | METHOD FOR DETERMINATION OF TARGET SUBSTANCE - A method for highly sensitive determination of a target substance by means of an aptamer includes: causing an aptamer capable of specific binding with a target substance to bind competitively with said target substance and a nucleic acid strand having a base sequence complementary to at least a portion of said target substance, detecting at least either of the physical change and the chemical change that results from said aptamer binding with said nucleic acid strand, and determining said target substance based on the result of detection. | 12-16-2010 |
| 20100323455 | DIAGNOSTIC ASSAY FOR HUMAN MATRIX GLA-PROTEIN AND ITS USE AS A BIOMARKER - The present invention includes a diagnostic assay for the detection and determination of MGP in a human serum sample, which comprises the use of one or more antibodies, preferably monoclonal antibodies, specifically recognizing epitopes on and/or conformations of human Matrix Gla-Protein. A method is provided for using MGP-related antigens as biomarkers for certain diseases, for example, atherosclerosis and other vascular diseases, and angiogenesis/neogenesis in tumor development. Monoclonal antibodies of class IgG are described for use in the assay, which are defined herein as mAb3-15, mAb35-49[Glu], mAb35-49[Gla], mAb35-53[Glu], and mAb35-53[Gla]. Polyclonal antibodies and methods are also disclosed for measuring MGP in a human serum sample. | 12-23-2010 |
| 20100323456 | Endothelin Receptors in Morphine Withdrawal - The present invention relates to compositions and methods for managing opioid tolerance and reducing opioid withdrawal. More specifically, the present invention provides for endothelin, endothelin receptors, and endothelin receptor antagonists and agonists as a means for managing G-protein activity in the context of opioid tolerance and withdrawal. | 12-23-2010 |
| 20100330696 | Method of diagnosing endometriosis in human subjects - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to EPP2 (SEQ ID NO:9) polypeptide or a peptide comprising an epitope of EPP2 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis. | 12-30-2010 |
| 20100330697 | COMPLEXES OF TRPC DOMAINS AND SESTD1 DOMAINS AND METHODS AND USES INVOLVING THE SAME - The present invention relates to an isolated complex comprising a first protein comprising or consisting of a classical transient receptor potential channel (TRPC) or a functionally active variant thereof and a second protein comprising or consisting of the first spectrin (Spec 1) domain of SEC14 and spectrin domains 1 (SESTD1), a test system comprising the first protein and the second protein as well as means for detecting interaction of the first and the second protein, a method for screening for a TRPC modulator using the system and the use of the test system for the identification of a TRPC modulator. | 12-30-2010 |
| 20100330698 | DETECTION OF TARGET COMPONENTS WITH THE HELP OF INDICATOR PARTICLES - The invention relates to a system and a method for the detection of target components ( | 12-30-2010 |
| 20100330699 | APPARATUS AND METHOD FOR THE DETECTION OF LIQUIDS OR SUBSTANCES FROM LIQUIDS, AND USE OF SAID APPARATUS - The embodiments relate to an apparatus and a method for detecting liquids or substances from liquids in spatially separate reaction zones. The embodiments further relate to the use of the apparatus in a plug-in module or a chip card which can be used for rapid immunological tests, for example, with the help of a reading device. The liquids or substances from liquids are detected by means of a sensor array which includes at least two sensors and on which at least one diaphragm is arranged. Individual sensors are spatially separated from each other on a plane by means of walls. The diaphragm can be filled with liquid that is to be analyzed. Sealed reaction chambers are created when pressure is applied to the diaphragm. Pores in the diaphragm are completely closed in the zone of the walls while the pores are merely reduced in size and liquid can continue to be exchanged in zones directly above the sensors. No liquid can be exchanged between adjacent reaction chambers as long as the pressure is applied to and compresses the diaphragm. In the sealed reaction chambers, reactions can take place independently of reactions in adjacent reaction chamber. Reaction products or substances in the liquid can be measured with smaller measurement errors in sealed reaction chamber than when the liquid flows across the entire diaphragm. | 12-30-2010 |
| 20110003399 | Tumor Necrosis Factor-Gamma - Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed. | 01-06-2011 |
| 20110003400 | METHODS AND SYSTEMS FOR GROUND AND SURFACE WATER SAMPLING AND ANALYSIS - The invention provides devices, methods, and kits for collection of dry samples from fluid samples such as ground or surface water. Devices of the invention include a casing including a water intake zone wherein the casing encloses, a fluid reservoir, a pump, a non-aqueous collection matrix cartridge, and a waste water conduit, wherein the water intake zone, the fluid reservoir, the pump, the non-aqueous collection matrix cartridge, and the waste water conduit are all operably linked in sequence. Methods for using the device of the invention are provided. Kits including the device of the invention or for use with the invention are also provided. | 01-06-2011 |
| 20110008908 | APPARATUS AND METHOD FOR SEPARATING AND ANALYZING BLOOD - An apparatus, comprising at least separating means ( | 01-13-2011 |
| 20110008909 | Assay Device - Disclosed is an assay device for the determination of the presence and/or amount of a species in a liquid sample, the assay device comprising one or more reagents for providing an analyte of interest wherein the assay device further comprises a control species which is capable of interacting with the one or more reagents to provide a detectable control antigen. | 01-13-2011 |
| 20110008910 | METHOD FOR THE IMMOBILIZATION OF A CAPTURE MOLECULE ON A SOLID SUPPORT - This invention is in the field of diagnostic assays, more in particular immunoassays wherein a capture molecule is immobilized on a solid support in order to capture an analyte. The invention relates to a method for the immobilization of a capture molecule on a solid support wherein the capture molecule is covalently attached to a biotin molecule to obtain a biotinylated capture molecule and wherein the biotinylated capture molecule is subsequently contacted with a high affinity binding member to form an capture molecule complex where after the capture molecule complex is contacted with the solid support. | 01-13-2011 |
| 20110008911 | DIAGNOSTIC METHOD FOR DISORDERS USING COPEPTIN - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases. | 01-13-2011 |
| 20110008912 | Polymer-coated substrates for binding biomolecules and methods of making and using Thereof - Described herein are polymer-coated substrates for binding biomolecules and methods of making and using thereof. | 01-13-2011 |
| 20110008913 | TUMOR SUPPRESSOR GENE - A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) was also isolated. The colony forming activity of cells exogenously expressing Gros1-L was significantly reduced, while that of cells expressing Gros1 antisense RNA was significantly increased. | 01-13-2011 |
| 20110014723 | COMPOSITIONS AND PROCESSES RELATING TO HUMAN BOCAVIRUS - Non-replicating, antigenic, human bocavirus virus-like particles (HBoV VLPs) are provided by the present invention along with assays using the HBoV VLPs to detect anti-HBoV antibodies in a biological sample. Pharmaceutical compositions including HBoV VLPs and/or anti-HBoV antibodies are described herein along with novel antibodies generated using HBoV VLPs as an antigen. A recombinant baculovirus is provided including a DNA sequence encoding an expressible human bocavirus VP2 with or without a DNA sequence encoding an expressible human bocavirus VP1 polypeptide, and/or a non-HBoV peptide or protein, and culturing the cells to form the VP1 and/or VP2 proteins that self assemble to form the HBoV VLPs which are then amenable to isolation. | 01-20-2011 |
| 20110020950 | SCAFFOLD FOR COMPOSITE BIOMIMETIC MEMBRANE - Disclosed herein is a membrane scaffold comprising a planar material having a hydrophobic surface and a functional area comprising a plurality of apertures. The apertures have a diameter of from about 80 μm to about 3000 μm and the rims of the apertures comprise bulges extending above and/or below the surface level of the planar material. The membrane scaffold is useful in the preparation of a composite biomimetic membrane wherein functional channel forming molecules have been incorporated in said membrane. | 01-27-2011 |
| 20110020951 | PURIFIED SR-P70 PROTEIN - The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences. | 01-27-2011 |
| 20110020952 | METHOD FOR DETERMINING THE STAGE OF ULCERATIVE COLITIS OR INTERSTITIAL PNEUMONITIS AND REAGENT KIT THEREOF - The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body. | 01-27-2011 |
| 20110027907 | SSL7 MUTANTS AND USES THEREFOR - The invention relates to SSL7 mutants which have no, or at least reduced, ability to bind to IgA. The mutants have significant application in the purification or isolation of C5 from samples and in the identification or detection, including quantitation, of C5 in samples. Use of the mutants has the benefit of minimising or preventing simultaneous isolation and/or detection of IgA in a sample, simplifying and improving methods relying on wild type SSL7. | 02-03-2011 |
| 20110027908 | DEVICE FOR DETECTION OF ANTIGENS AND USES THEREOF - Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed. | 02-03-2011 |
| 20110027909 | Chimera Compositions and Methods of Use - This invention is directed to novel compositions, process methods, research tools, and use of these in the identification and development of novel therapeutic and/or diagnostic products. The compositions of the invention are chimera proteins that in essence recreate and/or potentiate one or more protein complex interactions that occur in vivo in the modulation of biological processes. | 02-03-2011 |
| 20110027910 | SCREENING - A method of producing a conformational specific binding partner of a GPCR, the method comprising: a) providing a mutant GPCR of a parent GPCR, wherein the mutant GPCR has increased stability in a particular conformation relative to the parent GPCR; b) providing a test compound; c) determining whether the test compound binds to the mutant GPCR when residing in a particular conformation; and d) isolating a test compound that binds to the mutant GPCR when residing in the particular conformation. Methods of producing GPCRs with increased stability relative to a parent GPCR are also disclosed. | 02-03-2011 |
| 20110027911 | SOLUBILIZATION AND STUDY OF MEMBRANE PROTEINS - Provided are methods for solubilizing a membrane protein in order to provide substantially homogeneous membrane proteins that are solubilized within reverse micelle systems at concentrations that are suitable for analytical study of such membrane proteins, including nuclear magnetic resonance spectroscopy. Also provided are substantially homogeneous membrane proteins that are solubilized within a reverse micelle system, as well as methods for the study of solubilized membrane proteins, and for the screening of drug candidates that target such membrane proteins. | 02-03-2011 |
| 20110027912 | PURIFIED SERUM ALBUMIN, AND IMMUNOLOGICAL MEASUREMENT METHOD - An object of the present invention is to provide: a purified serum albumin having less lot-to-lot variation; and an immunoassay method utilizing the purified serum albumin, in which high reactivity and less non-specific reactions are achieved. | 02-03-2011 |
| 20110033950 | TURBIDIMETRIC IMMUNOASSAY FOR ASSESSING HUMAN CYSTATIN C - There is a demand for improved turbidimetric immunoassays for human Cystatin C in biological samples, especially in human clinical samples of body fluids. The present invention provides a turbidimetric immunoassay method and reagent set enabling measurement of human Cystatin C by turbidimetric methods, resulting in a surprisingly stronger and faster turbidimetric signal than in the present state of the art. The increased and faster signal is accomplished by the use of new reagents and compositions, and enables shorter assay times and kinetic reading with a stronger signal, improving overall assay speed and quality. Improved robustness to lipid interference and improved linearity is achieved. | 02-10-2011 |
| 20110033951 | ASSAY METHOD AND KIT FOR NUCLEIC ACID BINDING PROTEIN - An object of the present invention is to provide a method of detecting a nucleic acid binding protein and a method of screening for a binding inhibitor or promoter for a nucleic acid binding protein. According to the present invention, there is provided a method of detecting binding between a nucleic acid and a nucleic acid binding protein, comprising determining the degree of structural change in a nucleic acid complex having at least two nucleic acid duplex moieties. | 02-10-2011 |
| 20110039352 | METHODS TO MEASURE DISSOCIATION RATES FOR LIGANDS THAT FORM REVERSIBLE COVALENT BONDS - The crystal structure of the ligand binding domain of ERR-α in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-α, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-α activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-α and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target. | 02-17-2011 |
| 20110039353 | METHOD FOR DIRECT DETECTION OF ISCHEMIA-MODIFIED ALBUMIN USING A PARTNER FOR BINDING TO AN ALDEHYDE DERIVATIVE RESULTING FROM THE PEROXIDATION OF LIPIDS IN BOUND FORM - The present invention relates to the use of at least one partner for binding to an aldehyde derivative resulting from the peroxidation of lipids in protein-bound form, for instance to 4-hydroxy-2-nonenal, to 4-hydroxy-2-hexenal or to malondialdehyde, for the detection of ischemia-modified albumin (IMA) in a biological sample. | 02-17-2011 |
| 20110039354 | Method of Characterizing and Quantifying Calcifying Nanoparticles - A method of characterizing calcifying nanoparticles (CNPs) can include creating a test sample comprising CNPs isolated from a biological source, a buffer solution, a plurality of calibration beads, and a fluorescent marker specifically linked to the CNPs; evaluating the test sample using a flow cytometer; and analyzing results from the flow cytometer to determine a characterizing feature of the calcifying nanoparticles. The characterizing feature of the calcifying nanoparticles can be the number of CNPs, concentration of CNPs, size of CNPs, level of CNP aggregation, size and light dispersion characteristics of CNPs, fluorescence intensity of the CNPs when labeled with a specific antibody, or a combinations thereof The method can also include evaluating an isotype control comprising CNPs isolated from the biological source, the buffer solution, a plurality of calibration beads, and a fluorescent marker that is not linked to the CNPs. | 02-17-2011 |
| 20110045603 | Serine, Threonine, and Tyrosine Phosphorylation Sites - The invention discloses 990 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 02-24-2011 |
| 20110045604 | MOLECULAR AFFINITY CLAMP TECHNOLOGY AND USES THEREOF - The invention provides a molecular affinity clamp. The architecture of the affinity clamp is modular with two biorecognition modules, each capable of binding a target motif. The first biorecognition module has a recognition domain that possesses inherent or natural specificity for the target motif. The second biorecognition module also has a recognition domain that binds the motif. The two biorecognition modules are tethered together either directly, e.g., via a peptide bond between the two modules, or indirectly, e.g., via a linker moiety or linker. The invention further provides a novel affinity ligand which is specifically bound by the molecular affinity clamps of the invention. | 02-24-2011 |
| 20110045605 | Characterization of Granulocytic Ehrlichia and Methods of Use - The present invention relates, in general, to granulocytic ehrlichia (GE) proteins. In particular, the present invention relates to nucleic acid molecules coding for GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; purified GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins; a method of detecting nucleic acids encoding GE S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with ehrlichiosis; therapeutic uses, specifically vaccines comprising S2, S7, S22, S23, C6.1, C6.2, S11, E8, E46#1, and E46#2 proteins or polypeptides or nucleic acids; and methods of preventing or inhibiting ehrlichiosis in an animal. | 02-24-2011 |
| 20110045606 | METHOD FOR DETECTING A TARGET MOLECULE IN A BIOLOGICAL SAMPLE - A method is provided for detecting a target molecule in a biological sample. One step of the method includes immobilizing the biological sample on a membrane. Next, the membrane-bound biological sample is contacted with at least one detection moiety. The membrane-bound biological sample is then separately mated with a substrate and the target molecule detected. At least one step of the method is performed under positive pressure or a vacuum. | 02-24-2011 |
| 20110053289 | Assay Device and Method - An assay method and device can perform at least one (e.g., at least two) assays on a single aliquot of a sample liquid. The device can mix a sample liquid with assay reagents including magnetically susceptible particles. The device is configured to create a sample liquid-air interface with the sample liquid. The magnetically susceptible particles can be located (via an applied magnetic field) at the liquid-air interface when a second liquid contacts the interface to form a liquid-liquid interface. The magnetic particles travel across the liquid-liquid interface to the second liquid. The magnetically susceptible particles are configured to trans-port an analyte across the interface into the second liquid. An assay for the analyte is performed in the second liquid. An assay for another analyte can also be performed in the sample liquid. | 03-03-2011 |
| 20110053290 | LIGHT ADDRESSING BIOSENSOR CHIP AND METHOD OF DRIVING THE SAME - Provided is a biosensor chip. The biosensor chip includes a plurality of biosensor cells that are arranged in a matrix and selectively generate and output a sensed signal by addressing of external light, at least one sensing line that is simultaneously connected with the plurality of biosensor cells and transmits the sensed signal from one selected from the biosensor cells, and an output terminal that receives the sensed signal from the sensing line and outputs the sensed signal to an external reader. Thus, the biosensor cells are set in array in the biosensor chip without a separate driving unit, so that a process of manufacturing the biosensor chip is simplified. The biosensor cell to be sensed is selectively addressed through the external light, so that it is possible to reduce a price of the biosensor chip used as a disposable chip. | 03-03-2011 |
| 20110059549 | METHODS AND SYSTEMS FOR PRODUCING NANOLIPOPROTEIN PARTICLES - Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein. | 03-10-2011 |
| 20110059550 | MINIMALLY INVASIVE ASSESSMENT OF IgE MEDIATED ALLERGY - A system and method for determining the presence and level of allergy indicators in a human fluid sample such as, but not limited to, blood serum and saliva, is disclosed. In another embodiment, the method may assess a level of allergens in a consumable product. The system and method may make use of functionalized magnetic nanoparticles that have modified surfaces suitable for attracting allergy indicators from human fluid sample and allergens from consumable products. The system and method may provide a minimally invasive assessment of allergy indicators to determine whether one is allergic to a substance. | 03-10-2011 |
| 20110059551 | Assay Device - Disclosed is an assay device to determine the presence of at least one analyte of interest in a liquid sample, the device comprising means for generating a first signal (the ‘test’ signal) which indicates the presence and/or amount of analyte of interest in the sample; and means for generating a second signal, the generation of which second signal indicates both (a) the test has been successfully conducted, and that (b) sufficient time has elapsed following contact of the assay device with the liquid sample for the test to be read and the first signal to have been properly generated. | 03-10-2011 |
| 20110059552 | RUBELLA E1 ENVELOPE PROTEIN VARIANTS AND THEIR USE IN DETECTION OF ANTI-RUBELLA ANTIBODIES - The invention relates to soluble rubella E1 antigens and variants of these antigens. The antigens contain amino acids 201 to 432 or 169 to 432 and are lacking amino acids 453 to 481 as well as at least the amino acids 143 to 164. They further contain a region spanning two disulfide-bridges. The invention also relates to a recombinant DNA molecule encoding the rubella E1 antigens, the expression of rubella E1 antigens as chaperone fusion proteins and their use in a method of detecting antibodies against rubella in a sample. | 03-10-2011 |
| 20110059553 | METHODS AND COMPOSITIONS FOR DETECTING HERPES SIMPLEX VIRUS TYPE 2 - The invention provides methods for sensitive and specific detection of anti-HSV-2 antibodies by depletion of cross-reactive (non-specific) antibodies in a biological sample that can lead to a false positive result. The invention also features compositions, including nucleic acids, polypeptides, and kits, for use in the methods of the invention. | 03-10-2011 |
| 20110059554 | DETERMINING AN EXPRESSION STATUS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN A BIOLOGICAL SAMPLE - A method for determining an expression of human epidermal growth factor receptor 2 (HER2) of a subject. The method includes providing a sample from the subject; measuring one of (i) amounts of two or more proteins in the sample, each protein having a molecular weight substantially equal to 4740, 8404, 8419, 8435, 8450, 8455, 8465, 8570, 8607 or 8626 atomic mass units, and (ii) amounts of at least one of human cystein-rich intestinal protein 1 (CRIP1), one or more variants of the human cystein-rich intestinal protein 1 (CRIP1 variants), and proteolytic digestion products thereof in the sample; and comparing the amounts of the proteins to control amounts, which control amounts are determinative of the expression of the human epidermal growth factor receptor 2. | 03-10-2011 |
| 20110059555 | BRANCHED AND MULTI-CHAIN NUCLEIC ACID SWITCHES FOR SENSING AND SCREENING - Embodiments of the invention relate to a branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding. The switch includes a probe strand, P, which includes the ligand binding domain; a switching framework which includes a cover strand (C), and a tether that holds P and C together and a signaling apparatus. Some embodiments include a toggle strand (T) where now the tether holds P, C, T, and the signaling apparatus together. As the switch changes between the first and second conformations; the signaling apparatus reports the state of the switch. The signaling entity is typically a lumiphore and a quencher located along the switching framework. Nucleic acid switches have applications in real time assays for diverse agents including infectious agents, environmental toxins, and terrorist agents, as well as screening methods for such agents. Further applications are found for nanoelectronics, nanofabrication and nanomachines. | 03-10-2011 |
| 20110065204 | ASSESSING RISK OF CARDIAC INTERVENTION BASED ON GDF-15 - The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and/or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods. | 03-17-2011 |
| 20110065205 | METHOD FOR DETERMINING PROGNOSIS OF ACUTE CENTRAL NERVOUS SYSTEM DISORDER - The present invention has its main object of providing a method for determining prognosis scientifically by searching an early marker for predicting neurological prognosis in order to grasp the disease state of a patient with an acute central nervous system disorder in the early stage and enabling an appropriate treatment to be performed. The method for determining the prognosis is provided in which the expression level of SH3BGRL3 in the biological fluid of the patient within 48 hours after resuscitation from cardiopulmonary arrest is measured, and the prognosis of the disorder classified into a good prognosis group and a poor prognosis group depending on the expression level or the presence or absence of the expression based on the Glasgow Outcome Scale (GOS) is predicted. | 03-17-2011 |
| 20110065206 | Thrombospondin Fragments and Uses Thereof in Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents - The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer. | 03-17-2011 |
| 20110065207 | COMBINATORIAL MULTIDOMAIN MESOPOROUS CHIPS AND A METHOD FOR FRACTIONATION, STABILIZATION, AND STORAGE OF BIOMOLECULES - A new fractionation device shows desirable features for exploratory screening and biomarker discovery. The constituent MSCs may be tailored for desired pore sizes and surface properties and for the sequestration and enrichment of extremely low abundant protein and peptides in desired ranges of the mass/charge spectrum. The MSCs are effective in yielding reproducible extracts from complex biological samples as small as 10 μl in a time as short as 30 minutes. They are inexpensive to manufacture, and allow for scaled up production to attain the simultaneous processing of a large number of samples. The MSCs are multiplexed, label-free diagnostic tools with the potential of biological recognition moiety modification for enhanced specificity. The MSCs may store, protect and stabilize biological fluids, enabling the simplified and cost-effective collection and transportation of clinical samples. The MSC-based device may serve as a diagnostic tool to complement histopathology, imaging, and other conventional clinical techniques. The MSCs mediated identification of disease-specific protein signatures may help in the selection of personalized therapeutic combinations, in the real-time assessment of therapeutic efficacy and toxicity, and in the rational modulation of therapy based on the changes in the protein networks associated with the prognosis and the drug resistance of the disease. | 03-17-2011 |
| 20110065208 | DETERMINATION AND ESTIMATION OF ABSORPTION AND DISTRIBUTION OF SUBSTANCES IN BRAIN TISSUE - A method determines or estimates the absorption and partition of substances into brain tissue and parameters derivable therefrom, such as the permeability of substances through the blood-brain barrier and also, more particularly, the proportion of substances freely available in the brain. The partition coefficient of the corresponding substance between an aqueous phase and the lipid phase is determined with the help of lipid membranes which are preferably contained in a test kit and immobilized on a solid body as a carrier material. The partition coefficient can be subsequently used as a parameter in a QSAR model to determine the blood-brain partition coefficient. | 03-17-2011 |
| 20110065209 | Integrated Sample Preparation and Analyte Detection - A system for sample preparation and analyte detection includes a cartridge, with a fluidic channel, a waveguide, and a capture spot. The system further includes a force field generator, an imaging system, and a fluid, which includes a sample potentially containing a target analyte, first type particles, which include binding moieties specific for the target analyte and are responsive to a force field, and second type particles, which include binding moieties specific for the target analyte and are capable of generating a signal. When the sample contains the target analyte, specific binding interactions between the target analyte and binding moieties link first and second type particles via the target analyte to form multiple-particle complex capturable at a capture spot. The force field allows manipulation of the particles and multiple-particle complex such that the detected signal from the second type particles is indicative of the target analyte within the sample. | 03-17-2011 |
| 20110065210 | Use of B-Type Natriuretic Peptide as a Prognostic Indicator in Acute Coronary Syndromes - The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI. | 03-17-2011 |
| 20110065211 | DEVICE AND METHODS FOR DETECTING ANALYTES IN SALIVA - The invention provides a device for detecting drugs of abuse or other compounds in saliva. The invention thus provides a device for detecting the presence of one or more analytes in a saliva sample, comprising: (a) One or more pre-treatment regions for specifically or non-specifically removing at least a part of the fraction of the saliva sample interfering with detection of the one or more analytes; and (b) A detection region comprising a biosensor surface, the surface comprising: molecules capable of specifically binding the one or more analytes; or the one or more analytes and/or analyte analogues. | 03-17-2011 |
| 20110065212 | GRAFT POLYMER-CONTAINING SUBSTRATE, METHOD FOR PRODUCING THE SAME, TARGET SUBSTANCE-DETECTING ELEMENT, AND TARGET SUBSTANCE DETECTION KIT - There is provided a graft polymer-containing substrate that reduces nonspecific adsorption of impurities onto a substrate surface and specifically captures a target substance. There is provided a graft polymer-containing substrate with a graft polymer formed on the surface thereof, characterized in that the graft polymer includes monomer units represented by the following general formulas (1) and (2): | 03-17-2011 |
| 20110070656 | Fluorescent Proteins - A fluorescent protein (bFP) having chemiluminescence activity is a complex composed of the apoprotein of a calcium-binding photoprotein, coelenteramid or an analog thereof, and calcium ions or divalent or trivalent ions that can be substituted for the calcium ions. In the complex, the ratio of the number of molecules of the apoprotein to that of the coelenteramid is 1:1 and the ratio of the number of molecules of the apoprotein to that of the divalent or trivalent ions is 1:1 to 1:4. The fluorescent protein is used as a marker because it catalyzes luminescence of coelenterazine and has fluorescence capability. Removal of calcium ions etc. from this fluorescent protein (bFP) having luminescence activity provides a novel fluorescent protein (gFP). Mixing this gFP with the coelenterazine provides a calcium-binding photoprotein, which emit light instantaneously, enabling use as a marker. | 03-24-2011 |
| 20110070657 | DETECTING IONS AND MEASURING ION CONCENTRATIONS - The present inventions include methods and compositions for detecting the presence of ions and measuring the level or concentration of ions in a sample by nuclear magnetic resonance (NMR) using magnetic particles. In particular, the inventions include the preparation and use of magnetic particles having synthetic ion chelators covalently bound to their surfaces. In the presence of target ions, the surface-modified magnetic particles form clusters, which can be monitored by NMR relaxation measurements. The relaxation times can then be used to detect specific ions and determine their concentration. The described methods, compositions, and devices are useful for a variety of applications including biomedical applications in diagnostics and imaging. | 03-24-2011 |
| 20110070658 | SYSTEMS AND METHODS FOR DETERMINING THE PERCENTAGE OF GLYCATED HEMOGLOBIN - Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample. | 03-24-2011 |
| 20110070659 | SAMPLE PRESENTATION DEVICE - The present invention relates to sample presentation devices useful in performing analytical measurements. These devices have been configured to enable various aspects of liquid handling such as: retention, storage, transport, concentration, positioning, and transfer. Additionally, these devices can enhance the detection and characterization of analytes. The sample presentation devices of the present invention are comprised of one or more substrates having a plurality of zones of differing wettability. Methods of analyzing samples using the sample presentation device of the invention, as well as methods of making the sample presentation devices are disclosed. | 03-24-2011 |
| 20110070660 | DETECTION OF POLYMERIC ANALYTES - The present invention relates to methods for detecting polymeric analytes, especially biopolymers, and sensors for detecting the polymeric analytes. The present invention uses magnetic beads in a rotating magnetic field to provide a visual detection of the presence of a polymeric analyte, such as nucleic acids, lipids, polysaccharides, proteins, etc. When a polymeric analyte binds to the magnetic beads, application of a rotating magnetic field to the beads results in unique pinwheel formations. Without the presence of the polymeric analyte, the movement of the magnetic beads induced by the rotating magnetic field differs significantly from the pinwheel formations. The pinwheel, therefore, is used to detect the presence of polymeric analytes. | 03-24-2011 |
| 20110070661 | RAMAN-ACTIVE REAGENTS AND THE USE THEREOF - The present invention provides a new class of Raman-active reagents for use in biological and other applications, as well as methods and kits for their use and manufacture. Each reagent includes a Raman-active reporter molecule, a binding molecule, and a surface enhancing particle capable of causing surface enhanced Raman scattering (SERS). The Raman-active reporter molecule and the binding molecule are affixed to the particle to give both a strong SERS signal and to provide biological functionality, i.e. antigen or drug recognition. The Raman-active reagents can function as an alternative to fluorescence-labeled reagents, with advantages in detection including signal stability, sensitivity, and the ability to simultaneously detect several biological materials. The Raman-active reagents also have a wide range of applications, especially in clinical fields (e.g., immunoassays, imaging, and drug screening). | 03-24-2011 |
| 20110070662 | RAMAN-ACTIVE REAGENTS AND THE USE THEREOF - The present invention provides a new class of Raman-active reagents for use in biological and other applications, as well as methods and kits for their use and manufacture. Each reagent includes a Raman-active reporter molecule, a binding molecule, and a surface enhancing particle capable of causing surface enhanced Raman scattering (SERS). The Raman-active reporter molecule and the binding molecule are affixed to the particle to give both a strong SERS signal and to provide biological functionality, i.e. antigen or drug recognition. The Raman-active reagents can function as an alternative to fluorescence-labeled reagents, with advantages in detection including signal stability, sensitivity, and the ability to simultaneously detect several biological materials. The Raman-active reagents also have a wide range of applications, especially in clinical fields (e.g., immunoassays, imaging, and drug screening). | 03-24-2011 |
| 20110070663 | Method for the enrichment of phosphorylated and/or glycosylated analytes - The present invention relates to a method for the purification and isolation of phosphorylated and glycosylated analytes using titanium dioxide particles. | 03-24-2011 |
| 20110076781 | EXPANDING THE DYNAMIC RANGE OF A TEST STRIP - The present invention provides a test strip with an expanded dynamic range for performing an assay to determine the presence of, or measure the quantity of, an analyte in a sample. It also provides methods for determining the presence of, or measuring the quantity of, an analyte in a sample, and for detecting a prozone sample. | 03-31-2011 |
| 20110076782 | READ-AFTER-WRITE DETECTION OF ANALYTES VIA NANOPARTICLE-LABELED SUBSTANCES - Embodiments of the invention relate to magnetizing and detecting nanoparticle-labeled antigens on biosample tracks deposited on a tape media. An aspect of the invention comprises apparatus and methods for labeling antigens with demagnetized nanoparticles, magnetizing the nanoparticles with an electromagnetic write head, and detecting the antigens via the magnetized nanoparticles by reading the tape media with a read sensor in a read-after-write operation. The write head and read sensor are part of a head-module of magnetic tape drive. Target antigens are attached to the biosample tracks by antibodies. Nanoparticles of differing magnetic properties may be selectively paired with antibodies associated with different antigens to allow multiple antigens to be detected upon a single scan by the read sensor. | 03-31-2011 |
| 20110076783 | MULTI-DIMENSIONAL FLUID SENSORS AND RELATED DETECTORS AND METHODS - The present invention provides multi-dimensional sensors with fluidic flow channels for processing fluid samples. | 03-31-2011 |
| 20110081730 | ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGET - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 04-07-2011 |
| 20110081731 | Method of Assaying Antigen and Reagent Therefor - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured. | 04-07-2011 |
| 20110086434 | MICROFLUIDIC DEVICE AND METHOD FOR CONTROLLING FLUID FLOW USING THE SAME - A microfluidic device includes: a lower plate having a first channel; a first upper plate fixedly stacked on the lower plate and having grooves on an upper portion thereof, a fluid inlet and a fluid outlet formed at positions corresponding to both ends of the first channel; and a second upper plate movably inserted into the grooves of the first upper plate and including a second channel, a hole connected to a right end of the second channel, and a third channel connected to the right side of the hole. | 04-14-2011 |
| 20110086435 | DETERMINATION OF DISSOCIATION CONSTANTS USING PIEZOELECTRIC MICROCANTILEVERS - A method for determining the dissociation constant (K | 04-14-2011 |
| 20110086436 | METHOD FOR DETECTING ANTIGEN, AND APPARATUS FOR DETECTING ANTIGEN USING THE SAME, AND MICROFLUIDIC CHIP USING THE SAME - A method for detecting an antigen, an apparatus for detecting an antigen using the same, and a microfluidic chip using the same are disclosed. The method for detecting an antigen, includes: binding a first antibody and nano-beads to generate antibody nano-beads; binding the generated antibody nano-beads and an antigen to generate antigen-antibody nano-beads; forming at least one of an electric field and a magnetic field on the generated antigen-antibody nano-beads to bind the generated antigen-antibody nano-beads and a second antibody; and detecting the antigen-antibody nano-beads bound to the second antibody. Thus, when nano-beads affected by an electromagnetic field exist within the electromagnetic field that temporally and spatially changes, the nano-beads move according to non-uniformity of the electromagnetic field. In particular, an active mixing can be performed by using the electromagnetic field which is spatially non-uniform and changes temporally, a reaction time can be reduced. In addition, a flow can be controlled to make nano-beads move to a capture antibody, thus detecting an antigen with a small amount of a test sample within a short time. | 04-14-2011 |
| 20110086437 | METHODS TO INHIBIT CELL GROWTH - A novel gene 109P1D4 and its encoded protein, and variants thereof, are described wherein 109P1D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 109P1D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 109P1D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 109P1D4 can be used in active or passive immunization. | 04-14-2011 |
| 20110091991 | Protein Biomarkers for Alzheimer's Disease Detection - Protein biomarkers are selected for diagnosing Alzheimer's disease. Samples of Alzheimer's disease are used to find the biomarkers. It is done through methods including 2-dimentional differential in-gel electrophoresis (2D-DIGE), isotope-coded protein labeling (ICPL) and western blotting. Through examining density differences of the selected biomarkers, Alzheimer's disease can be early diagnosed or prevented. | 04-21-2011 |
| 20110091992 | CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT - The present invention provides crystalline forms of a human IgG Fc variant comprising one or more amino acid residues that provides for enhanced effector function, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them. The present invention also provides human IgG Gc variants with reduced binding to at least one FcγR. | 04-21-2011 |
| 20110091993 | METHOD FOR QUANTIFICATION OF SOLUBLE LR11 - Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid. | 04-21-2011 |
| 20110091994 | Methods for Screening Compounds for Treating and/or Preventing an Hepatitis C Virus Infection - The present invention relates to methods for screening compounds for treating and/or preventing an Hepatitis C Virus (HCV) infection. | 04-21-2011 |
| 20110091995 | Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - antigens that can be used to differentiate | 04-21-2011 |
| 20110091996 | ORGANIC NON-SUGAR COMPOUNDS FOR PROTECTION OF BIOLOGICALLY ACTIVE MOLECULES AND CONJUGATE LABELS AND METHODS OF USE THEREOF - Provided are methods comprising the use of non-sugar organic compatible solutes for protection and preservation of the activity of biologically active molecules and conjugate labels. The methods are particularly adaptable for use in conjunction with immunoassays, such as for example, immunochromatographic test assays and may be incorporated into any test methodology wherein a dry test strip is used as a carrier for depositing, mobilizeable and/or immobilized biologically active molecules and/or conjugate labels. | 04-21-2011 |
| 20110091997 | IMMUNOSUPPRESSANT DRUG EXTRACTION REAGENT FOR IMMUNOASSAYS - An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays. | 04-21-2011 |
| 20110097817 | REACTION DEVICE FOR ANALYZING BIOLOGICAL SAMPLES AND RELATIVE METHOD - A reaction device and method provided with a reaction cell in which, in sequence, a plurality of biological samples, liquid, semi-liquid or mixed, of analogous or different type, are subjected to a reaction for a determinate analysis. The device comprises a first dispenser element which introduces a predetermined quantity of the biological sample inside the cell; a plurality of microvalve dispensers, each of which nebulizes a determinate microvolume of a desired reagent inside the cell, wherein the type of reagent and the amount of the microvolume of reagent are chosen as a function of the specific reaction to be carried out, selected from a group comprising reactions for analyses of a chemical-biological type, such as immunological or coagulative reactions, or of a chemical-physical type; a mixer element which mixes the biological sample with the selected reagent; a second dispenser element which sends to analytical measurement a determinate quantity of the biological sample after reaction with the selected reagent; washing members and discharge members, able respectively to wash the inside of the cell and to discharge the content of the cell, so as to prepare the cell for a subsequent reaction; an electronic processor which commands and controls, in the desired times and modes, the functioning of both the first dispenser element which dispenses the sample, of the microvalve dispensers which dispense the reagents, and of the mixer element, and also of the second dispenser element which sends the reacted sample for measurement, and of the washing members and discharge members, as a function of the type of reaction to be performed and the type of biological sample to be analyzed, so that their functioning is synchronized and automated according to pre-determined memorized reaction programs, selectable by an operator. | 04-28-2011 |
| 20110097818 | DEVELOPING SOLUTION FOR IMMUNOCHROMATOGRAPHY, AND MEASUREMENT METHOD USING SAME - Provided is a developing solution for immunochromatography that is precise and highly sensitive and is able to sufficiently detect even a low-concentration substance to be detected while controlling false positive reactions caused by non-specific adsorption of components other than the substance to be detected contained in a sample. The invention relates to a developing solution that contains a non-ionic surfactant and a vinyl-based water-soluble polymer having oxygen atom- and nitrogen atom-containing polar groups, for immunochromatography using a detection reagent labeled with an insoluble carrier. | 04-28-2011 |
| 20110104818 | CARBAMYLATED PROTEINS AND RISK OF CARDIOVASCULAR DISEASE - Methods for characterizing a test subject's, particularly a human test subject's, risk of having cardiovascular disease or developing cardiovascular disease are provided. Also provided are methods for characterizing a test subject's risk of experiencing a complication of cardiovascular disease near term. The methods comprise determining levels of one or more carbamylated biomarkers in a bodily fluid of the test subject and/or comparing these levels with a reference value. In certain embodiments, the carbamylated biomarkers are carbamylated albumin, carbamylated fibrinogen, carbamylated immunoglobulin and carbamylated apolipoprotein A. In other embodiments, particularly where the test subject does not have clinical evidence of renal disease, the carbamylated biomarker is free and/or total peptide-bound homocitrulline. | 05-05-2011 |
| 20110104819 | Modification of Bioassays for Detection of Antigens Characteristic of Bacteria that are Causative of Ear and Respiratory Infections to Eliminate False Positive Results Caused by Nasopharyngeal Colonization of Children - The present invention relates to modifying rapid immunochromatographic (“ICT”) tests for the detection of characteristic carbohydrate antigens of bacteria that are known to be causative of otitis media and respiratory diseases in children under the age of approximately 12 years. Children of this age group are also prone to nasopharyngeal colonization with the same bacteria, and urine samples taken from colonized, but otherwise healthy, children were shown to exhibit an unduly high incidence of test results that were false positive for the presence of disease. | 05-05-2011 |
| 20110104820 | Tyrosine, Serine, And Threonine Phosphorylation Sites - The invention discloses 94 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies that specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 05-05-2011 |
| 20110104821 | ABeta-OLIGOMER MEASUREMENT METHOD - Provided is a measurement method of an Aβ oligomer by the ELISA method, particularly, a method of selectively measuring an Aβ oligomer with a comparatively high molecular weight. | 05-05-2011 |
| 20110104822 | Determination of Distribution - A method for determining the occurrence of an analyte subpopulation of heteroforms of a substance (=S) in a liquid sample. The method comprises as its main characteristic features the step of: (i) providing a flow path which a) comprises an outlet part and an inlet part, b) comprises a capture zone (CZ) containing a solid phase exhibiting an immobilized analyte specific binder (B) [=affinity counterpart to the substance] which is capable of affinity binding to S with an affinity that differs for the various heteroforms of S, and c) permits capillary suction from the outlet part for driving a liquid flow through CZ, (ii) flowing said liquid sample containing S in the downstream direction through CZ while S is captured by said binder B in CZ, (iii) determining the distribution of S along the flow direction in CZ by measuring the relative amount of S in at least one subzonei of CZ, and (iv) determining the occurrence of the analyte subpopulation based on the distribution determined in step (iii). | 05-05-2011 |
| 20110104823 | MEASURING LIPOPROTEIN CONTAINING PARTICLES - This document provides methods and materials involved in assessing samples (e.g., serum samples) for lipoprotein containing particles. For example, methods and materials involved in using anti-apoprotein antibodies (e.g., fluorescently labeled anti-apoprotein antibodies) to label lipoprotein containing particles that can be detected or measured using flow cytometry are provided. | 05-05-2011 |
| 20110111522 | NON-VISIBLE DETECTABLE MARKING FOR MEDICAL DIAGNOSTICS - Sample media for the analysis of analytes in a fluid test sample includes a carrier, at least one test field on the surface of the carrier including at least one reagent reactive with the analytes and capable of providing a detectable response. A non-visible bar code formed by at least two distinct non-visible marker fields is located on the carrier. The marker fields are configured to reflect electro-magnetic (EM) radiation within one or more ranges of non-visible wavelengths to form a coded sequence of reflectances correlated to identification of the sample media. | 05-12-2011 |
| 20110111523 | METHOD FOR ASSESSING OOCYTE MATURATION - The present invention provides methods and kits for assessing the state of oocyte maturation in a female mammal based on the level of PAPP-A found in the female's bodily fluid sample. | 05-12-2011 |
| 20110111524 | Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 05-12-2011 |
| 20110111525 | PRO-ENDOTHELIN-1 LEVELS FOR THE PREDICTION OF RISK OF TACHYARRHYTMIC EVENTS - The invention relates to in vitro methods for prognosis and risk-stratification for a patient having a cardiac disease as heart failure. The invention further relates to the use of such a method. | 05-12-2011 |
| 20110111526 | PRO-ENDOTHELIN-1 FOR THE PREDICTION OF IMPAIRED PEAK OXYGEN CONSUMPTION - Subject of the present invention is an in vitro method for the alternative assessment of peak oxygen consumption (VO | 05-12-2011 |
| 20110111527 | MULTIMARKER PANEL FOR DIFFERENTIATION OF DILATED CARDIOMYOPATHY AND AS A BASIS FOR DIFFERENTIAL THERAPY - The present invention relates to a method for diagnosing if a subject suffering from dilated cardiomyopathy is suffering from ischemic or non-ischemic dilated cardiomyopathy. Further, it relates to a method of determining which medication is to be applied in a subject suffering form after dilated cardiomyopathy. The method includes the steps of determining amounts of troponin, GDF-15, and an angiogenic markers selected from the group of PlGF, endoglin, and sFlt-1 in a sample from the subject and comparing the amounts determined With reference amounts. In one embodiment, the method of the invention further comprises also measuring an amount of a natriuretic peptide. | 05-12-2011 |
| 20110111528 | MODIFIED POLYPEPTIDES STABILIZED IN A DESIRED CONFORMATION AND METHODS FOR PRODUCING SAME - The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. | 05-12-2011 |
| 20110111529 | METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE - Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE. Specifically disclosed is a method for quantifying an antigen-specific canine IgE, which comprises the following steps (A) to (D): (A) contacting a biological sample collected from a subject with an antigen to conjugate IgE contained in the sample with the antigen; (B) measuring the quantity of IgE in a standard sample collected from an experimental animal which is different from the subject and has been sensitized with the same antigen as that used in step (A) by using a substance capable of recognizing both IgE from the subject and IgE from the experimental animal, thereby producing a standard curve; (C) detecting a conjugate formed in step (A) by using the same substance capable of recognizing both IgE from the subject and IgE from the experimental animal as that used in step (B); and (D) determining the quantity of IgE in the biological sample collected from the subject by utilizing the quantity of the conjugate detected in step (C) and the standard curve produced in step (B). Also specifically disclosed is a method for quantifying an antigen-specific human IgE. | 05-12-2011 |
| 20110111530 | HOMOGENEOUS IMMUNOASSAYS FOR MULTIPLE ALLERGENS - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels. | 05-12-2011 |
| 20110117669 | MATERIALS AND METHODS FOR DETECTING TOXINS, PATHOGENS AND OTHER BIOLOGICAL MATERIALS - Embodiments of the present invention provide binding molecule-functionalized high electron mobility transistors (HEMTs) that can be used to detect toxins, pathogens and other biological materials. In a specific embodiment, an antibody-functionalized HEMT can be used to detect botulinum toxin. The antibody can be anchored to a gold-layered gate area of the HEMT through immobilized thioglycolic acid. Embodiments of the subject detectors can be used in field-deployable electronic biological applications based on AlGaN/GaN HEMTs. | 05-19-2011 |
| 20110117670 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 05-19-2011 |
| 20110117671 | Method for Stabilizing Microparticles Having Reactive Substance Bound Thereto, and Reagent Containing the Microparticles - Provided is a method for maintaining the reactivity of microparticles having a reactive substance bound thereto in a dispersion liquid of the microparticles over a long period of time by stabilizing the microparticles in the dispersion liquid. The method for stabilizing microparticles having a reactive substance bound thereto includes the step of allowing a sulfur-containing amino acid or a derivative thereof to coexist in a dispersion liquid of the microparticles. The sulfur-containing amino acid includes one or more of cysteine, cystine, and methionine. The method is particularly useful when a precipitation preventing substance, such as a polyanion, dextran, or the like, is allowed to coexist in the dispersion liquid. | 05-19-2011 |
| 20110124117 | SERS NANOTAG ASSAYS WITH ENHANCED ASSAY KINETICS - Methods and systems for the use of surface-enhanced Raman scattering nanotags (SERS nanotags) in various assay platforms which feature accelerated reaction kinetics. One embodiment includes a method detecting a substance of interest by associating a SERS nanotag with the substance of interest while accelerating the reaction kinetics of the association steps. This method also includes detecting a Raman spectrum of a reporter molecule associated with the SERS nanotag. The reaction kinetics of the assay may be accelerated by applying microwave radiation to the sample, heating the sample, agitating the sample, mixing the sample, vibrating the sample or other methods. | 05-26-2011 |
| 20110124118 | MICROFLUIDIC STRUCTURE FOR DETECTING BIOMOLECULE AND MICROFLUIDIC DEVICE COMPRISING THE SAME - Disclosed are a micro-fluidic structure for detecting biomolecules and a micro-fluidic device having the same. More particularly, a target material including at least two cis-diols is detected by a first material containing a boronate moiety and a second material containing another boronate moiety while generating electrical signals. | 05-26-2011 |
| 20110124119 | Methods For Assessing Modified LDL Immune Complexes in Subjects Having or at Risk of Coronary Artery Disease - The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes. | 05-26-2011 |
| 20110124120 | ASSAY FOR EVALUATING AFFINITY AND SPECIFICITY OF LIGAND-ALBUMIN BINDING - A method for identifying a ligand or compound which binds to albumin comprises the steps of contacting a reaction mixture comprising a site-specific probe and albumin in the presence and the absence of the ligand or compound and measuring either dissociation constant K | 05-26-2011 |
| 20110124121 | METHODS FOR PREDICTING WEIGHT LOSS SUCCESS - Methods and kits for predicting weight loss success are provided. The methods generally include the steps of selecting a patient or other person undergoing or considering undergoing a weight loss therapy, obtaining a measurement of one or more hormone responses of the person to caloric intake, and subsequently predicting success of a weight loss therapy based on the hormone response. | 05-26-2011 |
| 20110124122 | BIOMARKERS AND ASSAYS FOR MYOCARDIAL INFARCTION - Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included. | 05-26-2011 |
| 20110124123 | METHOD FOR EXAMINING WT1-RELATED DISEASE - The invention provides a method for testing a WT1-related disease, such as leukemia, a solid cancer, or an atypia, for diagnosing the disease, evaluating the course of cure and the prognosis of the disease more simply with high reliability, the method comprises measuring the amount of antibody against WT1 in a sample and using the measurement value and the time course of the value as a clinical marker for the testing. | 05-26-2011 |
| 20110124124 | ENHANCED DETECTION SENSITIVITY WITH PIEZOELECTRIC MICROCANTILEVER SENSORS - A method for enhancing the detection sensitivity of a piezoelectric microcantilever sensor. The method may involve providing a piezoelectric microcantilever and inducing a change in the Young's modulus during detection of a species of interest. The change in the Young's modulus may be induced or enhanced by the application of a DC bias electric field to the piezoelectric layer that enhances non-180° polarization domain switching of the piezoelectric layer. The change in the Young's modulus may also result from binding of the species of interest to the piezoelectric microcantilever sensor or a combination of binding and application of a DC bias electric field Significantly enhanced detection sensitivity results from the changed Young's modulus of the piezoelectric layer. | 05-26-2011 |
| 20110124125 | PEPTIDES, DEVICES, AND METHODS FOR THE DETECTION OF EHRLICHIA ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to | 05-26-2011 |
| 20110124126 | DETECTION OF AN ANALYTE IN AQUEOUS MEDIA - Test kit for the detection of an analyte in an aqueous solution, including chromatographic test strips for a hapten-antihapten complex and first and second standardized vessels for receiving and positioning test strips, which include first and second hapten-coupled receptors against the analyte dried onto the interior wall for the formation of the hapten-antihapten complex, where a portion of the standardized vessels further include a known amount of analyte embedded in a glass-like layer of trehalose, which are dried onto the interior wall of the control vessel so that they dissolve during reaction of the sample with the hapten-coupled receptors. Through this standardization, analytes in unknown samples may be safely detected by immunochromatography within minutes through a hapten-antihapten complex. | 05-26-2011 |
| 20110129942 | FLUORESCENCE DETECTING METHOD - An amount of fluorescent labels corresponding to an amount of a detection target substance are caused to bind on a detecting portion. The fluorescent labels are excited, and the amount of the detection target substance is detected based on the intensity of fluorescence emitted due to the excitation. Fine inorganic fluorescent particles which do not become discolored are employed as the fluorescent labels. | 06-02-2011 |
| 20110129943 | Method for Analyzing Proteins - A method for analyzing proteins makes use of an array of first capture molecules which are specific for peptide epitopes. The proteins to be analyzed or a protein mixture containing the proteins to be analyzed is degraded to peptide fragments corresponding to the peptide epitopes, after which the array of capture molecules is incubated with the peptide fragments. The peptide fragments bound to the capture molecules are then detected. | 06-02-2011 |
| 20110136253 | Irinotecan Immunoassay - Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids. | 06-09-2011 |
| 20110136254 | ALZHEIMER'S DIAGNOSIS - Evaluation of VLP-I levels in combination with at least one of amyloid-β peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease. | 06-09-2011 |
| 20110136255 | COMPOSITION AND METHOD FOR PREDICTION OF COMPLICATED DISEASE COURSE IN CROHN'S DISEASE - Methods of identifying Crohn's disease patients who may require early surgery and/or who are susceptible to developing complications during the course of disease. Anti-laminarin (anti-L) and anti-chitin (anti-C) antibodies, both independently and combined, can serve as diagnostic and prognostic indices for Crohn's disease. | 06-09-2011 |
| 20110136256 | METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay. | 06-09-2011 |
| 20110136257 | Agglutination Based Sample Testing Device - A sample testing device for testing for the presence of a component of interest in a liquid sample comprises: (a) at least one capillary pathway which has an upstream end and a downstream end and which incorporates a reagent system capable of causing agglutination with said component to be detected (the test capillary); (b) preferably, but optionally, at least one capillary pathway having an upstream end and a downstream end (the control capillary); (c) a sampling region to which the liquid sample is applied and from which the sample is able to enter the upstream ends of the test capillary(s) and if present the control capillary(s); (d) a power source; (c) detection arrangements electrically associated with said power source for detecting the presence of liquid at a downstream region of said testing capillary(s) and if present the control capillary(s); (f) display means operated by said power source for indicating the result of the test; and (g) signal processing means associated with the power source, detection arrangement and display means for evaluating the result of the test and providing said result on the display means. The device may be used for a pregnancy test, more particularly for determining the presence of hCG in urine. | 06-09-2011 |
| 20110136258 | Multiplanar Lateral Flow Assay with Sample Compressor - A sample compressor applies pressure to a sample collector and a sample application zone of a test strip to transfer a sample from the sample collector and a binding partner of an analyte to the sample application zone in a lateral flow device. At least one of the binding partners of the analyte is not located on the test strip prior to use of the lateral flow device. The test strip may be a universal test strip with no molecule that specifically binds the analyte is located on the test strip. The sample compressor may be a universal sample compressor also with no molecule that specifically binds the analyte on the sample compressor. The lateral flow device may also include one or more enhancement elements, where the enhancement elements bind to the analyte sandwich to increase a detection signal in the test zone. | 06-09-2011 |
| 20110136259 | IMMUNOASSAY FOR CROSS-REACTING SUBSTANCES - The present disclosure provides an immunoassay involving a multiplex of antibodies that recognize the same analyte but that have a different cross-reactivity to structurally similar compounds. Data obtained from the immunoassay involving observed analyte concentrations is input into an algorithm to determine the true concentration of the analyte in a sample. | 06-09-2011 |
| 20110136260 | SNAPIN AND METHODS FOR REGULATION OF MICROTUBULE ASSEMBLY AND DENDRITE GROWTH AND BRANCHING - Fragments of snapin important for interaction with cypin and thus regulating microtubule assembly are provided. Also provided are methods of use of said fragments and kits to facilitate said methods. | 06-09-2011 |
| 20110136261 | METHOD OF ASSAYING COMPLEX AND KIT TO BE USED THEREFOR - In the case of assaying the level of complex AB in a sample which likely contains the complex AB composed of substance A with another substance B, the complex is assayed by the competitive homogeneous assay method with the use of reagents including a reagent containing partner C specifically binding to substance A, a reagent containing partner D specifically binding to substance B, a reagent containing fine particles carrying substance A or an analogue thereof and substance B or an analogue thereof, and a reagent containing partner C specifically binding to substance A and partner D specifically binding to substance B. Thus, the complex in the sample can be easily assayed. The above method is applicable to general-purpose biochemical automatic analyzers. | 06-09-2011 |
| 20110143453 | ALBUMIN-BOUND PROTEIN/PEPTIDE COMPLEX AS A BIOMARKER FOR DISEASE - Methods and kits for diagnosis and prognosis using biomarkers comprising albumin-bound protein/peptide complex (ABPPC). | 06-16-2011 |
| 20110143454 | METHOD FOR DETECTION OF SPECIFIC IMMUNOGLOBULIN CLASS G ANTIBODIES - The invention relates to a method for determining an analyte in a sample by means of an assay that can be carried out in a one-step format without performing washing steps. The method includes a first analyte-specific receptor that contains at least one bonding point for the analyte, e.g., several antibodies on a particle, as well as a second analyte-specific receptor that can selectively bond to an arrangement comprising at least two analyte molecules which are bound to the first receptor. An antibody sandwich immune assay is described in which the detection is based on electrochemiluminescence. | 06-16-2011 |
| 20110143455 | NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. | 06-16-2011 |
| 20110143456 | METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 06-16-2011 |
| 20110143457 | CYSTATIN C ADSORPTION INHIBITOR - Disclosed is a method by which the adsorption of cystatin C to a container can be inhibited in a simple manner to improve the accuracy of the measurement of cystatin C. Provided are: a cystatin C adsorption inhibitor comprising a non-ionic surfactant; a cystatin C measurement reagent comprising the adsorption inhibitor; and a cystatin C measurement kit. Also provided is a method of inhibiting the adsorption of cystatin C, the method comprising bringing a cystatin C-containing sample into contact with a measurement instrument in the presence of a non-ionic surfactant. The aforementioned non-ionic surfactant is preferably a polyoxyethylene-type surfactant. Alternatively, the aforementioned non-ionic surfactant has preferably a phenoxy structure, more preferably a benzylphenoxy structure. | 06-16-2011 |
| 20110151579 | Secreted Epithelial Stromal-1 Molecules and Uses Thereof - The present invention provides novel Secreted Epithelial Colon Stromal-1 (Secs-1) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing Secs-1 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with Secs-1 polypeptides. | 06-23-2011 |
| 20110151580 | METHOD FOR THE DETECTION OF BREAST CANCER BY DETERMINING ALCAM AND/OR BCAM LEVELS IN A PATIENT - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting the presence and severity of breast cancer in a subject. The present application also provides methods for determining the prognosis of a subject with breast cancer as well as methods for monitoring the therapeutic response to a breast cancer treatment or therapy. | 06-23-2011 |
| 20110151581 | TRIGGER ASSAY FOR DIFFERENTIATING BETWEEN RHEUMATIC AND NON-RHEUMATIC DISORDERS - The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject including determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of the autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject—either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit. | 06-23-2011 |
| 20110151582 | METHOD FOR DETECTION OF ANTIGEN-SPECIFIC ANTIBODIES IN BIOLOGICAL SAMPLES - Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously. | 06-23-2011 |
| 20110151583 | METHOD FOR EVALUATING MYOCARDIAL ISCHEMIC STATE USING BLOOD SAMPLE - The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method. A method for determining myocardial ischemia comprising subjecting a blood sample which is derived from a test subject and which contains a BNP molecular group containing at least two selected from the group consisting of BNP 1-32 molecule, BNP 3-32 molecule, BNP 4-32 molecule, BNP 5-32 molecule, and a molecule having a mass number larger than that of BNP 5-32 molecule by 16 Da to a detection process capable of distinguishing and quantifying the individual BNP molecules different in mass number to detect the BNP molecular group, wherein myocardial ischemia in the test subject is determined using, as an index, a ratio between a detected intensity of at least one molecule selected from the BNP molecular group and a detected intensity of at least one other molecule selected from the BNP molecular group. | 06-23-2011 |
| 20110159607 | BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF - The invention relates to the identification of a biomarker whose abundance in biological samples is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. | 06-30-2011 |
| 20110159608 | GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION - The application relates to methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody. | 06-30-2011 |
| 20110165696 | Method to detect Beryllium by Flourescence - A method of determining beryllium or a beryllium compound thereof in a sample is disclosed by measuring fluorescence. This method discloses improved sample preparation methods, particularly for refractory beryllium materials. The method also discloses methods to improve the detection limit of beryllium including use of optical filters with specific characteristics for selecting the emission wavelengths of the fluorescence signal. | 07-07-2011 |
| 20110165697 | MONOCLONAL ANTIBODIES AGAINST OSTEOPONTIN - The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis. | 07-07-2011 |
| 20110165698 | COMPOSITIONS AND METHODS RELATING TO DETECTION OF SOLUBLE E-CADHERIN IN NEURODEGENERATIVE DISEASE - Disclosed herein are compositions and methods for diagnosing, detecting, or monitoring neural disease, conditions, or disorders involving detection of soluble E-cadherin. | 07-07-2011 |
| 20110165699 | IRINOTECAN IMMUNOASSAY - Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids. | 07-07-2011 |
| 20110165700 | CLASSES OF COMPOUNDS THAT INTERACT WITH INTEGRINS - A method of inhibiting or effecting the activity of an integrin receptor comprises contacting an integrin with a pyranose of formula I, or a pharmaceutically acceptable salt thereof. | 07-07-2011 |
| 20110165701 | MONOCLONAL ANTIBODY AND IMMUNOASSAY USING THE SAME - An objective of the present invention is to provide an anti-human IgM monoclonal antibody that is capable of reacting specifically with human IgM and inducing immunoagglutination based on an antigen-antibody reaction with human IgM in solution, and an immunoassay using the said monoclonal antibody. Another objective of the present invention is to provide an agent for suppressing non-specific reactions caused by human IgM that could not be prevented by conventional methods, and an immunoassay in which non-specific reactions caused by human IgM are suppressed. | 07-07-2011 |
| 20110171749 | NANOPARTICLE TRACER-BASED ELECTROCHEMICAL DNA SENSOR FOR DETECTION OF PATHOGENS-AMPLIFICATION BY A UNIVERSAL NANO-TRACER (AUNT) - The present invention relates to methods and compositions for identifying a pathogen. The inventions provide an antibody-based biosensor probe comprising (AUNT) in combination with a polymer-coated magnetic nanoparticle. In particular, a nanoparticle-based biosensor was developed for detection of | 07-14-2011 |
| 20110171750 | MARKER FOR GRAFT FAILURE AND MORTALITY - Subject of the present invention is a biomarker for graft failure and/or mortality after organ transplantation. Procalcitonin was found to be a useful marker for the prediction or risk stratification for graft failure and/or mortality of a subject who has received an organ transplant and monitoring and therapy guidance of such subject. | 07-14-2011 |
| 20110171751 | RECOMBINANT POLYPEPTIDES FOR DIAGNOSING INFECTION WITH TRYPANOSOMA CRUZI - Recombinant polypeptides are disclosed that are useful for diagnosing American trypanosomiasis, or Chagas disease, a disease caused by the infectious agent | 07-14-2011 |
| 20110171752 | Methods and Systems for Detecting MHC Class I binding peptides - The present invention is based on the discovery that MHC heavy chain monomers immobilized to a solid surface are still capable of forming detectable conformational epitopes and being detected by conformation-dependent antibodies. Methods for detecting peptide binding to HLA monomers, and methods for measuring the relative degree of binding between two MHC-binding peptides as well as a method of measurement for the rate of dissociation of peptides from MHC complexes are provided. The present invention also provides systems and kits useful for conducting the methods of the present invention. | 07-14-2011 |
| 20110171753 | MODIFIED ANTI-HEPARIN/PF4 COMPLEX ANTIBODY AND HIT ANTIBODY STANDARD - Provided is a modified antibody which enables the quantitative measurement of the amount of a heparin/PF4 complex, an onset factor of heparin-induced trombocytopenia (HIT), without the influence of the presence of PF4, and which can be used as an HIT antibody standard specific for the heparin/PF4 complex. The modified antibody is prepared by linking a human IgG, or an antibody fragment derived from a human IgG, to a monoclonal antibody obtained by immunizing an animal (excluding a human) with the heparin/PF4 complex. | 07-14-2011 |
| 20110177610 | NOVEL MARKER FOR ARTERIOSCLEROTIC DISEASE - Disclosed is a novel marker for an arteriosclerotic disease. Also disclosed is a method for evaluating the presence or level of an arteriosclerotic disease in a mammal, or a method for evaluating the prophylactic or therapeutic effect on an arteriosclerotic disease in a mammal, which is characterized by detecting a soluble LR11 in a sample collected from the mammal. | 07-21-2011 |
| 20110177611 | LIGAND BINDING DOMAINS OF NUCLEAR RECEPTORS IN CONTROLLABLE FORM AND METHODS INVOLVING THE SAME - The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system. | 07-21-2011 |
| 20110177612 | Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders - The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes. | 07-21-2011 |
| 20110177613 | Use of periostin as a novel biomarker - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 07-21-2011 |
| 20110177614 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The invention provides sialylated glycans and antibodies that specifically bind to them. The invention's compositions and methods for using them are useful for early detection and diagnosis of cancer. | 07-21-2011 |
| 20110177615 | PROTEIN EXPRESSION - The present invention is concerned with improved expression of recombinant proteins, in particular fusion proteins, and methods for their expression. The present invention is also concerned with proteins for use in detection assays, and especially for directed surface immobilisation. | 07-21-2011 |
| 20110177616 | Diagnostic Test Kits Employing an Internal Calibration System - A diagnostic test kit that employs a lateral flow assay device and a plurality of assay reagents for detecting a test analyte within a test sample is disclosed. The assay reagents include detection probes that are capable of producing a detection signal representing the presence or quantity of the test analyte in the test sample. To further enhance detection accuracy, calibration probes are also used that are capable of producing a calibration signal representing the presence or quantity of a calibration analyte. The calibration signal may be utilized to calibrate the detection signal. | 07-21-2011 |
| 20110177617 | CROSS-LINKING REAGENTS FOR MOLECULAR INTERACTIONS ANALYSIS - The invention describes the use of particular cross-linking reagents containing 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole groups as reactive groups for cross-linking reactions of supramolecular target-ligand-complexes. The resulting cross-linked products may be directly analyzed using mass spectrometry, gel or fluorescence based technologies, X-ray crystallography, NMR or other analytical technologies. The method using High-Mass MALDI mass spectrometry provides various biological applications such as characterization of antibodies, drug discovery, and protein complex analysis including automated or higher throughput applications. | 07-21-2011 |
| 20110183434 | DIAGNOSTIC METHODS AND KITS USING FIBROBLAST GROWTH FACTOR-23 - The present invention describes the ability to identify chronic kidney disease (CKD) mortality risk in asymptomatic patients. For example, a patient having a normal glomerular filtration rate would be considered likely to have an increased mortality risk for chronic kidney disease upon the detection of an FGF-23 amino acid sequence that is above a normal level, but below CKD Stage 1 levels. Consequently, therapeutic strategies may be implements to prevent morbidity and mortality following chronic kidney disease progression. Such therapeutic strategies can involve phosphate reduction strategies (i.e., for example, reduced dietary intake of phosphorus and/or administration of phosphate binding compound). Further, kits are described providing instruction to determine a specific mortality risk based upon measured FGF-23 levels and estimated glomerular filtration rates. | 07-28-2011 |
| 20110183435 | Biodegradable Photoluminescent Polymers - The present invention describes a novel elastomeric biodegradable photoluminescent polymer (BPLP). The BPLPs of the present invention possess great processability and tunable fluorescence emission characteristics and are cell-compatible and biodegradable. The BPLPs of the present invention can serve as both implant materials and bioimaging probes. | 07-28-2011 |
| 20110183436 | DIAGNOSTIC METHODS FOR CONGESTIVE HEART FAILURE - The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF). | 07-28-2011 |
| 20110183437 | METHODS OF IDENTIFYING COMBINATIONS OF ANTIBODIES WITH AN IMPROVED ANTI-TUMOR ACTIVITY AND COMPOSITIONS AND METHODS USING THE ANTIBODIES - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 07-28-2011 |
| 20110183438 | Method for Sensing a Substance to be Detected in a Sample - A single-electron transistor comprising at least a substrate, a source electrode and a drain electrode formed on top of the substrate opposing to each other, and a channel arranged between the source electrode is disclosed wherein the channel is composed of ultra fine fibers. By having such a constitution, a sensor can have excellent sensitivity. | 07-28-2011 |
| 20110189789 | NOVEL TARGET PROTEIN OF ANTICANCER AGENT AND NOVEL ANTICANCER AGENT (SPNAL) CORRESPONDING THERETO - The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound that specifically binds to KSRP or a functional fragment thereof, and a screening method for the compound. KSRP is a novel target protein for anticancer agents; a compound capable of regulating the expression and activity of such a protein and a pharmaceutical composition containing it are highly useful for proliferative diseases, particularly as anticancer agents. By providing the novel target protein, the mechanism behind the anticancer effect that has conventionally been unexplainable can be elucidated. | 08-04-2011 |
| 20110189790 | Methods of Predicting Antibody Solubility - The invention provides methods for testing and ranking therapeutic antibody candidates for biophysical properties related to solubility and the susceptibility of the antibody to aggregate in aqueous solutions. The methods are useful for selecting among antibody libraries or variants for candidates which can be formulated at high concentrations. | 08-04-2011 |
| 20110189791 | Diagnostic Devices - The present invention relates to analytical methods, platforms, and devices for the rapid and efficient immunochromatic determination of one or more components in fluid samples. | 08-04-2011 |
| 20110189792 | LIQUID-TRANSFER DEVICE PARTICULARLY USEFUL AS A CAPTURING DEVICE IN A BIOLOGICAL ASSAY PROCESS - A capturing device ( | 08-04-2011 |
| 20110189793 | METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention. | 08-04-2011 |
| 20110189794 | IMMUNOASSAY WITH EXTENDED DETECTION WINDOW - The immunoassay method and kit are provided for the detection and/or the determination of zolpidem. The disclosure provides novel antibodies, derived from a novel immunogen, that are highly sensitive and bind to zolpidem and its main urinary metabolite [3-(2-N,N-dimethylamino-2-oxoethyl)-6-methylimidazo[1,2-a]pyridin-2-yl]benzoic acid, enabling an extension of the detection window of zolpidem in individuals who have abused the drug, or have been victim of its side-effects or its criminal misuse. | 08-04-2011 |
| 20110189795 | USE OF PERFLUOROPOLYMER SUBMICROMETRIC LATEXES IN THE DETERMINATION OF MOLECULAR INTERACTIONS BY LASER LIGHT SCATTERING (LLS) - Use of a latex of perfluorinated polymers having particles with an average diameter between 5 and 200 nm for determining the binding constant of two interacting molecular species by Laser Light Scattering (LLS), said polymeric particles comprising on the surface an amphiphilic non ionic surfactant, the same or a different surfactant ended with a receptor and a ligand interacting with the receptor. | 08-04-2011 |
| 20110195520 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN - Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population. | 08-11-2011 |
| 20110195521 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN - Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In one embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing said measured drug level as a function of one or more parameters associated with the subject. The normalized drug level is compared to a reference value and associated confidence intervals or to a concentration range. The reference value and associated confidence intervals and/or the concentration range may be normalized based on one or more parameters associated with subjects in a reference population. | 08-11-2011 |
| 20110195522 | ASSAY FOR GENERATION OF A LIPID PROFILE USING FLUORESCENCE MEASUREMENT - The present invention relates to a method of generating a lipid profile for a sample solution. The method comprising: a first step of determining the concentration of total lipoprotein in a first aliquot of the sample using fluorescence analysis; a second step of determining the concentration of total cholesterol in a second aliquot of the sample using fluorescence analysis; and optionally a third step of determining the concentration of HDL in a third aliquot of the sample using fluorescence analysis. The concentrations of the total lipoprotein, and of total cholesterol may be used to calculate other lipid components and thereby generate a lipid profile. The invention also concerns apparatus that may be used to perform the method of the invention. | 08-11-2011 |
| 20110195523 | METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed. | 08-11-2011 |
| 20110195524 | SEMI-SEQUENTIAL ASSAY FOR DETECTION OF AN ANALYTE IN A SAMPLE - The invention is related to a method for detection of an analyte in a sample, wherein the method is a semi-sequential assay procedure. | 08-11-2011 |
| 20110201128 | BLOOD MARKERS OF TRANSPLANTED INTESTINE REJECTION - The present invention relates to a method for detecting bowel transplant rejection. | 08-18-2011 |
| 20110201129 | METHOD FOR THE DETECTION OF ENDOMETRIOSIS USING AN ME-2 ANTIGEN - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO: 6 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 6 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis. | 08-18-2011 |
| 20110201130 | HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure provides among other things assays, methods and kits for assessing the presence or amount of human B-type natriuretic peptide in a test sample wherein the assay exhibits reduced cross-reactivity with other forms of the peptide. | 08-18-2011 |
| 20110207233 | METHOD FOR MEASURING INHIBITORY ACTIVITY ON LIGAND-RECEPTOR BINDING - A method for measuring the presence or absence and/or strength of the inhibitory activity of a test substance on binding between a ligand and a receptor thereof, which comprises the following steps (1) to (3): | 08-25-2011 |
| 20110207234 | Synthesis and Use of Cross-Linked Hydrophilic Hollow Spheres for Encapsulating Hydrophilic Cargo - Cross-linked hydrophilic nanocapsules and various compositions and methods for their preparation and use are provided. | 08-25-2011 |
| 20110207235 | USE OF PERFLUOROPOLYMERS IN THE DETERMINATION OF THE RECEPTOR-LIGAND BINDING CONSTANT - A method for determining the binding constant of interacting molecular species comprises the use of flat surfaces comprising perfluorinated polymers and measurements of reflected light intensity. The surfaces comprise at least one molecule with the receptor function absorbed or immobilized on the surface and at least one ligand that interacts with the receptor. | 08-25-2011 |
| 20110207236 | SONICATION-ASSISTED METAL-ENHANCED FLUORESCENCE (SAMEF)-BASED BIOASSAYS - The present invention provides for sonication-assisted metal-enhanced fluorescence, luminescence, and/or chemiluminescence assay systems using low-intensity ultrasound waves to significantly reduce the assay time by increasing the kinetic movement of molecules within the system. | 08-25-2011 |
| 20110212540 | Probe and method for DNA detection - A hybridization probe containing two linear strands of DNA lights up upon hybridization to a target DNA using silver nanoclusters that have been templated onto one of the DNA strands. Hybridization induces proximity between the nanoclusters on one strand and an overhang on the other strand, which results in enhanced fluorescence emission from the nanoclusters. | 09-01-2011 |
| 20110212541 | COMPOSITIONS AND METHODS TO PROTECT CELLS BY BLOCKING ENTRY OF PATHOGEN PROTEINS - Pathogenic effector proteins include one or more virulence motifs of amino acid consensus sequence BXZ, where B=RK or H; X=any amino acid or is absent; Z=L, M, I, W, Y or F) which bind to target polar lipids on a host (plant or animal) cell as a prerequisite for translocation of the pathogenic effector proteins into the cell. Translocation is prevented by binding blocking compounds to one or more motifs of the effector protein or to the lipid ligands of the host cell. The blocking compounds include synthetic or naturally occurring polypeptides which bind the polar lipids or the motifs, various polar lipids, the hydrophilic head-groups of polar lipids, etc. Suitable blocking compounds can be identified by assays demonstrating binding to the motifs or to the target polar lipids. | 09-01-2011 |
| 20110212542 | LABELS FOR ELECTRONIC DETECTION OF INDIVIDUAL MOLECULES AND METHODS FOR THEIR DETECTION - The invention provides labels for electronic detection of individual molecules. The labels are comprised of elements with different electrical properties that affect the electric current flowing through a nanoelectrode. The labels are of polymeric or filamentous structure where the elements are arranged linearly along their length. The arrangement of the elements is predetermined and combinatorial, so that a high diversity of labels can be generated in a manner that resembles barcoding on a nanoscale level. Methods for the synthesis of said barcode labels and for the binding of the barcode labels to individual molecules, their movement past a nanoelectrode, and their detection are also provided. | 09-01-2011 |
| 20110212543 | METHOD FOR PREPARING AGGLUTINATABLE PLATELET FRAGMENTS AND THE USE THEREOF - The present invention relates to a method for preparing agglutinatable platelet fragments, in which native platelets are treated with ultrasound and a fixative. The platelet fragments are suitable for use in diagnostic assay methods which include an agglutination reaction, such as, for example, in a method for determining WWF activity. | 09-01-2011 |
| 20110212544 | Method and Reagent Kit for Immunological Measurement - A method for measuring an analyte in a sample, includes the steps of (a) mixing a sample containing the analyte, a complex comprising a plurality of molecules of a substance that specifically binds to the analyte, and microparticles each having the analyte or an analog of the analyte bound to an insoluble support; and (b) measuring an agglutination reaction of the microparticles in a mixture obtained in the step (a). In the method, for example, an antibody is used in the form of a complex of a plurality of molecules of the antibody, rather than in the form of a single molecule of the antibody. Therefore, the sensitivity to the measurement is increased, and the measurement in a lower concentration range becomes possible. A reagent kit for measuring is also disclosed. | 09-01-2011 |
| 20110217790 | Novel CD3 Epsilon Immunogens And Antibodies - The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides. | 09-08-2011 |
| 20110217791 | METHOD FOR QUANTIFYING OR DETECTING DNA - The present invention relates to a method for quantifying or detecting DNA having a target DNA region, and so on. | 09-08-2011 |
| 20110223683 | AFFINITY SELECTOR BASED RECOGNITION AND QUANTIFICATION SYSTEM AND METHOD FOR MULTIPLE ANALYTES IN A SINGLE ANALYSIS - A multi-dimensional method for simultaneously analyzing multiple analytes within a sample solution, comprising adding affinity selectors to a sample solution containing analytes to be measured, the affinity selectors having an affinity for one or more of the analytes within the sample solution; allowing immune complexes to form between the affinity selectors and the analytes; partially or totally resolving the formed immune complexes from non-analyte substances within the sample solution; dissociating the resolved immune complexes; separating the analytes and the affinity selectors of the dissociated immune complexes from one another by capturing the analytes through a surface adsorption process; transferring the captured analytes to a detection means; and resolving the analytes with the detection means in accordance with their mass-to-charge ratios. | 09-15-2011 |
| 20110223684 | DETECTION OF SPECIFIC NITRATED MARKERS - Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein. | 09-15-2011 |
| 20110223685 | OXIDIZED APOA1 DETERMINATION BY MASS SPECTROMETRY - Methods are provided for the detection and quantitation of proteins generally and apolipoprotein A-I and oxidized derivatives thereof in particular. Further provided are methods for the assessment of the risk cardiovascular disease in a subject, wherein the assessment is based on the amount of oxidized and unoxidized apolipoprotein A-I in a biological sample obtained from a subject. | 09-15-2011 |
| 20110223686 | PROTEIN PRODUCTION METHOD, FUSION PROTEIN, AND ANTISERUM - Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by | 09-15-2011 |
| 20110223687 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER - Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1. | 09-15-2011 |
| 20110223688 | GRATING-BASED EVANESCENT FIELD MOLECULAR SENSOR USING A THIN SILICON WAVEGUIDE LAYER - A technique for high sensitivity evanescent field molecular sensing employs a detection scheme that simultaneously couples a polarized beam to a single mode of a waveguide, and couples the polarized beam out of the waveguide to specularly reflect the beam by the same grating. Strong interaction with the single (preferably TM) mode is provided by using a silicon on insulator (SOI) wafer having a waveguide thickness chosen between 10-400 nm so that the majority of the mode field strength spans the evanescent field. Well known, robust techniques for producing a grating on the waveguide are provided. Interrogation from a backside of the SOI wafer is taught. | 09-15-2011 |
| 20110229979 | RISPERIDONE IMMUNOASSAY - Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids. | 09-22-2011 |
| 20110229980 | OLIGONUCLEOTIDE PROBE AND USE THEREOF - The present teaching provides a fluorescent oligonucleotide probe having a high degree of design flexibility and wide applicability, as well as the use thereof. This is an oligonucleotide probe capable of forming a stem and loop, comprising at least one fluorophore located between adjacent nucleotides in the stem and is linked to a unit represented by Formula (1) and at least one quencher located at a site capable of pairing up with the at least one fluorophore located between the adjacent nucleotides in the stem and is linked to a unit represented by Formula (2). (In the formulae, X represents the fluorophore, Y represents the quencher, R1 represents an optionally substituted C | 09-22-2011 |
| 20110229981 | DETECTION OF SHED CD31, DIAGNOSIS OF ATHEROTHROMBOSIS AND AUTOIMMUNE DISORDERS, AND METHODS FOR ANALYZING SIGNALING PATHWAYS - The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. A method for detecting shed CD31 is further disclosed. The invention therefore relates to a method for detecting a shed ectodomain of a transmembrane protein such as CD31 and to the use of such a method as a diagnostic tool. The invention further provides methods for determining whether a candidate protein is part of a molecular complex. | 09-22-2011 |
| 20110229982 | METHOD FOR BINDING A PROTEIN CONSISTING OF PROTEIN A OR CONSISTING OF AT LEAST ONE DOMAIN OF THE A TO E DOMAINS OF THE PROTEIN A TO THE SUBSTRATE - The object of the present invention is to provide a method for immobilizing the SpA protein on the surface of a substrate with high density without causing dimerization. | 09-22-2011 |
| 20110229983 | MARKING FUEL FOR AUTHENTICATION - A first fuel and a second fuel are marked with a marker that can be detected quantitatively in a predetermined concentration range. The second fuel is marked with a binary marker. Decreased concentration of the quantitative marker, presence of a binary marker, or both may be indicative of a fuel that is altered (e.g., mixed, laundered, diluted, or adulterated). Testing a fuel includes testing the fuel for a presence of a first marker in the fuel in a predetermined concentration range, and testing the fuel for a presence of a second marker. The presence of the first marker in the predetermined concentration range and an absence of the second marker may be indicative that the fuel is unaltered. The presence of the first marker in the fuel in a concentration less than the predetermined concentration range or the presence of the second marker may be indicative that the fuel is altered. | 09-22-2011 |
| 20110229984 | MATERIALS AND METHODS DIRECTED TO ASPARAGINE SYNTHETASE AND ASPARAGINASE THERAPIES - Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies. | 09-22-2011 |
| 20110236991 | Aptamer-Based Colorimetric Sensor Systems - The present invention provides an aptamer-based colorimetric sensor system for determining the presence and optionally the concentration of an analyte in a sample. Methods of utilizing the sensor system and kits that include the sensor also are provided. The sensor utilizes a linker and oligonucleotide functionalized particles to form an aggregate, which disaggregates in response to the analyte. | 09-29-2011 |
| 20110236992 | METHOD OF DETECTING A SPECIFIC NUCLEOPHILE AND SURFACE ACOUSTIC WAVE SENSOR FOR DETECTING THE SPECIFIC NUCLEOPHILE - Provided herein is a method of detecting the presence of a specific nucleophile, which uses a material Y degraded by nucleophilic substitution of reacting with a specific nucleophile X, and a material Z selectively binding to a material Y′ produced by the degradation. According to the method, the nucleophile X can be easily analyzed according to the bonding between the materials Y′ and Z. | 09-29-2011 |
| 20110236993 | PANCREATIC CANCER MARKERS - The present invention relates to pancreatic cancer markers. In particular, the present invention provides methods and compositions for the identification of protein glycosylation patterns associated with pancreatic cancer. | 09-29-2011 |
| 20110236994 | MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease. | 09-29-2011 |
| 20110236995 | METHOD FOR DETERMINING PROSTATE CANCER - The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)), and benign prostatic hyperplasia is determined in the case of 30% or less. | 09-29-2011 |
| 20110236996 | METHOD FOR MEASURING CYSTATIN C IN HUMAN BODY FLUID - There is provided a particle-enhanced immunoassay method for cystatin C in a human body fluid, which has higher specificity and is easily automatable at low cost as compared with conventional assay methods that use large amounts of polyclonal antibodies having low specificity or monoclonal antibodies having high specificity but having poor agglutinability. | 09-29-2011 |
| 20110236997 | Methods and Reagents for Shortening Incubation Times in Hybridization Assays - The methods and reagents described herein can be used to shorten incubation times in hybridization assays. As demonstrated in the examples, we have identified specific sulfonic acid polymers and hybridization conditions that lead to significantly shorter incubation times (e.g., signals after three hours that are comparable to signals that could traditionally only be obtained after overnight incubation). In some embodiments, shorter incubation times are achieved by adding the sulfonic acid polymer(s) during the hybridization process. Alternatively or additionally, in some embodiments, shorter incubation times are achieved via changes to the hybridizing conditions, e.g., by reducing the hybridization volume, increasing the salt concentration, and/or increasing the probe concentration (capture extender probe and/or label extender probe). | 09-29-2011 |
| 20110244594 | TARGET SUBSTANCE DETECTING METHOD AND TARGET SUBSTANCE DETECTING APPARATUS - A target substance detecting method employs a detecting chip equipped with a fine flow channel. Examinations, in which clogging of the flow channel and inhibition of immune reactions can be easily and expediently prevented without preliminary processes, are enabled to be performed without fluctuations in hemolysis rates. The detecting chip having a flow channel base having the flow channel and a detecting portion formed in the flow channel is employed. A liquid sample that may contain a target substance and contains cellular non target substances is caused to flow into the flow channel. An ultrasonic wave emitting section provided upstream of the detecting portion emits ultrasonic waves into the liquid sample from a direction perpendicular to the longitudinal direction of the flow channel such that a standing wave is generated within the flow channel. | 10-06-2011 |
| 20110244595 | BIOMEDICAL CHIP FOR BLOOD COAGULATION TEST, METHOD OF PRODUCTION AND USE THEREOF - In a biomedical chip for blood coagulation tests and its manufacturing method and use, the biomedical chip comprises a substrate layer, a middle layer, and a cap layer, engaged and stacked with each other to define a microfluidic channel which has a first inlet and an outlet of the microfluidic channel respectively. A mixing interval is expanded outward from the microfluidic channel and interconnected to a second inlet, and has an interconnect portion and a capillary portion disposed between the substrate layer and the cap layer, and more specifically disposed around the periphery of the interconnect portion. With the biomedical chip having the substrate layer and cap layer made of a hydrophilic material, the blood and the reagent can be driven automatically by the capillary force of the microfluidic channel to flow and mix with each other, and the hydrophilic capillary force can be permanently maintained. | 10-06-2011 |
| 20110250700 | Methods for Sequencing Individual Nucleic Acids Under Tension - The invention provides apparatuses and methods of use thereof for sequencing nucleic acids subjected to a force, and thus considered under tension. The methods may employ but are not dependent upon incorporation of extrinsically detectably labeled nucleotides. | 10-13-2011 |
| 20110250701 | NOVEL APPLICATION OF AIMP1 POLYPEPTIDE - The present invention relates to a novel use of AIMP1 polypeptide, more particularly to a composition for diagnosis of arthritis comprising an antibody against AIMP1, a kit for diagnosis comprising the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The present invention provides a composition for diagnosis of arthritis including an antibody against AIMP1 polypeptide as a novel diagnosis marker of arthritis, a kit for diagnosis including the same, a method for diagnosis of arthritis comprising: acquiring a specimen from a subject; and detecting AIMP1 polypeptide included in the specimen, and an antibody against the AIMP1 polypeptide for diagnosis of arthritis. The composition, kit for diagnosis, method for diagnosis and antibody against the AIMP1 polypeptide may be used to diagnose arthritis early since they allow easy diagnosis of arthritis using a specimen from the patient. | 10-13-2011 |
| 20110250702 | ISOLATED PEPTIDES OF RABBIT FACTOR VII - The present disclosure relates to peptides isolated from rabbit factor VII and to the use of thereof for the generation of antibodies specifically directed against the latter. The disclosure also relates to the use of antibodies directed against rabbit factor VII for the detection or purification of rabbit factor VII, specifically when said rabbit factor VII is in a biological sample which also contains human factor VII. | 10-13-2011 |
| 20110250703 | IL1RL-1 AS A CARDIOVASCULAR DISEASE MARKER AND THERAPEUTIC TARGET - This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure. | 10-13-2011 |
| 20110250704 | Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification - The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide. | 10-13-2011 |
| 20110256633 | Secretory Granules and Granulogenic Factors as a Target for Cancer Treatment - The present invention relates to a method for screening a cancer therapeutic agent, comprising the steps of: (a) contacting a test substance of interest with a cell containing a granulogenic factor-encoding nucleotide sequence; and (b) analyzing expression of the granulogenic factor or production of secretory granules, wherein the test substance is determined as the cancer therapeutic agent where it inhibits the expression of the granulogenic factor or the production of secretory granules. In the present invention, the expression of the granulogenic factor contributes to induction of secretory granule formation in non-secretory cells, and inhibition of the granulogenic factor expression leads to inhibition of secretory granule formation in secretory cells. In addition, the secretory granules produced by the present granulogenic factor change cell activities via the IP | 10-20-2011 |
| 20110256634 | SENSOR MEASURING METHOD AND SENSING APPARATUS - A method of performing a measurement with a sensor having a sensing surface and at least one capture molecule attached to the sensing surface for forming a binding pair with an analyte of interest, the binding pair having a flexible spatial orientation, the method comprising capturing the analyte of interest with the capture molecule, thereby forming the binding pair in an initial spatial orientation; applying a first electromagnetic force to the sensing surface to alter the spatial orientation of the binding pair; and performing a sensor measurement with the binding pair in the altered spatial orientation. A sensor apparatus implementing this method is also disclosed. | 10-20-2011 |
| 20110256635 | SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments. | 10-20-2011 |
| 20110256636 | METHODS AND REAGENTS FOR DIAGNOSING RHEUMATOID ARTHRTIS - Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described. | 10-20-2011 |
| 20110256637 | Target Detection Using a Single-Stranded, Self-Complementary, Triple-Stem DNA Probe - Provided are novel single-stranded oligonucleotide probes that have a triple-stem configuration in the absence of target binding to the target binding sequence. The probes also have a fluorophore and a quencher. In the absence of target binding to the target binding sequence, these single-stranded oligonucleotide probes are capable of forming self-complementary duplexes such that the probe is in the triple-stem configuration and the fluorophore is positioned adjacent the quencher. In the presence of target binding to the target binding sequence, formation of the self-complementary duplexes is inhibited such that the probe is configured to position the fluorophore away from the quencher such that a signal of the fluorophore is detectable. Also provided are methods of using the probes. | 10-20-2011 |
| 20110256638 | DOWNWARD OR VERTICAL FLOW DIAGNOSTIC DEVICE AND ASSAY - A downward or vertical flow-through rapid diagnostic device and assay are provided. The device comprises a test area and reagent storage area, which are linked via a channel. The test area further comprises a reaction zone and an absorbent zone. A capture reagent is immobilized on the reaction zone to detect a target analyte in the fluid test sample. The fluid test sample flows downward or vertically through the reaction zone and into the absorbent zone, with the capture reagent and target analyte forming a two-membered complex that is concentrated in the reaction zone. The reagent storage area comprises a breakable cartridge positioned directly and vertically above the test area and a channel. A reagent used in the assay is housed in the breakable cartridge. Once liberated, the reagent passes through the channel and flows to test area for depositing on the reaction zone. The storage of predetermined amounts of reagents in the diagnostic device reduces the number of manual operations required to produce a result. | 10-20-2011 |
| 20110256639 | ASSESSMENT OF PROTEIN DEGRADATION BY MEASUREMENT OF ISOMERISED NEO-EPITOPE CONTAINING FRAGMENTS - A method of immunoassay for fragments of a protein such as type II collagen in a biological sample detects fragments having a first epitope containing an isomerised amino acid residue and a second epitope generated by cleavage of the protein by the use of respective antibodies binding each of the two epitopes. | 10-20-2011 |
| 20110256640 | ASSAY FOR TROPONIN I USING MAGNETIC LABELS - The present invention relates to a method for measuring Troponin I in a sample comprising the steps of providing a sample, contacting the sample with a monoclonal anti-Troponin I antibody coupled to a magnetic label, contacting the sample with a polyclonal anti-Troponin I antibody coupled to a sensor surface and detecting the magnetic label on the sensor surface. The invention further relates to a device and a cartridge for measuring Troponin I in a sample. | 10-20-2011 |
| 20110263041 | COMPOSITION FOR MEASURING THE BINDING AFFINITY BETWEEN NUCLEIC ACID AND TEST SUBSTANCE, AND USE THEREOF - In one embodiment of the present invention, a composition is disclosed for measuring a binding affinity between a nucleic acid and a test substance, which contains an organic fluorescent substance capable of binding to an RNA and which emits fluorescence having an intensity greater while the organic fluorescent substance is liberated from an RNA than while the organic fluorescent substance is bound to an RNA. This enables a highly accurate and easy measurement of a binding affinity between a test substance and a nucleic acid, and allows various substances to be examined as a test substance. | 10-27-2011 |
| 20110263042 | ASSAY METHOD FOR ANTIBODIES AGAINST CYCLIC CITRULLINATED PEPTIDE - The present invention relates to method for assaying anti-cyclic citrullinated peptide antibodies in a clinical sample, said method comprising contacting said sample with at least one homogeneous reagent comprising at least one specific binder for anti-CCP antibodies, whereby to form a solution or suspension of an anti-CCP-binding partner complex in a homogeneous sample mixture and detecting the presence or level of said anti-CCP-binding partner complex in a homogeneous liquid-phase. The invention also relates to a method for the assessment of the existence of; risk of; potential for; or propensity to RA in a subject. | 10-27-2011 |
| 20110263043 | Scanning Analyzer for Single Molecule Detection and Methods of Use - The invention encompasses analyzers and analyzer systems that include a single molecule analyzer, methods of using the analyzer and analyzer systems to analyze samples, either for single molecules or for molecular complexes. The single molecule uses electromagnetic radiation that is translated through the sample to detect the presence or absence of a single molecule. The single molecule analyzer provided herein is useful for diagnostics because the analyzer detects single molecules with zero carryover between samples. | 10-27-2011 |
| 20110263044 | DEVICE AND METHOD FOR THE AUTOMATIC DETECTION OF BIOLOGICAL PARTICLES - An apparatus and a method for automatic detection of particles, in particular, biological particles such as micro-organisms. The apparatus has a device for binding the particles to separating particles which can be bound selectively to the particles. The apparatus further includes a separating device for extraction of the separating particles with bound particles from a collecting fluid, and a detection unit for detecting a number and/or concentration of the particles separated in this manner. The device for binding the particles to the separating particles includes a collecting device for collecting a collecting fluid including the separating particles and the particles that are provided by a particle-fluid mixture. | 10-27-2011 |
| 20110263045 | Method of Detection of Nucleic Acids With a Specific Sequence Composition - This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the use of nucleic acid Target Binding Assemblies to detect and localize specific Target Nucleic Acids. The detection and localization of the Target Nucleic Acid is accomplished even in the presence of nucleic acids which have similar sequences. The method provides for a high degree of amplification of the signal produced by each specific binding event. In particular, methods and compositions are presented for the detection of HIV and HPV nucleic acid in samples. These methods and compositions find use in diagnosis of disease, genetic monitoring, forensics, and analysis of nucleic acid mixtures. Some of the novel compositions used in the detection method are useful in preventing or treating pathogenic conditions. | 10-27-2011 |
| 20110263046 | Methods of identification of novel ligands for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (NR1F3) activity - The invention relates to modulators for the orphan nuclear receptor RORgamma and methods for identification and screening of novel modulators for RORgamma activity as well as methods for treating RORgamma mediated diseases with novel RORgamma modulators identified by such methods. | 10-27-2011 |
| 20110263047 | PEPTIDE TAG AND USES THEREOF - The present invention provides a novel peptide tag, uses of the same and methods and systems for the purification of proteins. In particular, the invention provides the use of a beta-lactam (β-lactam) binding protein or fragment, analogue, homologue, variant or derivative thereof, as a tag or label. | 10-27-2011 |
| 20110269244 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN - The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use. | 11-03-2011 |
| 20110269245 | METHODS AND KITS FOR DETECTION OF TOXEMIA - Various embodiments of methods and kits are disclosed for prognosis, detection, and/or diagnosis of toxemia in a subject patient by analyzing an aliquot of the subject patient's extracellular fluid (e.g., blood serum) that contains carrier proteins. | 11-03-2011 |
| 20110269246 | MEASURING LEVELS OF FRATAXIN - This document relates to methods and materials involved in measuring levels of a frataxin polypeptide present in a biological sample. For example, methods and materials related to the use of anti-frataxin antibody-bound microspheres and biotinylated anti-frataxin antibodies to measure the levels of a frataxin polypeptide in a biological sample from a mammal (e.g., a newborn human) are provided. | 11-03-2011 |
| 20110269247 | MEASUREMENT KIT AND AN IMMUNOCHROMATOGRAPHY METHOD - It is an object of the present invention to provide a measurement kit for developing a first developing solution and a second developing solution from different directions to suppress background noise, and an immunochromatography kit. The present invention provides a measurement kit, which comprises a first developing member for supplying a first developing solution and a second developing member for supplying a second developing solution, wherein the developing direction of the first developing solution is allowed to intersect with the developing direction of the second developing solution, so that development is carried out by developing the first and second developing solutions in different developing directions, and a water absorbent portion is established on the downstream of each of the developing directions. | 11-03-2011 |
| 20110269248 | BIO-MARKERS FOR DIAGNOSING DIABETIC RETINOPATHY - Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins. | 11-03-2011 |
| 20110281374 | BIOMARKER - A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1α (IL-1α) in a serum or plasma sample. | 11-17-2011 |
| 20110287556 | BLOOD GROUP ANTIGENS OF DIFFERENT TYPES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing. | 11-24-2011 |
| 20110287557 | SINGLE QUANTUM-DOT BASED APTAMERIC NANOSENSORS - A signal-off-quantum-dot-based sensor for detecting the presence of a target molecule comprising: an aptamer probe having a nucleotide sequence which specifically interacts with the target molecule by sequence-dependent interaction, wherein the aptamer probe is sandwiched between (a) an oligonucleotide which is immobilized on the surface of a quantum dot (QD), and (b) a fluorophore-labeled oligonucleotide, wherein when the sensor is excited by an energy source: (i) in the absence of specific interaction between the target molecule and the aptamer probe, a baseline signal is emitted, and (ii) in the presence of specific interaction between the target molecule and the aptamer probe, a detection signal is emitted, wherein the baseline signal is greater than the detection signal, whereby the presence of the target molecule is detected. | 11-24-2011 |
| 20110287558 | RESPONSIVE LUMINESCENT LANTHANIDE COMPLEXES - A compound of formula (I) is provided: | 11-24-2011 |
| 20110294226 | Survival motor Neurons (SMN) gene: a gene for spinal muscular atrophy - The present invention relates to the discovery of the human survival motor-neuron gene or SMD gene, which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene. | 12-01-2011 |
| 20110294227 | METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS - The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably P1GF-2 and P1GF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations. | 12-01-2011 |
| 20110294228 | DETECTION DEVICES AND METHODS - The present invention relates to devices and methods for rapid and easy to use quantitative detection of one or more analytes in, for example, food, food ingredients, drinking water or pharmaceuticals. Analytes that can be detected by the devices and methods herein include, for example, adulterants, toxins, allergens, pathogens, pesticides, pharmaceuticals, pharmaceutical intermediates, biopolymers and biotechnology products. | 12-01-2011 |
| 20110294229 | COLORIMETRIC AND FLUORIMETRIC FLUORIDE SENSING - The present invention generally relates to fluoride receptor reagent compounds comprising one or more N-aryl or heteroaryl substituted 1,4,5,8-naphthalenetetracarboxydiimide (NDI) units and an associated method for the detection of fluoride in a composition. π-electron orbitals present in the NDI unit of the reagents form a complex with fluoride anions. It is believed that the anion-π interaction results in a charge transfer process between the fluoride anion and the NDI unit, resulting in a number of measurable effects (e.g., colorimetric response). | 12-01-2011 |
| 20110300640 | METHOD AND DEVICE FOR AUTHENTICATING OBJECTS PROVIDED WITH A MARKER, THE SPECIFICATION OF WHICH: - The invention relates to a method for authenticating objects provided with a marker that contains nucleic acid. | 12-08-2011 |
| 20110300641 | PROTEIN ISOFORMS FOR DIAGNOSIS - Several aspects of this invention relate to diagnosis of diabetic states in a mammal using protein isoforms. In some aspects, it relates to a method for determining the diabetic state of a mammal. This method can include, for example, (a) measuring the serum concentration of one or more protein isoforms, (b) analyzing the serum concentration of the one or more protein isoforms, and (c) determining the diabetic state of the mammal. Other aspects include kits used to perform the method. Further aspects are the isolated protein isoforms themselves, and their methods of isolation. | 12-08-2011 |
| 20110300642 | METHODS FOR DIFFERENTIATING AND MONITORING PARATHYROID AND BONE STATUS RELATED DISEASES - The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values, one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states. | 12-08-2011 |
| 20110306148 | COMPOSITION FOR USE AS AN ASSAY REAGENT - A composition for use as an assay reagent comprises a solid support comprising a member of a signal producing system and a coating of a synthetic copolymer. The synthetic copolymer comprises a first polymerized monomer comprising a pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and a second polymerized monomer comprising a pendant moiety comprising at least 1 carbon atoms and at least 2 heteroatoms. In some embodiments the copolymer comprises a polyethylenic backbone comprising the pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and the pendant moiety comprising at least 1 carbon atom and at least 2 heteroatoms. | 12-15-2011 |
| 20110306149 | OBSERVATION APPARATUS AND OBSERVATION METHOD - An observation apparatus and an observation method capable of changing the stimulation position in accordance with the position and the shape of a cell and of observing the cell immediately after stimulation are provided. The observation apparatus | 12-15-2011 |
| 20110306150 | ALLERGEN DETECTION METHOD USING IMMUNOCHROMATOGRAPHY - A method is disclosed which rapidly detect allergens with good accuracy by efficiently extracting the allergens from a test sample such as food containing various allergens and eliminating non-specific reactions accompanying the disintegration of colloidal gold conjugated to antibodies by not using a reducing agent. The method uses a developing solution containing at least 10% by weight of FBS in an immunochromatography method which comprises using a colloidal gold-labeled antibody in which a colloidal gold is bound to a monoclonal antibody against denatured and native allergen, a development support wherein a monoclonal antibody against denatured and native allergen recognizing an epitope different from that recognized by the colloidal gold-labeled antibody is fixed, measurement samples of the allergens extracted from the test sample with an anionic surfactant such as SDS and a thiosulfate or an anionic surfactant such as SDS and a non-ionic surfactant such as Tween 20, and the developing solution; developing the developing solution on the development support; and then detecting the allergens based on the presence of the deposition of the colloidal gold. | 12-15-2011 |
| 20110306151 | WESTERN BLOT BY INCORPORATING AN AFFINITY PURIFICATION ZONE - A mixture of components is flowed through a binding channel region comprising a component-binding moiety, thereby binding at least a portion of a component of interest. The mixture is then flowed through a separation channel region that includes a buffer comprising a detergent, resulting in separated components. Diluent is mixed with the separated components, diluting the detergent, and the separated components are detected. The component of interest is released from the component-binding moiety and flowed through the separation channel region. Diluent is mixed with the released component of interest, diluting the detergent, and the released component of interest is detected. | 12-15-2011 |
| 20110312103 | SAMPLE DETECTION SENSOR AND SAMPLE DETECTION METHOD - The present invention uses a detecting plate having a transparent substrate on which a single-crystal Si thin film layer, a transparent thin film layer, and a sample capturing layer for capturing a sample are provided. The present invention comprises a light directing mechanism for directing light through said transparent substrate of the detecting plate, and a light detection mechanism for detecting reflected light of the incident light from the detecting plate. The present invention is configured so that a change in absorbance occurs at the sample capturing layer or in the vicinity thereof, when said sample is captured on said sample capturing layer. The wavelengths of said incident light are determined in a range of wavelengths within which said change in absorbance occurs. In this way, the sample is detected by means of measuring a significant change in intensity of the reflected light which is generated when the sample is captured on the sample capturing layer. | 12-22-2011 |
| 20110312104 | IMMUNOASSAY METHOD - Provided is an immunoassay method that can reduce the effort of establishing an immunoassay system due to not needing two or more antibodies, and that is applicable to not only high molecular weight antigens but also to low molecular weight antigens such as hapten. The method is for releasing, from a surface of a base plate, immunoglobulin G antibody bound to the surface via protein A. The method includes the following steps (A) and (B): (A) a step of preparing the base plate having the surface to which immunoglobulin G antibody produced by a producer cell line of deposit No. FERM BP-10459 is bound via protein A; and (B) a step of providing a solution (from pH 6 to pH 8.9; preferably, from pH 7.4 to pH 8.9) containing human serum albumin onto the surface so as to release the immunoglobulin G antibody from the protein A. | 12-22-2011 |
| 20110312105 | DETECTION SYSTEM AND METHOD FOR HIGH SENSITIVITY FLUORESCENT ASSAYS - This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (≦5 mm) and a high molecular weight polymer (≧1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked Ficoll molecule having a plurality of binding molecules and a plurality of fluorescent labels. | 12-22-2011 |
| 20110318846 | Aptamer and detection method for C-reactive protein - An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g. | 12-29-2011 |
| 20110318847 | CVD ASSAY - An assay method and kit for the detection of potential for CVD or propensity to CVD in a human or non-human animal subject, said method comprising assessing the concentration of calprotectin in a calprotectin-containing sample taken from said subject. | 12-29-2011 |
| 20120003749 | NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO 2,4,6-TRINITROPHENYL SKELETON, METHOD FOR DETECTING COMPOUND HAVING 2,4,6-TRINITROPHENYL SKELETON USING THE NUCLEIC ACID MOLECULE, AND USE OF THE NUCLEIC ACID MOLECULE - The present invention relates to a nucleic acid molecule capable of binding to a 2,4,6-trinitrophenyl skeleton, a method for detecting a compound having the 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, use of the nucleic acid molecule for detecting a compound having the 2,4,6-trinitrophenyl skeleton, and a method for detecting a compound having the 2,4,6-trinitrophenyl skeleton. | 01-05-2012 |
| 20120003750 | DETECTION OF ACTUATED CLUSTERS BY SCATTERING - A method for detecting clusters of superparamagnetic particles coated with a bioreactive agent is provided. A suspension of the superparamagnetic particles in a fluid to be analyzed is provided. The particles are allowed to form clusters due to an analyte present within the fluid and a magnetic field rotating at a given frequency is applied to the solution. Light is directed to the fluid and the amplitude of the intensity of scattered light at twice the frequency of the magnetic field is extracted. By determining the amplitude of the measured intensity of scattered light at twice the field depending on the frequency of the magnetic field a frequency-dependent measurement may be achieved. The frequency-dependent measurement may be used to determine the critical frequency of clusters, to distinguish clusters having different sizes or to measure the average value of the susceptibility and the spread of the susceptibility of the particles in the fluid. Furthermore, an apparatus for apparatus for detecting clusters of superparamagnetic particles is provided. | 01-05-2012 |
| 20120003751 | BIOMARKER FOR THE PREDICTION OF FIRST ADVERSE EVENTS - Subject of the present invention are assays and in vitro methods for the prediction of first coronary and cardiovascular events and biomarkers useful therein. | 01-05-2012 |
| 20120003752 | Prognostic biomarkers for the progression of primary chronic kidney disease - Subject of the present invention are assays and in vitro methods for prediction of the progression of primary chronic kidney disease (CKD) or for monitoring chronic kidney disease therapy comprising the determination of the level of ANP and/or ADM or its precursors or fragments thereof. | 01-05-2012 |
| 20120003753 | CHEMILUMINESCENT COMPOSITIONS, ENHANCING REAGENTS FOR CHEMILUMINESCENCE AND METHODS FOR THE PREPARATION AND USE THEREOF - A enhancing reagent for enhancing chemiluminescence of 1,2-dioxetane compounds and a method for using the enhancing reagent to enhance chemiluminescence are provided, in which the enhancing reagent contains a multi-alkyl quaternary ammonium salt of Formula I. A chemiluminescent composition with a 1,2-dioxetane compound as a substrate and a kit thereof are further provided, which contain a 1,2-dioxetane compound and a multi-alkyl quaternary ammonium salt of Formula I. | 01-05-2012 |
| 20120003754 | METHODS, PRODUCTS AND TREATMENTS FOR DIABETES - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided. | 01-05-2012 |
| 20120003755 | High Precision Scanning of Encoded Hydrogel Microparticles - Techniques are provided for high precision scanning of hydrogel microparticles. The high precision is achieved by one or more modifications to the microparticle composition, or microfluidics apparatus that align the microparticles in a detection channel, or method of preparing a sample for introduction into the apparatus, or some combination. An apparatus comprises a body structure having formed therein a central channel and multiple focusing channels in fluid communication with the central channel through multiple junctions. A width of the central channel is smaller in a portion downstream of each junction. A particle comprises a hydrogel matrix and a probe molecule. The particle has an aspect ratio greater than about three. A method includes loading into a sample fluid inlet a mixture, wherein a number of particles lies within a range from about 5 to about 10 particles/μl. | 01-05-2012 |
| 20120015448 | ASSAY DEVICE WITH SHARED ZONES - Disclosed is an assay device for determining the presence and/or extent of one or more analytes in liquid sample containing a) first and second assays each comprising a flow-path having a detection zone for immobilising a labelled binding reagent, wherein detection of a labelled binding reagent at one or both detection zones is indicative of the presence and/or extent of one or more analytes; b) a shared reference zone; c) one or more light sources to illuminate the detection zones and the reference zone; d) one or more photodetectors to detect light from the detection zones and the reference zone, which photodetector/s generate a signal, the magnitude of which signal is related to the amount of light detected; and e) signal processing means for processing signals from the photodetector/s. | 01-19-2012 |
| 20120015449 | METHOD AND DEVICE FOR DETERMINING A FOREIGN SUBSTANCE CONTENT IN A MATRIX - A method and a device are provided for determining a content of at least one foreign substance in a matrix of a solid or liquid food. At least one reagent area for providing at least one reagent has a receptacle for a replaceable reagent container for replaceably connecting a sample container including at least the matrix; a transfer line is provided between the reagent area and the reaction area, by which the at least one reagent can be fed to the reaction area; a sensor area is provided for demonstrating the foreign substance released from the matrix; a carrier gas line is provided between the reaction area and the sensor area, by which the released foreign substance can be fed to the sensor area; and an output line is provided through which the dissolved foreign substance can be fed outward from the sensor area. | 01-19-2012 |
| 20120015450 | Method for Detecting Prozone Phenomenon, Analysis Method, Device for Detecting Prozone Phenomenon, and Analysis Device - Provided is a prozone phenomenon detecting method, by which generation of a prozone phenomenon can be detected even when a conventional specimen analysis tool is used, and examinations using an immunochromatography method and the like can be performed efficiently. In the method, a specimen analysis tool containing substances that specifically bind to a target component contained in a sample is used. The specimen analysis tool is obtained by arranging a sample supplying portion, a reagent portion, and a detection portion on the porous base material from upstream to downstream in a sample moving direction in this order. The reagent portion contains a labeled substance that specifically binds to the target component. The detection portion contains an immobilized substance that specifically binds to the target component. The target component is detected by detecting a complex of the target component, the labeled substance, and the immobilized substance through detection of a label of the labeled substance in the detection portion. The method includes at least one of the following processes A and B: the process A: a process in which detection results obtained in the detection portion are plotted along the sample moving direction, and generation of a prozone phenomenon is detected on the basis of a position of a peak in plots thus obtained; and the process B: a process in which the label is detected at two or more different time points in the detection portion, and generation of a prozone phenomenon is detected on the basis of a magnitude relationship between two or more detection results thus obtained. | 01-19-2012 |
| 20120021530 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS - Disclosed are isolated, unnatural polypeptides containing cyclically-constrained β-amino acid residues and cyclically-constrained γ-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions. | 01-26-2012 |
| 20120021531 | Assay Reader, Device and Method of Measuring HCG - Disclosed is a method for determining a quantitative estimate of the length of time since conception in a female mammalian subject, the method comprising: a)providing a liquid sample suspected of containing hCG; b)measuring, by means of an assay or assay device, an analyte measurement signal, whose value is dependent upon the level of hCG; c)comparing the measured signal value to an analyte threshold, wherein said analyte threshold corresponds to a time since conception; d)providing an quantitative estimate of the length of time since conception based upon the comparison in step (c). | 01-26-2012 |
| 20120021532 | Methods of Detecting and Treating Pulmonary Disease and Markers Thereof - The present invention relates to the treatment of pulmonary diseases. More specifically, the invention relates to new methods of detecting and treating chronic obstructive pulmonary disease (COPD). In particular, the invention relates to a method of measuring one or more lipid metabolites in human body fluids as an indicator/biomarker of the progress of chronic obstructive pulmonary disease. The present invention also relates to a method of detecting and/or monitoring chronic obstructive pulmonary disease in a subject, the method comprising measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD. The present invention also relates to a method of assessing the efficacy of a COPD treatment in a subject, the method comprising a step of measuring the level of at least one lipid metabolite in a sample from the subject, wherein said level is indicative of COPD severity or status. | 01-26-2012 |
| 20120021533 | SENSITIVE METHOD TO ANALYSE FREE PEG-MALEIMIDE - The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal. | 01-26-2012 |
| 20120021534 | MARKERS FOR BRAIN DAMAGE - Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed. | 01-26-2012 |
| 20120028369 | QUANTIFYING LOCAL INFLAMMATORY ACTIVITY AND ITS USE TO PREDICT DISEASE PROGRESSION AND TAILOR TREATMENTS - This invention relates to a method of predicting progression of an inflammatory condition in a subject, which involves providing a medium comprising hyaluronan or a fragment thereof; contacting the medium with a fluid sample from a subject with an inflammatory condition, where the fluid sample comprises proteins or proteoglycans and a transfer agent; incubating the fluid sample with the medium under conditions effective for the transfer agent in the fluid sample to mediate transfer of heavy chains from the proteins or proteoglycans to the hyaluronan or a fragment thereof to form a complex; detecting, using an antibody, occurrence levels of the complex; and comparing occurrence levels of the complex from said detecting to a reference standard to predict progression of an inflammatory condition in the subject. Also disclosed are methods of tailoring treatment of an inflammatory condition and quantifying local inflammatory activity in a body fluid. | 02-02-2012 |
| 20120028370 | REAGENT FOR ASSAYING D-DIMER AND KIT OF REAGENT FOR ASSAYING D-DIMER - The present invention provides a reagent for assaying D-dimer which includes carriers sensitized to first and second monoclonal antibodies which react with D-dimer, but have different reactivity to D-dimer in which the first monoclonal antibody reacts with high- and low-molecular fractions of D-dimer, the second monoclonal antibody reacts with the high-molecular fraction, but reactivity of the second monoclonal antibody with the low-molecular fraction is different from that of the first monoclonal antibody and a kit of reagent for assaying D-dimer. | 02-02-2012 |
| 20120028371 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 02-02-2012 |
| 20120034706 | METHOD FOR ASSESSING INFLAMMATORY CONDITION - Provided a method for correctly assessing an inflammatory condition of a patient who is receiving a therapy with an IL-6 inhibitor. The method for assessing an inflammatory condition of a patient who is receiving an IL-6 inhibitor, including determining a PTX3 level of a sample derived from a patient who is receiving an IL-6 inhibitor. | 02-09-2012 |
| 20120034707 | ATOMICALLY PRECISE NANORIBBONS AND RELATED METHODS - Disclosed are atomically precise nanoribbons formed by gradient-driven catalytic etching of crystalline substrates to produce edges formed along specific crystallographic axes by thermally-activated particles. Also provided are related methods for fabrication of these nanoribbon structures. Further provided are devices and related methods for power generation and for detection of specific targets using the disclosed structures. | 02-09-2012 |
| 20120034708 | Sample Carrier for Effecting Chemical Assays - There is disclosed apparatus and a system for effecting testing on a sample, such as for medical testing. The apparatus includes a sample chip ( | 02-09-2012 |
| 20120034709 | SURFACE MODIFIED SUBSTRATE, BIOTIP AND A METHOD FOR PRODUCING THEREOF - A surface modified substrate is produced by a method including reacting a substrate having a reactive functional group on a surface thereof with a functional group being reactive to the reactive functional group, and reacting the substrate with a compound represented by the general formula, | 02-09-2012 |
| 20120034710 | Detection of Degradation Products of NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from animals. The method includes detecting degradation products of NT-proBNP by various methods, including using antibodies, kits and device. | 02-09-2012 |
| 20120034711 | Digital immunochromatographic test strip for semi-quantitative detection of aflatoxin B1 and preparation method thereof - The present invention belongs to the field of biological detection. Multi-line immunochromatographic test strip for semi-quantitative detection of aflatoxin B | 02-09-2012 |
| 20120040473 | ANALYSIS OF SEVERAL TARGET ANTIGENS IN A LIQUID SAMPLE - A method of individually analyzing with a surface acoustic wave (SAW) sensor apparatus the presence or absence of at least two different target antigens in a liquid sample is described. The method comprises providing and running a single flow cell comprising a SAW sensor chip with at least two, e.g. twelve, SAW sensor elements, each comprising an individual coating immobilizing and exposing a modified antigen that has a weaker affinity for an antibody which is specific for one of the target antigens than the target antigen itself. Such a flow cell and surface acoustic wave (SAW) sensor chip for immunological displacement reactions are also disclosed. | 02-16-2012 |
| 20120040474 | Glycan-Specific Analytical Tools - Provided are lectenz molecules, which are mutated carbohydrate processing enzyme enzymes that are catalytically inactive and that have had their substrate affinity increased by at least 1.2 fold. Further provided are methods for making and methods of using such lectenz. Additional mutated proteins following the lectenz approach are further provided. | 02-16-2012 |
| 20120040475 | SENSING DEVICE FOR DETECTING A TARGET SUBSTANCE - The present invention relates to a sensing device ( | 02-16-2012 |
| 20120040476 | IMMUNOASSAY REAGENT FOR KL-6 ASSAY - The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized. | 02-16-2012 |
| 20120045847 | ASSAY FOR ANALYTES USING MULTIPLE RECEPTORS - A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample. | 02-23-2012 |
| 20120045848 | PYRENYLOXYSULFONIC ACID FLUORESCENT AGENTS - The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention. | 02-23-2012 |
| 20120045849 | SYSTEM AND METHOD TO MEASURE DISSOCIATION CONSTANTS - A system and method for determining the dissociation constant for a particular ligand is disclosed. In accordance with certain embodiments, the method creates a chemical denaturation curve of a protein in the absence of the ligand. A particular point is selected from this curve, such as the point at which 90% of the protein is unfolded. The molarity of chemical denaturant is determined for this selected point. A one point test is then performed for the protein with a predetermined concentration of the particular ligand. The fraction of protein which is unfolded at this point is then used to determine the dissociation constant for the ligand. This constant is used to quickly determine whether a particular ligard is well suited to be considered a potential drug candidate against that protein target. | 02-23-2012 |
| 20120045850 | SILICA NANOPARTICLE EMBEDDING QUANTUM DOTS, PREPARATION METHOD THEREOF AND BIOSUBSTANCE LABELING AGENT BY USE THEREOF - Disclosed is a quantum dot-embedded silica nanoparticle having plural quantum dots embedded within the silica nanoparticle, wherein the number of quantum dots existing in a concentric area within 10% of a radius from a center of the silica nanoparticle accounts for 10 to 70% of the number of total quantum dots embedded in the silica nanoparticle. | 02-23-2012 |
| 20120058572 | ANTIBODY AGAINST PERIOSTIN, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT FOR PREVENTING OR TREATING A DISEASE IN WHICH PERIOSTIN IS INVOLVED - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method. | 03-08-2012 |
| 20120058573 | INNOVATIVE BLOOD PLATELETS BIOMARKER FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE - The present invention is directed to a method for early, non-invasive, rapid, efficient, reliable and accurate diagnose of Alzheimer's disease. The present invention particularly addresses obtaining blood samples, and stabilizing platelets from healthy persons and patients with probable cognitive impairment and/or Alzheimer's disease; extracting proteins from the platelets; identifying both monomeric and oligomeric tau proteins in the platelets with at least two monoclonal antibodies against the tau proteins, quantifying the amounts of the identified tau proteins, and comparing the amounts and protein profiles of the tau molecular species in the platelets of the healthy person and the patient. | 03-08-2012 |
| 20120064637 | PREWETTING LATERAL FLOW TEST STRIP - A test strip and method for detecting an analyte present in a sample. The test strip comprising: a buffer addition zone to which a buffer may be added; an absorbent zone proximal to the buffer addition zone; one or more test zones distal to the buffer addition zone, at least one of the test zones including a first analyte binding agent immobilized therein which is capable of binding to the analyte to be detected; a terminal buffer flow zone distal to the one or more test zones, the absorbent zone being positioned relative to the buffer addition zone and having an absorption capacity relative to the other zones of the test strip such that when a volume of buffer within a predetermined buffer volume range for the test strip is added to the buffer addition zone, a distal diffusion front of the buffer diffuses from the buffer addition zone to a distal diffusion point within the terminal buffer flow zone and then diffuses proximal relative to the one or more test zones; and a sample addition zone distal to the terminal buffer flow zone to which a sample may be added. | 03-15-2012 |
| 20120064638 | SAMPLE PROCESSING APPARATUS AND SAMPLE PROCESSING METHOD - A sample processing apparatus for performing a process including a plurality of steps on a sample, the sample processing apparatus sequentially processing a plurality of samples, is disclosed. The apparatus comprises a plurality of units corresponding to the respective steps in the process; a transfer section which transfers a sample to the units according to a flow of the steps; and a controller. Specifically, when an operation was not performed successfully, the controller interrupts the process for a sample that had not reached the location where the unsuccessful operation was performed while continuing the process for a sample that had already passed the location, retries the operation that was not performed successfully, and resumes the interrupted process when the retried operation has been performed successfully. | 03-15-2012 |
| 20120064639 | STABLE ELASTOMERIC NEGATIVE ACOUSTIC CONTRAST PARTICLES AND THEIR USE IN ACOUSTIC RADIATION FIELDS - We describe methods for synthesis and formulations of stable elastomeric negative acoustic contrast particles with controllable compressibility and density. These elastomeric negative acoustic contrast particles have a density/compressibility ratio that is less than that of water and therefore exhibit negative acoustic contrast under acoustic radiation exposure. This negative acoustic contrast allows our elastomeric negative acoustic contrast particles to be acoustically manipulated (e.g. separated) differently from other components (e.g. cells) within an aqueous solution. This disclosure also describes methods for biofunctionalization of the elastomeric negative acoustic contrast particles and as an example their use as platforms for bioassays. Potential applications of these elastomeric negative acoustic contrast particles include sensitive bioassays based on acoustic flow cytometry and other types of techniques that utilize acoustic fields, including ultrasound imaging and ultrasound triggered drug delivery. | 03-15-2012 |
| 20120070908 | IMMUNO CONJUGATE AND PROCESS FOR PREPARATION THEREOF - Present invention deals with a new immuno-reagent comprising hapten (MPAD)-protein-gold for pesticides detection. The conjugate MPAD-protein-gold competes with the analyte of interest for a finite number of binding sites provided by anti-atrazine antibodies coated on nitrocellulose membrane. The newly developed conjugate has a long shelf life with high stability at 4° C. The dynamic concentration range for standard atrazine solutions shows a linear inhibition (decrease in intensity of color) between 10 ppb to 1 ppm atrazine in water samples. | 03-22-2012 |
| 20120070909 | LABEL-FREE METHOD FOR DETECTING PRESENCE OR ABSENCE OF NUCLEIC ACIDS - The present invention is directed to a method of detecting presence or absence of a target nucleic acid using negatively charged metallic nanoparticles dissolved in a solution. A nucleic acid probe with a substantially neutral net charge is used for detecting the target nucleic acid. The present invention is also directed to a kit including at least one nucleic acid probe with a substantially neutral net charge and at least one type of negatively charged metallic nanoparticles for carrying out the method. | 03-22-2012 |
| 20120070910 | MICROANALYSIS METHODS AND SYSTEMS USING FIELD EFFECT TRANSISTOR - Provided is a microanalysis method and system using a Field Effect Transistor (FET). The microanalysis method includes a channel region having a receptor molecule fixed; forming a nano-particle conjugate in the channel region by supplying a sample for test and the nano-particle conjugate to the FET; growing a probe material on the channel region; and measuring a current flowing through the channel region, wherein the receptor molecule is a material that is selectively bonded to a target molecule in the sample for test. | 03-22-2012 |
| 20120070911 | Method of Detecting and Quantifying Analytes of Interest in a Liquid and Implementation Device - The invention provides a method of detecting and quantifying analytes present in a solution, which is portable, rapid, inexpensive, selective and ultra-sensitive. For this purpose, the subject of the invention is a method of detecting and quantifying analytes of interest ( | 03-22-2012 |
| 20120070912 | DETECTION METHOD AND QUANTIFICATION METHOD FOR TARGET SUBSTANCE - Provided are a detection method and a quantification method for a detection target, which can detect and quantify the detection target rapidly, inexpensively, simply, and with high accuracy in a variety of environments. A method for detecting the detection target in a specimen includes processes in which there are mixed a first binding substance which binds a first material containing a stimuli-responsive polymer and a first affinity substance which has affinity for the detection target, a second binding substance which binds a hydrophilic second material and a second affinity substance which has affinity for the detection target, and a specimen; the resulting mixture is placed under conditions where the stimuli-responsive polymer agglutinates and the mixture is developed into a developing carrier, or the resulting mixture is developed into a developing carrier and the mixture is placed under conditions where the stimuli-responsive polymer agglutinates; the signal produced by the presence of the first binding substance or the second binding substance in the developing carrier is verified; and the presence of the detection target in the specimen is determined when the signal is different from that when the detection target is absent. The first affinity substance and the second affinity substance can bind to different positions of the detection target. | 03-22-2012 |
| 20120077284 | Binding Surfaces for Affinity Assays - Non-saturated or non-saturated and orientated binding surfaces for an affinity assay are provided, as are methods and compositions for their preparation. The non-saturated or non-saturated and orientated binding surfaces may further comprise paramagnetic microparticles. The methods include methods for making ligand::support coupler-based complexes by a process optionally employing a low input ratio of ligand to support coupler, by dilution, and by methods employing a dispersion and/or coating step using a block copolymer. Specific examples employing biotin-BSA and biotin-ovalbumin binding surfaces are provided, as well as strepavidin-coated microparticles and microparticles coated with capture moieties such as biotinylated immunoglobulins or fragments thereof. Other examples couple a ligand to the solid surface. Further provided are dispersed microparticles and methods for making them. Use of the methods and compositions in connection with a wide variety of analytes and capture moieties is provided, particularly for use in immunoassays. | 03-29-2012 |
| 20120077285 | LAYERING FOR SEPARATING PARTICLES - The present invention relates to a method for purifying biomolecules or for analyzing whether an aqueous phase contains biomolecules by means of magnetic separation. The invention further relates to uses, to devices, and to kits that relate to the method according to the invention. | 03-29-2012 |
| 20120077286 | HIGHLY SENSITIVE IMMUNOASSAY SYSTEMS FOR DETECTING MULTIPLE ALLERGENS - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels. | 03-29-2012 |
| 20120083047 | OVULATION PREDICTOR TEST - The present invention is related to a diagnostic test kit for detecting luteinizing hormone (LH) in a biological sample at a concentration relative to a threshold concentration of LH. The device can include a release medium formed of a first material and including a labeled conjugate with a detectable label and a first binding member reactive with a first epitope of LH and a capture medium formed of a second, different material, in fluid communication with the release medium. The capture medium includes a result site having immobilized thereon a capture component capable of directly or indirectly binding LH that is bound to the labeled conjugate. The device is calibrated such that color development at the result site occurs only when the LH concentration of the liquid sample is greater than the threshold concentration. | 04-05-2012 |
| 20120083048 | METHOD FOR DETECTING LIGAND USING FRET BIOSENSOR - The present application relates to a method for detecting ligand using a biosensor applied the FRET(fluorescence resonance energy transfer) phenomenon. More particularly, the method may be used for simply detecting a ligand in a sample by measuring the FRET of a biosensor under the conditions in which a specific critical temperature is maintained. The method may use a phenomenon in which a ligand-binding protein in a biosensor shows reversible unfolding at a temperature higher than the specific critical temperature and the level of the unfolding changes depending on the concentration of a ligand. The method can be widely applied to a variety of kinds of FRET biosensors using the ligand-binding protein. | 04-05-2012 |
| 20120088311 | Immuno-Detection of a Cancerous State in a Subject - The present invention is based on the finding that antibodies raised against a fragment of PAR1-released peptide may be used to detect in a bodily fluid sample from a subject a marker associated with cancer state, if said subject has cancer. Thus, the present invention provides the methods and packages for conducting one or more of the following: determining a cancerous state in a subject, the method comprises determining binding of an antibody raised against a protease-activated receptor 1 (PAR1) released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, wherein binding of said antibody to said marker being indicative of a cancerous state; determining severity of a cancerous state in a subject comprising determining level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject, and comparing the level of binding with the level of prior determined standards that correlate level of antibody binding to PAR1 released peptide with severity of cancerous state; and determining the effectiveness of a therapeutic treatment of a subject with an anti-cancer agent to the subject comprising determining the level of binding of an antibody raised against PAR1 released peptide or a fragment derived therefrom to a marker within a fluid sample obtained from said subject in two or more successive time points, one or more time points are during the therapeutic treatment, wherein a difference in the level being indicative of effectiveness of therapeutic treatment. | 04-12-2012 |
| 20120088312 | VINCRISTINE IMMUNOASSAY - Novel conjugates and immunogens derived from vincristine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of vincristine in biological fluids. | 04-12-2012 |
| 20120088313 | METHOD FOR DETECTING SUBSTANCE IN BIOLOGICAL SAMPLE - The present invention provides a method for detecting a substance in a biological sample, a carrier for using in the method, and a kit. The method of the present invention includes 1) providing a carrier on which a biotin-binding protein is bound and providing a biotinylated protein by biotinylating a protein that specifically binds to a substance to be detected; 2) binding the biotinylated protein to the carrier provided in step 1) to produce a biotinylated protein-bound carrier; 3) mixing (a) a biological sample, and (b-i) a cell homogenate extract prepared from cells of the same species as that of the host cells used for expressing, for example, the biotin-binding protein in step 1), and a biotin-binding protein, or (b-ii) a cell homogenate extract prepared from cells of the same species as that of the host cells used for expressing, for example, the biotin-binding protein in step 1) and genetically engineered to express a biotin-binding protein, and adding the mixture to the biotinylated protein-bound carrier produced in step 2); and 4) detecting the substance specifically bound to the biotinylated protein. | 04-12-2012 |
| 20120088314 | ASSAY FOR MONITORING ACTIVITY OF FRIZZLED RECEPTORS - The present invention relates to cell free assays for measuring receptor activity, especially for measuring a constitutive or a non-constitutive activity of frizzled receptors and uses thereof. The present invention further concerns a method for measuring a constitutive or non-constitutive activity of a frizzled receptor and a method for obtaining an active frizzled receptor ligand. | 04-12-2012 |
| 20120088315 | DEVICE HAVING SELF-ASSEMBLED-MONOLAYER - A device for bio-sensing applications is disclosed, comprising a substrate such as a semiconductor chip having Cu electrodes thereon, and a self assembled monolayer bonded to at least one of the Cu electrodes, wherein molecules of the self-assembled monolayer comprise a head group which bonds to Cu, a carbon-comprising chain comprising a chain of at least 12 C atoms, and a terminal group which is hydrophilic and for binding a bio-receptor. The terminal group is hydrophilic to allow binding to the bio-receptor, and inclusion of the carbon-comprising chain, limits or avoids corrosion of the copper. Also disclosed is a method of providing such a device, activating the terminal group and coupling a bio-receptor to the activated terminal group. Disclosure further extends to use of such a device for bio-sensing applications. | 04-12-2012 |
| 20120094394 | HOMOGENEOUS AGGLUTINATION IMMUNOASSAY METHOD AND KIT FOR SUCH METHOD - A homogeneous agglutination immunoassay method wherein a sample possibly containing the analyte to be measured is mixed with a binding partner for the analyte and with at least one chaotropic agent, monovalent ions in form of at least one salt, or with a combination of at least one chaotropic agent and monovalent ions in form of at least one salt, measuring at least one signal related to interactions of the binding partner with the analyte over a reaction time and calculating from at least one of the signals measured the concentration of analyte in the sample. | 04-19-2012 |
| 20120094395 | Methods for identifying a subject who has developed an anti-antibody response - Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies. | 04-19-2012 |
| 20120094396 | METHODS AND COMPOSITION FOR MEASURING THE AMOUNT OF VITAMIN D DERIVATIVES - Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed. | 04-19-2012 |
| 20120100631 | BIOSENSOR DEVICE FOR SENSING AMPHIPATHIC ANALYTES - The current invention relates to sensing elements and devices comprising at least one amphipathic lipid-binding protein or fatty acid binding protein, wherein the binding proteins are associated with a luminescent reporter group. The binding proteins and luminescent reporter groups are encapsulated within a hydrogel matrix that comprises at least one co-monomer, wherein the co-monomer is present at a concentration that decreases or inhibits micelle formation of the amphipathic lipid. Binding of the amphipathic lipid or fatty acid to the appropriate binding protein can produce at least one detectable change in the property of the luminescent reporter group. | 04-26-2012 |
| 20120100632 | MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF - The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample. | 04-26-2012 |
| 20120100633 | CLICK CHEMISTRY ON HETEROGENEOUS CATALYSTS - The present invention relates to new methods and reagents for coupling molecules by a Click reaction using a heterogeneous catalyst system. Further, the present invention refers to novel devices for carrying out Click reactions | 04-26-2012 |
| 20120100634 | ASSAY SYSTEM FOR DETERMINING BINDING OF HYDROPHOBIC DRUGS - The invention comprises a method for the determination of the binding coefficient of a hydrophobic chemical compound comprising: g. Providing an assay plate with a plurality of rows and columns of test vessels; h. Providing the majority of the test vessels in said assay plate with a polymer, wherein in each row the amount of polymer coating per test vessel is increased; i. Filling each test vessel with a solution of binding partner to which the binding coefficient should be assayed, wherein in each column the amount of binding partner is increased; j. Adding the hydrophobic compound and incubate the plate; k. Determining the concentration of said compound in said polymer or in the solution; l. Calculating the protein binding coefficient of the compound. | 04-26-2012 |
| 20120100635 | RISK ASSESSMENT FOR ANTIBOTICS TREATMENT IN PATIENTS SUFFERING FROM PRIMARY NON-INFECTIOUS DISEASE BY DETERMINING THE LEVEL OF PROCALCITONIN - The present invention relates to a diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic. | 04-26-2012 |
| 20120100636 | APPARATUS AND METHOD FOR MEASURING BINDING KINETICS WITH A RESONATING SENSOR - A subject material in a fluid sample is detected using a resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material. Prior to exposing the resonating sensor to the fluid sample, operation of the resonating sensor is initiated, producing a sensor output signal representing a resonance characteristic of the resonating sensor. Optionally, a reference resonator that lacks binding sites for the analyte is used to produce a reference output signal. Introduction of a fluid sample to the resonating sensor is automatically detected based on a characteristic change in the sensor output signal or a reference output signal. In response to the detecting of the introduction of the fluid sample, automated measurement of the binding kinetics are measured. | 04-26-2012 |
| 20120100637 | GENETIC MARKERS OF SCHIZOPHRENIA ENDOPHENOTYPES - This document provides methods and materials related to genetic markers of schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD), (collectively referred to herein as “schizophrenia spectrum disorders” or SSDs). For example, methods for using such genetic markers to identify an SSD (e.g., SZ) endophenotype are provided. | 04-26-2012 |
| 20120100638 | Method and Test Strip for Detection of Residues - A method, test strip and method of manufacturing a test strip useful for detecting one or more analytes, such as an antibiotic, in a test sample such as a milk sample. The test strip and method include a labeled specific binder and test capture agent for the specific binder that increases test sensitivity to the analyte for which the specific binder has affinity while decreasing test sensitivity to an analyte for which a multianalyte binder has affinity. | 04-26-2012 |
| 20120107952 | MICROWAVE-ACCELERATED PLASMONICS - The present invention relates to systems and methods using microwave accelerated surface plasmonics for the detection of target species, wherein the system has a metallic surface and the system is exposed to microwave energy for increasing detection time and/or the reaction kinetics of the target species and other interacting participants in the system and wherein plasmonic emissions from the metallic surface alone or coupled with emissions from a luminescing entity are detected. | 05-03-2012 |
| 20120107953 | STABILIZATION OF INTERLEUKIN 6 IN SERUM BASED SOLUTIONS - Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C | 05-03-2012 |
| 20120107954 | PHYSIOLOGIC SAMPLE PREPARATION FOR NANOSENSORS - The present invention provides a microfluidic purification chip for capturing a biomarker from a physiological solution. The present invention also provides a method of capturing and releasing a biomarker, wherein the biomarker is originally in a physiological solution. The present invention further provides a method of pre-purifying and measuring the concentration of a biomarker in a physiological solution. | 05-03-2012 |
| 20120107955 | METABOLITE BIOMARKERS FOR THE DETECTION OF ESOPHAGEAL CANCER USING MS - Results of studies of nucleosides in biofluid specimens from patients with esophageal adenocarcinoma and related disorders have identified five biomarkers of the conditions: 1-methyladenosine, N | 05-03-2012 |
| 20120107956 | INDIRECT LATERAL FLOW SANDWICH ASSAY - Disclosed herein are indirect lateral flow sandwich assays, in which the target analyte binds an analyte-specific reagent comprising a first member of a conjugate pair, forming a complex which contacts and binds a colored particulate label comprising a complementary member of said conjugate pair, forming a second complex. Capture of this analyte-comprising, second complex by an immobilized analyte specific capture reagent results in the formation of an immobilized labeled sandwich complex that can be detected. | 05-03-2012 |
| 20120107957 | TEST REAGENT, AND METHOD FOR MEASURING ANALYTE IN TEST SAMPLE USING SAME - Object: To provide a test reagent for the analyte in a test sample, utilizing the level of agglutination of a particle suspension which suspend insoluble carrier particles carrying a substance for capturing the analyte as an indicator, which reagent does not undergo self-agglutination during storage, and which non-specific agglutination rarely occurs during measurement, as well as to provide a method for the analyte to be measured in a test sample. Means for Solution: The test reagent for the analyte comprises at least a Solution A which is a buffer solution having an electric conductivity of not less than 30 ms/cm; and a Solution B having an electric conductivity of not more than 6.5 ms/cm, the Solution B being a particle suspension which suspends particles which are insoluble carrier particles carrying a substance for capturing the analyte. | 05-03-2012 |
| 20120107958 | MICROBEAD OPTICAL SENSOR WITH LAYERED PLASMON STRUCTURE FOR ENHANCED DETECTION OF CHEMICAL GROUPS BY SERS - An optical sensor and method for use with a visible-light laser excitation beam and a Raman spectroscopy detector, for detecting the presence chemical groups in an analyte applied to the sensor are disclosed. The sensor includes a substrate, a plasmon resonance mirror formed on a sensor surface of the substrate, a plasmon resonance particle layer disposed over the mirror, and an optically transparent dielectric layer about 2-40 nm thick separating the mirror and particle layer. The particle layer is composed of a periodic array of plasmon resonance particles having (i) a coating effective to binding analyte molecules, (ii) substantially uniform particle sizes and shapes in a selected size range between 50-200 nm (ii) a regular periodic particle-to-particle spacing less than the wavelength of the laser excitation beam. The device is capable of detecting analyte with an amplification factor of up to 10 | 05-03-2012 |
| 20120107959 | BAIT CHEMISTRIES IN HYDROGEL PARTICLES FOR SERUM BIOMARKER ANALYSIS - This invention describes the identification of novel organic dye chemistries that can be used as affinity baits to capture proteins and other biomolecules useful in the fields of medical diagnostics, environmental science, toxicology, and infectious disease. Incorporation of unique affinity dye compounds within hydrogel capture particles improves analyte yield and preanalytical precision, and stabilizes the analyte against degradation, while increasing measurement sensitivity. The particles in this invention can be used for routine clinical testing as well as for discovery of low abundance disease biomarkers. Example hydrogel particles containing new high affinity bait chemistries were used to identify a new set of human serum biomarkers. | 05-03-2012 |
| 20120107960 | NONLINEAR LUMINESCENT MOLECULE, FLUORESCENT STAIN, AND OBSERVATION METHOD(AS AMENDED) - The present invention relates to a nonlinear fluorescent molecule that generates a nonlinear fluorescence reaction by incidence of excitation light. This nonlinear fluorescence molecule includes donors and, and an acceptor that is coupled to the donors and. As the donor is excited by the incidence of the excitation light, electric charge moves from the donor to the acceptor. Then, the donor and the acceptor form a charge separated state. In a state in which the charge separated state is maintained, the donor fluoresces when transiting from an excited state to a ground state. | 05-03-2012 |
| 20120107961 | MAGNETIC SENSOR DEVICE, METHOD OF OPERATING SUCH A DEVICE AND SAMPLE - A sensor device ( | 05-03-2012 |
| 20120115244 | MATERIALS AND METHODS FOR IMMUNOASSAY OF PTERINS - Methods of assaying for (i) a pterin by immunoassay employing a pterin as capture agent, (ii) neopterin by chemiluminescent microparticle immunoassay (CMIA) employing an anti-neopterin antibody (Ab) as capture agent, (iii) neopterin by an immunoassay (IA) employing an acridinium (Acr)-labeled anti-neopterin Ab as conjugate, and (iv) neopterin by an IA employing Acr-labeled neopterin as tracer; an Acr-labeled anti-neopterin Ab; a conjugate/complex comprising anti-neopterin Ab and a carrier scaffold; a conjugated pterin; a conjugate comprising an Acr-labeled pterin and a carrier scaffold; an immunogen comprising neopterin and a carrier protein; a conjugate comprising such an immunogen and an Acr compound; an immunogen comprising a carrier protein and a neopterin hapten; a conjugate comprising such an immunogen and an Acr compound; a kit for assaying a pterin comprising a pterin as a capture agent and instructions for IA; and a kit for assaying neopterin comprising an anti-neopterin Ab as a capture agent and instructions for CMIA, neopterin comprising an Acr-labeled anti-neopterin Ab as a conjugate and instructions for IA, or Acr-labeled neopterin as a tracer and instructions for IA. | 05-10-2012 |
| 20120115245 | ASSAYING SUBSTRATE WITH SURFACE-ENHANCED RAMAN SCATTERING ACTIVITY - A metal substrate obtained by agglomerating 5 nm to 100 nm metal nano-particles (including clusters) having SERS activity on a metal substrate having a lower electrode potential (higher ionization tendency) than the electrode potential of the metal nano-particles, and fixing the metal nano-particles in an optimally agglomerated state that acts as hot sites, when a detection specimen is adsorbed in a non-dried state, and a predetermined laser light is irradiated, the surface enhanced Raman scattered (SERS) light of antigen detection specimen can be detected by surface Raman resonance in an optimally agglomerated state. | 05-10-2012 |
| 20120115246 | MICROFLUIDIC DEVICE COMPRISING SENSOR - The invention relates to a microfluidic device for performing detection of a substance in a liquid sample, wherein a cavity ( | 05-10-2012 |
| 20120115247 | DRUG MONITORING ASSAY - A method for obtaining at least one binding agent which binds a pharmaceutically active form of the compound with a higher specificity than a pharmaceutically inactive form of the compound is described by using special derivatives of said parent compound. The invention also pertains to the respectively created binding agents and derivatives. Furthermore, drug monitoring assays using said binding agents for monitoring pharmaceutically active forms of said parent compound are provided. | 05-10-2012 |
| 20120115248 | METHODS OF DETERMINING THE PRESENCE AND/OR CONCENTRATION OF AN ANALYTE IN A SAMPLE - Compositions, methods, and systems for monitoring analyte levels are provided herein. The disclosure provides methods and systems for the real-time monitoring of analytes, such as citrate, calcium, phosphate and magnesium, in a biological fluid in a clinical setting. | 05-10-2012 |
| 20120115249 | Biomarker for Selecting Patients and Related Methods - The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment. | 05-10-2012 |
| 20120122233 | METHOD FOR RISK STRATIFICATION IN STABLE CORONARY ARTERY DISEASE - An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations. | 05-17-2012 |
| 20120122234 | FLUIDIC INDICATOR DEVICE - Disclosed is a fluidic assay device for assaying at least one property of a liquid sample comprising: a liquid sample application region; at least one test flow path in liquid flow communication with the sample application region; a reference flow path in liquid flow communication with the sample application region; and a junction region, at which the test flow path and the reference flow path contact one another, the junction region typically comprising an outlet, conduit, chamber or other portion which permits the onward flow of liquid; wherein a liquid flowing along the reference flow path, upon reaching the junction region, has the effect of preventing the flow of liquid along the test flow path. The invention relates to a fluidic device for the passage of a liquid and an assay device suitable for measurement of the amount and/or presence of an analyte in, or property of, a fluid sample. | 05-17-2012 |
| 20120122235 | Devices and Methods for Detection of Biomolecular Interactions - Devices, systems, and methods are provided for the detection of biomolecular interactions. The interactions between one or more target DNA strands, one or more receptor DNA strands, and one or more probe DNA strands, if necessary, are used to detect the one or more target DNA strands. The one or more target DNA strands or the one or more probe DNA strands may be coupled to a magnetic bead, and the one or more receptor strands may be coupled to the Hall device. | 05-17-2012 |
| 20120122236 | METHOD AND SYSTEM UTILIZING LATERAL FLOW IMMUNOASSAY TEST DEVICE WITH INTEGRATED QUALITY ASSURANCE LABEL - The present invention provides a method and system for performing analyte analysis with improved reliability of test results through use of quality assurance labels for accuracy and robust results. | 05-17-2012 |
| 20120122237 | HOMOGENEOUS NONCOMPETITIVE DETECTION OF POST TRANSLATIONAL MODIFICATIONS FOR USE IN HIGH THROUGHPUT ASSAYS - A non-competitive immunoassay method for detection of post-translationally modified (PTM) proteins is disclosed. The method will enable the direct detection of PTM proteins in solution or on solid phase with a single reagent addition step, and with improved selectivity for specific PTM sites on target proteins. The key to the method is the use of a secondary binding molecule that specifically recognizes the immune complex between the primary antibody and the antigen. | 05-17-2012 |
| 20120122238 | VMP-Like Sequences of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies. | 05-17-2012 |
| 20120122239 | HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide or human NT-pro B-type natriuretic peptide fragment in a test sample. | 05-17-2012 |
| 20120122240 | BIOASSAYS USING PLASMONIC SCATTERING FROM NOBLE METAL NANOSTRUCTURES - The present invention relates to detecting and/or measuring scattering effects due to the aggregating metallic nanostructures or the interaction of plasmonic emissions from approaching metallic nanoparticles. The scattering effects may be measured at different angles, different wavelengths, changes in absorption and/or changes in polarization relative to changes in the distances between nanoparticles. | 05-17-2012 |
| 20120122241 | IDENTIFICATION AND MONITORING OF SYSTEMIC LUPUS ERYTHEMATOSUS - A method for identifying or monitoring SLE in an individual is provided. The method includes quantitating complement component C4 | 05-17-2012 |
| 20120122242 | METHOD FOR ASSESSING ARTERIOSCLEROSIS AND DIABETIC NEPHROPATHY - A method for assessing arteriosclerosis comprising measuring the serotonin level in whole blood, serum or platelet-rich plasma and rating the serotonin level on such a scale that the lower it is, the more serious the arteriosclerosis is. | 05-17-2012 |
| 20120122243 | MEANS AND METHOD AND MEANS FOR DIAGNOSING PROSTATE CARCINOMAS - The present invention relates to a method, preferably an ex vivo method, for diagnosing prostate carcinomas and/or predisposition thereof comprising determining at least one metabolite in a test sample of a subject suspected to suffer from prostate carcinomas or to have a predisposition therefor and comparing said at least one metabolite to a reference, whereby prostate carcinomas or a predisposition therefor is to be diagnosed. Moreover, the present invention encompasses a collection of metabolites, a data collection comprising characteristic values of metabolites and a storage medium comprising said data collection. Furthermore, the present invention also relates to a system comprising means for comparing characteristic values of metabolites of a sample operatively linked to a data storage medium. Further encompassed by the present invention are diagnostic means comprising at least one metabolite and the use of said at least one metabolite for the manufacture of diagnostic means for or for diagnosing prostate carcinomas. Finally, the present invention pertains to a method for identifying prostate carcinoma-related metabolites. | 05-17-2012 |
| 20120122244 | Method Of Identifying Compounds That Inhibit Fertilization - A method of identifying compounds that inhibit fertilization is provided. The method can include selecting compounds that bind to equatorin protein. Two types of equatorin protein, a long form and a short form, can be present in the testis. The amino acid sequence of mouse equatorin from positions 101 to 146 including the 138th O-glycosylated threonine residue contains an epitope recognized by anti-equatorin antibody MN9 that has an effect of inhibiting fertilization. In addition, the MN9 antibody also binds to human sperm. Compounds that bind to the epitope can inhibit fertilization. Both forms of mouse equatorin can be used as well as human equatorin to identify compounds that inhibit fertilization. | 05-17-2012 |
| 20120122245 | ALLOYED METAL COLLOID - Provided is a metal colloid having higher visibility and higher sensitivity than a gold colloid and a Au-core Pt-shell composite colloid and suitable as a labeling agent for use in a test such as an immunoassay. An alloyed Au/Pt composite colloid formed by mixing a gold salt and a platinum salt with at least one reducing agent selected from the group consisting of an amino acid and a derivative thereof, an oligopeptide and a derivative thereof, and an amino sugar in the presence of an alkali, thereby reducing the gold salt and platinum salt. | 05-17-2012 |
| 20120129270 | VESICULAR SYSTEM AND USES THEREOF - Disclosed is a vesicular system comprising a surface with a vesicle immobilized thereon. The immobilized vesicle has a circumferential membrane of an amphiphilic polymer. The vesicle is coupled to a surface by means of a molecule with a non-polar moiety. The non-polar moiety comprises a main chain of 3 to about 30 carbon atoms and 0 to about 12 heteroatoms selected from Si, O, S, and Se. The molecule with the non-polar moiety is coupled to the surface via a covalent or non-covalent bond. A portion of the non-polar moiety is integrated in the circumferential membrane. | 05-24-2012 |
| 20120135538 | AGENT AND METHOD FOR IDENTIFYING LYSINE CROTONYLATION IN PROTEINS - A method and related agent for detecting novel post-translational modification. This novel post-translational modification is in the form of crotonylation of lysine residues in proteins. The method includes the steps of (a) preparing a mixture of polypeptides from a protein sample; (b) separating the polypeptides by molecular weight; (c) contacting the separated polypeptides with a binding affinity reagent which binds specifically to a polypeptide containing a crotonyllysine residue; and (d) detecting presence of a binding complex between the affinity reagent and one or more of the polypeptides. An example of the binding agent is an antibody, which may be prepared from animal serums, or is a monoclonal antibody or single-chain variable fragment. | 05-31-2012 |
| 20120135539 | Split DNA Enzyme for Visual Single Nucleotide Polymorphism Typing - A probe that changes solution color in the presence of only one of the two DNA sequences, which differ by a single nucleotide, is reported. The probe consists of two oligodeoxyribonucleotides, which form a hydrogen peroxidase-like DNA enzyme when hybridized to the abutting fragments of the complementary analyte. The active peroxidase catalyses oxidation of colorless substrates to the colored products. The probe allows visual detection of a mutation in Alzheimer's disease-related DNA. | 05-31-2012 |
| 20120135540 | Methods and compositions of nucleic acid ligands for detection of clinical analytes related to human health - Specific DNA sequences for binding various clinically relevant analytes from the human body are described. Each of these sequences or their linear, two- and three-dimensional linked sequences can function in varying assay and sensor formats with varying degrees of success. Linkage of the whole or partial DNA sequences (putative binding sites) can be used to enhance specificity and affinity towards complex targets, thereby improving assay selectivity and sensitivity in many instances. In addition, a FRET-based quantitative method is described for normalizing analyte data by assessing urine creatinine and urea levels. Finally, a method is described for removing creatinine or urea by size-exclusion chromatography prior to a FRET-based aptamer assay to avoid the denaturing effects of these compounds. | 05-31-2012 |
| 20120135541 | MULTI-DIRECTIONAL MICROFLUIDIC DEVICES COMPRISING A PAN-CAPTURE BINDING REGION AND METHODS OF USING THE SAME - Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays. | 05-31-2012 |
| 20120135542 | METHODS AND MATERIALS FOR DIAGNOSING LIGHT CHAIN AMYLOIDOSIS - This document relates to methods and materials involved in diagnosing light chain amyloidosis. For example, methods and materials for using exosomes to diagnose a mammal (e.g., a human) as having immunoglobulin light chain amyloidosis are provided. | 05-31-2012 |
| 20120142119 | Novel gold nanoparticle aggregates and their applications - The invention is drawn to a method of using nanoparticle aggregates to form sensors and optical filters. Properly sized (60 and 200 nm) nanoparticle aggregates with cores having a sulfur-oxygen molecular species and a shell with a surface in contact with the core are obtained. Those nanoparticle aggregates have a first resonance profile to wavelengths between 350 nm and 1075 nm. A modified resonance profile for those nanoparticle aggregates is determined. The nanoparticle aggregates are then selectively sized by irradiating them with electromagnetic energy at sufficient intensity and spectral content to modify the first resonance profile towards the modified resonance profile. The resulting nanoparticle aggregates can be used as sensors or optical filters at a selected wavelength. | 06-07-2012 |
| 20120142120 | VASOACTIVE HORMONE-BASED STRATIFICATION OF PATIENTS SUFFERING FROM DISEASES RELATED TO ENDOTHELIAL FUNCTION/DYSFUNCTION - The present invention relates to a method for the stratification of a subject having an acute or a chronic disease, wherein said disease effects endothelial function/dysfunction, comprising the steps of (i) taking a sample of bodily fluid from said subject; (ii) determining in said sample of bodily fluid the concentration of a vasoactive hormone or fragments thereof or precursors or fragments thereof having a length of at least 12 amino acid residues; (iii) stratifying said subjects into either of the categories: (a) responder to a medication for treatment of said disease, (b) non-responder to a medication for treatment of said disease not showing an unfavourable effect after having received said medication; (c) subjects showing an unfavourable effect after having received said medication. The invention also relates to the use of an antibody or a functional fragment thereof in the method according to the invention. | 06-07-2012 |
| 20120149128 | ASSAYS AND ASSAY DEVICES - Methods and apparatus for conducting analyte assays, including multiplexed assays are described. Such methods include assays adapted for low volume assay devices in which assays can be performed using undiluted biological liquid samples by exchanging binding medium with detection medium, using layered labels, and/or using droplet based mixing in an assay device. | 06-14-2012 |
| 20120149129 | LOW COST, PORTABLE SENSOR FOR MOLECULAR ASSAYS - An integrated sensor that is capable of discriminating the distance of a label from the sensor without using an optical signal. The label is attached to a single probe molecule or a group of probe molecules that interacts with a single or group of target molecules. As a consequence of this interaction, the probe molecule and/or the target molecule undergo a conformal change. This conformal change leads to perturbations in the distance of the label from the sensor. Thus, measurements and properties such as the concentration and the identity of one or more target molecules can be discerned from signals generated by the sensor (or by a plurality of sensors in a sensor array) and subjected to analysis using general purpose programmable computers programmed with suitable software that controls the analytical process, and such measurements and properties can be provided as a result of the analysis. | 06-14-2012 |
| 20120149130 | POLYPEPTIDES FOR THE IN VITRO ASSESSMENT OF THE SENSITISING POTENTIAL OF A TEST COMPOUND - The invention relates to novel polypeptides and to the use thereof for the in vitro assessment of the sensitising potential of a test compound, to a method for the in vitro assessment of the sensitising potential of a test compound, to an in vitro method for selecting a compound suitable for reducing the sensitisation, as well as to kits for implementing such methods. | 06-14-2012 |
| 20120149131 | PROCALCITONIN FOR THE PROGNOSIS OF ADVERSE EVENTS - The present invention relates to an in vitro method for the prognosis of an adverse event in asymptomatic subjects comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk of sustaining an adverse event. | 06-14-2012 |
| 20120156802 | SWEPT-FREQUENCY SEMICONDUCTOR LASER COUPLED TO MICROFABRICATED BIOMOLECULAR SENSOR AND METHODS RELATED THERETO - An optoelectronic swept-frequency semiconductor laser coupled to a microfabricated optical biomolecular sensor with integrated resonator and waveguide and methods related thereto are described. Biomolecular sensors with optical resonator microfabricated with integrated waveguide operation can be in a microfluidic flow cell. | 06-21-2012 |
| 20120156803 | BIOLOGICALLY-ACTIVE RADIOLABELED CRY1FA AND RECEPTOR BINDING ASSAY METHODS - Cysteine-specific radiolabeled Cry1Fa protein retains insecticidal activity against insect pests and binds to insect brush border membrane vesicle receptors in a saturable manner. The biologically-active radiolabeled Cry1Fa protein is useful in competitive binding assays with other Cry toxins. | 06-21-2012 |
| 20120156804 | METHOD FOR DETERMINING PROTEIN-NUCLEIC ACID INTERACTION - The present invention refers to a method of determining protein-nucleic acid interaction. The method comprises mixing a protein with a sample comprising a nucleic acid which is suspected to interact with the protein to form a first mixture. The first mixture can be incubated to allow interaction between the protein and nucleic acid. Metallic nanoparticles are added to the first mixture to obtain a second mixture. An electrolyte is added to the first or second mixture to determine the protein-nucleic acid interaction. The present invention also refers to a kit for determining protein-nucleic acid interaction. The kit comprises a protein capable of interacting with a nucleic acid or a nucleic acid capable of interacting with a protein, and at least one type of metallic nanoparticle. | 06-21-2012 |
| 20120156805 | Assay For Immunosuppressant Drugs - The invention provides immunoassays for immunosuppressant drugs, wherein the assay is carried out under high salt conditions to achieve improved sensitivity. The invention also provides kits that are useful for performing the methods of the invention. | 06-21-2012 |
| 20120164751 | Rapid Test Apparatus - Provided herein are methods and devices for rapid testing of solid, semi-solid, or liquid specimens, such a stool, blood, urine, saliva, or swab specimens of the cervix, urethra, nostril, throat, and for environmental testing. | 06-28-2012 |
| 20120164752 | IMMUNOASSAY METHOD AND REAGENT THEREFOR - [Problems] An object of the present invention is to provide a novel method which can expand the measurement range in an immunoassay method. | 06-28-2012 |
| 20120164753 | MONOLITHIC FBAR-CMOS STRUCTURE SUCH AS FOR MASS SENSING - An apparatus comprises a thin-film bulk acoustic resonator such as including an acoustic mirror, a piezoelectric region acoustically coupled to the acoustic mirror, and first and second conductors electrically coupled to the piezoelectric region. In an example, an integrated circuit substrate can include an interface circuit connected to the first and second conductors of the resonator, the integrated circuit substrate configured to mechanically support the resonator. An example can include an array of such resonators co-integrated with the interface circuit and configured to detect a mass change associated with one or more of a specified protein binding, a specified antibody-antigen coupling, a specified hybridization of a DNA oligomer, or an adsorption of specified gas molecules. | 06-28-2012 |
| 20120164754 | KIT AND METHOD OF DETERMINING NUCLEOTIDE SEQUENCE OF TARGET NUCLEIC ACID - A kit for determining a nucleotide sequence of a target nucleic acid, and a method of determining a nucleotide sequence of a target nucleic acid using the kit are disclosed. | 06-28-2012 |
| 20120164755 | Selective Ion Binding Nanomaterials - Nanoparticles with a patterned ligand coat can bind ions selectively. The ligand patterning can arise via self-assembly when two chemically dissimilar (e.g., in size and/or hydrophilicity) ligands are used together. One of the ligands can include one or more moieties capable of interacting with an ion, such as ether oxygens, hydroxyl groups, amine nitrogens, or other groups having a lone pair of electrons. Ion binding can be both selective and reversible. | 06-28-2012 |
| 20120164756 | ASPIRIN ASSAY - The invention describes a method for monitoring and detecting non-therapeutic, therapeutic and toxic concentrations of aspirin in individuals which uses the urinary salicylic acid to salicyluric acid ratio. | 06-28-2012 |
| 20120171778 | FUNCTIONALIZATION OF NANOFLUIDIC CHANNELS - A functionalized nanofluidic channel and method for functionalization that provides control over the ionic environment and geometry of the nanofluidic channel with the immobilization of biomolecules on the inner surface of the channel and use of high ionic concentration solutions. In one embodiment, the surface charge of the nanochannel is controlled with the immobilization of a protein such as streptavidin in the nanochannel. In another embodiment, the biomolecules are receptors and changes in nanochannel conductance indicates ligand binding events. The functionalized nanofluidic channel can be easily adapted for use with microchannel arrays. | 07-05-2012 |
| 20120171779 | ANTIBODIES THAT SPECIFICALLY BIND HEDGEHOG-DERIVED POLYPEPTIDES - The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′ CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. | 07-05-2012 |
| 20120171780 | FLUORESCENT POLYMERS AND METHODS FOR SOLID-PHASE EXTRACTION - The apparatus of the present invention comprises a fluorescent polymer contained within a solid-phase extraction (SPE) carrier. The fluorescent polymer is capable of adsorbing an analyte by means of functional monomers. In use of the apparatus, a sample, such as a foodstuff sample, is applied to the fluorescent polymer. If the sample comprises the analyte, adsorption of the analyte onto the fluorescent polymer causes quenching of the fluorescence of the fluorescent polymer. Fluorescence quenching can be detected using a fluorometer or transillumination system. The method can be used to determine whether mycotoxins are present in foodstuff samples. | 07-05-2012 |
| 20120171781 | HIGHLY SENSITIVE IMMUNOASSAY WITH LARGE PARTICLE LABELS - The present invention is related to an immunoassay for the detection of an analyte in a sample, said assay comprising a plurality of moieties capable of binding to said analyte, wherein capture moieties which are not specific for the same epitope are bound to a solid substrate, and at least one epitope-specific detection moiety is bound to a detectable marker, and wherein the detectable marker to which the epitope-specific detection moiety is bound is a large particle marker having a particle size of ≧50 nm and ≦5000 nm. | 07-05-2012 |
| 20120178180 | METHODS FOR THE IDENTIFICATION OF ZAP-70 INTERACTING MOLECULES AND FOR THE PURIFICATION OF ZAP-70 - The invention provides in a first aspect a method for the identification of an ZAP-70 interacting compound, comprising the steps of a) providing a protein preparation containing phosphorylated ZAP-70, b) contacting the protein preparation with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, c) incubating the aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex with a given compound, and d) determining whether the compound is able to separate phosphorylated ZAP-70 from the immobilized aminopyrido-pyrimidine ligand 24. In a second aspect, the present invention relates to A method for the identification of an ZAP-70 interacting compound, comprising the steps of a) providing a protein preparation containing phosphorylated ZAP-70, b) contacting the protein preparation with ligand aminopyrido-pyrimidine ligand 24 immobilized on a solid support and with a given compound under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and c) detecting the aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in step b). In a third aspect, the invention provides a method for the identification of an ZAP-70 interacting compound, comprising the steps of: a) providing two aliquots of a protein preparation containing phosphorylated ZAP-70, b) contacting one aliquot with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, c) contacting the other aliquot with aminopyrido-pyrimidine ligand 24 immobilized on a solid support and with a given compound under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and d) determining the amount of aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in steps b) and c). In a forth aspect, the invention relates to a method for the identification of an ZAP-70 interacting compound, comprising the steps of: a) providing two aliquots comprising each at least one cell containing phosphorylated ZAP-70, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, d) lysing the cells in order to obtain protein preparations, e) contacting the protein preparations with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, and f) determining the amount of aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex formed in each aliquot in step e). | 07-12-2012 |
| 20120178181 | DEVICE AND METHOD FOR LABEL-FREE DETECTION OF DNA HYBRIDIZATION - A device and method for detecting the hybridization of an unmodified target deoxyribonucleic acid (DNA) molecule including exposing a Raman substrate to the unmodified target DNA molecule, where the unmodified target DNA molecule is a complementary DNA molecule to a thiol-terminated probe DNA molecule covalently linked to the Raman substrate. Also, the thiol-terminated probe DNA molecule includes an adenine analog substituted for adenine. The hybridization of the unmodified target DNA molecule to the thiol-terminated probe DNA molecule is detected by measuring a Raman spectroscopic response of the Raman substrate. | 07-12-2012 |
| 20120178182 | MICROFLUIDIC DEVICE AND ANALYTE DETECTION METHOD USING THE SAME - Provided are a micro-fluidic device having multiple reaction chambers to simultaneously detect a plurality of different analytes, and an analyte detection method using the same. The micro-fluidic device includes multiple reaction chambers containing a plurality of capture materials to be combined with different analytes, multiple channels connecting the multiple reaction chambers, and valves provided within the multiple channels to control fluid flowing through the channels. | 07-12-2012 |
| 20120178183 | Mass Dots: Nanoparticle Isotope Tags - Compositions and methods are provided for the use of nanoparticles, which may be referred to herein as mass dots, as mass tags for probes such as antibodies, aptamers, nucleic acids, etc. in multiplexed bioassays with ICP-MS detection. | 07-12-2012 |
| 20120178184 | T CELL PROTEINS AND NUCLEOTIDES ENCODING THE SAME - The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma. | 07-12-2012 |
| 20120178185 | IMMUNODIFFUSION ASSAY FOR INFLUENZA VIRUS - A method for performing an immunodiffusion assay comprising at least the following steps of: | 07-12-2012 |
| 20120178186 | BINDING ASSAY WITH MULTIPLE MAGNETICALLY LABELLED TRACER BINDING AGENTS - The present invention relates to a cartridge ( | 07-12-2012 |
| 20120184049 | METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis. | 07-19-2012 |
| 20120184050 | MULTIPLEX SCREENING FOR LYSOSOMAL STORAGE DISORDERS (LSDS) - A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity. Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins. | 07-19-2012 |
| 20120184051 | DEVICE AND METHOD FOR DETECTING AT LEAST ONE SUBSTANCE - A device for detecting at least one substance may include a resonator which, on its surface facing away from the carrier, is provided with a chemically sensitive layer for selectively binding a substance that is to be detected. An acoustic mirror is arranged between the carrier and the resonator. The acoustic mirror constitutes a band elimination filter having two closely adjacent notch frequencies, as a result of which the device is capable of oscillating in two resonant frequencies. The mass binding of the substance and the temperature can be determined computationally from the measured resonant frequencies. | 07-19-2012 |
| 20120190129 | TEST DEVICE, REACTION APPARATUS AND REACTIVE TEST METHOD - A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times. | 07-26-2012 |
| 20120190130 | CARTRIDGE FOR DETECTING TARGET ANTIGEN AND METHOD FOR DETECTING TARGET ANTIGEN USING THE SAME - There are provided a cartridge for detecting a target antigen and a method for detecting a target antigen existing in a biological sample using the cartridge. In the cartridge, multiple detections of various antigens can be rapidly and conveniently performed, and a plurality of target antigens can be quantitatively analyzed using one cartridge, thereby reducing time and cost. | 07-26-2012 |
| 20120190131 | Biosensor Electronics - The electrostatic resonators of bridge, cantilever and comb type or piezoelectric resonators with detection electronics are key components of chemical, biological, biochemical and biomedical sensors with sensitivity down to the single molecule detection of ligands. The detection electronics relies on measurement of frequency changes of resonators using phase or signal comparator. The large arrays of these sensors with individual or common sensing circuitry improve detection sensitivity, selectivity and lower incidence of false positives and negatives. | 07-26-2012 |
| 20120190132 | Device and method of monitoring a patient - A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients. | 07-26-2012 |
| 20120196381 | Miniaturized Microparticles - An encoded microparticle having a spatial code is provided; and a set of encoded microparticles possessing subsets each provided with a distinguishable spatial code, wherein the codes comply with a pre-determined coding scheme. Presented are also methods of using the encoded microparticles in various biological assays, such as various multiplex assays and visualizing them by creating a digital image of the encoded microparticles and determining whether false positives are present. Further are provided methods of manufacture of the encoded microparticles which employ ferromagnetic nanoparticles applied using spin-on-glass techniques. | 08-02-2012 |
| 20120196382 | Multicoded Analytical Nanostrips - Analytical nanostrips for clinical analysis are improved by using multifunctional coding (“multicoding”) to allow simultaneous identification of the particular assay, the value of the assayed analyte, and a calibration of the analyte. The multicoding layout on the nanostrip minimizes the number of zones that are required for a given assay. Moreover, the nanostrip can be scanned in real time during flow of the nanostrip through a detection beam. This both simplifies the assay and allows for alternative means of coding. | 08-02-2012 |
| 20120196383 | INTEGRATED OPTOFLUIDIC SYSTEM USING MICROSPHERES - An integrated optofluidic system for trapping and transporting particles for analysis is provided comprising a planar substrate; a microfluidic channel; and a waveguide integrated with the channel. A microsphere particle in the integrated optofluidic system can act as a cavity, allowing light to circulate many thousands of times around the circumference of the microsphere. Optical trapping and transport is used for nanoscale positioning to excite the microsphere resonances. Sensitive measurements on molecules can be accomplished by monitoring changes in whispering gallery modes (WGMs) that propagate around the circumference of the microsphere. By using a broadband or supercontinuum light source, a microsphere can be trapped and many WGM resonances can be excited through the visible and near-infrared wavelengths simultaneously. After the resonances are measured using the waveguide transmission, the microsphere can be freed by decreasing the optical power and the process repeated with a different microsphere. | 08-02-2012 |
| 20120196384 | BIOSENSOR UTILIZING A RESONATOR HAVING A FUNCTIONALIZED SURFACE - Systems and methods for detecting the presence of biomolecules in a sample using biosensors that incorporate resonators which have functionalized surfaces for reacting with target biomolecules. In one embodiment, a device includes a piezoelectric resonator having a functionalized surface configured to react with target molecules, thereby changing the mass and/or charge of the resonator which consequently changes the frequency response of the resonator. The resonator's frequency response after exposure to a sample is compared to a reference, such as the frequency response before exposure to the sample, a stored baseline frequency response or a control resonator's frequency response. | 08-02-2012 |
| 20120202295 | MATERIALS AND METHODS FOR ASSAY OF ANTI-HEPATITIS C VIRUS (HCV) ANTIBODIES - A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample. | 08-09-2012 |
| 20120202296 | SYSTEM, METHOD, AND APPARATUS FOR MEASURING AFFINITY CONSTANTS - Nonlinear spectroscopic systems, methods, and apparatuses for measuring affinity constants of molecule-molecule reactions and/or for determining a maximum number of molecule-molecule complexes. Second harmonic generation (“SHG”) or sum-frequency generation is used to probe a sample. A magnitude of a net electric charge at a solid/water interface can be detected and used to determine characteristics of the molecule-molecule complex. | 08-09-2012 |
| 20120202297 | GENDER DETERMINATION METHOD - A non-invasive gender determination method and kits for accomplishing the same are disclosed herein. The present invention is based on difference in testosterone levels in the maternal body fluids of females carrying male fetuses relative to that of females carrying a female fetus. The present invention does not need specialized equipment and can quickly and rapidly detect the presence of testosterone in maternal urine or serum and thus indicate fetal gender. The kits and methods disclosed herein are useful for breeders of single-fetus mammals, veterinarians, and interested parents. | 08-09-2012 |
| 20120202298 | HTS Fluorescence Polarization Assay for Inhibitors of Keap1-Nrf2 Interaction - Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke. | 08-09-2012 |
| 20120202299 | ILLUMINATION DETECTION SYSTEM AND METHOD - An optical analysis apparatus and method in which a detector provides two different signals, based on responses to incident light absorbed within the detector over different depths. These signals are processed to discriminate between incident light of two different frequencies and thereby determine the intensity of the light of one desired frequency. | 08-09-2012 |
| 20120208290 | METHOD FOR ENHANCING MASS OF GOLD NANOPARTICLE THROUGH LIGHT-IRRADIATION, METHOD AND SENSOR FOR DETECTING MOLECULAR BINDING USING THE METHOD FOR ENHANCING MASS - Provided are a sensor for detecting molecular binding by increasing the mass of a gold nanoparticle through light-irradiation and a method thereof. In the method, light-irradiation increases the size of gold nanoparticles without using a reducing agent, to enhance the mass. Accordingly, selectivity may be improved, and the sensitivity of detection may be improved due to a change in various properties of a gold nanoparticle. | 08-16-2012 |
| 20120208291 | METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) - Disclosed herein are methods and compositions relating to the detection and measuring of kinetic binding interactions. | 08-16-2012 |
| 20120208292 | FLUORESCENT MEASUREMENT IN A DISPOSABLE MICROFLUIDIC DEVICE, AND METHOD THEREOF - A device including a shallow chamber for analyzing a target analyte in a body fluid using the signal generated by fluorescent detector molecules specific for the target analyte and attenuating the signal emitted by fluorescent detector molecules non-specifically bound to the surfaces of the chamber by a signal attenuating dye; and method thereof. | 08-16-2012 |
| 20120208293 | NOVEL METHOD FOR TESTING VASCULAR ENDOTHELIAL DAMAGE AND TESTING KIT - An object of the present invention is to provide a method which is capable of carrying out detection and evaluation of the vascular endothelial damage with a high degree of accuracy. According to an aspect of the present invention, there is provided a method for testing vascular endothelial damage with respect to a blood sample collected from living organism comprising the steps of: 1) detecting or determining quantitatively vascular endothelial cell-derived microparticle; and 2) detecting or determining quantitatively tissue factor-containing microparticle. Furthermore, according to another aspect of the present invention, there is provided a testing kit of vascular endothelial damage comprising a first antibody which specifically recognizes the vascular endothelium-derived microparticle, and a second antibody which specifically recognizes the tissue factor-containing microparticle. | 08-16-2012 |
| 20120208294 | IMMUNODETECTION AND QUANTIFICATION OF PYRAZOLOPYRIMIDINE SEDATIVES - The invention relates to novel immunogens, antibodies, methods and kits for use in immunoassays to detect and quantify zaleplon, metabolites of zaleplon and indiplon. These are the first described immunoassays for these compounds and have greater sensitivity than alternative analytical techniques. | 08-16-2012 |
| 20120208295 | Methods and compositions for mass spectrometry analysis - Methods and compounds are provided to improve the desorption and ionization of analyte for mass spectrometry analysis. More specifically, it is for Electrospray ionization (ESI) mass spectrometry. The method uses charged affinity molecules that can bind with analyte either temporarily or permanently to improve the desorption and ionization of analyte. The charged affinity molecules can be positively charged or negatively charged. | 08-16-2012 |
| 20120208296 | DETECTION OF DIFFERENT TARGET COMPONENTS BY CLUSTER FORMATION - The invention relates to a method, a test kit, and an apparatus ( | 08-16-2012 |
| 20120208297 | COMPOSITION FOR USE AS AN ASSAY REAGENT - A composition for use as an assay reagent comprises a solid support comprising a member of a signal producing system and a coating of a synthetic copolymer. The synthetic copolymer comprises a first polymerized monomer comprising a pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and a second polymerized monomer comprising a pendant moiety comprising at least 1 carbon atoms and at least 2 heteroatoms. In some embodiments the copolymer comprises a polyethylenic backbone comprising the pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and the pendant moiety comprising at least 1 carbon atom and at least 2 heteroatoms. | 08-16-2012 |
| 20120208298 | METHOD FOR DETERMINATION OF MACROMOLECULAR MULTIMERS - A method of determining multimers of a macromolecule monomer in a sample containing the macromolecule comprises the steps of (i) determining the total concentration of macromolecule in the sample, (ii) determining by a biosensor-based detection method, especially mass-sensing, the active concentration of macromolecule in the sample, wherein physical characteristics of the macromolecule monomer are used, (iii) comparing the relationship of determined active macromolecule concentration to total macromolecule concentration for the sample with a corresponding relationship for an at least substantially multimer-free macromolecule-containing sample, and (iv) from a resulting difference determining the presence of multimers in the sample. The method may be used in the purification of macromolecules, such as proteins. | 08-16-2012 |
| 20120214255 | METHODS AND COMPOSITIONS FOR ASSAYING A SAMPLE FOR AN AGGREGANT - This invention relates to an aggregation sensor useful for the detection and analysis of aggregants in a sample, and methods, articles and compositions relating to such a sensor. The sensor comprises first and second optically active units, where energy may be transferred from an excited state of the first optically active unit to the second optically active unit. The second optically active unit is present in a lesser amount, but its relative concentration is increased upon aggregation, increasing its absorption of energy from the first optically active units. This increase in energy transfer can be detected in variety of formats to produce an aggregation sensing system for various aggregants, including for quantitation. Other variations of the inventions are described further herein. | 08-23-2012 |
| 20120214256 | METHOD OF ANALYSIS OF GENETIC MARKERS - A method of analyzing genetic markers includes binding a set of probes to a segment of single stranded nucleic acids. The segment of single stranded nucleic acids includes a repeat region formed of at least two of a repeat unit. The repeat unit can include at least two nucleic acids. The set of probes includes a first probe complementary to the repeat unit. The method can further include directing the segment through a nanopore device and measuring a signal through the nanopore device. The signal can be indicative of the number of repeat units. | 08-23-2012 |
| 20120214257 | Reagent Kit for Determining an Analyte in a Sample by Agglutination - A reagent kit for determining an analyte in a sample by agglutination includes a first reagent containing a first specific binding substance that is a substance that can specifically bind to the analyte; and a second reagent containing microparticles having a second specific binding substance bound thereto, the second specific binding substance being a monoclonal antibody against the first specific binding substance. | 08-23-2012 |
| 20120220048 | MAGNETIC MARKER PARTICLE AND METHOD FOR PRODUCING THE SAME - There is provided a magnetic marker particle. The magnetic marker particle comprises a magnetic particle and a polymer deposited on the surface of the magnetic particle, wherein the deposited polymer comprises a combination of a carboxyl group and a polyethylene glycol chain or a combination of a carboxyl group and a sulfo group. | 08-30-2012 |
| 20120220049 | ASSAY METHOD AND DEVICE - The present invention relates to a method and a device for detecting the presence of an analyte. More particularly, the present invention relates to the method and device for detecting the presence of immunoglobulins directed at polymorphic alloantigens such as HLA antigens and/or other products of the major histocompatibility complex (MHC). | 08-30-2012 |
| 20120220050 | METHOD OF PURIFYING 8-ISOPROSTANE - A method of purifying 8-isoprostane is provided that includes a step of contacting a liquid sample containing 8-isoprostane with an ion exchange support having a quaternary ammonium salt immobilized thereon such that 8-isoprostane in the liquid sample is retained on the ion exchange support and a step of eluting 8-isoprostane from the ion exchange support using a first eluent containing a water-soluble organic solvent and water as main components. | 08-30-2012 |
| 20120220051 | Immunogenicity Assay - Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described. | 08-30-2012 |
| 20120220052 | SURVIVAL PROGNOSTIC ASSAY - Assay kit and Assay for determination of likely survival of a subject Assay kits for determining the total amount of free-light chains (FLC) in a sample are provided. Also provided are a general health screen method comprising detecting an amount of free light chains (FLC) in a sample from a subject, wherein a lower amount of FLC is associated with increased survival and/or better general health of the subject, and a higher level of FLC indicates the possible presence of an undetected medical problem. | 08-30-2012 |
| 20120220053 | GRAPHENE-ENCAPSULATED NANOPARTICLE-BASED BIOSENSOR FOR THE SELECTIVE DETECTION OF BIOMARKERS - A field effect transistor (FET) with a source electrode and a drain electrode distanced apart from each other on a semi-conductor substrate, and a gate electrode consisting of a uniform layer of reduced graphene oxide encapsulated semiconductor nanoparticles (rGO-NPs), wherein the gate electrode is disposed between and contacts both the source and drain electrodes. Methods of making and assay methods using the FETs are also disclosed, including methods in which the rGO-NPs are functionalized with binding partners for biomarkers. | 08-30-2012 |
| 20120220054 | DEVICE FOR DETECTION OF TARGET MOLECULES AND USES THEREOF - Devices and methods for the detection of target molecules are disclosed. Devices and methods for detecting food-borne target molecules are also disclosed. | 08-30-2012 |
| 20120220055 | Method for Detecting Cardiac Ischemia via Changes in B-Natriuretic Peptide Levels - The present invention relates to a method of detecting cardiac ischemia by measuring the levels of BNP or NTproBNP. Increases in BNP or NTproBNP levels in an individual are indicative of cardiac ischemia. | 08-30-2012 |
| 20120225491 | PORTABLE DETECTION DEVICES AND METHODS FOR DETECTION OF BIOMARKERS AND OTHER ANALYTES - A detection device and method for detecting one or more analytes of interest in a test sample are provided. Some embodiments use analyte-specific binding partners that are conjugated to quantum dots (Qdots) for use in detecting the presence and/or quantity of the analytes of interest in a test sample. FRET based methods may to used enhance the quantum dot (Qdot) signal through complexing of the quantum dots with lanthanide chelates, such as terbium. Some embodiments of the invention provide a novel disposable testing device that contains, all in one, the components necessary for carrying out the novel assay detection system of the invention. The disposable testing device may be used at home, for example, to detect and quantitate, at ultrasensitive levels, multiple analytes in a biological sample with no requirement for professional assistance. | 09-06-2012 |
| 20120225492 | Starch Binding Domain and Use Thereof - The present invention provides a method for identifying starch binding sites of starch binding domain in CBM family. The CBM family is consisting of CBM20, CBM21, CBM25, CBM26, CBM34, and CBM41. The method further comprises predicting starch binding sites of starch binding domain in CBM family using the identified starch binding sites of starch binding domain with same topology. | 09-06-2012 |
| 20120225493 | Electronic-Chemometric Controlled System and Process for the Analysis of Analytes - A series of electronic-chemometric control processes to enhance the selectivity, concentration, analysis, and detec tion of chemical species (analytes) in the gas phase, such as when using SERS-based techniques. Controls consist variously of: 1) feedback of electronic signals corresponding to changes of static and variable parameters in targeted chemical species that vary according to a reduction, increase, maximization, linearization, or improved confidence in one or more chemometric output parameters; 2) methods for spatially locating the source of an analyte species; and, 3) variable duty cycling to save power and materials according to altered physical and environmental conditions within a monitored zone. | 09-06-2012 |
| 20120225494 | DNA LIGANDS FOR AFLATOXIN AND ZEARALENONE - The present invention relates to DNA ligands capable of binding to aflatoxin and zearalenone. The invention relates also to methods for determining the presence and concentration of aflatoxin and zearalenone in samples such as agricultural and food products, and to methods for removing or reducing the level of aflatoxin and zearalenone in samples such as agricultural and food products. The invention further relates to methods for identifying DNA ligands capable of binding to aflatoxin and zearalenone. The invention further relates to new DNA sequences. | 09-06-2012 |
| 20120225495 | DEVICE FOR DISTRIBUTING PARTICLES IN A FLUID AND METHODS THEREOF - A vial and particles for distributing reagent bound particles in a fluid, a kit, and methods for distributing particles in a fluid. | 09-06-2012 |
| 20120231551 | Methods and Compositions to Detect Nucleic Acids in a Biological Sample - Kits, reaction mixtures and methods for separating a target nucleic acid from a sample by using at least one hairpin capture probe oligonucleotide that has the structure 5′-X.sub.n a′ b′ c′ Y.sub.n-3′, wherein X and Y each comprise nucleic acid sequences that can form a double stranded stem portion, one of X or Y is a capture sequence that is a first member of a specific binding pair and the other of X or Y is a terminal sequence of the hairpin capture probe, and a′ b′ c′ comprises a target-complementary sequence flanked by X and Y to thereby form a loop portion of the hairpin, thus forming a capture hybrid that is separated from other sample components before the target nucleic acid is released from the capture support and hybridized to a detection probe that hybridizes specifically to the same sequence that is at least partially hybridized by the a′ b′ c′ portion of the capture probe, thus forming a detectable detection hybrid to indicate the presence of the target nucleic acid in the sample. | 09-13-2012 |
| 20120231552 | DEVICE FOR A TEST STRIP HOLDER, METHOD AND ARRANGEMENT - For the simplified use of a test strip holder, a device having a holding or positioning device is provided, comprising a mixing chamber, a lid for closing the mixing chamber, and an obvious fluid opening for a fluid passage from the mixing chamber to the test strip holder. This allows for the test strip holder to be inserted into the device in a simple way and a sample can be prepared in the mixing chamber of the device. The device is provided with a mixing chamber that can be closed, wherein a reaction partner, for example a gold conjugate, can be dissolved in the sample for increasing the sensitivity of the test strip. | 09-13-2012 |
| 20120238035 | MULTICOLOR MICROWAVE-ACCELERATED METAL-ENHANCED FLUORESCENCE (M-MAMEF) - The present invention relates to the use of multiple different light emitting molecules that emit different and detectable emission signals to provide systems and methods to detect different target products in a single assay sample, wherein the different light emitting molecules are positioned an optimal distance from metallic particles thereby enhancing emissions. Preferably, the systems and methods further comprise use of either microwave or sonic energy to increase binding reactions, timing of such reactions within the assay sample and reduce background non-specific biological absorption. | 09-20-2012 |
| 20120238036 | METHOD FOR IMMOBILIZING PROTEIN A ON A SELF-ASSEMBLED MONOLAYER - The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented following formula (II) obviates the object. | 09-20-2012 |
| 20120238037 | IMMUNOLOGICAL ASSAY AND IMMUNOLOGICAL ASSAY KIT - An antibody enabling a rapid measurement of HMGB1, for example a combination of antibodies to HMGB1, is elucidated and an immunological assay and an immunological assay kit are provided. It is intended to provide an immunological assay kit for determining the presence or absence, or the concentration, or both of HMGB1, including a first antibody and a second antibody, wherein the first antibody is immobilized on a carrier and the second antibody is modified with a labeling substance, and the first antibody and the second antibody are any of the following antibody (A), antibody (B), antibody (C), and antibody (D), and a permutation combination of the first antibody and the second antibody is any one of antibody (A) and antibody (B), antibody (A) and antibody (C), antibody (B) and antibody (A), antibody (B) and antibody (C), antibody (B) and antibody (D), and antibody (C) and antibody (B). | 09-20-2012 |
| 20120238038 | PEPTIDE BINDING TO METHYLATED DNA - The present invention aims to provide a tool etc. capable of detecting a methylated region of a DNA in a short time, in a labor-saving manner and without being limited by nucleotide sequences, and further capable of quantifying the methylation. The present invention provides a peptide containing a metal finger motif and a tyrosine derivative in a helix forming part of the motif, which recognizes and binds to a methylated region of a double stranded DNA. | 09-20-2012 |
| 20120244630 | MULTIPLEXED ANALYTE CONCENTRATION MEASUREMENT - Disclosed is a method of multiplexed concentration measurement of one or more analytes in a sample by means of electrical impedance measurements, the method comprises the steps of : providing the sample; providing a plurality of subsets of particles with capture molecules specific for at least one of the analytes, where the particles in each subset are distinguishable from the particles in the other subsets; mixing the sample with the subsets of particles, wherein the method further comprises the steps of: measure the change in the electrical impedance measurement, when the particles pass one or more sets of electrodes; determining the concentration of the one or more analytes by analyzing the electrical measurement change associated with the particles passing by the electrodes, where the concentration of the one or more analytes are determined based on a change in a property of the respective particles. | 09-27-2012 |
| 20120244631 | Apparatus and Method for Determining Microscale Interactions Based on Compressive Sensors such as Crystal Structures - Techniques for determining values for a metric of microscale interactions include determining a mesoscale metric for a plurality of mesoscale interaction types, wherein a value of the mesoscale metric for each mesoscale interaction type is based on a corresponding function of values of the microscale metric for the plurality of the microscale interaction types. A plurality of observations that indicate the values of the mesoscale metric are determined for the plurality of mesoscale interaction types. Values of the microscale metric are determined for the plurality of microscale interaction types based on the plurality of observations and the corresponding functions and compressed sensing. | 09-27-2012 |
| 20120244632 | STEROL GLUCOSIDE TOXINS - The invention relates to the identification of sterol glucoside toxins, and provides methods for detecting and detoxifying the compounds, as well as therapeutic methods for treating subjects exposed to such toxins. In alternative embodiments, the toxins may for example include beta-sitostrol-beta-D-glucoside (5-cholesten-24b-ethyl-3b-ol-D-glucoside) or cholesterol glucoside (5-cholesten-3b-ol-3b-D-glucoside). | 09-27-2012 |
| 20120244633 | LIGHT-EMITTING INTRA-CAVITY INTERFEROMETRIC SENSORS - Light-emitting intra-cavity interferometric (ICI) optical sensors based on channel waveguide structures which include an internal light emitting material and a functionalized region. In some embodiments, the waveguides are made of a sol-gel which incorporates the light emitting material. In some embodiments, the waveguide structure includes an ICI resonator backbone and the ICI sensor is a laser sensor. In some embodiments, the resonator backbone has an interferometric Y-branch shape. In some embodiments, the resonator backbone has a Mach Zehnder interferometer shape. In some embodiments, an ICI laser sensor has an interferometric arrayed waveguide grating shape. In some embodiments, an ICI sensor may be remotely optically pumped and remotely read. | 09-27-2012 |
| 20120244634 | METHOD FOR DETECTION OF BASIC PEPTIDE AND REAGENT FOR DETECTION OF BASIC PEPTIDE - The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin. | 09-27-2012 |
| 20120244635 | NANOCHANNEL ARRAYS AND NEAR-FIELD ILLUMINATION DEVICES FOR POLYMER ANALYSIS AND RELATED METHODS - Provided are devices and methods for polymer analysis, in which labeled polymers are translocated along nanochannels that have illuminated detection regions within. As a labeled polymer translocates along the nanochannel and the labels pass over the illuminated detection regions, the labels become detectable (e.g., where different labels fluoresce in response to different wavelengths present at different illumination regions), and the user generates a spatial map of the location of the various labels along the length of the polymer. The location of the labels is then correlated to one or more structural characteristics of the polymer. | 09-27-2012 |
| 20120244636 | INCORPORATION OF METHYL LYSINE INTO POLYPEPTIDES - The invention relates to A method of making a polypeptide comprising at least one N | 09-27-2012 |
| 20120244637 | METHOD AND SYSTEM FOR INTERACTION ANALYSIS - A method of determining one or more interaction parameters for the interaction between an analyte and a ligand using a biosensor, which comprises the steps of: A: providing a sensor surface having the ligand immobilized thereto, B: contacting the sensor surface with a control analyte, C: registering the sensor response from binding of the control analyte to binding sites of the ligand, D: determining the control saturation response (R | 09-27-2012 |
| 20120244638 | METHOD AND SYSTEM FOR BINDING BEHAVIOR ANALYSIS - A method of evaluating an interaction parameter for the interaction between a plurality of analytes and a ligand using a biosensor, which comprises the steps of:
| 09-27-2012 |
| 20120252136 | MARKER SOLUTION TO BE APPLIED BY MEANS OF AN INKJET PRINTER - The invention relates to a marker solution which is to be applied by means of an inkjet printer and contains (i) at least one organic solvent that has a greater steam pressure than water at 20° C. and a water content of less than 50 percent (v/v), (ii) predefined first synthetically produced nucleic acids, and (iii) a nucleic acid-complexing, organic auxiliary agent as components. | 10-04-2012 |
| 20120252137 | Fluorescence Polarization Assay For Bacterial Endotoxin - The present invention comprises methods of detecting and quantifying bacterial endotoxin by using a tracer or a fluorescently labeled polymyxin wherein fluorescent tags include bodipy, NHS-fluorescein, FITC, 5-carboxyfluorescein, boron dipyrromethene, or tetramethylrhodamine. The polymyxins utilized include polymyxin B | 10-04-2012 |
| 20120252138 | Methods and Related Devices for Continuous Sensing Utilizing Magnetic Beads - Provided is a fluidic device including a main channel, wherein a first inlet fluidly connects to an upstream end of the main channel and introduces magnetic beads into a first side of the main channel. A second inlet is fluidly connected to the upstream end of the main channel and introduces a sample stream into a second side of the main channel. A magnet disposed adjacent to the second side of the main channel pulls the magnetic beads towards a sidewall of the second side, and thus into the sample stream. The beads continue through an extended incubation channel before entering a return channel. The return channel includes a detection region. Also provided is a multi-layer micro-fluidic assay device. An assay method that utilizes a microfluidic assay device is provided as well. | 10-04-2012 |
| 20120252139 | Novel Process - A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to:
| 10-04-2012 |
| 20120252140 | FLUORESCENT SUBSTANCE-CONTAINING SILICA NANOPARTICLES AND BIOSUBSTANCE LABELING AGENT - Disclosed are fluorescent substance-containing silica nanoparticles containing a fluorescent substance therein featured in that the surface of the silica nanoparticles is coated with a material having a bulk refractive index of from 1.60 to 4.00. The invention can provide fluorescent substance-containing silica nanoparticles excellent in long term storage stability and a biosubstance labeling agent employing the same. | 10-04-2012 |
| 20120258549 | External cavity laser biosensor arrangements - A label-free biosensor detection arrangement incorporating an external cavity laser (ECL) includes a tunable lasing element (e.g. an antireflection coated laser diode or semiconductor optical amplifier) and a narrow bandwidth resonant reflectance filter as the wavelength-selective element for the tunable lasing element. A sample is deposited on the surface of the resonant reflectance filter containing a biological material. The wavelength emitted by the external cavity laser is continuously tunable by binding interactions between the biological material and the resonant reflectance filter or adsorption of the biological material present in the sample on resonant reflectance filter. The narrow bandwidth resonance reflectance filter can take the form of photonic crystal (PC), a Bragg stack, or a Brag fiber reflection filter. | 10-11-2012 |
| 20120258550 | REGULATION OF AUTOPHAGY PATHWAY PHOSPHORYLATION AND USES THEREOF - The invention relates to polypeptides and proteins known to function in the autophagy pathway that have novel phosphorylation sites. The invention also relates to antibodies specific to these polypeptides and proteins that are phosphorylated or not phosphorylated at novel phosphorylated sites. The invention also relates to methods of producing these antibodies and use of these antibodies in the treatment of diseases related to autophagocytosis. | 10-11-2012 |
| 20120258551 | STABILIZATION OF BIO-SENSORS FOR IN VIVO APPLICATIONS - The present invention relates to the use of preparations for stabilizing isolated proteins. In particular, the use of such a preparation for stabilizing receptors in biochemical sensors is disclosed. The invention in addition relates to biochemical sensors containing such preparations. | 10-11-2012 |
| 20120258552 | HOMOGENEOUS MEASUREMENT METHOD AND MEASURING REAGENT - Provided is a homogenous measurement method using insoluble carrier particles that suppresses the matrix effect originating from the sample and also suppresses differences in measurement accuracy among different models of automated analyzers. Also provided is a measuring reagent for use in an automated analyzer. Inclusion of a silicone-based defoaming agent in the reagent reduces the matrix effect originating from the sample and reduces variability of measurement accuracy among different automated analyzers having differing specifications. | 10-11-2012 |
| 20120258553 | ANALYTE MEASUREMENT APPARATUS AND METHOD - An apparatus for measuring a target molecule in a sample is disclosed. The apparatus comprises a moiety comprising a magnetic label ( | 10-11-2012 |
| 20120264230 | HOME OR POINT-OF-CARE ALLERGY TESTING - An allergy testing method based on a highly sensitive testing of a small blood sample is provided. The method includes collecting a blood sample from a subject, the blood sample being limited to a volume taken from a skin-prick; and, testing serum from the blood sample without dilution for an allergic response of the subject to one or more allergens, the testing having a high detection sensitivity ranging from about 10 | 10-18-2012 |
| 20120264231 | ASSAY FOR ORAI CALCIUM CHANNEL REGULATORS - The methods and systems described herein are based, in part, on the discovery that STIM modulates calcium release from store-operated channels through a direct interaction with the ORAI channel. Based on this discovery, methods and systems are described herein for identifying an agent that modulates calcium flux through the ORAI channel and/or regulates intracellular calcium via the ORAI channel. The methods and systems can also be used to detect an interaction between STIM and a functional ORAI channel. | 10-18-2012 |
| 20120264232 | ANTIGEN DETECTION SYSTEM AND METHODS OF USE - A system and method for testing for the presence of antigens in food stuffs permits a user to test food products for the presence of antigens for a given food allergy that the user may have. The system comprises two main components, a base station and a test well. The user places a sample of food into the test well. A macerator homogenizes the food in the test well. Antibodies to a particular antigen are bound to an antigen detector in the test well. The base station includes a cartridge dock which powers the macerator and the antigen detector. Antigen-antibody binding provides a change detectable by the detector, which signals the base station of the presence of a threshold degree of antigen-antibody binding and alerts the user of the presence of the antigen, such as by a visual or audible indicator. | 10-18-2012 |
| 20120264233 | METHOD OF ANALYSIS WITH IMPROVED MIXING - The invention is a method for characterizing an interaction in a liquid environment, between at least one species in solution and a target immobilized on a surface of a flow cell. The method comprises the following steps: (a) activating the surface of the flow cell and immobilizing the target thereon; (b) providing, in a flow of liquid, at least one of the species; (c) passing the flow of liquid comprising at least one of the species through the surface of the flow cell which contains the immobilized target; and (d) detecting a result of an interaction between the at least one species and the target using surface plasmon resonance (SPR) technique. The improvement of the method comprises in at least one of steps (a) or (b), inline mixing at least two liquid solutions to generate a mixed solution before it is passed through the surface of the flow cell. | 10-18-2012 |
| 20120270335 | REACTIVE POLYMERS FOR SOLID-PHASE EXTRACTION - Apparatus, methods and polymers for solid phase extraction by binding an analyte containing a primary amino group. The polymer is a reactive polymer, wherein binding of the analyte to the polymer causes fluorescent isoindole complex formation. A method of binding comprises use of an SPE carrier, such as an SPE cartridge, loaded with a reactive polymer. Binding of an analyte is detected by observing changes in fluorescence after applying the analyte to the polymer. Fluorescence can be detected using a fluorometer or transilluminator, for example. In a preferred embodiment, the reactive polymer is prepared from a monomer mixture comprising acetonitrile and triethylamine. | 10-25-2012 |
| 20120270336 | AUTOMATIC ANALYZER - Using a microplate having wells for the dispensing and reaction of a sample including blood and a reagent, an automatic analyzer captures an image of whether reactions have occurred inside the wells and performs analysis, the automatic analyzer comprising: a section for, with captured images obtained by capturing images of the inside of the wells corresponding to categories, calculating photometric parameters of the images, evaluating whether a measurement result based on the images is negative for each test, and analyzing characteristic information of the sample; a section for matching and storing characteristic information of samples and measurement results; a section for extracting a photometric parameter of a measurement result judged as negative; and a section for calculating a difference between maximum and minimum values of an extracted photometric parameter, determining whether a measurement is valid using the difference, and adding a result of the determination to characteristic information. | 10-25-2012 |
| 20120270337 | METHOD FOR MAKING AND USING A DIAGNOSTIC ELEMENT - The invention relates to a method for making a diagnostic element. The method comprises providing a shaped channel comprising at least one holding port and an inlet passage and outlet passage on either side of the holding port; flowing in a diagnostic gel into the inlet passage of the shaped channel; and encapsulating the diagnostic gel in the at least one holding port to form a diagnostic element. The invention also provides a method for using a diagnostic element, wherein the method comprises flowing sample through the diagnostic gel to provide an analyte diagnostic gel; analyzing the analyte diagnostic gel. | 10-25-2012 |
| 20120270338 | FLUOROIMMUNOASSAY METHOD - An object is to provide an immunoassay method requiring neither a solid-phase immobilization step nor a washing step, enabling quick and simple quantitative measurement of a target substance in a liquid phase and capable of visualizing an antigen. Such an object is attained by measuring the concentration of a target antigen present in a test substance by sequentially performing a step (a) of bringing an antibody light-chain variable region polypeptide and an antibody heavy-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; or bringing an antibody heavy-chain variable region polypeptide and an antibody light-chain variable region polypeptide labeled with a fluorescent dye into contact with an antigen in a test substance in a liquid phase; a step (b) of measuring the fluorescence intensity of the fluorescent dye; and a step (c) of computationally obtaining the level of the antigen contained in the test substance with reference to a positive correlation between the concentration of the antigen in a liquid phase and the fluorescence intensity of the fluorescent dye. | 10-25-2012 |
| 20120276655 | DETECTION OF ANTIBODIES - The present invention relates to a method of detecting a target antibody, particularly a target autoantibody, in a sample, using a small molecule fluorophore-labelled target antigen, or a functional fragment, functional variant or functional derivative thereof that specifically binds to the target antibody. Detection is typically carried out using immunodiffusion or immunoelectrophoresis. The invention also relates to methods of diagnosing disease, particularly autoimmune disease, using small molecule fluorophore labelled target antigens and autoantigens. Small molecule fluorophore labelled target antigens, including autoantigens, are also disclosed, as are uses such. | 11-01-2012 |
| 20120276656 | Multiplexed Assay Methods - The present invention is directed to methods for conducting multiplexed assays. The methods are particularly well suited for measuring a plurality of analytes that may be present in very different abundances. The invention also relates to systems, devices, equipment, kits and reagents for use in such methods. | 11-01-2012 |
| 20120282708 | Method and Apparatus for Conducting an Assay - The present invention relates to methods and apparatus for conducting an assay. In particular, the present invention relates to a rotatable platform which can be used for conducting an assay, in particular multi-step assays. The present invention provides a rotatable platform adapted to immobilise a first binding partner in one or more discrete areas on a surface of said platform, or to selectively immobilise a second binding partner in one or more discrete areas on a surface of said platform. The invention also relates to methods, apparatus, a kit and the use of the rotatable platform for conducting an assay. In particular, the invention has been developed primarily for use in sequencing nucleic acid by pyrosequencing, however the invention is not limited to this field. | 11-08-2012 |
| 20120282709 | METHOD AND DEVICE FOR DNA SEQUENCE ANALYSIS USING MULTIPLE PNA - Provided are a DNA sequence analysis method of high precision providing improved optical limits by detecting wavelengths of lights emitted from labels in the state where a DNA is electrically tethered and completely stretch, and a nanodevice chip for automating the method. Also provided are a DNA sequence analysis method capable of removing binding errors through complementarily binding between a plurality of peptide nucleic acids (PNAs) labeled with labels emitting lights of different wavelengths and a target DNA to be sequenced, and resolving the limit in optical spatial resolution. | 11-08-2012 |
| 20120282710 | LIGAND BINDING DOMAINS OF NUCLEAR RECEPTORS IN CONTROLLABLE FORM AND METHODS INVOLVING THE SAME - The present invention relates to an isolated protein comprising a ligand binding domain of a nuclear receptor in controllable form, a method of producing the same, its use for the identification of a ligand, a test system comprising the isolated protein and a method for screening for a ligand for a nuclear receptor using the test system. | 11-08-2012 |
| 20120288959 | RAPID DETECTION OF CEREBROSPINAL FLUID, METHODS AND SYSTEMS THEREFORE - Methods and systems are disclosed for rapid detection of cerebrospinal fluid (CSF) in a sample. In some embodiments, the methods comprise depleting a biological sample of beta-1 transferrin by contacting the sample with a sialic acid-specific lectin bound to a solid support, followed by subjecting the beta-1 transferrin-depleted sample to a lateral flow immunoassay. The methods can be used to detect CSF comprised by a sample in under one hour. Furthermore, the methods can detect CSF in a biological sample such as a plasma sample of a volume as small as about 10 μl. | 11-15-2012 |
| 20120288960 | METHOD FOR MEASURING CONCENTRATION OF ANTIGEN CONTAINED IN TEST SOLUTION - A biogenic substance concentration measuring apparatus includes an optical measuring apparatus for measuring optical properties of a first substrate and a second substrate by using a cell for biogenic substance concentration measurement that includes: the first substrate on which a plurality of first metallic nanorods, each of which is modified with a substance that bonds specifically to a test substance, are immobilized such that the long axes thereof are aligned in the same direction; and the second substrate on which a plurality of second metallic nanorods, each of which is modified with a blocking substance, are immobilized such that the long axes thereof are aligned perpendicularly to the long axes of the first metallic nanorods on the first substrate, and calculates a biogenic substance concentration with high accuracy from the optical properties. | 11-15-2012 |
| 20120288961 | CAPILLARITY-BASED DEVICES FOR PERFORMING CHEMICAL PROCESSES AND ASSOCIATED SYSTEMS AND METHODS - The present technology is directed to capillarity-based devices for performing chemical processes and associated system and methods. In one embodiment, for example, a device can include a base configured to receive one or more fluids, a porous wick carried by the base portion, and a flow-metering element along the porous wick to modify a rate or volume of fluid flow along the porous wick. The porous wick can comprise a first pathway, a second pathway, and an intersection at which the first pathway and the second pathway converge. Input ends of the first and second pathways can be wettably distinct. Upon wetting of the input ends, fluid is configured to travel by capillary action along each pathway. The device may also include volume-metering features configured to automatically and independently control or modify a volume of fluid flow along one or more pathways of the porous wick. | 11-15-2012 |
| 20120288962 | METHOD OF DETECTING RAW PORK AND DETECTION KIT THEREFOR - [Object] To provide preparation of a detection antibody optimal for detecting by immunoassay raw pork in non-heated food with high performance and high sensitivity without causing non-specific reaction, a convenient and high-accuracy detection process using the detection antibody, and a detection kit therefor. | 11-15-2012 |
| 20120295366 | DIAGNOSTIC SYSTEM - The invention relates to a device for contactless control of magnetic beads on a microfluidic card by means of external magnetic fields, without having to use complicated mechanics or hydraulics. Based on a modulation of the gradient of a magnetic field, magnetic beads are lifted in a first step in a contactless way out of different reaction chambers of the microfluidic card. By means of a translation movement or a variation or modulation of the gradient of a magnetic field, horizontal transport of the magnetic beads over a mechanical barrier of the microfluidic card is facilitated in a second step. It is possible in a third step to use a further modulation of the gradient of the magnetic field to lower the magnetic beads into a desired further fluid zone. | 11-22-2012 |
| 20120295367 | COMPOSITION AND METHOD FOR ANALYSIS OF TARGET ANALYTES - A method of detecting first and second analytes includes providing a mixture containing first analytes and second analytes; adding microparticles of a first size coated with first competitive inhibitors that compete with the first analytes for binding to first antibodies to the first analytes, and adding microparticles of a second size coated with second competitive inhibitors that compete with the second analytes for binding to first antibodies to the second analytes, adding second antibodies specific to the first antibodies to the first analytes and second antibodies specific to the first antibodies to the second analytes, wherein the second antibodies specific to the first antibodies to the first analytes are labeled with a first fluorescent moiety, and the second antibodies specific to the first antibodies to the second analytes are labeled with a second fluorescent moiety | 11-22-2012 |
| 20120295368 | KITS FOR DETECTING TARGET MATERIAL AND METHODS OF DETECTING TARGET MATERIAL USING THE KITS - Kits for detecting a target material and methods of detecting a target material by using the kits are provided, the kits include a target material binding portion including a first molecule and a probe linked to the first molecule, and a target material detection portion including a plurality of nanoparticles each having a surface to which a compound having a zwitterion and a second molecule are linked. The first molecule is specifically bound to the second molecule in a pair. | 11-22-2012 |
| 20120295369 | METHOD FOR DETERMINATION OF AGGREGATES - A method of determining aggregates of a macromolecule monomer in a fluid containing the macromolecule, comprises the steps of:
| 11-22-2012 |
| 20120301973 | CLOZAPINE IMMUNOASSAY - Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine and N-desmethylclozapine in biological fluids. | 11-29-2012 |
| 20120301974 | Clozapine Immunoassay - Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids. | 11-29-2012 |
| 20120309106 | DETECTION OF A TARGET IN A SAMPLE - The invention concerns a system, device, kit and method for detecting the presence, or concentration of a target in a sample. An assay set comprising at least two spaced apart electrodes is used, comprising a recognition moiety, capable of specific binding to the target, which is attached to at least one of the electrodes or the substrate therein between. If the recognition moiety binds the target then a conductive bridge can be formed between the electrodes, based on the complex between the recognition moiety and the target. The conductive bridge is formed by using nucleation-center forming entities attached to the complexes or to the targets from which a conductive substance is substantially grown. Alternatively the conducting bridge forms a conductive polymer between the electrodes. | 12-06-2012 |
| 20120309107 | Direct Sensing of Molecular Species by Polyfluors on a DNA Backbone - Nucleoside analogs are provided; and fluorescent sensors comprising the nucleoside analogs. The sensors comprise multiple chromophores built on a DNA backbone, in which all the natural DNA bases are replaced by excimeric or exciplex-forming fluorophores, ligands, quenchers and spacers in thousands of combinations. The sensors find use in the detection and identification of target analytes by fluorescence, e.g., detection of metal ions, neutral organic compounds and anions. The sensors find use in the detection and identification of molecular species in the vapor or gaseous phase, or the liquid phase. The sensors find use in qualitative and quantitative screening and detection methods. | 12-06-2012 |
| 20120309108 | MULTI-ANALYTE SYSTEM AND METHOD BASED ON IMPEDIMETRIC MEASUREMENTS - The invention discloses a system for the simultaneous detection and/or quantification of various analytes in a sample or for the simultaneous detection and/or quantification of an analyte in various samples, comprising: a multi-electrode chip ( | 12-06-2012 |
| 20120309109 | METHOD FOR DETERMINING THE BINDING CONSTANT OF HIGH AFFINITY COMPOUNDS - The invention relates to a method for determining the binding constant of a compound of interest to proteins comprising the following steps: a) adding the high affinity compound to a two-chamber system, wherein the two chambers are separated by a semipermeable membrane, which is permeable for the compound of interest, and determining the amount of the high affinity compound of interest in one of the chambers after the distribution equilibrium has been reached, b) adding a sink compound to one of the chambers whereby the sink compound can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the sink compound after the distribution equilibrium has been reached, c) adding an unspecific protein to the other chamber, whereby the unspecific protein can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the unspecific protein in presence of a sink compound after the distribution equilibrium has been reached, and d) determining the binding constant of the test compound with the distribution coefficient of steps b) and c). | 12-06-2012 |
| 20120315706 | LIPOPROTEIN ANALYSIS BY DIFFERENTIAL CHARGED-PARTICLE MOBILITY - The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention. | 12-13-2012 |
| 20120322164 | NANOWIRE ARRAY STRUCTURES FOR SENSING, SOLAR CELL AND OTHER APPLICATIONS - Nanowire array structures based on periodic or aperiodic nanowires are provided in various configurations for sensing and interacting with light and substances to provide various functions such as sensors for detecting DNAs and others and solar cells for converting light into electricity. | 12-20-2012 |
| 20120322165 | HIGHLY SENSITIVE IMMUNOCHROMATOGRAPHY METHOD AND IMMUNOCHROMATOGRAPHY KIT - The present invention is to provide an immunochromatography method which is capable of performing a detection with high-sensitivity or reduced false-positives by suppressing the occurrence of false-positive when a signal is amplified. An immunochromatography method includes in a state of forming a complex from a test substance and a labeling substance containing a metal modified with a first binding substance for the test substance, developing the complex on an insoluble carrier in presence of a protease hydrolyzate of protein; capturing the test substance and the labeling substance in a detection site on the insoluble carrier containing a substance which has a binding property to a second binding substance for the test substance or the first binding substance for the test substance; and detecting the test substance by amplifying the labeling substance captured. | 12-20-2012 |
| 20120322166 | FLUORESCENCE DETECTING APPARATUS, SAMPLE CELL FOR DETECTING FLUORESCENCE, AND FLUORESCENCE DETECTING METHOD - Excitation light from a light source is caused to enter a finely apertured thin metal film, having fine apertures with diameters less than or equal to the wavelength of the excitation light, formed on a surface of a substrate different from a light incident surface thereof, through the substrate, to cause near field light to be generated at the fine apertures. Fluorescent labels included in a sample liquid supplied to contact the thin metal film are caused to emit light by the near field light and by surface plasmon which are induced in the finely apertured thin metal film by the near field light. Fluorescence emitted by the fluorescent labels is detected with a detector. Fluorescent particles having a plurality of fluorescent pigments enveloped in a transmitting material that transmits both the excitation light and the fluorescence are employed as the fluorescent labels. | 12-20-2012 |
| 20120329172 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES - The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug. | 12-27-2012 |
| 20120329173 | METHOD AND FOR THE DETECTION OF BIOLOGICAL MOLECULES USING A TWO PARTICLE COMPLEX - Methods, compositions and kits for detecting analytes of interest in a sample using electrogenerated chemiluminescence are provided. Compositions comprising at least one solid support that entraps or contains an electrogenerated chemiluminescent moiety also provided. | 12-27-2012 |
| 20120329174 | LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands. | 12-27-2012 |
| 20120329175 | Detection of Degradation Products of Feline NT-proBNP - A method for determining the amount of NT-proBNP in blood samples from felines. The method includes detecting degradation products of feline NT-proBNP by various methods, including using antibodies, kits and devices. | 12-27-2012 |
| 20120329176 | INDIRECTLY LABELLED ASSAY CONJUGATES AND METHODS OF PREPARING AND USING SAME - Indirectly labelled assay conjugates prepared by a method that includes the step of submitting the binding member comprised by the conjugate to denaturing conditions prior to labelling the binding member. The indirectly labelled assay conjugates demonstrate an increased sensitivity when employed in diagnostic assays compared to assay conjugates prepared by methods that do not include a step of submitting the binding member to denaturing conditions prior to labelling. Processes for the preparation of the indirectly labelled assay conjugates, methods of detecting an analyte comprising the use of the indirectly labelled assay conjugate and kits comprising the indirectly labelled conjugates are also provided. | 12-27-2012 |
| 20130005049 | DEVICES AND METHODS FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS - A device for detecting Single Nucleotide Polymorphism (SNP) and associated methods has been described. The stochastic behavior of a single-molecule probe is utilized to recognize wild type and SNP sequences in a microfluidic platform using a laser-tweezers instrument. The mechanical signal provides substantially noise free sensing with high sensitivity and the selectivity. The method has an inherent capacity to develop as a generic biosensor using other recognition elements such as aptamer for example. | 01-03-2013 |
| 20130005050 | GLUCAGON DETECTION AND QUANTITATION BY MASS SPECTROMETRY - Methods are described for measuring the amount of glucagon in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying glucagon in a sample. | 01-03-2013 |
| 20130011932 | REAGENT COMPOSITION FOR IMMUNOCHROMATOGRAPHY - [Object] To provide a reagent composition, or a sample thinner, for immunochromatography which are more effective in suppressing nonspecific reactions than the conventional counterparts, which use an immunochromatography device to detect a target substance; also to provide a high performance and highly sensitive immunochromatography device and a detective kit capable of prompt and simple detection work. | 01-10-2013 |
| 20130011933 | METHOD OF DIAGNOSING BLADDER CANCER - Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. The present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. Specifically, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer. | 01-10-2013 |
| 20130011934 | BIOPOLYMER SEQUENCING BY HYBRIDIZATION OF PROBES TO FORM TERNARY COMPLEXES AND VARIABLE RANGE ALIGNMENT - Methods for sequencing a biopolymer by forming local ternary complexes along the length of the double-stranded biopolymer target molecule using one or more probes and obtaining information about the location of the probe(s) using a detector. These methods offer particular advantage when implemented with nanopore (including micropore) detection systems. | 01-10-2013 |
| 20130011935 | METHOD OF MEASURING CHARACTERISTICS OF SPECIMEN AND SENSING DEVICE FOR USE WITH THE SAME - A method of measuring characteristics of a specimen, the measuring method including the steps of bonding the specimen to a host molecule on a sensing device, emitting an electromagnetic wave of a particular frequency to the sensing device to which the specimen is bonded, measuring a frequency characteristic of the transmitted or reflected light, and measuring the characteristics of the specimen based on a change of the frequency characteristic, wherein an absorbance of the host molecule per unit quantity at the particular frequency is smaller than that of the specimen. | 01-10-2013 |
| 20130017622 | METHOD AND SYSTEM FOR ANALYTE MONITORING USING SURFACE PLASMONS WITH A REFRESHABLE SURFACEAANM Rahn; John RichardAACI SammamishAAST WAAACO USAAGP Rahn; John Richard Sammamish WA US - The present technology provides an illustrative method for analyte monitoring using surface plasmons with a refreshable surface. The method includes placing a solution to be monitored in contact with a working surface of a surface plasmon resonance (SPR) generation system. The working surface includes a metal surface disposed on a glass surface, and the metal surface includes a first binding substance that provides binding sites for an analyte. The method further includes applying light to the metal surface at a plurality of angles over a period of time, measuring a reflectance of the light at each of the plurality of angles to determine an SPR angle, and monitoring changes to the SPR angle over the period of time. The working surface of the SPR generation system is refreshed by depositing a new layer of the first binding substance on the working surface of the SPR generation system. | 01-17-2013 |
| 20130017623 | Fluid sample collecting and analyzing apparatus and method - A spongy swab ( | 01-17-2013 |
| 20130017624 | METHOD FOR DETERMINATION OF BINDING STOICHIOMETRYAANM Karlsson; RobertAACI UppsalaAACO SEAAGP Karlsson; Robert Uppsala SE - A method is provided for determining binding stoichiometry for the interaction between a first molecule and a second molecule forming a complex between them. Either (i) a solution having a fixed initial active concentration of the first molecule is titrated with solutions of varying active concentrations of the second molecule, and the free active concentrations of the second molecule are measured; or (ii) a solution with fixed initial concentrations of the first molecule and the second molecule is incubated, and the free active concentrations of both molecules are measured. In the first case, the binding stoichiometry can be determined from the initial concentration values of both molecules and the free concentration value(s) of the second molecule at saturation; and in the second case from the initial concentration values of both molecules and the free concentration values of both molecules. Active concentration measurements are typically performed by an interaction analysis sensor, using a calibration-free analytical format at least for the determination of active initial concentrations. | 01-17-2013 |
| 20130023058 | METHOD AND APPARATUS FOR SELECTING A PRODUCT - A method of selecting a product suited to an individual. The method includes: identifying a product category from a predefined set of product categories, each product category being associated with a set of products; on the basis of said selected product category, selecting a genetic testing cartridge type from a set of available cartridge types, each cartridge type being configured to perform a genotype profiling test on a polynucleotide sample; collecting a polynucleotide sample from the individual; performing a genotype profiling test on said polynucleotide sample using a genetic testing cartridge of the selected genetic testing cartridge type; and using the result of said test to select a product from within the identified product category. | 01-24-2013 |
| 20130023059 | METHOD FOR IMMOBILIZING STREPTAVIDIN ON A SELF-ASSEMBLED MONOLAYER - Provided are a method for increasing an amount of streptavidin to be immobilized on the self-assembled monolayer and a sensor which comprises streptavidin immobilized with the method. The method of the current technology is characterized by that one molecule of an amino acid is interposed between the self-assembled monolayer and the molecule of streptavidin. | 01-24-2013 |
| 20130023060 | MICROFLUIDIC ELEMENT WITH MULTI-FUNCTIONAL MEASURING CHAMBER FOR THE ANALYSIS OF A FLUID SAMPLE - A test element, analytical system and method for optical analysis of fluid samples is provided. The test element has a substrate and a microfluidic channel structure, which is enclosed by the substrate and a cover layer. The channel structure has a measuring chamber with an inlet opening. The test element has a first level, which faces the cover layer, and a second level, which interconnects with the first level such that the first level is positioned between the cover layer and the second level. A part of the measuring chamber extending through the first level forms a measuring zone connecting with a part of the measuring chamber that extends partially into the second level, forming a mixing zone. Optical analysis of fluid samples is carried out by light guided through the first level parallel to the cover layer, such that the light traverses the measuring zone along an optical axis. | 01-24-2013 |
| 20130023061 | METHOD FOR STABILIZING GLYCEROPHOSPHOLIPIDS AND REAGENTS USING SAME - Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system. | 01-24-2013 |
| 20130029428 | PREPARATION METHOD OF ANTIGEN-IMMOBILIZED IMMUNO- FLUORESCENCE SLIDE AND IMMUNO-FLUOROSCENCE SLIDE PREPARED THEREBY - A method of preparing an antigen-immobilized immuno-fluorescence slide, the method comprising: immobilizing a C-reactive protein on a slide to prepare a protein chip; mixing an antibody that specifically binds to a target protein, with streptavidin to label the antibody with a fluorescent nanoparticle; immuno-reacting the antibody by competitive mixing, assaying with a fluorescence camera, wherein the immobilizing of the C-reactive protein on the slide comprises: modifying the slide with 3-aminopropyltrimethoxysilane to prepare a modified slide; hydrating the slide modified with 3-aminopropyltrimethoxysilane; activating the modified slide by using a glutaraldehyde solution; dissolving a C-reactive protein at a concentration of 0.01-0.5 mg/ml in a 30-70 mM phosphate buffer solution (pH 6.5-7.8) to prepare an antigen solution for immobilization; placing a petri dish comprising the slide on a spotting guide and spotting 1-100 μl of the antigen solution on spotting points; and performing a reaction on the slide prepared as described above for 1-6 hours to immobilize the antigen, and an immune-fluorescence slide prepared by using the method. | 01-31-2013 |
| 20130029429 | METHOD FOR AVOIDING INFLUENCE OF ENDOGENOUS LIPOPROTEIN AND REAGENT - To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component. | 01-31-2013 |
| 20130029430 | PLASMON SENSOR, AND USAGE METHOD AND MANUFACTURING METHOD THEREOF - A plasmon sensor has a first metal layer and a second metal layer. The first metal layer has a bottom surface and a top surface configured to be supplied with an electromagnetic wave. The second metal layer has a top surface confronting the bottom surface of the first metal layer. Between the first metal layer and the second metal layer, there is provided a hollow region configured to be filled with a specimen containing a medium. Analyte capturing bodies are physically adsorbed at least one of below the first metal layer and above the second metal layer. | 01-31-2013 |
| 20130034914 | FLUORESCENCE-BASED APPROACH TO MONITOR RELEASE FACTOR-CATALYZED TERMINATION OF PROTEIN SYNTHESIS - Provided are probes comprising a class 1 release factor conjugated to a fluorescent label and methods of making the probes. Also provided are methods for detecting conformational changes in ribosomes and associated molecules, such as class 1 release factors. In addition, methods of identifying a compound for reducing nonsense-mediated decay of mRNA and/or for inhibiting termination of protein synthesis at a premature stop codon, are described. Methods of assaying RF3 activity are also included. | 02-07-2013 |
| 20130034915 | Device and method for measuring analytes - The present invention is directed to a system, device and method for measuring the concentration of an analyte in a fluid or matrix. A thermodynamically stabilized analyte binding ligand for use in the system, device and method is disclosed. The thermodynamically stabilized analyte binding ligand is resistant to degradation at physiological temperatures and its use within the device provides a minimally invasive sensor for monitoring the concentration of an analyte in a fluid or matrix as are present in the body of an animal. | 02-07-2013 |
| 20130034916 | FUNCTIONALIZED FLUORESCENT NANOCRYSTAL COMPOSITIONS AND METHODS FOR THEIR PREPARATION - The present invention provides for functionalized fluorescent nanocrystal compositions and methods for making these compositions. The compositions are fluorescent nanocrystals coated with at least one material. The coating material has chemical compounds or ligands with functional groups or moieties with conjugated electrons and moieties for imparting solubility to coated fluorescent nanocrystals in aqueous solutions. The coating material provides for functionalized fluorescent nanocrystal compositions which are water soluble, chemically stable, and emit light with a high quantum yield and/or luminescence efficiency when excited with light. The coating material may also have chemical compounds or ligands with moieties for bonding to target molecules and cells as well as moieties for cross-linking the coating. In the presence of reagents suitable for reacting to form capping layers, the compounds in the coating may form a capping layer on the fluorescent nanocrystal with the coating compounds operably bonded to the capping layer. | 02-07-2013 |
| 20130040403 | METHOD AND APPARATUS FOR AUTOMATED ANALYSIS - A method and apparatus for pretreatment of a desired sample in a discrete fluid analyzing instrument comprises automated means for handling and analyzing the sample and means for performing a pretreatment step on the sample or a sub-sample of the sample. The means for pretreatment are used for immobilizing at least one substance or analyte from the sample or sub-sample wherein the substance or analyte is reversibly immobilized. Usually, the apparatus further comprises means for eluting the substance or analyte from the capture means prior to analysis. | 02-14-2013 |
| 20130040404 | BARRIER LAYER FOR GLUCOSE SENSOR - An optical glucose sensor comprising: a sensing region comprising a boronic acid receptor for binding to glucose and a fluorophore associated with said receptor; an optical waveguide for directing incident light onto the sensing region; and a hydrophilic, polymeric, glucose-permeable barrier layer which is provided on at least a part of the sensing region; wherein the sensor is adapted so that glucose enters the sensing region of the sensor through said barrier layer. | 02-14-2013 |
| 20130040405 | METHODS FOR SENSITIVE AND RAPID DETECTION OF MOLECULES - In some embodiments, the present invention provides methods of detecting a molecule in a sample, such as an explosive. In some embodiments, the method comprises: associating the sample with an antigen/binding agent complex; measuring a rate of displacement of the binding agent from the antigen by the molecule in the sample; and correlating the measured rate of displacement to the presence of the molecule in the sample. In some embodiments, the measuring step comprises a determination of a change in frequency of the sample and a change in energy dissipation of the sample over a time interval. In some embodiments, the correlating step comprises a calculation of a ratio of a change in energy dissipation of the sample over a change in frequency of the sample over the time interval. In some embodiments, the method is used to determine the molecule concentration in the sample. | 02-14-2013 |
| 20130040406 | Device for Preparing And/Or Treating a Biological Sample - The present invention relates to a device for preparation and/or treatment of a biological sample comprising a set of storage chambers and/or reaction chambers intended for receiving a fluid, the chambers being separated by walls so as to constitute a set of adjacent chambers. It also relates to an analysis apparatus capable of using such a device and also a method of using this device. | 02-14-2013 |
| 20130040407 | SOLUBLE FMS-LIKE TYROSINE KINASE-1 (sFLT-1) ANTIBODY AND RELATED COMPOSITION, KIT, METHODS OF USING, AND MATERIALS AND METHOD FOR MAKING - An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid. | 02-14-2013 |
| 20130045542 | NEW FORMULATIONS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - A method of using at least one quantitative ratio of two different amyloid beta-peptides in a sample of a body fluid from a patient for determining the patient's probability of contracting Alzheimer's disease (AD) or for determining the patient's suffering from a precursor of Alzheimer's disease includes obtaining the sample of the body fluid from the patient. The at least one quantitative ratio is calculated from the two different amyloid beta-peptides from the sample. The patient's probability of contracting Alzheimer's disease (AD) or the patient's suffering from a precursor of Alzheimer's disease is calculated using the at least one quantitative ratio. The two different amyloid beta-peptides are selected from (a) Aβ(1-42), (b) Aβ(2-40) and (c) Aβ(2-42). The at least one quantitative ratio is selected from (a) Aβ(1-42)/(b) Aβ(2-40), (a) Aβ(1-42)/(c) Aβ(2-42), (b) Aβ(2-40)/(a) Aβ(1-42) and (c) Aβ(2-42)/(a) Aβ(1-42). | 02-21-2013 |
| 20130045543 | NOVEL MUC1 ANTIBODY - An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1. | 02-21-2013 |
| 20130045544 | VCJD CONFIRMATORY SCREENING ASSAY - The present invention related to an improved method for the detection of prion proteins, especially abnormal prion proteins (PrP | 02-21-2013 |
| 20130052748 | ASSAY DEVICE AND METHOD OF ASSAYING - A device for testing an analyte comprises a pathway allowing passage of analyte from an application zone to a waste zone. The device includes label material that emits or modifies light and which binds to the analyte. Between the application and waste zones there is a capture zone having capture material for binding any analyte traversing the pathway to the pathway. A first optical filter on one surface of the device allows transmission of light emitted or modified by the label and blocks light of at least one other wavelength range. This enables the device to be illuminated from one surface and light emitted or modified by the label to be detected from the opposite surface. The device may include a second filter allowing shorter wavelength light to reach the label. The device may be viewed using an illuminating reader or held up to a light source for viewing. | 02-28-2013 |
| 20130052749 | METHODS OF TRIGGERING ACTIVATION OF ENCAPSULATED SIGNAL-GENERATING SUBSTANCES AND APPARATUS UTILISING ACTIVATED SIGNAL-GENERATING SUBSTANCES - A method of performing a bioassay comprising activating capsules containing a signal precursor that is hydrolysable from a latent form in which substantially no signal is generated to a form in which it is able to generate a detectable signal, said activating comprising treating said capsules with heat and with an acid or a base catalysing solution, the combination of said heat and the pH of the catalysing solution being such as to hydrolyse said precursor to the form in which it is able to generate a detectable signal. | 02-28-2013 |
| 20130052750 | DIAGNOSTIC SYSTEM - The present invention provides, among other things, methods of creating an external marker for diagnosis and/or analysis of one or more diseases, disorders, or conditions, which may or may not otherwise have an external marker. | 02-28-2013 |
| 20130059399 | Lateral Flow Test Kit and Method for Detecting an Analyte - A method and device for detecting analytes in a test sample. Embodiments include methods for quantitatively detecting analytes within a range of concentrations. In an embodiment the method includes a lateral flow test strip with multiple test areas for capturing a labeled receptor to provide a detectable signal. | 03-07-2013 |
| 20130059400 | Scanning Analyzer for Single Molecule Detection and Methods of Use - The invention encompasses analyzers and analyzer systems that include a single molecule analyzer, methods of using the analyzer and analyzer systems to analyze samples, either for single molecules or for molecular complexes. The single molecule uses electromagnetic radiation that is translated through the sample to detect the presence or absence of a single molecule. The single molecule analyzer provided herein is useful for diagnostics because the analyzer detects single molecules with zero carryover between samples. | 03-07-2013 |
| 20130065322 | Radioimmunoassay with a 96-Welled Micro-plate - A method for using a multi-welled micro-plate in radioimmunoassay (“RIA”) is disclosed to improve the performance of RIA. At first, there is provided a multi-welled micro-plate that can be dismantled and divided into multiple wells. Then, samples are filled into the wells of the multi-welled micro-plate for incubation. Washing, tracer-adding, incubation, and washing are executed. At a final step, the multi-welled micro-plate is separated into wells, and each of to the wells is put into a test tube for gamma counting by a gamma counter. | 03-14-2013 |
| 20130065323 | Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the CP family. Unique antibodies derived from novel immunogens enable said methods and kits. | 03-14-2013 |
| 20130065324 | IMMUNOASSAY APPARATUS INCORPORATING MICROFLUIDIC CHANNEL - An assay apparatus having an assay strip. The assay strip has a first area with a plurality of magnetic particles bonded thereto. The assay strip also has a microfluidic (or nanofluidic) channel or chamber, having a sensing area including one or more magnetic particle traps and a magnetic field source provided adjacent to the sensing area. Introduction of a fluid causes the magnetic particles to become attached to or displaced by a substance of interest, travel along the microfluidic channel to the sensing area and become concentrated in the one or more traps thus providing an indication of the presence or absence of a substance of interest in the fluid. There may be a plurality of traps. | 03-14-2013 |
| 20130065325 | ZWITTERIONIC REAGENTS - Zwitterion-containing compounds for the modification of hydrophobic molecules to improve their solubility and/or to lower their non-specific binding as provided. The zwitterion-containing compounds may be suitable for modification of detectable labels such as biotin and fluorescein to improve their solubility. The zwitterion-containing compounds may also be useful for the preparation of conjugates of proteins, peptides and other macromolecules or for crosslinking molecules and/or macromolecules. | 03-14-2013 |
| 20130071946 | Suspension Container For Binding Particles For The Isolation Of Biological Material - A device, method and system is provided for binding particles for the separation and/or isolation of biological materials. In particular, a container is provided including a suspension of binding particles for the isolation of biological material, inner walls forming an elongate groove at the bottom of said container, and a cover having openings and/or being penetrable for a linear arrangement of multiple pipets or pipet tips, said openings being located above and parallel to said elongate groove. | 03-21-2013 |
| 20130071947 | CHIRALITY SENSOR AND METHOD FOR DETECTION OF AFLATOXIN BY USING THE SENSOR - A universal chirality sensor based on immuno-recognition-driven nanoparticle assembly has been fabricated. The design of smart 10 nm AuNP-antigen and 20 nmAuNP-antibody described for the detection of aflatoxin B1. 10 nm AuNP-antigen and 20 nmAuNP-antibody assemble to symmetric plasmonic nanoparticle dimers, which induced CD signal. The addition of aflatoxin B1 to the chirality sensor resulted in transverse CD signal compared to a blank control as shown by CD measurements. This process also allowed the rapid and facile determination of concentrations of aflatoxin B1 in drinking water (tap water). Good linearity for all calibration curves was obtained, and the limit of detection (LOD) for aflatoxin B1 was 0.02 ng/mL in tap water. | 03-21-2013 |
| 20130071948 | PROCESS FOR PRODUCING SUPRAMOLECULAR FIBER - A method for preparing a linearly extended supramolecular fiber or a plurality of linearly aligned supramolecular fibers, which comprises the step of allowing supramolecular monomers to be self-assembled in a microfluidic channel. | 03-21-2013 |
| 20130071949 | IMMUNOASSAY FOR QUANTIFICATION OF AN UNSTABLE ANTIGEN SELECTED FROM BNP AND proBNP - The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex. | 03-21-2013 |
| 20130071950 | Agglutination Based Sample Testing Device - A sample testing device for testing for the presence of a component of interest in a liquid sample includes: (a) a capillary pathway having an upstream end and a downstream end and incorporating a reagent system capable of causing agglutination with the component; (b) optionally, a control capillary pathway; (c) a sampling region to which the liquid sample is applied and from which the sample is able to enter the upstream ends of the test and control capillaries; (d) a power source; (e) detection arrangements electrically associated with the power source for detecting the presence of liquid at a downstream region of the capillaries; (f) a display operated by the power source for indicating the result of the test; and (g) a signal processor associated with the power source, detection arrangement and display for evaluating the result of the test and providing the result on the display. | 03-21-2013 |
| 20130071951 | METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies. | 03-21-2013 |
| 20130071952 | LUMINESCENT POLYMER CYCLIC AMPLIFICATION - The present invention is directed to a luminescent immunoassay method for detecting an analyte in a liquid sample with high sensitivity. The invention provides a unique combination of (i) using a probe having a small sensing surface area for binding analyte molecules, (ii) using a high molecular weight branched polymer conjugated with multiple binding molecules and multiple luminescent labels, and (iii) cycling the probe having immunocomplex formed back to the reagent vessel and amplification vessel 1-10 times and repeating the reaction with the reagent and the amplification polymer, to improve the sensitivity of detection level. For each cycling, the luminescent signal is increased significantly over the noise. | 03-21-2013 |
| 20130071953 | GDF-15 BASED MEANS AND METHODS FOR SURVIVAL AND RECOVERY PREDICTION IN ACUTE INFLAMMATION - A method for diagnosing whether a subject suffering from an acute inflammation and in some cases systemic inflammatory response syndrome (SIRS) is at increased risk for mortality. The method comprises determining the amount of the biomarker GDF-15 in a sample of said subject and comparing said amount to a reference. The method also relates to monitoring the development of acute inflammation in a subject by determining the amount of the biomarker GDF-15 in a first and a second sample of said subject wherein said first sample has been obtained prior to said second sample and comparing the amount of GDF-15 in said first and said second sample. Further encompassed are diagnostic devices and kits for carrying out the aforementioned methods. | 03-21-2013 |
| 20130078738 | METHOD FOR MEASURING SUBSTANCE TO BE MEASURED USING FLUORESCENT PARTICLES, TEST SUBSANCE MEASUREMENT CHIP, AND TEST SUBSANCE MEASUREMENT KIT - A method for measuring a test substance including (1) reacting fluorescent particles and a test substance by bringing the test substance and the fluorescent particles into contact with a test area and a control area present on a substrate, (2) removing the unreacted fluorescent particles, (3) measuring the fluorescence of the fluorescent particles of the test area and the control area, and (4) correcting a fluorescence signal value in the test area using a fluorescence signal value in the control area, wherein the fluorescent particles are binding substance-labeling fluorescent particles in which one or more of a first binding substance which can bind to the test substance, and a third binding substance which can bind to a second binding substance and which does not bind to the test substance are bound, and the second binding substance which can bind to the first binding substance is immobilized on the control area. | 03-28-2013 |
| 20130078739 | CORTISOL IMMUNOASSAY USING FLUORESCENT PARTICLES - Provided are a base plate and a method for cortisol immunoassay, which enable immunoassay of cortisol with high sensitivity particularly in a clinically significant cortisol concentration range (that is, 1 μg/dL to 30 μg/dL). A base plate for cortisol immunoassay which has a cortisol albumin conjugate having a cortisol/albumin ratio of from 12 to 20 immobilized thereon is disclosed. | 03-28-2013 |
| 20130078740 | PREPARATION OF MICROFLUIDIC DEVICE ON METAL NANOPARTICLE COATED SURFACE, AND USE THEREOF FOR NUCLEIC ACID DETECTION - The invention relates to a microfluidic device that utilizes nucleic acid-based detection and a detection system containing the same, as well as a process for preparing the micro fluidic device and for using the same to detect the presence of a target nucleic acid molecule in a sample. | 03-28-2013 |
| 20130078741 | IGA-BINDING PEPTIDE AND PURIFICATION OF IGA USING THE SAME - This invention relates to: a peptide which comprises an amino acid sequence consisting of 12 to 18 amino acid residues represented by (X | 03-28-2013 |
| 20130084648 | POLYPEPTIDE SEPARATION METHODS - The present disclosure provides methods and compositions for separating polypeptide glycoforms using a medium that includes an Fc receptor. In certain embodiments, a medium includes an Fc receptor which comprises an extracellular portion of an Fc gamma RIII receptor. | 04-04-2013 |
| 20130084649 | FLUORESCENCE MEASUREMENT - A sensor for fluorescence measurement comprising: a light source arranged for emitting light to a sample region, wherein the light source intensity is modulatable; an indicator system located at the sample region, said indicator system comprising: a receptor for an analyte; and a fluorophore associated with said receptor, wherein the fluorophore has a fluorescence lifetime that changes in response to the presence of analyte at the receptor; a single photon avalanche diode arranged to receive fluorescence light emitted from said sample region in response to the light incident on the sample region from the light source, and to generate an output signal; a driver arranged to modulate the light source intensity at a first frequency; a bias voltage source arranged to apply a bias voltage to the single photon avalanche diode, wherein the bias voltage is modulated at a second frequency, different from the first frequency, and wherein the bias voltage is above the breakdown voltage of the single photon avalanche diode; and a signal processor arranged to determine information related to a fluorescence lifetime of the fluorophore based on at least the output signal of the single photon avalanche diode. | 04-04-2013 |
| 20130084651 | TEST INSTRUMENT FOR MEASURING ANALYTE IN SAMPLE, AND METHOD FOR MEASURING ANALYTE USING SAME - Disclosed is a test instrument for measuring an analyte in a liquid sample by a noble metal colloid aggregation measurement method. The test instrument involves a reaction chamber in which at least the liquid sample is to be reacted with a reagent, wherein the reagent is adhered on at least a part of a surface constituting the reaction chamber in a dried state, and the reagent enables the measurement of the analyte by a noble metal colloid aggregation measurement method. The test instrument additionally involves a supply section for supplying the liquid sample and a flow path for delivering the liquid sample that has been supplied to the supply section to the reaction chamber, wherein the liquid sample that has been supplied to the supply section is delivered to the reaction chamber through the flow path to cause the liquid sample to be brought into contact with the reagent that has been adhered in a dried state, thereby producing a difference in pressure between the supply section and the reaction chamber for the purpose of dispersing the reagent in the liquid sample. When the test instrument is used, the measurement based on an absorbance at a visible region can be achieved, the analyte can be measured accurately within a short time, and the measurement suitable for a POCT field can be achieved. | 04-04-2013 |
| 20130084652 | Homogeneous Chemiluminescence Assay Methods with Increased Sensitivity - Methods are disclosed for determining an analyte in a medium suspected of containing the analyte. One method comprises treating a medium suspected of containing an analyte under conditions such that the analyte, if present, causes a photosensitizer and a chemiluminescent compound to come into close proximity. The photosensitizer generates singlet oxygen and activates the chemiluminescent compound when it is in close proximity. Non-specific signal generated by singlet oxygen not in proximity is reduced or suppressed using a singlet oxygen quencher (SOQ). The activated chemiluminescent compound subsequently produces light. The amount of light produced is related to the amount of analyte in the medium. Use of Noise Modulation Agents significantly improves signal-to-noise ratios and assay sensitivity. Compositions and kits are also disclosed. | 04-04-2013 |
| 20130089932 | FET Sensor and Methods for Detecting Melamine - The present invention provides a device and methods for the detection and quantification melamine in a sample by rapid and specific electrochemical detection. The present invention includes using a field-effect transistor (FET) biosensor having an open Si channel with a melamine antigen, or hapten, or an antibody, anchored via a linker molecule such as self assembled monolayer to the surface of the gate dielectric of the said open Si channel. The anchoring molecule having the capability of detecting melamine directly or indirectly by selectively binding melamine antibodies, which changes a field-effect on a Si channel, causing a change in conductivity of the FET. This change in conductivity can be measured and is used to determine the presence or absence of melamine in a sample compared to a standard signal or pre-measured database. | 04-11-2013 |
| 20130095574 | METHOD FOR PRODUCING MICROPARTICLES - Silicon microcarriers suitable for fluorescent assays as a well as a method of producing such microcarriers are provided. The method includes the steps of providing a SOI wafer having a bottom layer of monocristalline silicone, an insulator layer and a bottom layer of monocristalline silicon, delineating microparticles, etching away the insulator layer and then depositing an oxide layer on the wafer still holding the microparticles before finally lifting-off the microparticles. | 04-18-2013 |
| 20130095575 | Methods for Fractionation, Analysis and Collection of Microvesicles From Patient Samples - A methods are provided for the flow cytometry profiling of microvesicles, including exosomes. | 04-18-2013 |
| 20130102090 | OPTICAL ANALYTE SENSOR - A waveguide sensor capable of direct, real-time detection and monitoring of analytes in the vicinity of the waveguide surface without requiring the tagging or labeling of the analyte, is described. Analytic and numerical calculations have predicted that by locally detecting either changes in the evanescent field or changes in the light coupled out of the waveguide as a result of the presence of the analyte, high detection sensitivity will be able to be achieved. | 04-25-2013 |
| 20130109107 | DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASE | 05-02-2013 |
| 20130115713 | QUANTUM DOT-BASED OPTICAL SENSORS FOR RAPID DETECTION AND QUANTITATIVE ANALYSIS OF BIOMOLECULES AND BIOLOGICAL MATERIALS - The invention generally relates to detection and analysis of biological materials. In particular; the invention relates to quantum dot-based optical, sensors and methods for rapid detection and quantitative analysis of various biomolecules and biological materials, such as nucleic acids, proteins, cells, etc. | 05-09-2013 |
| 20130115714 | WESTERN BLOT ANALYTICAL TECHNIQUE - In accordance with an embodiment of the present invention, there is provided a method of performing the western blot analytical technique, wherein the method comprises carrying out the following steps in the following order: a), pre-staining the proteins within a sample; b). separating the proteins using gel electrophoresis; c). analysing the separated proteins to determine the total protein load and/or at least one housekeeping protein load; d). transferring the proteins onto at least one membrane; e). probing the separated proteins to detect a target protein; and f). analysing the probed proteins to determine the target protein's molecular weight and/or load. | 05-09-2013 |
| 20130115715 | METHOD OF SENSOR MEASUREMENT - The present invention provides a method of determining the amount of an optical probe species binding to or releasing from an optical sensor surface characterized in that the determination comprises the steps of determining at least one physical measurand (x | 05-09-2013 |
| 20130115716 | METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD - A method for determining A.beta. turnover in blood includes the use of a labeled amino acid to assess the turnover rate. | 05-09-2013 |
| 20130115717 | ANALYZING CHEMICAL AND BIOLOGICAL SUBSTANCES USING NANO-STRUCTURE BASED SPECTRAL SENSING - An integrated chromatography-immunoassay system for integrated chromatography-immunoassay system includes a chromatographic unit that receives labeled nano-structured probes comprising nano particles and antibodies attached to the nano particles, and a test membrane comprising coating antigens. The chromatographic unit allows the labeled nano-structured probes to diffuse there through and into the test membrane, wherein the antibodies on the nano particles are bound to the coating antigens. A laser device emits a laser light to illuminate the labeled nano-structured probes having the antibodies bound to the coating antigens on the test membrane. A spectral analyzer obtains a Raman spectrum from light scattered from the labeled nano-structured probes having the antibodies bound to the coating antigens on the test membrane, and to identify a spectral signature in the Raman spectrum associated with the antibody-antigen pair, which enables detection and identification of the antibody. | 05-09-2013 |
| 20130115718 | Carrier Carrying Identifying Information for Identifying an Identification Subject and Use Thereof - Disclosed are a carrier that carries identifying information having favorable identification performance and a use thereof. The carrier carries identifying information for identifying an identification subject, and comprises one or more pieces of DNA having a thymine-rich base sequence and having, as the identifying information, an identifying base sequence pre-associated with the identification subject. | 05-09-2013 |
| 20130122605 | Methods for Ionophorically Screening Pore Forming Bacterial Protein Toxins and Receptors - A method for determining the amount of live pore forming bacterial toxin protein in a sample is provided, the method including the steps of a) forming a membrane comprising a lipid bilayer and a receptor, b) contacting the membrane with an ion solution and the sample, c) measuring ion flow through the membrane, d) comparing the ion flow through the membrane to a standard curve, and e) determining the amount of pore forming bacterial toxin protein in the sample. A kit for determining the amount of live pore forming bacterial toxin protein present in the sample is also provided. | 05-16-2013 |
| 20130122606 | METHOD AND DEVICE FOR CHEMICAL AND/OR BIOLOGICAL ANALYSIS - A method of chemical and/or biological analysis including: providing a container delimited by a wall including an inner surface on which there is deposited an active component intended to make possible a chemical and/or biological reaction with a solution disposed in the container; filling the container with a liquid solution containing an analyte which is to be detected; and in applying to the liquid a succession of movements of aspirating/discharging a volume in the container at a suitable frequency to bring about resonance of the liquid so as to deform the free surface thereof and to result in a preferential distribution of the fluid along the inner surface of the wall of the container. | 05-16-2013 |
| 20130122607 | DETECTION DEVICE AND DETECTION METHOD FOR INTERMOLECULAR INTERACTION - In order to improve the detection accuracy of a reflection spectrum, a detection device for intermolecular interaction is provided with a detector ( | 05-16-2013 |
| 20130130402 | FLUORESCENT COMPOUNDS, COMPOSITIONS, AND METHODS FOR USING THE COMPOUNDS AND COMPOSITIONS - Low pKa fluorescent compounds, compositions that include the compounds, bioconjugates made from the compounds, and methods for making and using the compounds and bioconjugates. | 05-23-2013 |
| 20130130403 | Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 05-23-2013 |
| 20130130404 | SIGNAL AMPLIFICATION IN LATERAL FLOW AND RELATED IMMUNOASSAYS - The present invention provides methods, devices, compositions (e.g., capture complexes), and kits useful for enhancing the detection of antibodies in a test sample. The methods, devices, and compositions utilize detectable Fc-binding molecules such as Protein A, Protein G, and/or an Fc-specific antibody to amplify the signal of a detected antibody in immunoassays, such as lateral flow assays. | 05-23-2013 |
| 20130137187 | SYNTHETIC ACTIVE PEPTIDE FRAGMENTS - The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of | 05-30-2013 |
| 20130137188 | METHOD OF DETECTING RUPTURE OF MEMBRANES - The present invention relates to a method of detecting rupture of fetal membranes and to a device for implementing said method. In particular, a method of in-vitro detection of a rupture of fetal membranes comprising a step of simultaneously searching, within a specimen of vaginal or cervical secretions, for the alpha fetal protein (AFP) and for the insulinomimetic growth factor-binding protein 1 (IGFBP-1). The present invention finds, in particular, an application in the medical field, especially in the obstetric field. | 05-30-2013 |
| 20130137189 | METHOD AND APPARATUS FOR PERFORMING A LATERAL FLOW ASSAY - An embodiment of the present invention provides a method for performing a lateral flow assay. The method includes depositing a sample on a test strip at an application region, detecting a first detection signal arising from the test strip in the first detection zone, and generating a baseline for the first measurement zone by interpolating between values of the detection signal outside of the first measurement zone and inside of the first detection zone. The method may include locating a beginning boundary and an ending boundary for the first measurement zone on the test strip. Additional detection zones having measurement zones may also be incorporated with the embodiment. | 05-30-2013 |
| 20130137190 | IMMUNOCHROMATOGRAPHIC DEVICE - The present invention provides an immunochromatographic device, which contains the following (a) and (b): (a) a first device part holding a first insoluble carrier used for developing a complex formed with an analyte and a labeling substance comprising a metal labeled with a first binding substance that can bind to the analyte and capturing the analyte and the labeling substance at a reaction portion containing a second binding substance that can bind to the analyte, and (b) a second device part holding a second insoluble carrier used for developing a liquid and a third insoluble carrier used for absorbing a liquid, in such a way that the first insoluble carrier does not come into contact with the second insoluble carrier and the third insoluble carrier. | 05-30-2013 |
| 20130137191 | METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker, NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule ceil injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents. | 05-30-2013 |
| 20130137192 | IMMUNOCHROMATOGRAPHY REAGENT COMPOSITION, AND MEASUREMENT METHOD USING SAME - When an immunochromatography reagent composition containing a nonionic surfactant, an N,N-bis(2-hydroxyethyl)glycine buffer, and casein is used as a specimen treatment solution or developing solution in detecting a detection object in a specimen according to an immunochromatographic method, an immunochromatography reagent composition which suppresses a non-specific reaction; does not cause aggregation of antibody-immobilized colloidal gold; and has a high developing rate, in comparison with conventional technology which detects a detection object by using an immunochromatographic device; and a high-performance and highly-sensitivity immunochromatographic method and a detection kit capable of rapid, simple and easy virus detection, which use the immunochromatography reagent composition are provided. | 05-30-2013 |
| 20130143332 | SPFS SENSOR EQUIPPED WITH MECHANISM PURIFYING NON-SPECIFICALLY ADSORPTIVE CONTAMINANTS - [Object] It is an object of the invention to provide a sensor area which can suppress a decrease in assay signal and an increase in assay blank in an SPFS measurement. | 06-06-2013 |
| 20130149792 | CANCER PROGNOSIS ASSAY - The invention provides a method of prognosis of a subject with a cancer, identifying a subject having a greater risk of having an undiagnosed cancer and/or identifying a subject at greater risk of developing a cancer the method comprising detecting an amount of free light chains (FLC) in a sample from a subject, wherein a higher amount of FLC is associated with decreased survival due to a cancer and/or increased risk of the subject having an undiagnosed cancer and/or having an increased risk of developing a cancer. | 06-13-2013 |
| 20130149793 | ANTI-FDP MONOCLONAL ANTIBODY, FDP MEASUREMENT REAGENT AND REAGENT KIT USING SAME, AND FDP MEASUREMENT METHOD - The present invention relates to an anti-FDP monoclonal antibody selected from the first, second and third monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent and reagent kit for the measurement of FDP and a method for measurement of FDP using the anti-FDP monoclonal antibodies. | 06-13-2013 |
| 20130157378 | ATTENUATING DYE FOR INTERROGATING MULTIPLE SURFACES, AND METHOD THEREOF - A device including a shallow chamber for analyzing a plurality of target analytes in a body fluid using the signal generated by fluorescent detector molecules each specific for a target analyte, an attenuating dye for attenuating the signal emitted by fluorescent detector molecules specifically bound to the surfaces of the chamber other than an optically clear surface, and method for determining the signal generated by each of the plurality of analytes. | 06-20-2013 |
| 20130157379 | DIAGNOSTIC DETECTION DEVICES AND METHODS - Described herein are methods and devices for detecting the presence of an analyte in a liquid sample. In some embodiments, methods and devices for the detection of an antigen in a body fluid using a plurality of species-specific antibodies are provided. A sandwich complex may be formed using primary antibodies derived from two different species. | 06-20-2013 |
| 20130157380 | MULTIASSAY IMMUNOCHROMATOGRAPHIC CHIP - A multiassay immunochromatographic chip comprises: a viscous bottom lining ( | 06-20-2013 |
| 20130157381 | SAMPLE TESTING APPARATUS AND METHOD - Apparatus for performing an assay to detect the presence of an analyte in a test sample. A housing defines a slot for receiving a sample collector, and a capsule contains a buffer liquid, the capsule being sealed by an openable lid, and being connected to the housing such that insertion of a sample collector into the slot causes the lid to open releasing the buffer liquid into the slot. The housing further defines an incubation chamber containing or configured to receive a reagent, and an aperture permitting liquid communication between said slot and the incubation chamber. The apparatus comprises one or more test elements, a substantially liquid tight sealing member separating the incubation chamber and the test element(s), and an activation mechanism operable to open said liquid tight sealing member thereby bringing at least a portion of the or each test element into liquid communication with said incubation chamber. | 06-20-2013 |
| 20130164858 | DIAGNOSTIC DETECTION DEVICE - The invention comprises a device for detecting an analyte in a liquid sample deposited on a first portion of the device for transport to a second portion of the device that is in fluid contact with the first portion. In specific embodiments, the device is a pregnancy test device, which detects human chorionic gonadotropin (hCG) as an indicator of pregnancy. Devices with improved clinical sensitivity are provided which are capable of detecting all clinically relevant hCG isoforms. | 06-27-2013 |
| 20130164859 | DNA-DECORATED GRAPHENE CHEMICAL SENSORS - The present invention provides a broad response single-stranded DNA-graphene chemical sensor device. The present invention also provides methods for improving the ability of graphene to work as a chemical sensor by using single-stranded DNA as a sensitizing agent. | 06-27-2013 |
| 20130164860 | AFFINITY METHODS AND COMPOSITIONS EMPLOYING ELECTRONIC CONTROL OF PH - Methods and apparatuses for detection of target molecules are provided. | 06-27-2013 |
| 20130164861 | BIOLOGICAL MOLECULE DETECTING APPARATUS AND BIOLOGICAL MOLECULE DETECTING METHOD - A laser beam is emitted onto fluorescent molecules within a solution to orient the fluorescent molecules. The direction in which the laser beam is emitted is switched to switch the transition moment direction of the fluorescent particles to be parallel or perpendicular to the vibrating direction of linearly polarized excitation light. Thereby, the fluorescent molecules of free molecules and binding molecules can be switched between an excited and a non excited state. There is a difference in the speeds at which the orientation directions change for molecules which have undergone and molecules which have not undergone antigen antibody reactions. Therefore, the fluorescence contributed by fluorescent molecules associated with free molecules and the fluorescence contributed by fluorescent molecules associated with binding molecules can be calculated respectively, to measure the concentration of a detection target substance with high sensitivity. | 06-27-2013 |
| 20130164862 | SENSING METHOD FOR BIOPOLYMERS AND SENSING DEVICE THEREFOR - A sensing method for biopolymers by detecting the magnetic signal generated from a labeled biopolymer under AC magnetic field with thermo-responsive magnetic nano particles as label having a critical solution temperature across which the particles have the ability to aggregate or disperse with cooling or heating. | 06-27-2013 |
| 20130171739 | MICROCHIP SOLUTION SENDING SYSTEM - [Technical Problem] | 07-04-2013 |
| 20130171740 | REAGENT COMPOSITION FOR NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY, METHOD FOR MEASUREMENT BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY, AND KIT FOR MEASUREMENT BY NUCLEIC ACID CHROMATOGRAPHY OR IMMUNOCHROMATOGRAPHY - A reagent composition for nucleic acid chromatography or immunochromatography which includes a water-soluble polymer having a weight average molecular weight of 8,000 or more, a salt of a divalent or trivalent metal, a nonionic surfactant, and an aprotic water-soluble organic compound. The reagent composition is capable of determining an analyte accurately and rapidly even when it has a low concentration in a measurement by nucleic acid chromatography or immunochromatography, by reducing the binding of components other than the analyte through a non-specific reaction and enhancing the dispersion capability of the analyte to improve the developability on a chromatography carrier and to promote a specific reaction. | 07-04-2013 |
| 20130177996 | Device and Method for Testing Biological Samples - Devices and methods for testing a biological sample for an analyte of interest are provided that make use of a reaction chamber for receiving a reaction mixture, a housing positioned below the reaction chamber for receiving a test cassette, and a door that is positioned in the top portion of the housing. The door includes a ramp that extends downwardly into the housing such that biasing the ramp upwards opens the door into the cavity of the reaction chamber and places the reaction chamber in fluid communication with the insertion area to thereby allow the reaction mixture to flow onto a test cassette and allow for the determination of an amount of an analyte of interest. | 07-11-2013 |
| 20130183770 | METHODS FOR ANALYSIS OF FREE AND AUTOANTIBODY-BOUND BIOMARKERS AND ASSOCIATED COMPOSITIONS, DEVICES, AND SYSTEMS - The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample. | 07-18-2013 |
| 20130183771 | NOVEL LUMINESCENT LANTHANIDE CHELATES WITH ENHANCED EXCITATION PROPERTIES - The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) | 07-18-2013 |
| 20130183772 | APPARATUS, METHOD AND ARTICLE TO PERFORM ASSAYS USING ASSAY STRIPS - An assay system includes an optical imager to acquire high resolution images of assay strips (e.g., lateral flow immunochromatographic test strips) and performs image processing to identify individual assay strips and determine results for each assay strip, by quantifies the presence or absence of test signal line(s) and control signal line(s). Assay strips may be in a holder or carrier contained in a specimen container also holding a specimen. The assay system automatically logs all results and data to a database that stores a high resolution image of the original immunochromatographic assay, the values of test line(s) and control line(s), and the test result. A user interface directs an end user through operation. | 07-18-2013 |
| 20130189794 | Optical Assay Device with Pneumatic Sample Actuation - This invention relates generally to devices and methods for performing optical and electrochemical assays and, more particularly, to test devices, e.g., cartridges, methods and systems, wherein the test devices have an entry port configured to receive a test sample into a holding chamber; a first conduit having at least one lateral flow test strip; and a displacement device, such as a pneumatic pump, configured to move a portion of said test sample from said holding chamber into said first conduit. The present invention is particularly useful for performing immunoassays and/or electrochemical assays at the point-of-care. | 07-25-2013 |
| 20130189795 | BLAST, BALLISTIC AND BLUNT TRAUMA SENSOR - A molecular biosensor is provided including a lipid vesicle and a housing wherein the vesicle is contained on or within the housing and where the housing has a portion capable of transmitting a force generated, external to the housing to the vesicle. The biosensor is used in processes of detecting the presence or absence of an event force such as a blast or blunt force sufficient to produce a medical complication such as traumatic brain injury. | 07-25-2013 |
| 20130189796 | Assay Device Having Uniform Flow Around Corners - An assay device includes: a liquid sample zone; a reagent zone downstream and in fluid communication with the sample zone containing a reagent material; a detection zone in fluid communication with the reagent zone having capture elements bound thereto; and a wicking zone in fluid communication with the capture zone having a capacity to receive liquid sample flowing from the detection zone. The sample receiving zone, the reagent zone, the detection zone and the wicking zone define a fluid flow path and at least a part of the fluid flow path has a substrate and projections which extend substantially vertically from the substrate, wherein the projections have a height, cross-section and a distance between one another that defines a space between the projections capable of generating capillary flow parallel to the substrate surface. In addition, the fluid flow path having projections includes a corner section which changes the direction of the flow path. The projections in or around the corner section are modified to maintain the configuration of the flow front of the sample flowing through the flow path after the corner is substantially the same configuration as before the corner. | 07-25-2013 |
| 20130189797 | OPTICAL BIOSENSOR REFERENCING METHOD - A referencing method for an optical biosensor system using a single sensing region is provided. The method involves limiting the ligand immobilized in a single sensing region to only a portion thereof. In one embodiment, this is accomplished by selectively deactivating a portion of the sensing surface to prevent immobilization of ligand to that portion. As a result, a reference response can be recorded in the same sensing region as a molecular interaction response. Thus, the bulk refractive index can be accurately accounted for in measuring the kinetics of a molecular interaction. | 07-25-2013 |
| 20130189798 | LUMINESCENCE METHOD OF DETECTING AN ANALYTE IN A LIQUID SAMPLE AND ANALYSIS SYSTEM - The present disclosure relates to a luminescence method of detecting an analyte in a liquid sample comprising marking the analyte with a marker capable of effecting luminescence upon application of excitation energy, wherein reference data descriptive of the luminescence decay is stored in an electronic memory; applying the excitation energy for causing the luminescence; time-resolved measuring of the luminescence over a period of time for acquisition of a measurement signal; reading the reference data from the electronic memory; comparing the measurement signal with the luminescence decay described by the reference data; generating an output signal indicative of the presence of the analyte in the liquid sample using the measurement signal; in case of a mismatch of the measurement signal and the luminescence decay described by the reference data, generating an error signal. | 07-25-2013 |
| 20130196448 | SURFACE PLASMON RESONANCE SENSOR - An SPR sensor comprising a thin conducting layer comprising at least one conductive element formed on a surface of a transparent substrate, a light source that illuminates an interface between the conducting layer and the substrate, a photosensitive surface that generates signals from light reflected from the interface, a flow cell formed with at least one flow channel having a lumen defined by a wall formed from an elastic material and from a region of the conducting layer, and at least one hollow fluid-providing flow control apparatus having a lumen and an orifice communicating with its lumen. Fluid flow is enabled between the flow channel and the lumen of the flow control apparatus by forcing an end of the flow control apparatus through the elastic material so that the orifice communicates with the flow channel lumen. | 08-01-2013 |
| 20130196449 | ELECTRICALLY DRIVEN DEVICES FOR SURFACE ENHANCED RAMAN SPECTROSCOPY - An electrically driven device for surface enhanced Raman spectroscopy includes a substrate, a Raman signal-amplifying structure positioned on the substrate, and an analyte receptor attached to a structure chosen from i) the Raman signal-amplifying structure, or ii) the substrate near the Raman signal-amplifying structure, or iii) combinations of i and ii. The analyte receptor has a selective binding affinity for an analyte. Conductive elements are positioned relative to one another and to the analyte receptor such that the conductive elements together produce an electric field in the vicinity of the analyte receptor when a voltage bias is applied between the conductive elements. | 08-01-2013 |
| 20130196450 | METHOD FOR COATING NANOPARTICLES - The invention relates to methods for coating nanoparticles with a limited amount of a binding partner and nanoparticles obtainable by the methods disclosed. In particular, the invention is of interest, when coating with only a limited amount of protein is desirable. | 08-01-2013 |
| 20130203181 | DETERMINATION OF INTERACTIONS BETWEEN A SUBSTANCE OR A SUBSTANCE MIXTURE AND A TARGET - A method includes incubating at least a first and a second sample of the substance or of the substance mixture with the target immobilized on a solid carrier. Incubation is in each case effected in a sample container. The first and the second sample are incubated with different amounts of the target, whereas all sample containers include the same amount of buffer solution during incubation. After incubation, the solid carrier is separated from the buffer solutions together with the target immobilized thereon as well as, if applicable, substance bound thereon. The concentration of the substance or of the substance mixture is then measured in the respective supernatant. | 08-08-2013 |
| 20130203182 | METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS - A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting a plurality of allergens to be tested for in the sample, c) determining for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed. | 08-08-2013 |
| 20130203183 | ASSAY DEVICE - An assay device for performing an assay on a liquid sample using a detection conjugate capable of binding to an antigen and containing a label. The device includes a substrate surface having a sample addition zone, a reaction zone and an absorbing zone, the zones being connected by at least one fluid passage, wherein the device has a first functionality verifying feature located between the sample addition zone and the reaction zone, and a second functionality verifying feature located within the absorbing zone. Both functionality verifying features are capable of undergoing a detectable change when contacted by the sample, in which the assay device further includes at least one alignment verification zone. There is further provided a kit of parts and a method of conducting an assay. | 08-08-2013 |
| 20130203184 | METHOD FOR DETECTION OF CLEAVAGE PRODUCT OF SOLUBLE AMYLOID-B PRECURSOR PROTEIN 770B FOR DIAGNOSIS OF DISEASES ASSOCIATED WITH ACCUMULATION OF AMYLOID-B PEPTIDE - The present invention provides a method of detecting soluble amyloid β precursor protein 770β derived from vascular endothelial cell, comprising the following steps:
| 08-08-2013 |
| 20130203185 | METHOD FOR IMMOBILIZING A PROTEIN ON SELF-ASSEMBLED MONOLAYER - One molecule of the amino acid selected from the five kinds of amino acids consisting of cysteine, lysine, histidine, phenylalanine, and glycine is interposed between a self-assembled monolayer and a molecule of a protein. A method for immobilizing an protein on a self-assembled monolayer includes the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the protein to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecular of the amino acid and the amino group of the protein. | 08-08-2013 |
| 20130210165 | Luminescent Lanthanide Chelates Having Three Chromophores and Their Use - The present application discloses a luminescent lanthanide chelate of formula (I) | 08-15-2013 |
| 20130210166 | Low-Cost Electrode Chip Variants and Methods for Multi Analyte Analysis and Referencing Based on Cathodic Electroluminescence - The invention relates to electrode chip (EChip) cartridge devices which are used in hot electron -induced electro-chemiluminescence (HECL) and electroluminescence (EL) methods and instrumentation based on the electrical excitation of label molecules with subsequent measurement of the luminescence in order to quantitate analyte concentrations in bioaffinity assays, especially outside of central laboratories, but also in rapid screening tests. | 08-15-2013 |
| 20130210167 | IMMUNOASSAY FOR PYRROLIDINOPHENONES - The invention describes antibodies that bind molecules of the pyrrolidinophenone class of synthetic drugs. The antibodies are derived from novel chemical intermediates, haptens and immunogens and are used in methods and kits to detect and quantify pyrrolidinophenones. | 08-15-2013 |
| 20130210168 | ASSAY FOR DETECTING FREE LIGHT CHAINS BY CAPILLARY ZONE ELECTROPHORESIS - The invention provides a method detecting free light chains (FLCs) comprising: (i)providing a sample from a subject; (ii)mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii)passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv)detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided. | 08-15-2013 |
| 20130217145 | ANTIBODIES WHICH DETECT PIVKAII AND METHODS OF USE THEREOF - The present invention relates to antibodies or binding proteins which bind to PIVKA II and may be used, for example, in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions. | 08-22-2013 |
| 20130217146 | VIRTUAL SEPARATION OF BOUND AND FREE LABEL IN A LIGAND ASSAY FOR PERFORMING IMMUNOASSAYS OF BIOLOGICAL FLUIDS, INCLUDING WHOLE BLOOD - Detection and characterization of immunologically detected substances are performed electronically on human and animal biological fluids such as whole blood, serum, plasma, urine, milk, pleural and peritoneal fluids, and semen, which fluids are contained in a thin chamber forming a quiescent fluid sample, which chamber has at least two parallel planar walls, at least one of which is transparent. | 08-22-2013 |
| 20130217147 | DETECTION OF COMPLEXES OF TAU AND AMYLOID - The invention relates to methods for detecting complexes of Tau, Tau variants, including phosphorylated variants, and amyloid containing molecules, as well as autoantibodies to those complexes or components of those complexes, in physiological fluid samples. | 08-22-2013 |
| 20130217148 | Methods Of Determining Skeletal Maturity - The present invention provides methods to determine skeletal maturity. | 08-22-2013 |
| 20130217149 | COMPETITION ASSAY - The application provides competition assays used to detect free-light chains or intact immunoglobulins comprising incubating the sample with anti-FLC antibody, or heavy chain class-light chain type-specific antibodies, or fragments of such antibodies, and a known amount of FLC or intact immunoglobulin and detecting the binding of the antibody to the known amount of FLC or immunoglobulin. Assay kits and methods of producing particles coated with FLC are also provided. | 08-22-2013 |
| 20130217150 | ASSAY APPARATUS AND ITS CONTROL METHOD AND REACTION CONTAINER FOR ASSAY - In an assay apparatus for performing an assay related to a specimen received from the outside thereof based on a reaction between the specimen and a reagent by using a reaction container that holds the reagent, the apparatus includes a detection means that detects a state in which an assay has ended before completion, and a mark providing means that provides a predetermined mark for the reaction container when the state in which the assay has ended before completion is detected by the detection means. | 08-22-2013 |
| 20130224879 | SYSTEMS AND METHODS FOR A DNA-BASED THERMOMETER - DNA-based temperature sensor for measuring temperature through a transition of one or more strands of DNA from a coupled configuration to a decoupled configuration at a temperature threshold, and a fluorescent dye adapted to emit fluorescence when the DNA is in the coupled configuration, includes a receptacle adapted to receive the DNA and the fluorescent dye in a solution, an imaging device adapted to acquire an image of fluorescence emitted from the solution, the image having a plurality of regions, and a processor adapted to determine a plurality of fluorescence levels corresponding to each of the plurality of regions of the image and to generate a temperature map based on the determined fluorescence levels. A method for measuring temperature and a DNA-based temperature sensing solution are also provided. | 08-29-2013 |
| 20130224880 | REAGENTS AND METHODS FOR DETECTING PROTEIN CROTONYLATION - The invention provides an isolated peptide comprising a crotonylation site, a Kcr-specific affinity reagent that specifically binds to the peptide, and a method for detecting protein crotonylation in a sample using the reagent. | 08-29-2013 |
| 20130224881 | POLYROTAXANES AND USES THEREOF - A polyrotaxane containing an affinity binding group has been designed and prepared. The polyrotaxane of the invention can be used for characterization and determination of the three-dimensional structures of biological molecules, such as proteins. | 08-29-2013 |
| 20130224882 | Assay for the Detection of the Phenylpiperazine Family - The current invention describes novel immunogens which are used in the production of novel antibodies with unique binding properties in that they cross-react with a variety of phenylpiperazine derivatives. These antibodies enable methods and kits to detect and/or determine phenylpiperazine derivatives (for example mCPP, TFMPP and MeOPP) in an in vitro sample which are advantageous over currently available analytical methods in terms of cost, ease of use, speed and sensitivity. | 08-29-2013 |
| 20130224883 | Method for recognizing interferences in in vitro diagnostic assays - The present invention is in the field of in vitro diagnostics and relates to a method for recognizing interfering disruptive factors, such as heterophile antibodies or rheumatoid factors for example, in a sample. | 08-29-2013 |
| 20130224884 | DEVICE AND METHOD FOR IMMUNOASSAYS - A device for performing a test to determine the presence or the absence of at least one analyte in a liquid sample includes: a support and a matrix, fixed on the support. The matrix includes: a liquid sample application zone, a marking zone and at least one reaction zone. The one reaction zone includes: a test results display zone having at least a second immobilized binding partner which is able to bind to at least one analyte, and a monitoring zone downstream of the results display zone or parallel with the results display zone which allows monitoring of the correct functioning of the device and which includes at least one analogue of the at least one analyte which is able to bind to at least a first marked binding partner. The liquid sample application zone, marking zone and reaction zone are in fluid communication. | 08-29-2013 |
| 20130224885 | BLUE-COLORED GOLD NANOPARTICLES FOR IMMUNOLOGICAL MEASUREMENT, PROCESS FOR PRODUCTION OF SAME, AND MEASUREMENT METHOD USING SAME - Gold nanoparticles which comprises organic buffer containing a piperazine ring, gold, and an organic acid having reducing properties and which shows a blue color by visually view when it is dispersed as a colloidal solution, can be produced easily by conducting a nucleus formation step by reacting organic acid containing a piperazine ring with a solution of a first gold salt to form nucleus gold nanoparticles and a growth step by simultaneously adding and reacting a solution of a second gold salt and an organic acid having reducing properties with a solution of the nucleus gold nanoparticle to grow the nucleus gold nanoparticles. The produced gold nanoparticles can be used as labeling particles in an immunological measurement method. | 08-29-2013 |
| 20130230931 | TARGET SUBSTANCE DETECTING APPARATUS, AND TARGET SUBSTANCE DETECTING METHOD - A target substance detecting apparatus includes a photonic crystal biosensor configured to include a photonic crystal, which has a reflection surface including concave portions and convex portions formed regularly on its surface, covered by a metal film, and reflecting light irradiated to the reflection surface; an optical detecting unit configured to irradiate parallel light to the reflection surface, and to detect reflected light of the parallel light reflected on the reflection surface; and a processing unit configured to obtain a wavelength at an extreme value of the reflected light detected by the optical detecting unit, and to detect at least whether the target substance is present or not based upon a shift of the obtained wavelength at the extreme value. | 09-05-2013 |
| 20130236985 | METHOD AND DEVICE FOR OPTICAL EXAMINATION - A method and a device for the optical examination of a surface region are proposed. Fluorescence measurement is used to determine the amount of a substance bound to the surface region. Light interference is shut out thanks to the surface region being covered with an optically active liquid which filters, reflects, scatters and/or absorbs light with a wavelength at least substantially corresponding to the light radiated in and/or out. | 09-12-2013 |
| 20130236986 | METHODS OF SEPARATING NUCLEIC ACID POLYMER CONJUGATES - Described herein are nucleic acid-polymer conjugates and methods of separating these conjugates from a mixture, such as a reaction mixture. | 09-12-2013 |
| 20130244339 | DEVICE AND METHOD FOR PERFORMING A DIAGNOSTIC TEST - A device and method for performing a point of care diagnostic test for detecting and quantifying at least one analyte in a biological sample (e.g., a body fluid). A device may include an immunoassay apparatus and a holder with an adjustable variable angle stage for positioning the immunoassay apparatus relative to a light source and a detector device so as to optimize the angle of incidence and angle of radiation to optimize an elastic light scattering signal from the immunoassay apparatus. The elastic light scattering signal may be used to quantify the amount of the analyte(s) of interest present in the sample. The device is based upon elastic light scattering, so the variation in the angle of incidence and angle of reflection are optimized to maximize signal generation due to elastic light scattering. | 09-19-2013 |
| 20130244340 | Nanopore Based Molecular Detection and Sequencing - This disclosure provides systems and methods for molecular identification and polymer (e.g., nucleic acid) sequencing using nanopores. The polymer may be passed through or in proximity to the nanopore and various subunits of the polymer may affect the current flowing through the nanopore. The various subunits may be identified by measuring the current at a plurality of voltages applied across the nanopore and/or membrane. In some cases, the polymerization of tagged nucleotides presents tag molecules to the nanopore that can be identified by measuring the current at a plurality of voltages applied across the nanopore and/or membrane. Also provided herein are systems and methods for sequencing both the sense and anti-sense strand of a double stranded nucleic acid molecule with a nanopore and methods for using ribonucleic acid (RNA) speed bump molecules to slow the passage of a nucleic acid molecule through or in proximity to a nanopore. | 09-19-2013 |
| 20130244341 | huTNFR1 SELECTIVE ANTAGONISTS - The present invention relates to a ligand, which specifically binds to human tumor necrosis factor type 1 receptor (huTNFR1). The ligand includes one or more amino acid sequences of human origin capable of reducing the immunogenic response of the ligand in humans and one or more amino acid sequences capable of selectively binding to huTNFR1. The present invention also relates to a nucleic acid sequence encoding the ligand and to a pharmaceutical composition for the treatment of disorders related to huTNFR1. | 09-19-2013 |
| 20130252346 | Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin, Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 09-26-2013 |
| 20130252347 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 09-26-2013 |
| 20130260478 | SYSTEM AND PROCESS FOR SELECTIVE DETECTION OF VAPOR-PHASE ANALYTES - A system and method are disclosed that provide selective detection of gas-phase target analytes at concentrations below 1 part-per-trillion including explosives, explosives compounds, and other threat agents involving chemical adduct ions between reactant ions and the target analytes for detection of the target analytes. | 10-03-2013 |
| 20130260479 | DEVICE AND METHOD FOR DETECTING EXISTENCE OF TARGET BIOMOLECULES IN A SPECIMEN - A detecting device is used for detecting existence of target biomolecules in a specimen with use of antibody complexes labeled with fluorescent molecules. The detecting device includes a capture member coated with capture antibodies for immobilizing the antibody complexes on the capture member when the target biomolecules exist in the specimen, a light emitting unit emitting a beam for exciting the fluorescence molecules to generate a fluorescence signal, and a signal processing unit for receiving the fluorescence signal and determining existence of the target biomolecules in the specimen based upon receipt of the fluorescence signal. | 10-03-2013 |
| 20130260480 | DIAGNOSTIC METHODS USING BNP - The present invent ion provides a new method and kit tor determining the overload or atrium or ventricle in a subject, comprising at least a step of measuring levels of proBNP-108 in a sample from the subject. The disclosed methods and kits are useful, for example, in the diagnosis, prevention and/or treatment of cardiac diseases, particularly heart failure, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and atrial fibrillation. | 10-03-2013 |
| 20130260481 | ANALYSIS DEVICE AND ANALYSIS METHOD - To provide an analysis device capable of quantitatively measuring the concentration of a substance without diluting a sample containing the substance to be analyzed, detection portions ( | 10-03-2013 |
| 20130267039 | Single Molecule Assays - The present invention provides single molecule analyses of species of use in analytical, diagnostic or prognostic assays. In exemplary embodiments, the assays utilize samples prepared by novel methods, affording assays of unexpected sensitivity and robustness. The method is described in a non-limiting manner by reference to cytokine assays. | 10-10-2013 |
| 20130267040 | PEPTIDE CAPABLE FOR BINDING TO RHODIUM - The present invention provides a novel peptide capable for binding to rhodium. The peptide consists of an amino acid sequence represented by SQMMGHMGHGNMNHMNHGGKFDFHH. | 10-10-2013 |
| 20130267041 | METHODS FOR ISOLATION, USE AND ANALYSIS OF FERRITIN - This invention provides methods of isolating ferritin from plant and animal material. The isolated ferritin can be administered to humans or animals in need of iron, and can be used to treat or supplement iron deficiency. The isolated ferritin can be used in industrial applications, such as increasing the iron content in heat-processed food or beverages. The methods of the invention also include quantitation of iron derived from plant or animal ferritin. | 10-10-2013 |
| 20130273667 | WIDE RANGE LUMINESCENT IMMUNOASSAYS - The present invention relates to a method for quantitating an analyte having a wide range concentration in a single assay without having to dilute the sample and repeating the assay. The key feature of the invention is having two cycles of events including sample binding to probe, binding reactions, and detection. After the first cycle of binding and detecting, the probe is dipped into the same sample vessel to bind additional analyte in the sample vessel at a condition that is more favorable to binding than the condition in the first cycle. | 10-17-2013 |
| 20130273668 | PEPTIDE CAPABLE FOR BINDING TO IRIDIUM - The present invention provides a novel peptide capable for binding to iridium. The peptide consists of an amino acid sequence represented by SQMMGHMGHGNMNHMNHGGKFDFHH. | 10-17-2013 |
| 20130280820 | BIOMARKERS FOR PSORIASIS - A group of polypeptides that are modulated in a psoriatic sample as compared to a normal sample is provided. These polypeptides can be used as biomarkers for diagnosis and monitoring treatment of psoriasis. | 10-24-2013 |
| 20130280821 | METHOD FOR DETECTING AN INFECTION BY HEPATITIS B VIRUS - An immunological confirmation method is disclosed for the detection of hepatitis B virus infection wherein the testing of certain samples showing unclear reactivity is repeated once without and once in the presence of recombinantly produced HBcAg particles. If the sample is truly hepatitis B virus core antibody positive, the rHBcAg will trap the anti-HBcAg antibodies and influence the readout accordingly. | 10-24-2013 |
| 20130288383 | Highly Sensitive System and Method for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 10-31-2013 |
| 20130288384 | MAGNETIC IMMUNOASSAY USING AC SUSCEPTIBILITY MEASUREMENT - In a magnetic immunoassay using AC magnetic susceptibility measurement, a signal from non-coupled magnetic particles is prevented to mix with a desired measurement signal from magnetic particles coupled with an object to be measured. A sample vessel in which a mixed solution of an inspection objective sample and the magnetic particles are included is carried by a sample support, such that a precipitation of the magnetic particle coupled with the object to be measured dispersed in the solution by a magnetic field from a dissociating coil is promoted. Next, the sample vessel is carried to the magnetizing coil and the magnetic signal from the non-coupled magnetic particle remaining in a supernatant in the vessel is peculiarly measured by an MR sensor to perform AC magnetic susceptibility measurement with high precision. | 10-31-2013 |
| 20130288385 | MOLECULARLY IMPRINTED TETRAETHOXYSILANE POLYMER AND METHODS OF USING THE SAME TO DETECT SECOSTEROIDS - A molecular imprinted tetraethoxysilane polymer device for detecting secosteroids, or metabolites thereof, and a method for using the same are provided. | 10-31-2013 |
| 20130288386 | NANOSCALE CALORIMETER ON CHIP AND RELATED METHODS AND DEVICES - An article comprising: an array of calorimeter devices, wherein the device comprises: at least one fluidic enclosure disposed on a microfluidic chip, wherein the fluidic enclosure is substantially gas impermeable; at least one first chamber and at least one second chamber, wherein the first chamber and the second chamber are disposed within and enclosed by the fluidic enclosure, wherein the first chamber and the second chamber are not vacuum encapsulated; at least two microfluidic channels connected to the first chamber and at least two microfluidic channels connected to the second chamber; and at least one thermal sensor disposed between the chip and the first and second chambers, wherein the thermal sensor is adapted to measure a temperature differential between the first and second chambers. Examples include DSC and TSA devices. Biological binding and melting experiments can be done with high sensitivity. | 10-31-2013 |
| 20130288387 | ANTI-HLA MONOCLONAL CHIMERIC IMMUNOGLOBULIN, PROCESS AND KIT EMPLOYING SUCH A MONOCLONAL CHIMERIC IMMUNOGLOBULIN - A monoclonal chimeric immunoglobulin wherein the heavy chains and the light chains are human by nature in their constant parts, in particular, the heavy chain constant parts are chosen from the group formed of the heavy chain constant parts of an IgA, of an IgG or of an IgM and the light chain constant parts are chosen from the group formed of the kappa chains and the lambda chains, and the light chain and the heavy chain variable parts are chosen from the group formed of monoclonal antibodies specific to monomorphic epitopes of HLA class I antigens and monoclonal antibodies specific to monomorphic epitopes of HLA class II antigens. A process for standardization of the screening and for quantification of anti-HLA antibodies in a liquid medium is also described. | 10-31-2013 |
| 20130288388 | STAIN-FREE PROTEIN QUANTIFICATION AND NORMALIZATION - Disclosed herein are methods of protein quantification and normalization using haloalkylated tryptophan fluorescence. Complex protein samples, i.e., samples that each contain 1,000 or more distinct proteins, from diverse sources that do not have common protein profiles are treated with a halo-substituted organic compound (i.e. haloalkane) that reacts with tryptophan residues to form fluorescent products. Irradiation of the samples with ultraviolet light and the detection and quantification of the resultant fluorescent emissions from all proteins in each sample are then used to obtain comparative values for total protein content among the various samples. The values thus obtained are found to be valid indications of comparative total protein content, despite the fact that the tryptophan levels vary widely among the various proteins in any single sample and the samples, due to the diversity of their origins, tend to differ among themselves in the identities and relative amounts of the proteins that they contain. Protein samples are also normalized to correct for differences in sample dilution, sample loading, and protein transfer inconsistencies, by using stain-free detection of total protein in each of the samples, or detection of subsamples within each sample. | 10-31-2013 |
| 20130288389 | METHODS FOR AMPLIFICATION AND DETECTION OF PRIONS - Methods are disclosed for detecting prions and/or prion disease-associated forms of prion protein. These methods provide sensitive and specific identification of prions in both biological and environmental samples. These methods include the use of both immunoprecipitation and an amplification assay that uses shaking in the absence of sonication, such as QuIC(SQ) or RT-QuIC(RTQ). In specific non-limiting examples, the methods include the use of monoclonal antibody 15B3 and/or RT-QuIC(RTQ), and/or a substrate replacement step. | 10-31-2013 |
| 20130288390 | IMMUNOLOGICAL ASSAY METHOD - [Problem] To provide a so-called competitive immunological assay method capable of more uniformly immobilizing on a solid phase a substance equivalent to an antigen. [Solution] This immunological assay method measures an analyte substance in a sample by using: an equivalent substance immobilized on the solid phase during the execution of the assay, the equivalent substance being immunologically equivalent to the analyte substance; and a labeled antibody for specifically binding to the substance equivalent to the analyte substance. The assay method is characterized in that the equivalent substance is immobilized on the solid phase using: a bond between the equivalent substance and a carrier substance, the carrier substance being a substance to which the labeled antibody does not bind; and a bond between the carrier substance and a specific binding substance immobilized on the solid phase, the specific binding substance being a substance that binds specifically to the carrier substance. | 10-31-2013 |
| 20130295684 | CONJUGATED POLYMERS FOR USE IN HOMOGENEOUS AND SOLID STATE ASSAYS - Disclosed are multichromophores, and methods, articles and compositions employing them. Disclosed are methods, articles and compositions for the detection and analysis of biomolecules in a sample. Provided assays include those determining the presence of a target biomolecule in a sample or its relative amount, or the assays may be quantitative or semi-quantitative. The methods can be performed on a substrate or in an array format on a substrate. Disclosed are detection assays employing sensor biomolecules that do not comprise a fluorophore that can exchange energy with the cationic multichromophore. Disclosed are biological assays in which energy is transferred between one or more of the multichromophore, a label on the target biomolecule, a label on the sensor biomolecule, and/or a fluorescent dye specific for a polynucleotide, in all permutations. | 11-07-2013 |
| 20130295685 | MOBILITY SHIFT ASSAYS FOR DETECTING ANTI-TNF ALPHA DRUGS AND AUTOANTIBODIES - The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drugs and/or the autoantibodies to anti-TNFα drugs in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNFα drugs for the treatment of TNFα-mediated disease or disorders. | 11-07-2013 |
| 20130295686 | INTERCALATION METHODS AND DEVICES - The invention provides devices and methods for improving labeling of nucleic acids including intercalation of nucleic acids using for example mono intercalators such as mono cyanine intercalators. | 11-07-2013 |
| 20130295687 | Novel Method of Isolation of TLR4 from Cell Lysates of Mononuclear Cells - A novel method of isolation of TLR4 from cell lysates of mononuclear cells is provided. The method includes: collecting bovine adult filarial parasites ( | 11-07-2013 |
| 20130295688 | OPTICAL ANALYTE DETECTION SYSTEMS AND METHODS OF USE - Various embodiments are drawn to systems and methods for detecting an analyte of interest in a sample including an optical sensor, a capture probe attached to a surface of the optical sensor wherein the capture probe is capable of binding to the analyte to form a duplex or complex, and an antibody capable of binding to the analyte, duplex, or complex. In several embodiments, systems and methods further include a particle attached to the antibody or capable of binding to the antibody. In several embodiments, systems and methods for analyte detection feature one or more of the following: high detection sensitivity and specificity, scalability and multiplex capacity, ability to analyze large analytes, and ability to detect or measure multiple individual binding events in real-time. | 11-07-2013 |
| 20130295689 | METHOD FOR DETECTION OF BASIC PEPTIDE AND REAGENT FOR DETECTION OF BASIC PEPTIDE - The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin. | 11-07-2013 |
| 20130295690 | VERSATILE DRUG TESTING DEVICE - A versatile drug testing device (a lateral flow diagnostic testing device) includes a flat transparent carrier with a top and a bottom with the carrier having a series of independent parallel grooves formed therein running from adjacent to the top to adjacent to the bottom of the carrier, each groove having a first opening and a second opening above the first opening therein adjacent to the bottom of the carrier, at least one drug test strip installed in one of said grooves with its absorbent pad contiguous to the openings and a cover layer attached to the carrier operable to sealing close each of said grooves whereby the bottom of the device can be immersed in a specimen of urine, body fluid, or other biological specimen to wet the pad of the at least one test strip though the ingress of the specimen though the associated openings and the test results on the test strip can be easily viewed through the transparent carrier. Because of the unique construction the device will give accurate reading if temporarily immersed in the specimen or left in the specimen for an extended period of time, making it very user friendly. | 11-07-2013 |
| 20130295691 | Method of Attaching a Ligand to a Test Strip - The invention features a method of attaching a ligand that has a free carboxyl group to a solid support by adding an amino group to the ligand to form a ligand-amino derivative, converting the ligand amino derivative to a ligand sulfhydryl derivative, attaching the ligand sulfhydryl derivative to a protein to form a ligand-linker-protein conjugate, and applying the ligand-linker-protein conjugate to the solid support. The method is particularly useful for immobilizing small molecule ligands having a free carboxyl group, such as cloxicillin, to a lateral-flow test strip, in order to make a detection zone on the test strip that exhibits a clear signal and enhanced sensitivity. | 11-07-2013 |
| 20130295692 | MEANS AND METHODS FOR PREDICTING DIABETES - A method for diagnosing diabetes or a predisposition for diabetes is provided, which comprises determining the amount of glyoxylate in a test sample of a subject suspected to suffer from diabetes or to have a predisposition for diabetes and comparing said amount to a references, whereby diabetes or a predisposition for diabetes is to be diagnosed. Further, the use of glyoxylate or a detection agent for glyoxylate for diagnosing diabetes or a predisposition for diabetes is provided. Moreover, a device and a kit for diagnosing diabetes or a predisposition for diabetes are also provided. | 11-07-2013 |
| 20130302907 | METHOD OF ASSAYING ANTIGEN AND REAGENT THEREFOR - A latex agglutination method by which the measurement range is extended and the sensitivity of the measurement in the low concentration range is increased, is disclosed. The method for measuring a test antigen by latex agglutination uses two types of large and small particles, having different average particle sizes. Each latex particle is sensitized with an antibody which undergoes antigen-antibody reaction with the test antigen. The purity of the antibody immobilized on the latex particles is within a specific range. The ratio of the amount of the antibody immobilized per one small latex particle to the amount of the antibody immobilized per one large latex particle; the average particle size of the large latex particles; the average particle size of the small latex particles; the concentration of the large sensitized latex particles in the antigen-antibody reaction system; and the concentration of the small sensitized latex particles in the reaction system are within a specific range. The large sensitized latex particles and the small sensitized latex particles are reacted with the test antigen in the state suspended in a buffer, and then the agglutination of the sensitized latex particles is optically measured. | 11-14-2013 |
| 20130302908 | Thermostable Proteins and Methods Making and Using Thereof - The present invention relates to functional, modified glucose-galactose binding proteins (GGBPs), that have a greater melting temperature (T | 11-14-2013 |
| 20130302909 | ASSESSMENT OF IGF-1 LEVELS IN HIV-INFECTED SUBJECTS AND USES THEREOF - Improved methods for determining normal IGF-1 levels in HIV infected subjects, based on a determination of the log of IGF-1 values obtained in blood-derived samples from a population of HIV-infected subjects, are disclosed. Also disclosed are methods of determining whether a given HIV-infected subject exhibits a normal IGF-1 level, based on a comparison of either the IGF-1 value or the log of the IGF-1 value obtained from a blood-derived sample of the subject with a normative IGF-1 range determined using the exponentiation of the log of IGF-1 values or the log of IGF-values obtained in blood-derived samples from a population of age- and gender-matched HIV-infected subjects. Such methods are useful for example to monitor GH stimulation therapy in HIV-infected subjects. | 11-14-2013 |
| 20130302910 | ENCODED MICROCARRIERS, ASSAY SYSTEM USING THEM AND METHOD FOR PERFORMING AN ASSAY - The present invention relates to an encoded microcarrier comprising a readable code attached to it for identification, said encoded microcarrier comprising a body having at least a detection surface to detect a chemical and/or biological reaction, the microcarrier further comprising at least a spacing element projecting from the body and shaped to ensure that, when the encoded microcarrier is laid on a flat plane with the detection surface facing said flat plane, a gap exists between said flat plane and the detection surface. The invention also relates to an assay device designed to use a plurality of said encoded microcarriers to perform assays. The invention relates finally to a method for monitoring a chemical or biological reaction. | 11-14-2013 |
| 20130302911 | COMPOSITION FOR DETECTING PROTEINS CONTAINING TYROSINE OXIDE-COUPLED BIOMATERIAL - Provided is a composition for detecting a protein, containing a tyrosine oxide-coupled biomaterial. Various diseases may be easily and rapidly diagnosed by easily detecting the composition containing a tyrosine oxide-coupled biomaterial according to the present invention, by identifying a color of the protein bound with a tyrosine oxide-coupled biomaterial prepared by binding tyrosine oxide, which is a natural pigment present in a living body, with the biomaterial. Accordingly, the composition of the present invention may be used to easily and rapidly diagnose various diseases in real time in an operating room, and may usefully replace conventional histological analysis without a secondary antibody reaction and a final operation of color expression. | 11-14-2013 |
| 20130309778 | ASSAY DEVICE AND READER - The present invention relates to a microfluidic based assay system, comprising a disposable assay cartridge and associated reading device, as well as the individual components themselves. The present invention also relates to methods of conducting assays, using the cartridge and device of the invention, as well as kits for conducting assays. | 11-21-2013 |
| 20130309779 | OPTICAL WAVEGUIDE MEASUREMENT SYSTEM AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN - According one embodiment, an optical waveguide measurement system includes a first optical waveguide immobilizing a first substance, the first substance being able to be specifically bound to glycated hemoglobin; a plurality of first magnetic microparticles immobilizing a second substance immobilized, the second substance being able to be specifically bound to the glycated hemoglobin at a first site different from a second site, and the first substance can be specifically bound to the glycated hemoglobin at the second site; a first magnetic field applying section provided above the first optical waveguide and being able to move at least one of the plurality of first magnetic microparticles by magnetic force; a first light source being able to inject light into the first optical waveguide; and a first light receiving element being able to receive light ejected from the first optical waveguide. | 11-21-2013 |
| 20130309780 | DEVICE FOR STRETCHING A POLYMER IN A FLUID SAMPLE - The invention provides structures and methods that allow polymers of any length, including nucleic acids, to be stretched into a long, linear conformation for further analysis. | 11-21-2013 |
| 20130309781 | NOVEL ADHESIVE SURFACES FOR THE IMMOBILIZATION OF LIGANDS - A complex including: a support provided with at least two faces one of which is provided with a coating of an adhesive, at least one ligand, said ligand being immobilized on the adhesive surface. The ligand implemented within the framework of the present invention is chosen from among proteins, peptides, antibodies, nucleic acids, sugars or oligosaccharides, toxins, pesticides, hormones, herbicides, fungicides, neurotransmitters. | 11-21-2013 |
| 20130316467 | SPECTROSCOPIC ASSAYS AND TAGGING - A spectroscopic assay is provided. The assay comprises: a motive particle configured to move within a solution, the motive particle comprising a first analyte binding reagent for selectively binding to a target analyte; and a spectroscopic reporter particle configured to provide a predetermined spectroscopic signal in response to being interrogated by a spectrometer, the spectroscopic reporter particle comprising a second analyte binding reagent for selectively binding to the target analyte, wherein the motive particle and the spectroscopic reporter particle are configured to provide a sandwich assay in the presence of the target analyte via the first and second analyte binding reagents. | 11-28-2013 |
| 20130316468 | Biomarkers for Alzheimer's Disease - The disclosure is directed to the detection, early diagnosis, determination of the severity, and treatment of Alzheimer's disease (AD). A number of biomarkers and combination of biomarkers are disclosed for the determination of AD, including sTNFR2 and Abeta-42; TNFR2 and Ptau-181; sTNFR2, Abeta-42 and PTau-181; and IL-2 and Abeta oligomers. Method of treatment of AD are also disclosed. | 11-28-2013 |
| 20130316469 | Low Dead Volume Extraction Column Device - The invention provides extraction columns for the purification of an analyte (e.g., a biological macromolecule, such as a peptide, protein or nucleic acid) from a sample solution, as well as methods for making and using such columns. The invention is characterized by the use of low dead volume columns, which is achieved in part by the use of low pore volume frits (e.g., membrane screens) to contain a bed of extraction media in the column. Low dead volume facilitates the elution of the captured analyte into a very small volume of desorption solution, allowing for the preparation of low volume samples containing relatively high concentrations of analyte. | 11-28-2013 |
| 20130323857 | NEW IRIDIUM-BASED COMPLEXES FOR ECL - Novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, for example in electrochemiluminescence based detection of an analyte. | 12-05-2013 |
| 20130323858 | Optical Sensor with Enhanced Sensitivity - The invention is a surface plasmon resonance (SPR) sensor to determine the presence and quantity of biological or chemical entities in an analyte. The sensor comprises a metal periodic structure deposited as a thin layer of a noble metal, comprising a one dimensional array of nanoslits or a two dimensional array of nanoholes on a transparent dielectric substrate, a nm-thick layer of transparent dielectric protection layer on top of the metal periodic structure and a functionalization layer, which acts as a binding layer to biological or biochemical entities in an analyte that is in contact with the functionaliztion layer. | 12-05-2013 |
| 20130330835 | DEVICES AND METHODS FOR GRAVIMETRIC SENSING IN LIQUID ENVIRONMENTS - Devices and methods for gravimetric sensing are disclosed. A gravimetric sensor includes a piezoelectric resonator and an encapsulating layer formed on the surface of the resonator. The encapsulating layer defines a channel within the encapsulating layer on the surface of the resonator. The sensor is fabricated by forming a piezoelectric resonator, forming a sacrificial layer on a surface of the piezoelectric resonator, forming an encapsulating layer over the sacrificial layer on the resonator, and etching the sacrificial layer to remove the sacrificial layer and form a channel on the surface of the resonator. The sensor is used by supplying the liquid to the channel of the gravimetric sensor, operating the piezoelectric resonator, detecting a change in a resonant frequency of the resonator, and determining a presence of the analyte in the liquid from the change in resonant frequency of the resonator. | 12-12-2013 |
| 20130330836 | Diagnostic Device With Integrated Photodetector, And Diagnostic System Including The Same - A diagnostic device includes a photodiode ( | 12-12-2013 |
| 20130330837 | MONOCLONAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID BETA (ABETA) - Disclosed herein are antibodies that bind with high specificity to soluble oligomers of amyloid β (Abeta) and methods utilizing such antibodies. The antibodies are able to distinguish between Alzheimer's Disease (AD) and control human brain extracts. The antibodies identify endogenous Abeta oligomers in AD brain slices and also bind to Abeta oligomers on cultured hippocampal cells. The antibodies neutralize endogenous Abeta oligomers and Abeta oligomers produced in solution. | 12-12-2013 |
| 20130330838 | SURFACE PLASMON RESONANCE SENSOR - An SPR sensor comprising a thin conducting layer comprising at least one conductive element formed on a surface of a transparent substrate, a light source that illuminates an interface between the conducting layer and the substrate, a photosensitive surface that generates signals from light reflected from the interface, a flow cell formed with at least one flow channel having a lumen defined by a wall formed from an elastic material and from a region of the conducting layer, and at least one hollow fluid-providing flow control apparatus having a lumen and an orifice communicating with its lumen. Fluid flow is enabled between the flow channel and the lumen of the flow control apparatus by forcing an end of the flow control apparatus through the elastic material so that the orifice communicates with the flow channel lumen. | 12-12-2013 |
| 20130330839 | SINGLE NANOPARTICLE HAVING A NANOGAP BETWEEN A CORE MATERIAL AND A SHELL MATERIAL, AND PREPARATION METHOD THEREOF - The present invention is to provide a nanoparticle, which can be used effectively for Raman analysis based on very high amplification effect of electromagnetic signal by plasomonic coupling of nanogap formation inside thereof and high reproducibility, and which includes core and surrounding shell with nanogap formation between the same and the method of synthesis thereof. The present invention is also to provide the method for detecting the analyte using the above nanoparticle and the analyte detection kit including the above nanoparticle. | 12-12-2013 |
| 20130330840 | FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL SALTS - The invention utilises the techniques and instruments which are typically used in flow cytometry (FC) as a tool for analysing adsorbed materials. Thus the invention provides a method for analysing a component which is adsorbed to an insoluble metal salt, comprising steps of: (i) labelling the adsorbed component with a binding reagent; and (ii) analysing the labelled adsorbed component by flow cytometry. | 12-12-2013 |
| 20130330841 | METHOD FOR MEASURING CARDIAC TROPONIN - Disclosed are a method for immunologically measuring cardiac troponin in a biological sample, in which the formation of an immunological complex of cardiac troponin with an antibody specifically binding thereto is performed in the presence of a divalent cation at 4 mmol/L or more; and a kit for measuring cardiac troponin, comprising an antibody specifically binding to cardiac troponin, and a buffer containing a divalent cation at a high concentration. According to the method or the kit, a stable and highly-accurate measured value can be obtained without being affected by interfering substances in a specimen regardless of the type of specimen. | 12-12-2013 |
| 20130330842 | MULTIPLE SUBSTANCES-RESPONSIVE GEL, METHOD FOR PRODUCING SAME, AND UTILIZATION OF SAME - A multiple-substance-responsive substance is disclosed, which is capable of simultaneously detecting a plurality of detection target substances by a single measurement. By a multiple-substance-responsive gel including: a plurality of kinds of complexes including (i) specifically binding substances, and (ii) binding partners each specifically and reversibly binding to a corresponding one of the specifically binding substances; and a polymer gel to which the plurality of kinds of complexes are immobilized so as to form cross-links, the plurality of kinds of complexes each being formed by binding between (i) a specifically binding substance among the specifically binding substances and (ii) a corresponding binding partner among the binding partners, a plurality of detection target substances can be simultaneously detected by a single measurement. | 12-12-2013 |
| 20130337579 | Methods for Determining Protein Ligand Binding - Provided is a high-throughput differential radial capillary action of ligand assay (DRaCALA) that can be used to detect ligand binding to a protein. The assay is rapid, quantitative and allows detection of protein-ligand interactions for both purified proteins and proteins expressed in whole cells, which eliminates the need for protein purification. The method does not require a wash step, and can be performed without a drying step and without the aid of electrophoretic techniques. The method entails separating unbound ligand from bound ligand by placing a liquid composition that contains or is suspected of containing a protein and a detectably labeled ligand on a dry porous membrane to obtain a location on the membrane that contains the protein. Ligand that is bound to the protein does not migrate away from the location while unbound ligand radially migrates away from the location by capillary action, which separates unbound from bound ligand. The method includes determining whether a ligand binds to one or more proteins and whether a test composition contains a protein. | 12-19-2013 |
| 20130337580 | Immunoassay Device and Method - Devices, methods and kits for the detection of analytes in liquid samples. A device for conducting an assay to determine the presence or amount of an analyte in a fluid sample having a flow path matrix that facilitates fluidic flow and a fluid impermeable barrier. The flow path includes a first region on a top side of the barrier that facilitates fluid flow in a first direction and comprises a sample entry area and a second region on a bottom side of the barrier that facilitates fluid flow in a second direction substantially opposite the first direction and comprises a detection zone. Methods using the devices. Kits including the devices and various reagents necessary for conducting the methods. | 12-19-2013 |
| 20130337581 | NUCLEOBASE-FUNCTIONALIZED CONFORMATIONALLY RESTRICTED NUCLEOTIDES AND OLIGONUCLEOTIDES FOR TARGETING NUCLEIC ACIDS - Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be formed by coupling of an intermediate with a linker. Certain embodiments disclose the use of these compounds for detecting single nucleotide polymorphisms, and for increasing the thermal affinity of nucleic acid complements as compared to unmodified nucleic acid complements. In addition, the disclosed compounds can decrease enzymatic degradation of nucleic acids. | 12-19-2013 |
| 20130344618 | BIOSENSOR USING AGGLOMERATION OF MAGNETIC NANOPARTICLES AND DETECTION METHOD BY THE SAME - A biosensor and method for detecting a target material using an agglomeration of magnetic nanoparticles are provided. | 12-26-2013 |
| 20130344619 | GLUCOSE SENSOR - A method of quantifying the amount of glucose in a sample is provided herein that may further comprise an interferent such as mannitol. At least two measurements are obtained using measurement methods that differ in their sensitivity to the amount of interferent in the sample, thus enabling the results to be compared to determine whether any interferent is present in the sample. A glucose sensor for carrying out a method described herein is also provided | 12-26-2013 |
| 20130344620 | KITS AND METHODS FOR CYANIDE DETECTION - Provided herein are compositions, kits, methods and devices for cyanide detection, particularly for cyanide detection in biological samples such as whole blood. The method comprises (1) contacting a sample with a cobinamide conjugate comprising a cobinamide moiety and a carrier; and (2) measuring the absorbance of light by the cobinamide conjugate. The present disclosure provides field-deployable cyanide detection methods, compositions, kits and devices, which provide rapid, accurate readout at the point of contact. Further provided herein is a method for determining exposure of a subject to cyanide. | 12-26-2013 |
| 20130344621 | METHODS FOR DETERMINING ANTI-DRUG ANTIBODY ISOTYPES - The present invention provides assay methods for the determination of one or more anti-drug antibody (ADA) isotypes in a sample. As a non-limiting example, the assays of the present invention are particularly useful for determining different ADA isotypes in samples from ADA-positive patients receiving an anti-TNFα drug such as REMICADE™ (infliximab) or HUMIRA™ (adalimumab). The present invention also provides methods for optimizing therapy and/or reducing toxicity in subjects receiving TNFα inhibitors for the treatment of TNFα-mediated disease or disorders. | 12-26-2013 |
| 20130344622 | POSITION ADJUSTMENT METHOD FOR MOVABLE UNIT IN SAMPLE ANALYZER, AND SAMPLE ANALYZER - A position adjustment method for a movable unit in a sample analyzer which includes: a measurement section which causes a movable unit to operate in order to measure a sample; and a communication section for performing communication with outside, includes: a terminal screen displaying step of causing a portable terminal device to display a position adjustment screen for accepting an input for changing a position of the movable unit, the portable terminal device configured to be able to perform communication with the communication section; and a movement executing step of causing the measurement section to execute a movement of a corresponding movable unit in accordance with the input for changing the position received by the communication section. | 12-26-2013 |
| 20130344623 | NON-SCANNING SPR SYSTEM - A system for measuring an evanescent wave phenomenon at total internal reflection, the system comprising:
| 12-26-2013 |
| 20140004622 | RAPID DETECTION OF CEREBROSPINAL FLUID, METHODS AND SYSTEMS THEREFORE | 01-02-2014 |
| 20140004623 | Assay for Benzylpiperazine and Metabolites | 01-02-2014 |
| 20140004624 | LATERAL FLOW ASSAY SYSTEMS AND METHODS | 01-02-2014 |
| 20140017807 | NOVEL LUMINESCENT LANTHANIDE CHELATES WITH ENHANCED EXCITATION PROPERTIES - The present application discloses a luminescent lanthanide chelate comprising one or more chromophoric moieties of the formula (I) or of the formula (III) | 01-16-2014 |
| 20140017808 | PROGNOSIS AND RISK ASSESSMENT IN STROKE PATIENTS BY DETERMINING THE LEVEL OF MARKER PEPTIDES - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient. | 01-16-2014 |
| 20140017809 | OPTICAL FIBER PROBE - A biosensor having an optical fiber having at least one curved portion configured to enhance penetration of evanescent waves; and one or more nanoparticles associated with the optical fiber, and configured to enhance localized surface plasmon resonance. | 01-16-2014 |
| 20140017810 | BIO-MOLECULE DETECTING DEVICE AND BIO-MOLECULE DETECTING METHOD - A bio-molecule detecting device that enables a high-sensitivity measurement is provided. The orientation direction of third complexes included in blood plasma is switched by switching the vibration direction of an orientation control light. The orientation direction of the third complexes is switched between two directions in which the intensities of an electric field, which is generated between two gold nanoparticles included in the third complexes by surface plasmon resonance, are significantly different. Therefore, the intensity of fluorescence generated from the third complexes is significantly changed by the change in the orientation direction of the third complexes. | 01-16-2014 |
| 20140017811 | TEST DEVICE AND CONTROL METHOD THEREOF - A test device and a control method thereof are provided. The test device includes a rotary drive unit to rotate the microfluidic device, a light emitting element to emit light onto the microfluidic device, a detection module arranged at a position facing the light emitting element and provided with a light receiving element to receive light emitted from the light emitting element and transmitted through the microfluidic device, a detection module drive unit to move the detection module in a radial direction, and a controller to control the rotary drive unit and the detection module drive unit. | 01-16-2014 |
| 20140017812 | DIRECT READING DETECTION KITS FOR SURFACE CONTAMINATION BY ANTINEOPLASTIC DRUGS - Methods, kits and devices for detecting antineoplastic drug contamination of a surface are provided according to aspects of the present invention. According to aspects of the invention, methods for detecting antineoplastic drug contamination of a surface include providing a wetting solution compatible with the antineoplastic drug and formulated to promote release of the drug from the surface to be assayed; providing a solid matrix for reversible absorption of the antineoplastic drug; contacting the solid matrix with the wetting solution, generating an assay matrix; contacting the assay matrix and the surface, generating a surface sample; contacting the surface sample with a volume of wetting solution, generating a fluid test sample; and quantifying the antineoplastic drug in the fluid test sample by lateral flow assay to produce an assay result, thereby detecting antineoplastic drug contamination of the surface. | 01-16-2014 |
| 20140017813 | METHOD AND MEANS FOR SAMPLE PREPARATION - The present invention relates to a method for depletion of undesired molecules and/or enrichment of desired molecules from a sample comprising high abundant as well as low abundant molecules, comprising the following steps: a) providing a separation material comprising a solid phase (beads) comprising an inner porous core material comprising magnetic particles and an outer porous shell with a porosity equal or denser than that of the shell; b) adding the sample to the separation material; c) adsorbing a first fraction of molecules with a molecular weight of 500-50 000 Da in the core and simultaneously excluding a second fraction of molecules from binding to the core and the shell, wherein the molecular weight of the second fraction molecules is at least 5 preferably 10 times higher than the molecular weight of the first fraction and d) eluting the desired molecules from the separation material, wherein step d) and optionally step c) is performed using an oscillating power/field applied over the separation material. | 01-16-2014 |
| 20140017814 | METHOD FOR PRODUCING AGGLUTINATING REAGENT, AGGLUTINATING REAGENT OR PRODUCT PRODUCED THEREBY, AND METHOD FOR MEASURING ANALYSIS OBJECT USING THE SAME, AND TEST KIT AND ANALYSIS DEVICE - Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative. | 01-16-2014 |
| 20140017815 | MEASUREMENT OF C-TERMINAL proSP-B - In vitro methods for obtaining an indication of damage in the broncheoalveolar compartment of the lung comprising, measuring C-terminal proSP-B in a bodily fluid sample and comparing the level measured to a reference level of C-terminal proSP-B, wherein an increased level of C-terminal proSP-B is indicative of damage in the broncheoalveolar compartment of the lung. | 01-16-2014 |
| 20140024136 | MAGNETIC PARTICLE SEPARATOR - A magnetic particle separator ( | 01-23-2014 |
| 20140024137 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS - Small molecule fluorescent probes for established drug targets such as nucleic acids including DNA and RNA has been developed and disclosed herein. These nucleic acid probes bind to multiple DNA and RNA structures, and to sites crucial for nucleic acid function, such as DNA and RNA major grooves. Displacement of the probes by other binders such as small molecule compounds and/or proteins illicits a fluorescence change in the probe that once detected and analyzed provide binding information of these other binders of interest. Similarly, changes in fluorescence upon binding of the probes to nucleic acid have been applied to screen nucleic acid of different sequence and conformation. The nucleic acid probes and method of uses disclosed herein are advantageously suitable for high-through put screening of libraries of small molecule compounds, proteins, and nucleic acids. | 01-23-2014 |
| 20140030819 | NANOPILLAR FIELD-EFFECT AND JUNCTION TRANSISTORS WITH FUNCTIONALIZED GATE AND BASE ELECTRODES - Systems and methods for molecular sensing are described. Molecular sensors are described which are based on field-effect or bipolar junction transistors. These transistors have a nanopillar with a functionalized layer contacted to either the base or the gate electrode. The functional layer can bind molecules, which causes an electrical signal in the sensor. | 01-30-2014 |
| 20140030820 | TRIAZACYCLONONANE-BASED PHOSPHINATE LIGAND AND ITS USE FOR MOLECULAR IMAGING - The present invention relates to the field of molecular imaging, i.e. nuclear and fluorescent imaging using metal ion radionuclides in combination with chelates highly functionalized with peptidic, nonpeptidic or protein ligands or additional signalling moieties. | 01-30-2014 |
| 20140030821 | LOCALIZED PLASMON ENHANCING FLUORESCENCE PARTICLES, LOCALIZED PLASMON ENHANCED FLUORESCENCE DETECTING CARRIER, LOCALIZED PLASMON ENHANCED FLUORESCENCE DETECTING APPARATUS, AND FLUORESCENCE DETECTING METHOD - Enhancing fluorescent particles constituted by a plurality of fine metal particles and a plurality of fluorescent dye molecules dispersed and enveloped in a light transmitting dielectric material are employed. Here, the particle size of the fine metal particles is greater than 10 nm and 40 nm or less, and the volume within the enhancing fluorescent particles occupied by the fine metal particles is within a range from 5% to 40%. | 01-30-2014 |
| 20140030822 | METHOD FOR IMMOBILIZING AN ANTIBODY ON A SELF-ASSEMBLED MONOLAYER - The method of the present disclosure is characterized by that one molecule of the amino acid is interposed between the self-assembled monolayer and the molecule of the antibody. For example, a method for immobilizing an antibody on a self-assembled monolayer is provided and the method including the following steps (a) and (b) in this order: a step (a) of preparing a substrate comprising one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the antibody to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecule of the amino acid and the amino group of the antibody. | 01-30-2014 |
| 20140030823 | METHOD OF DETECTING PANCREATIC DISEASE AND PANCREAS TESTING KIT - A pancreatic disease is tested for with high sensitivity even with simple equipment and a simple procedure. Provided is a method of detecting pancreatic disease including detecting a concentration of S100P in at least one of a pancreatic juice and a body fluid containing pancreatic juice collected from a test subject by immunochromatography. Additionally provided is a pancreas testing kit including an immunochromatography device that holds an anti-S100P antibody and a collection vessel that retains a protease inhibitor that inhibits an activity of a protease contained in the pancreatic juice. | 01-30-2014 |
| 20140038308 | PROCESS FOR PRODUCING COMPOSITE DEVICE, AND PROCESS FOR BONDING DEVICE FORMED OF TRANSPARENT MATERIAL TO ADHEREND - Provided is a process for producing a composite device comprising a light shielding first member and a light transmissive second member, a first surface of the light shielding first member and a second surface of the light transmissive second member being bonded to each other through intermediation of an ultraviolet curing adhesive, the second surface being larger than the first surface, the process including irradiating a region of the second surface to which region the first surface is not bonded with an ultraviolet ray, wherein a reflective member having a reflective surface with an inclination with respect to the second surface onto the light transmissive second member so that the ultraviolet ray that has transmitted through the second surface is reflected toward the ultraviolet curing adhesive between the second surface and the first surface. | 02-06-2014 |
| 20140045276 | ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFALPHA DRUGS - The present invention provides assays for detecting and measuring the presence or level of autoantibodies to anti-TNFα drug therapeutics in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNFα drugs for the treatment of TNFα-mediated disease or disorders. | 02-13-2014 |
| 20140045277 | SYSTEM FOR TRAPPING, INTERACTING AND MODIFYING SINGLE PROTEIN MOLECULES USING A DOUBLE-NANOHOLE STRUCTURE - Molecules or particle having a hydrodynamic radius as small as 3.5 nm can be trapped using a double-nanohole structure defined in a metal film or other metallic layer. Application of a suitable optical radiation flux to the double-nanohole structure can provide a folding and/or binding of protein molecules that can be identified based on changes in optical transmission. Varying nanohole transmissions can thus be associated with trapping, binding and unfolding of biological particles. The double-nanohole defines cusps, but such cusps can be defined in other ways as well. | 02-13-2014 |
| 20140051183 | BIOMARKERS FOR THE PREDICTION OF INCIDENT CANCER - Subject of the present invention is a method of assessing the susceptibility of a subject to acquire cancer and/or assessing the risk of cancer mortality for a subject, who has not had clinically manifest cancer and/or does not have clinically manifest cancer at the time when applying this method. | 02-20-2014 |
| 20140051184 | MOBILITY SHIFT ASSAYS FOR DETECTING ANTI-TNF ALPHA DRUGS AND AUTOANTIBODIES THERETO - The present invention provides assays for detecting and measuring the presence or level anti-TNFα drugs and/or the autoantibodies to anti-TNFα drugs in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies against the drug. The present invention also provides methods for selecting therapy, optimizing therapy, and/or reducing toxicity in subjects receiving anti-TNFα drugs for the treatment of TNFα-mediated disease or disorders. | 02-20-2014 |
| 20140051185 | MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided. | 02-20-2014 |
| 20140051186 | METHOD OF PRODUCING FUNCTIONAL MOLECULE-CONTAINING SILICA NANOPARTICLES ON WHICH BIOMOLECULES ARE BONDED - A method of producing functional molecule-containing silica nanoparticles on which a biomolecule is bonded, containing the steps of:
| 02-20-2014 |
| 20140051187 | EVALUATING ASSAYS WHICH OPTICAL INHOMOGENEITIES - The invention relates to a method and a sensor device (100) for evaluating an assay with a sample. During the assay, optical measurements are made at a sensing surface (112), and at least one “homogeneity-image” of the sensing surface (112) is generated. From this image, an “homogeneity-indicator” is determined for at least one region of interest, and the optical measurements are then evaluated in dependence on said indicator. The homogeneity-indicator may for example be a binary value which indicates if an inhomogeneity was detected or not. If an inhomogeneity was detected, all optical measurements may be rejected, only measurements for the involved region of interest may be rejected, or measurements for a selected sub-area of the involved region of interest(ROI) may be rejected. | 02-20-2014 |
| 20140057364 | METHOD OF DIAGNOSING ALZHEIMERS DISEASE USING SALIVA - Provided is a method of diagnosing Alzheimer's disease. The method of diagnosing Alzheimer's disease includes preparing magnetic particles having primary capture antibodies specifically bonded with beta-amyloid adsorbed thereon, introducing saliva containing beta-amyloid into the magnetic particles to bond the beta-amyloid contained in the saliva with the primary capture antibodies, bonding secondary capture antibodies labeled with fluorescent substances to the magnetic particles bonded with the beta-amyloid to form a complex, disposing the complex in a channel region of an photoelectric conversion device in which photoelectric current is changed according to an amount of incident light, and measuring photoelectric current changed by light excited from the complex to quantify a concentration of the beta-amyloid contained in the saliva. | 02-27-2014 |
| 20140057365 | TEST DEVICE AND METHOD FOR COLORED PARTICLE IMMUNOASSAY - A test device and method for colored particle immunoassay. A colorimetric monoclonal antibody is disposed on a receiving piece having a simple structure or in an entrance of a through-hole of a transparent tubular body, such that the monoclonal antibody bonded to micro gold very rapidly reacts with an antigen of a liquid sample. The liquid sample can arrive at a C site and a T site without either a filter or a permeable material having capillary tubes. The C site and the T site are disposed on the interior of the through-hole. This simplifies the structure, thereby reducing the cost of manufacture. The liquid sample can rapidly arrive at the C site and the T site through the through-hole of the transparent tubular body without, so that antibodies of the C site and the T site can react with the antigen in a very short time. | 02-27-2014 |
| 20140057366 | SENSOR DEVICE FOR MAGNETICALLY ACTUATED PARTICLES - The invention relates to a sensor device ( | 02-27-2014 |
| 20140057367 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES - The present invention provides assays for detecting and measuring the presence or level of anti-TNFα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-TNFα drug therapeutics to detect the presence or level of autoantibodies (e.g., HACA and/or HAHA) against the drug. | 02-27-2014 |
| 20140057368 | METHODS FOR DETERMINING LIGAND BINDING TO A TARGET PROTEIN USING A THERMAL SHIFT ASSAY - The invention is directed to a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of: a) exposing said non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to said ligand; b) processing the product of step a) in order to separate soluble from insoluble protein; and c) analysing either or both the soluble and insoluble protein fractions of step b) for the presence of target protein, wherein said target protein is not detected on the basis of enzymatic activity of a tag, peptide, polypeptide or protein fused thereto. Particularly, the invention may be used to determine whether drugs can bind to their protein targets in samples derived from patients to ascertain whether a certain drug can be used in a therapy for that patient. Additionally, the invention is directed to an instrument for use in the methods of the invention and use of a kit in the methods of the invention comprising an antibody and/or a non-protein fusion tag. | 02-27-2014 |
| 20140065722 | Methods and Compositions for Highly Sensitive Detection of Molecules - Disclosed are methods, kits, and compositions for the highly sensitive detection of molecules. The methods, kits, and compositions are useful in determining concentrations of molecules in samples to levels of 1 femtomolar, 1 attomolar, or lower. The methods, kits, and compositions also allow the determination of concentration over a wide range, e.g., 7-log range, without need for sample dilution. | 03-06-2014 |
| 20140065723 | ENRICHMENT AND PURIFICATION OF INFECTIOUS PRION PROTEIN - Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein. | 03-06-2014 |
| 20140065724 | METHOD OF PROGNOSING AND DIAGNOSING HEREDITARY SPASTIC PARAPLEGIA, MUTANT NUCLEIC ACID MOLECULES AND POLYPEPTIDES - A method for diagnosing the presence of hereditary spastic paraplegia (HSP) or predicting the risk of developing HSP in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of FIG. | 03-06-2014 |
| 20140065725 | AMPLIFIED NUCLEIC ACID DETECTION METHOD AND DETECTION DEVICE - An object of the invention is to provide a nucleic acid detection method which takes advantage of the high specificity of hybridization techniques, reduces the time length and the number of steps required for detection of PCR products, and allows for easy and highly accurate detection by visual observation without the need of special equipment; and a nucleic acid detection device or kit. The invention provides a method for detecting a target nucleic acid in a sample, which includes performing amplification of the target nucleic acid sequence to synthesize an amplification product having a partially double-stranded structure where a single-stranded region is added to each end of the target sequence, and hybridizing a nucleic acid sequence bound to a development medium and a nucleic acid sequence labeled with a labeling compound with the single-stranded regions of the amplification product to form a sandwich hybridization complex; and a detection device thereof. | 03-06-2014 |
| 20140065726 | LATEX PARTICLE FOR MEASUREMENT REAGENT, COATED LATEX PARTICLE, AND MEASUREMENT REAGENT FOR IMMUNOTURBIDIMETRIC METHOD - An object of the present invention is to provide a latex particle for a measurement reagent with which highly sensitive measurement can be performed even in measuring a measurement sample containing a test substance in a dilute concentration. | 03-06-2014 |
| 20140065727 | METHOD FOR STABILIZING PROTEIN - An excellent protein stabilizer is provided, which has the following effects: (1) low probability with contamination of pathogens, (2) the effect of stabilization on photoproteins, and (3) minimization of loss of activity under lyophilizing conditions. A peptide from fish is used as the active ingredient for the protein stabilizer. | 03-06-2014 |
| 20140073062 | SPECIMEN SOLUTION ASSAY DEVICE, SPECIMEN SOLUTION ASSAY METHOD, AND IMMUNOCHROMATOGRAPHIC SENSOR DEVICE - A specimen solution assay device includes a specimen solution dropping device which drops a specimen solution sequentially onto each of sample pads of immunochromatographic sensors positioned adjacent to each other in a transverse direction of each of the immunochromatographic sensors, and an image information acquisition device which acquires image information of a test area of each of the immunochromatographic sensors onto which the specimen solution is dropped by the specimen solution dropping device. | 03-13-2014 |
| 20140087480 | Methods and Compositions for Assaying a Sample for an Aggregant - This invention relates to an aggregation sensor useful for the detection and analysis of aggregants in a sample, and methods, articles and compositions relating to such a sensor. The sensor comprises first and second optically active units, where energy may be transferred from an excited state of the first optically active unit to the second optically active unit. The second optically active unit is present in a lesser amount, but its relative concentration is increased upon aggregation, increasing its absorption of energy from the first optically active units. This increase in energy transfer can be detected in variety of formats to produce an aggregation sensing system for various aggregants, including for quantitation. Other variations of the inventions are described further herein. | 03-27-2014 |
| 20140087481 | SCD FINGERPRINTS - The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting and assessing the progression of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described. | 03-27-2014 |
| 20140087482 | METHOD FOR DETECTING TARGET PARTICLES - The present invention provides a method for detecting a target particle, comprising: (a) concentrating a test sample so as to enhance the concentration of target particles in the test sample, (b) preparing a sample solution containing the test sample concentrated in (a) and a luminescent probe that binds to the target particle, and allowing the target particle and the luminescent probe to bind in the sample solution, and (c) counting the number of target particles bound to the luminescent probe present in the sample solution according to a scanning molecule counting method, wherein the luminescence properties of the released light differ between the state in which the luminescent probe is bound to the target particle and the state in which the luminescent probe is present alone. | 03-27-2014 |
| 20140093973 | EPITOPE TESTING USING SOLUBLE HLA - The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule using fluorescence polarization. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein. | 04-03-2014 |
| 20140093974 | METHODS FOR ASSESSING MODIFIED LDL IMMUNE COMPLEXES IN SUBJECTS HAVING OR AT RISK OF CORONARY ARTERY DISEASE - The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes. | 04-03-2014 |
| 20140093975 | AUTOMATIC ANALYZER AND SAMPLE ANALYSIS METHOD - An automatic analyzer includes a reaction unit configured for holding a reaction container and carrying the reaction container to a determined operation position, the operation position including a detection operation position; a detection unit configured for detecting analyte in the reaction container of the reaction unit in the detection operation position; a bound-free (“B/F”) unit configured for removing unbound components of a reaction system; and a dispensing unit configured for dispensing reagent and/or a sample to the reaction container, wherein the reaction unit includes an incubation position for incubating a solution in the reaction container. | 04-03-2014 |
| 20140093976 | COMPOSITIONS, SYSTEMS AND METHODS THAT DETECT AND/OR REMOVE CROSS-REACTIVE ANTIBODIES FROM A BIOLOGICAL SAMPLE - The present invention generally relates to compositions, systems and methods that detect and/or remove cross-reactive antibodies from a biological sample. In many cases, the cross-reactive antibodies are human anti-animal antibodies. In certain cases, the cross-reactive antibodies are human anti-mouse antibodies. | 04-03-2014 |
| 20140093977 | LIGHT MICROSCOPY CHIPS AND DATA ANALYSIS METHODOLOGY FOR QUANTITATIVE LOCALZIED SURFACE PLASMON RESONANCE (LSPR) BIOSENSING AND IMAGING - A chip for localized surface plasmon resonance (LSPR) biosensing and imaging having a glass coverslip compatible for use in a standard microscope and at least one array of functionalized plasmonic nanostructures patterned onto the glass coverslip with electron beam nanolithography. The nanostructures can be regenerated allowing the chip to be used multiple times. Also disclosed is a method for determining the fractional occupancy values for surface-bound receptors as a function of time for LSPR biosensing from the spectroscopic response of the array and modeling the photon count in each spectrometer channel, allowing for a functional relationship to be determined between the acquired spectrum and the fractional occupancy of binding sites on the array. Additionally disclosed is a method for the spatiotemporal mapping of receptor-ligand binding kinetics in LSPR imaging using the chip and projecting a magnified image of the array to a CCD camera and monitoring the binding kinetics of the array. | 04-03-2014 |
| 20140093978 | Human Salty Taste Receptor And Methods Of Modulating Salty Taste Perception - Methods for identifying modulators of the epithelial sodium ion channel and for identifying modulators of salty taste perception are described. Also featured are isolated human salty taste receptors, artificial lipid bilayers comprising an epithelial sodium ion channels, and kits for practicing the claimed methods. | 04-03-2014 |
| 20140093979 | Microfabricated QLIDA Biosensors with an Embedded Heating and Mixing Element - An apparatus and method for detecting an analyte are described. The apparatus includes at least one microchannel adapted for an analyte to adhere to an interior surface thereof, a mixing element positioned within at least a portion of the at least one microchannel, a light source for energizing quantum dots conjugated with the analyte within the at least one microchannel, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, wherein each wavelength range being correlated to one and only one type of analyte. The method includes the steps of providing a sample to at least one microchannel coated with an antibody, contacting the sample with a conjugate comprising a quantum dot and an antibody that specifically binds to the analyte, increasing electrothrermal flow of the sample, energizing the quantum dot with a light source, detecting fluorescent emission from the quantum dot, and correlating the fluorescent emission to the presence of or the concentration of the analyte in the sample. | 04-03-2014 |
| 20140093980 | DISSOLVABLE BRIDGES FOR MANIPULATING FLUID VOLUMES AND ASSOCIATED DEVICES, SYSTEMS AND METHODS - The present technology is directed to capillarity-based devices for performing chemical processes and associated system and methods. In one embodiment, for example, a device can include a source configured to receive one or more fluids, a first material adjacent to and in fluid connection with the source, a second material, and a dissolvable volume-metering element positioned between the first material and the second material. The volume-metering element can be configured to provide a fluid connection between the first material and the second material. The volume-metering element can also be configured to at least partially dissolve and break the fluid connection between the first material and second material once a predetermined volume of fluid flows therethrough. | 04-03-2014 |
| 20140093981 | METHOD FOR IMMOBILIZING ALBUMIN ON A SELF-ASSEMBLED MONOLAYER - The method of the present disclosure is characterized by that one molecule of the amino acid is interposed between the self-assembled monolayer and the molecule of the albumin. For example, a method is provided for immobilizing albumin on a self-assembled monolayer, the method including the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the albumin to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecule of the amino acid and the amino group of the albumin. | 04-03-2014 |
| 20140099731 | Assays - A method for assaying a sample for each of multiple analytes is described. The method includes contacting an array of spaced-apart test zones with a liquid sample (e.g., whole blood). The test zones disposed within a channel of a microfluidic device. The channel is defined by at least one flexible wall and a second wall which may or may not be flexible. Each test zone comprising a probe compound specific for a respective target analyte. The microfluidic device is compressed to reduce the thickness of the channel, which is the distance between the inner surfaces of the walls within the channel. The presence of each analyte is determined by optically detecting an interaction at each of multiple test zones for which the distance between the inner surfaces at the corresponding location is reduced. The interaction at each test zone is indicative of the presence in the sample of a target analyte. | 04-10-2014 |
| 20140099732 | OPTICAL SENSOR FOR ANALYTE DETECTION - Devices, systems, and methods for detection of an analyte in a sample are disclosed. In some embodiments, an optical sensor can include a metallic layer and a plurality of dielectric pillars extending through the metallic layer. A plurality of regions of concentrated light can be supported in proximity to the ends of the plurality of dielectric pillars when a surface of the metallic layer is illuminated. Concentrated light within one or more of these regions can interact with an analyte molecule, allowing for detection of the analyte. | 04-10-2014 |
| 20140099733 | Methods of Detecting Antibodies Specific for Denatured HLA Antigents - The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ. | 04-10-2014 |
| 20140106468 | PHOTONIC CRYSTAL SENSOR - Optical sensor for detecting an analyte ( | 04-17-2014 |
| 20140106469 | Nanoparticle Plasmonic Sensor for Localized Surface Plasmon Resonance - The present invention provides a sensor for detecting the binding of molecules to membrane surfaces. The sensor comprises a nanoparticle coated with a continuous layer of silica, and having a ligand attached thereto, for detection of an analyte in a solution. The nanoparticle can be further coated with a continuous membrane, such as a lipid bilayer. | 04-17-2014 |
| 20140106470 | COMPACT ANALYZER FOR ACQUIRING CHARACTERISTICS OF SMALL TABS PLACED IN A VESSEL - Provided among other things is an analyzer for use with tabs placed in a vessel comprising: a stochastic sampling device adapted to receive the vessel; a light beam source adapted to enter the moving vessel and selectively illuminate tabs; an analytical signal receiver adapted to receive a signal indicative of an analytical process occurring on the surface of the tab as the tab is selectively illuminated; a tab ID receiver adapted to collect ID data from the tabs in coordination with their selective illumination; and a controller for associating identified tabs with analytical signals. | 04-17-2014 |
| 20140106471 | SENSOR USING MASS ENHANCEMENT OF NANOPARTICLES - Provided herein is a method of detecting a biomolecule, which enhances a mass of the target biomolecule by irradiating light to a photocatalytic nanoparticle binding to the target biomolecule. Accordingly, the method can effectively detect a change in mass, and provide economical and rapid detection using a low-priced photocatalyst. | 04-17-2014 |
| 20140106472 | SITE SPECIFIC CHEMICALLY MODIFIED NANOPORE DEVICES - Provided are site specific chemically modified nanopore devices and methods for manufacturing and using them. Site specific chemically modified nanopore devices can be used for analyte sensing and analysis, for example. | 04-17-2014 |
| 20140113383 | FULL RESOLUTION COLOR IMAGING OF AN OBJECT - The invention relates generally to both a method and apparatus for the creation of full resolution color digital images of diagnostic cassettes or objects of interest using a gray-scale digital camera or sensor combined with time sequential illumination using additive primary colors followed by post exposure digital processing. Such procedures and equipment is of significant economic value when employed in situations such as diagnostic clinical analyzers where space is limited and image quality requirements are high. | 04-24-2014 |
| 20140113384 | SENSOR INTEGRATION IN LATERAL FLOW IMMUNOASSAYS AND ITS APPLICATIONS - Lateral flow immunoassay devices for determining the concentration of an analyte in a sample and methods for measuring analyte concentration in sample using such lateral flow immunoassay devices. | 04-24-2014 |
| 20140113385 | Compositions and Methods for Identifying Single Antigens or Other Molecules in Cell Preparations - Disclosed are compositions and methods for identifying and preferably quantifying single antigens/molecules in tissue sections and other cell preparations. The methods make use of specific antibodies or aptomers linked with beads or other micro-particles using bright field microscopy having the purpose to identify and quantify single antigens or other molecules. | 04-24-2014 |
| 20140113386 | SYSTEMS AND DEVICES FOR MOLEUCLE SENSING AND METHOD OF MANUFACTURING THEREOF - Embodiments of the disclosure are directed to a device for molecule sensing. In some embodiments, the device includes a first electrode separated from a second electrode by a dielectric layer. The first electrode comprises a large area electrode and the second electrode comprises a small area electrode. At least one opening (e.g., trench) cut or otherwise created into the dielectric layer exposes a tunnel junction therebetween whereby target molecules in solution can bind across the tunnel junction. | 04-24-2014 |
| 20140113387 | METHOD OF INHIBITING NONSPECIFIC REACTION IN PIVKA-II ASSAY REAGENT - A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies. | 04-24-2014 |
| 20140113388 | TREATMENT PLANNING BASED ON POLYPEPTIDE RADIOTOXICITY SERUM MARKERS - A method includes at least one of creating or adapting a treatment plan for a patient based on a set of serum polypeptides of the patient that are indicative of a radiotoxicity of the patient at least one of before or after at least one of a plurality of radiotherapy treatments of the treatment plan, wherein the radiotoxicity is induced by radiation exposure from the radiotherapy treatment. A system includes a treatment planning device ( | 04-24-2014 |
| 20140120629 | NUCLEIC ACID STRUCTURE COMPLEX INCLUDING NUCLEIC ACIDS, RAMAN-ACTIVE MOLECULES, AND METAL PARTICLES, METHOD OF PREPARING THE SAME, AND METHOD OF DETECTING TARGET MATERIAL BY USING THE NUCLEIC ACID STRUCTURE COMPLEX - Provided are nucleic acid structures suitable for reproducible Raman spectroscopy, methods of preparing the same, and methods of detecting a target material using the nucleic acid structures, whereby various target materials may be analyzed by using reproducible Raman spectroscopy. | 05-01-2014 |
| 20140120630 | SENSORS USING HIGH ELECTRON MOBILITY TRANSISTORS - Embodiments of the invention include sensors comprising high electron mobility transistors (HEMTs) with capture reagents on a gate region of the HEMTs. Example sensors include HEMTs with a thin gold layer on the gate region and bound antibodies; a thin gold layer on the gate region and chelating agents; a non-native gate dielectric on the gate region; and nanorods of a non-native dielectric with an immobilized enzyme on the gate region. Embodiments including antibodies or enzymes can have the antibodies or enzymes bound to the Au-gate via a binding group. Other embodiments of the invention are methods of using the sensors for detecting breast cancer, prostate cancer, kidney injury, glucose, metals or pH where a signal is generated by the HEMT when a solution is contacted with the sensor. The solution can be blood, saliva, urine, breath condensate, or any solution suspected of containing any specific analyte for the sensor. | 05-01-2014 |
| 20140120631 | METHOD OF DETECTING PROTEIN AND DETECTING DEVICE - A protein detection device and method. The device has a main channel in which is attached either a polar rail molecule or a biomolecular motor which moves on the rail molecule in a direction corresponding to the polarity of the rail molecule. A sub-channel crosses the main channel for receiving a sample including tau-protein. The method includes feeding the sample to the device and detecting a ratio of mutated tau-protein included in the sample, based on motion of the biomolecular motor on the rail molecule or on motion of the rail molecule moved by action of the biomolecular motor. | 05-01-2014 |
| 20140120632 | DETECTION OF CLUSTERS OF MAGNETIC PARTICLES - The invention relates to a method and a sensor device ( | 05-01-2014 |
| 20140120633 | Devices and Methods for Detection and Quantification of Immunological Proteins, Pathogenic and Microbial Agents and Cells - The present invention provides a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a liquid sample by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD | 05-01-2014 |
| 20140127826 | METHOD FOR MEASURING BINDING KINETICS WITH A RESONATING SENSOR - Detecting a presence of a subject material in a fluid sample using at least one resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material. Prior to exposing the resonating sensor to the fluid sample, operation of the resonating sensor is initiated, which produces a sensor output signal representing a resonance characteristic of the resonating sensor. Optionally, a reference resonator is used that produces a reference output signal. The reference resonator lacks binding sites for the analyte. Introduction of a fluid sample to the resonating sensor is automatically detected based on detection of a characteristic change in the sensor output signal or a reference output signal, or both. In response to the detecting of the introduction of the fluid sample, automated measurement of the binding kinetics of the analyte material to the resonating sensor are measured. | 05-08-2014 |
| 20140127827 | METHOD FOR DETECTION OF ANTIGEN USING FLUORESCENCE RESONANCE ENERGY TRANSFER IMMUNOASSAY - Disclosed herein is a method for detecting an antigen. The method includes: reacting an antigen as an analyte having an absorption wavelength at 300 nm to 400 nm with an antibody to form an antigen-antibody conjugate; irradiating light to the antigen-antibody conjugate to induce fluorescence resonance energy transfer, thereby obtaining a fluorescence spectrum; and determining the presence of the antigen as the analyte by analyzing the fluorescence spectrum, and then measuring the concentration of the antigen. The method is capable of directly detecting various antigens in a homogeneous liquid state, which induces no competitive reaction, with high sensitivity and high selectivity through fluorescent resonance energy transfer, without any modification. | 05-08-2014 |
| 20140127828 | REACTION VESSEL, ASSAY DEVICE, AND MEASURING METHOD - The present invention related to a reaction vessel, an assay device and a measuring method. A reaction vessel includes a casing, a reagent and at least one individual element. The casing includes an opening and a detection zone. The opening may be formed on the edge of the casing and used to introduce a sample included an analyte. The detection zone is used to detect the analyte in the sample. The reagent is interacted with the sample. The individual element provides space and flow channel for mixing the sample and the reagent. The sample and the reagent are mixed in the individual element so as to determine the analyte in the detection zone, and thereby increasing accuracy of analyte detection. | 05-08-2014 |
| 20140127829 | Optical Device - An optical device has a deformable solid substrate, and a two dimensional array of metal particles which is carried by the substrate. The array provides a controlled separation between nearest-neighbour particles. Deformation of the substrate produces corresponding variation in the controlled separation such that the two dimensional array undergoes a transition between metallic and insulator surface reflectance. | 05-08-2014 |
| 20140134751 | DIAGNOSTIC METHOD - Disclosed herein is a method for diagnosing hepatic cancer by analysing a sample and determining the level of at least one compound selected from the group consisting of glycine, trimethylamine-N-oxide, hippurate and citrate and comparing the levels in the sample with control levels. The analysis of the sample can involve the determination of a profile for the sample. The methods disclosed are useful in distinguishing between a patient having hepatic cancer and a patient having cirrhosis. | 05-15-2014 |
| 20140134752 | METHOD FOR SPECIFIC IDENTIFICATION OF TARGET BIOMOLECULES - The present invention relates to a method for identification of specific target proteins in a protein sample following a detection procedure, such as a Western blotting procedure, wherein the membrane is probed with at least two primary antibodies directed against the same and/or different epitopes of the same target protein, and wherein specific binding to the target protein in a sample is differentiated from unspecific binding to the target protein by comparing the resulting sample patterns, such as bands or spot patterns, with each other. | 05-15-2014 |
| 20140134753 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES - Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed. | 05-15-2014 |
| 20140141524 | SYSTEM AND METHOD FOR DIAGNOSING SENSOR PERFORMANCE USING ANALYTE-INDEPENDENT RATIOMETRIC SIGNALS - A system and method are provided for utilizing radiometric fluorescence detection to determine a glucose independent concentration value when measuring frequency bands that do not contain the system isosbestic point. Preferably two bands are chosen such that a first band is below the system isosbestic point, and a second band is above the system isosbestic point, and both points are sufficiently far from the frequency endpoints to maximize the signal to noise ratio. | 05-22-2014 |
| 20140141525 | Bridged Element For Detection Of A Target Substance - Physical changes resulting from an association between a template molecule and a target molecule are detected by monitoring changes in the template molecule. Exemplary changes include a change in a physical dimension or stiffness of the template molecule, a change in electrical conductivity of the template molecule and a change in the energy required to dissociate the target molecule and the template molecule. The magnitude of the change is indicative of the specific identity of the target molecule. | 05-22-2014 |
| 20140141526 | METHOD AND DEVICE FOR BIOMOLECULE PREPARATION AND DETECTION USING MAGNETIC ARRAY - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises multiple zones such as a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 05-22-2014 |
| 20140141527 | QUALITY/PROCESS CONTROL OF A LATERAL FLOW ASSAY DEVICE BASED ON FLOW MONITORING - A method for providing quality control on a lateral flow assay device or for triggering a process-related step, the device including a substrate having at least one sample receiving area, at least one reagent zone downstream and in fluid communication with the at least one sample receiving area, at least one detection zone downstream and in fluid communication with the at least one reagent zone and at least one wicking zone downstream of the at least one detection zone, each fluidly interconnected therewith along at least one fluid flow path. The detection material provided in the at least one reagent zone produces a detectable signal that can be tracked and monitored prior to the completion of at least one test being performed on the lateral flow assay device. | 05-22-2014 |
| 20140141528 | DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect each of C-X-C motif chemokines-1, -2, and -3 as diagnostic and prognostic biomarker assays in renal injuries. | 05-22-2014 |
| 20140141529 | METHOD OF DETERMINING ACTIVE CONCENTRATION BY CALIBRATION-FREE ANALYSIS - A method of determining active concentration of an analyte in a liquid sample, comprises the steps of:
| 05-22-2014 |
| 20140147932 | Methods and Compositions for Highly Sensitive Detection of Molecules - The present invention discloses methods for the detection and monitoring of a condition in a subject using highly sensitive detection of molecules. The invention provides a method for detecting or monitoring a condition in a subject, comprising detecting a first marker in a first sample from the subject and detecting a second marker, wherein the first marker comprises a biomarker, e.g., Cardiac Troponin-I (cTnI) or Vascular Endothelial Growth Factor (VEGF), and wherein the limit of detection of the first marker is less than about 10 pg/ml. The second marker can be a biomarker, physiological marker, a molecular marker or a genetic marker. | 05-29-2014 |
| 20140147933 | COATED BEADS - The invention relates to a method of coating beads with a biological molecule comprising: (i) coating a plurality of beads with the biological molecule; (ii) mixing the coated beads with a liquid stabilising and/or blocking agent (iii) dispersing the coated beads still substantially surrounded by a liquid phase comprising the liquid stabilising and/or blocking agent across a surface that is at least partially liquid permeable; (iv) drying the beads on the surface to substantially remove the liquid phase; and (v) removing the dried beads from the surface. | 05-29-2014 |
| 20140147934 | Glucose sensor molecules - The present invention provides a glucose sensor having a glucose receptor containing a binding site of formula (I): wherein X, n, m and R | 05-29-2014 |
| 20140147935 | RELEASE REAGENT FOR VITAMIN D - Disclosed is an invention in the field of conducting an immunoassay of 25(OH) vitamin D in blood or blood components, notably serum or plasma. The invention employs a perfluoro alkyl acid, or a salt thereof, to release 25(OH) vitamin D from vitamin D binding protein. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound. | 05-29-2014 |
| 20140147936 | METHOD FOR DETERMINING PROGNOSIS OF RENAL FAILURE - The present invention relates to a method for determining the prognosis of renal failure, which comprises measuring fibroblast growth factor-23 and 25-hydroxyvitamin D in a biological sample, and a kit for determining the prognosis of renal failure, which comprises a reagent for measuring fibroblast growth factor-23 and a reagent for measuring 25-hydroxyvitamin D | 05-29-2014 |
| 20140147937 | METHOD OF DETERMINING ACTIVE CONCENTRATION - A method of determining active concentration of an analyte in a sample comprises the steps of: | 05-29-2014 |
| 20140147938 | NON COVALENT MOLECULAR STRUCTURE, COMPRISING A PYRENE BASED GLYCOCONJUGATE, DEVICE COMPRISING THE SAME AND ITS USE FOR DETECTION OF LECTIN - The present invention relates to a non covalent molecular structure comprising a carbon nanostructure and a pyrene based glycoconjugate (I) which is linked to the said carbon nanostructure by a non covalent link, the said glycoconjugate (I) having the formula: wherein B is a group which is present on any of the ten carbon atoms of the pyrene structure represented in (I) susceptible to bear a substituent, and is represented by the following group: —(CH2) | 05-29-2014 |
| 20140147939 | METHOD FOR IMMOBILIZING PROTEIN A ON A SELF-ASSEMBLED MONOLAYER - The object of the present invention is to provide a method for increasing an amount of Protein A to be immobilized on the self-assembled monolayer. Immobilizing Protein A to the self-assembled monolayer through the structure represented following formula (II) obviates the object. | 05-29-2014 |
| 20140154816 | DEVICES, SYSTEMS, AND METHODS FOR CONDUCTING ASSAYS WITH IMPROVED SENSITIVITY USING SEDIMENTATION - Embodiments of the present invention are directed toward devices, systems, and method for conducting assays using sedimentation. In one example, a method includes layering a mixture on a density medium, subjecting sedimentation particles in the mixture to sedimentation forces to cause the sedimentation particles to move to a detection area through a density medium, and detecting a target analyte in a detection region of the sedimentation channel. In some examples, the sedimentation particles and labeling agent may have like charges to reduce non-specific binding of labeling agent and sedimentation particles. In some examples, the density medium is provided with a separation layer for stabilizing the assay during storage and operation. In some examples, the sedimentation channel may be provided with a generally flat sedimentation chamber for dispersing the particle pellet over a larger surface area. | 06-05-2014 |
| 20140154817 | STRUCTURE OF THE C-TERMINAL REGION OF THE INSULIN RECEPTOR a-CHAIN AND OF THE INSULIN-LIKE GROWTH FACTOR RECEPTOR a-CHAIN - The present invention relates generally to structural studies of the insulin binding site of the insulin receptor (IR) and the insulin-like growth factor 1 receptor (IGF-1R). More particularly, the present invention relates to the crystal structure of the low affinity insulin binding site of the IR ectodomain comprising the C-terminal region of the IR α-chain, as well as the corresponding region of IGF-1R, and to methods of using the crystal and related structural information to screen for and design compounds that interact with or modulate the function of IR and/or IGF-1R. | 06-05-2014 |
| 20140162374 | METHOD FOR HOLDING MULTIPLE TYPES OF DIAGNOSTIC TEST CONSUMABLES IN A RANDOM ACCESS SINGLE CONTAINER - An immunodiagnostic test method includes holding a selection of immunological test elements or consumables in one or more containers attached to or positioned in the analyzer and providing random access to any test element therein. The container can hold multiple types of test elements in compartments or slots. Through sensing of a test element position in its slot, the detection mechanism of the invention provides for random access to multiple types of test elements in any sleeve and within a single sleeve, and provides efficient inventory control. The method increases the number of test element types that may be loaded onto an analyzer and maintains fast determination of inventory. | 06-12-2014 |
| 20140162375 | CARBON BASED BIOSENSORS AND PROCESSES OF MANUFACTURING THE SAME - Sensors, processes for manufacturing the sensors, and processes of detecting a target molecule with the sensor generally includes a substrate including a channel and first and second electrodes electrically connected to the channel, wherein the channel includes a monolayer of surface functionalized graphene or surface functionalized carbon nanotubes, wherein the surface functionalized graphene or surface functionalized carbon nanotubes include an imidazolidone compound. | 06-12-2014 |
| 20140162376 | COMPOSITIONS AND METHODS TO ASSESS THE CAPACITY OF HDL TO SUPPORT REVERSE CHOLESTEROL TRANSPORT - The invention provides compositions and methods for assessing the capacity of high density lipoprotein (HDL) to support reverse cholesterol transport in blood by measuring exchange if HDL-specific spin-labeled lipoprotein probes and electron paramagnetic spectroscopy. The invention also provides methods to identify individuals at risk for cardiovascular disease, to monitor the treatment of cardiovascular disease and in the development of therapies to treat cardiovascular disease. The invention also provides methods to identify individuals at risk for Alzheimer's disease, to monitor the treatment of Alzheimer's disease and in the development of therapies to treat Alzheimer's disease. | 06-12-2014 |
| 20140162377 | Lactoferrin Fragments And Use Thereof - Novel lactoferrin fragments that are characteristic of inflammation during resolution and uses thereof. Diagnostic compositions and methods for assessing the presence or absence of resolving inflammation and for monitoring the progression of inflammatory resolution in a subject. Methods for treating a subject having an inflammatory disease, the methods including determining whether the subject has inflammation in resolution by determining the molecular weight of lactoferrin fragments. | 06-12-2014 |
| 20140162378 | METHOD FOR DETECTING TARGET PARTICLE - This method for detecting a target particle comprises (a) preparing a solution containing a target particle, a luminescent probe that binds to the target particle and a particle for separation and recovery, or containing the target particle bound to the luminescent probe, the luminescent probe and the particle for separation and recovery, and forming a complex composed of the target particle, the luminescent probe and the particle for separation and recovery in the solution, (b) recovering the particle for separation and recovery from the solution by solid-liquid separation treatment after the (a) and preparing a sample solution containing the particle for separation and recovery, and (c) calculating the number of the complex present in the sample solution according to a scanning molecule counting method, wherein the particles for separation and recovery bind to a complex composed of the target particles and the luminescent probe. | 06-12-2014 |
| 20140170765 | SPECTROSCOPIC ASSEMBLY AND METHOD - A spectrometer assembly is provided having an optical transmission filter including a stack of continuous, non-patterned alternating dielectric and metal layers. Angle-dependent transmission wavelength shift of the optical transmission filter with continuous metal layers is small e.g. in comparison with multilayer dielectric filters, facilitating size reduction of the spectrometer assembly. | 06-19-2014 |
| 20140170766 | Aptamer Based Point-of-Care Test for Glycated Albumin - Disclosed herein is a point-of-care or home use device for measuring the ratio of glycated albumin to total albumin in saliva and other body fluids. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period. The test is performed using a disposable strip or cassette that contains the testing reagents and the results are measured in a measuring instrument that automatically reads, calculates and displays the final result. The results of tests performed over a period of time are stored in the instrument's memory and presented in a numerical or graphical format so that the individual's glycated albumin level can be monitored over time. | 06-19-2014 |
| 20140170767 | METHOD FOR DIAGNOSING BIOMARKERS AND BIOMARKER DIAGNOSIS KIT - A method for diagnosing a biomarker using magnetic particles and quantum dots for quantitative analysis and a biomarker diagnosis kit are provided. The method for diagnosing a biomarker includes: ii) providing magnetic particles having surfaces to which a primary antibody capable of collecting a biomarker using a linker is fixed; ii) providing quantum dots having surfaces to which a secondary antibody capable of detecting the biomarker is fixed; iii) sandwich-targeting the biomarker by the magnetic particles and the quantum dots; iv) selectively separating quantum dots sandwich-targeting the biomarker among the quantum dots; and v) quantifying the concentration of the biomarker by measuring absorbance or intensity of fluorescence of separated quantum dots. | 06-19-2014 |
| 20140170768 | METHOD FOR MONITORING AND ASSESSING PITUITARY FUNCTION - Methods for monitoring pituitary function and for distinguishing Cushing's disease from Cushing's syndrome. The methods includes (1) providing a subject, (2) administering to the subject a daily dosage of a glucocorticoid antagonist, (3) monitoring adrenocorticotropic hormone (“ACTH”) and/or cortisol levels in the subject. Subjects having normal pituitary function typically show an increase in ACTH and/or cortisol levels following glucocorticoid antagonist therapy, while subjects having abnormal pituitary function will typically show no significant change in ACTH or cortisol following glucocorticoid antagonist therapy. Similarly, subjects having Cushing's disease show a significant rise in ACTH and cortisol levels following glucocorticoid antagonist therapy, while, in contrast, subjects having Cushing's syndrome show no significant change in ACTH and/or cortisol following glucocorticoid antagonist therapy. | 06-19-2014 |
| 20140170769 | MICROSCOPE APPARATUS FOR DETECTING OR IMAGING PROTEIN USING PROBE FOR INTRINSIC FLUORESCENCE RESONANCE ENERGY TRANSFER AND METHOD FOR DETECTING OR IMAGING PROTEIN USING THE SAME - A microscope apparatus for detecting or imaging a target protein using a probe for intrinsic fluorescence resonance energy transfer (iFRET) according to the present invention comprises: a light irradiation unit that irradiates a first light having a wavelength range for exciting an amino acid in the target protein and a second light having a wavelength range for exciting a fluorescent molecule of the probe for iFRET; an objective lens that allows the lights irradiated from the light irradiation unit to be incident onto a sample into which the probe for iFRET is introduced; and a recognition unit that detects a first light emitting signal generated from the probe for iFRET by irradiating the first light having a wavelength range for exciting an amino acid in the target protein onto the sample and a second light emitting signal generated from the probe for iFRET by irradiating the second light having a wavelength range for exciting a fluorescent molecule of the probe for iFRET onto the sample, wherein the probe for iFRET includes: a binding site specific to a target protein or a molecule which has the binding site; and a fluorescent molecule having an acceptor function with respect to intrinsic fluorescence of the target protein, which are bonded to each other directly or by a linker. | 06-19-2014 |
| 20140170770 | METHODS OF USE FOR AN IMMUNOASSAY DETECTING FRAGMENT Ba - Methods, compositions and kits for detecting the complement Factor B cleavage product Ba in a biological sample are described. These methods, compositions and kits are useful in convenient, reliable and early diagnosis of or ruling out pre-eclampsia in a pregnant human subject. | 06-19-2014 |
| 20140170771 | MID-REGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE (PRO-ANP) FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION WITH AN ONSET OF LESS THAN 48 HOURS AGO - The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues. | 06-19-2014 |
| 20140170772 | Method for Measuring Amount of Analyte and Device for SPFS - [Problem] An object of the present invention is to provide a method by which the amount of a very small amount of analyte (in particular, one having a sugar chain) can be measured with a high accuracy and a device which is used for said measurement method. | 06-19-2014 |
| 20140170773 | METHOD FOR DETECTING ASBESTOS - In order to provide a method for more efficiently, easily, and accurately detecting asbestos without changing the asbestos detection criterion of the phase-contrast microscope/electron microscope method as compared with the phase-contrast microscope/electron microscope method, a phase-contrast microscope and a fluorescence microscope are used in combination to detect asbestos contained in a test sample after the test sample is made contact with an asbestos-binding protein having a fluorescent label. | 06-19-2014 |
| 20140179023 | METHOD FOR DETECTING A TARGET PARTICLE IN BIOSAMPLE CONTAINING PANCREATIC JUICE - Provided is a method for detecting a target particle in a biosample containing pancreatic juice, the method enabling the detection in a solution that has a lower concentration or number density of the target particles than the level possible for conventional photoanalysis techniques. This method comprises: a probe-binding step for preparing a sample solution, which contains a biosample containing pancreatic juice and a fluorescent probe capable of binding to a target particle, and binding the fluorescent probe to the target particle in the biosample; and a calculation step for calculating the number of molecules of the target particles bound to the fluorescent probes by the scanning molecule counting method. A light emission property of emitted light is different between a state where the fluorescent probe is bound to the target particle and a state where the fluorescent probe is present alone. In a state where the fluorescent probe is bound to the target particle, the fluorescent probe emits fluorescence having a wavelength of 600 nm or longer. | 06-26-2014 |
| 20140179024 | DEVICE AND METHODS FOR DETECTING ANALYTES IN SALIVA - The invention provides a device for detecting drugs of abuse or other compounds in saliva. The invention thus provides a device for detecting the presence of one or more analytes in a saliva sample, comprising: (a) One or more pre-treatment regions for specifically or non-specifically removing at least a part of the fraction of the saliva sample interfering with detection of the one or more analytes; and (b) A detection region comprising a biosensor surface, the surface comprising: molecules capable of specifically binding the one or more analytes; or the one or more analytes and/or analyte analogues. | 06-26-2014 |
| 20140186970 | IMPRINTED PHOTONIC POLYMERS AND METHODS FOR THEIR PREPARATION AND USE - Macroporous matrices containing molecularly imprinted photonic polymers (MIPPs) and methods of making these macroporous matrices are disclosed herein. The macroporous matrices can, for example, be used for detection of small molecules, such as metal ions, in a sample. | 07-03-2014 |
| 20140186971 | Testkit for Laboratory Diagnostics - A device for incubating an immunoblot strip ( | 07-03-2014 |
| 20140186972 | APPARATUS AND METHOD FOR IDENTIFYING A HOOK EFFECT AND EXPANDING THE DYNAMIC RANGE IN POINT OF CARE IMMUNOASSAYS - The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. The system may further include an attenuated sensor having second immobilized antibodies at a reduced concentration relative to a concentration of the first immobilized antibodies on the primary sensor and that may be configured to generate a second signal based on the presence or absence of the target analyte in the sample. The system may further include a processor configured to determine a presence of a hook effect in the immunoassay based on relative values of the first and second signals and optionally determine the target analyte concentration of the sample. | 07-03-2014 |
| 20140186973 | ASSAYS FOR DETECTING NEUTRALIZING AUTOANTIBODIES TO BIOLOGIC THERAPY - The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNFα drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy. | 07-03-2014 |
| 20140193925 | BIOSENSORS - A chemiresistive biosensor for detecting an analyte can include a high specific surface area substrate conformally coated with a conductive polymer, and a binding reagent immobilized on the conductive polymer, wherein the binding reagent has a specific affinity for the analyte. The conductive polymer can be deposited on a substrate by oCVD. | 07-10-2014 |
| 20140193926 | PYRENYLOXYSULFONIC ACID FLUORESCENT AGENTS - The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention. | 07-10-2014 |
| 20140193927 | PREDICTION OF RECURRENCE FOR BLADDER CANCER BY A PROTEIN SIGNATURE IN TISSUE SAMPLES - The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods. | 07-10-2014 |
| 20140199780 | Method - In one aspect, there is provided a method for isolating chromatin from a sample, comprising a step of passing a liquid sample comprising chromatin through a rigid porous matrix on which a ligand is immobilized, wherein the ligand binds to a protein associated with the chromatin. | 07-17-2014 |
| 20140199781 | NON-INVASIVE METHODS FOR DIAGNOSING CHRONIC ORGAN TRANSPLANT REJECTION - Presented herein are methods of diagnosing or assessing an individual at increased risk of developing chronic rejection, or chronic allograft vasculopathy, based on analysis the individual's biomarker profile. | 07-17-2014 |
| 20140199782 | METHOD TO SCREEN HIGH AFFINITY ANTIBODY - The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (II) to (XIII) at least the thermodynamic parameters (i) standard association binding entropy (ΔS°‡ass), (ii) standard dissociation binding entropy (ΔS°‡diss), (iii) standard binding entropy (ΔS°), (iv) free standard binding enthalpy (ΔG°), (v) standard dissociation free binding enthalpy (ΔG°‡diss), (vi) standard association free binding enthalpy (ΔG°‡ass), (vii) −TΔS°, (viii) dissociation rate constant k | 07-17-2014 |
| 20140199783 | CHARACTERIZATION OF REACTION VARIABLES - A microscale method for the characterization of one or more reaction variables that influence the formation or dissociation of an affinity complex comprising a ligand and a binder, which have mutual affinity for each other. The method is characterized in comprising the steps of: (i) providing a microfluidic device comprising a microchannel structures that are under a common flow control, each microchannel structure comprising a reaction microactivity; (ii) performing essentially in parallel an experiment in each of two or more of the plurality of microchannel structures, the experiment in these two or more microchannel structures comprising either a) formation of an immobilized form of the complex and retaining under flow conditions said form within the reaction microactivity, or b) dissociating, preferably under flow condition, an immobilized form of the complex which has been included in the microfluidic device provided in step (i), at least one reaction variable varies or is uncharacterized for said two or more microchannel structures while the remaining reaction variables are kept essentially constant; (iii) measuring the presentation of the complex in said reaction microactivity in said two or more microchannel structures; and (iv) characterizing said one or more reaction variables based on the values for presentation obtained in step (iii). | 07-17-2014 |
| 20140206098 | Low Volume Assay Device Having Increased Sensitivity - An assay device includes: a liquid sample zone; a reagent zone downstream and in fluid communication with the sample addition zone containing a reagent material; a detection zone in fluid communication with the reagent zone. The detection zone has a substrate and projections which extend substantially vertically from the substrate, wherein the projections have a height, cross-section and a distance between one another that defines a capillary space between the projections capable of generating capillary flow parallel to the substrate surface. The device is capable of creating a reagent plume in the detection zone that includes liquid sample and dissolved reagent, where the width of the reagent plume extends substantially across the width of the detection zone, The device further includes a wicking zone in fluid communication with the detection zone having a capacity to receive liquid sample flowing from the detection zone. | 07-24-2014 |
| 20140206099 | METHODS, COMPOSITIONS AND KITS FOR LABELING OF PROTEINS - Provided herein are methods, compositions and kits for labeling of target proteins such as antibodies. The methods, compositions and kits are suited for labeling of such proteins that are mixed with other non-target molecules including BSA, gelatin, and other complex biological molecules. | 07-24-2014 |
| 20140206100 | DETECTING A HIGH MOLECULAR WEIGHT SUBSTANCE - Label complexes, lateral flow apparatus and methods of detecting a high molecular weight substance are shown and described. In one embodiment, the label complex includes an antispecies antibody and another antibody having sensitivity to both the antispecies antibody and to a control line capture agent, an antibody binding protein and a detectable component. Typically, the antibody binding protein may bind to a receptor for the analyte or to the anti-species antibody. In yet other embodiments, a lateral flow test strip includes the label complex and a solid support that traverses lateral flow of a liquid sample and provides a detectable signal. | 07-24-2014 |
| 20140206101 | Plasmon Resonance Imaging Apparatus Having Nano-Lycurgus-Cup Arrays and Methods of Use - Apparatus and methods are disclosed that are configured to permit nanoplasmonic spectroscopy sensing in the form of colorimetric sensing. An example apparatus involves: (a) an array layer having a top surface and a bottom surface, wherein a plurality of nanoholes are defined in the top surface of the array layer, wherein the plurality of nanoholes each have at least one sidewall surface and a bottom surface, (b) a thin metal film disposed on the top surface of the array layer and on the bottom surface of each of the plurality of nanoholes, and (c) a plurality of nanoparticles disposed on the at least one sidewall surface of the plurality of nanoholes. | 07-24-2014 |
| 20140206102 | METHODS AND MATERIALS FOR DETECTING C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION POSITIVE FRONTOTEMPORAL LOBAR DEGENERATION OR C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSION POSITIVE AMYOTROPHIC LATERAL SCLEROSIS - This document provides methods and materials for detecting C9ORF72 hexanucleotide (GGGGCC) (SEQ ID NO: 3) repeat expansion positive (C9 | 07-24-2014 |
| 20140206103 | Immunochromatography Detection Sensor Comprising Optical Waveguide and a Detection Method Using the Same - The present invention relates to an immunochromatographic detection sensor comprising optical waveguides and a detection method using the same, and more particularly, to an immunochromatographic detection sensor comprising optical waveguides, in which the optical waveguides are provided under the membrane, probe beams transmitted through the optical waveguide maximize the interaction frequency between evanescent wave generated on the surface of the optical waveguide and the colored conjugate in the band formed on the membrane, resulting in the absorbance signal from the colored conjugate being greatly amplified to improve the sample detection sensitivity, and to a detection method using the same. | 07-24-2014 |
| 20140212987 | Signal Ratio in Assay Calibrators - Methods of enhancing signal ratio between calibrators in an assay for an analyte include conducting an assay for the analyte with zero concentration of analyte in a first calibrator to determine a first signal level. The reagents employed in the assay comprise an antibody reagent comprising an antibody for the analyte wherein a hinge region of the antibody is conjugated to a moiety. The assay for the analyte is also conducted with a second concentration of analyte in a second calibrator to determine a second signal level wherein the second analyte concentration is greater than zero and wherein the reagents employed in the assay comprise the antibody reagent. A ratio of the first signal level to the second signal level is determined and evaluated. | 07-31-2014 |
| 20140212988 | METHOD OF DETECTING AN ANALYTE USING COATED HOLLOW MICROSPHERES AND METHOD OF PRODUCING SAME - Disclosed in this specification is a method for detecting an analyte using buoyant particles and chemical moieties to give buoyant particle composites that exhibit SERS and can be used for detecting the analytes in a liquid sample. A method is provided for detecting analytes of interest by contacting the analyte with a buoyant particle that comprises a first chemical moiety, such as a SERS-active component, allowing the analyte of interest to bind to the first chemical moiety. The resulting composite localizes in a discrete location of the liquid sample through a buoyant force. The composite is then detected by measuring the Raman scattered light in the discrete location of the liquid sample. | 07-31-2014 |
| 20140212989 | PHENYTOIN BIOSENSOR AND METHOD FOR MEASURING CONCENTRATION OF PHENYTOIN - The present disclosure relates to a phenytoin biosensor. In some embodiments, the phenytoin biosensor may comprise a microcantilever, a self-assembly monolayer, and a phenytoin antibody layer. The self-assembly monolayer may immobilize on the microcantilever surface. The phenytoin antibody layer may immobilize on the self-assembly monolayer. The phenytoin antibody layer may be used to bind with phenytoin drug samples. The present disclosure further relates to methods for measuring the concentration of phenytoin drug samples. | 07-31-2014 |
| 20140212990 | DETECTION ASSAYS EMPLOYING MAGNETIC NANOPARTICLES - The present invention is directed to novel assays for detecting target molecules. The assays employ small size, detectably labeled, magnetic nanoparticles associated with a capture molecule. The detection assay is accelerated by applying magnetic field during the assay. The assays of the invention can be used to enhance the efficiency of the detection step in dot blot, Western blot and ELISA. | 07-31-2014 |
| 20140212991 | IMMUNOASSAY METHOD AND IMMUNOASSAY APPARATUS - In order to provide an immunoassay method and an immunoassay apparatus capable of further reducing errors due to non-target substances, a detector measures a measurement specimen and detects information regarding the binding number of carrier particles included in the measurement specimen. A controller classifies, based on the information regarding the binding number, particles included in the measurement specimen into groups, the groups being classified in accordance with the binding numbers. Further, for each classified group, the controller performs either one of a first removing process for removing, from a processing target, data of non-target substances different from the carrier particles, and a second removing process for removing, from the processing target, data of the non-target substances through a process different from the first removing process, and obtains information regarding the agglutination degree of the carrier particles, based on data of the carrier particles obtained by performing the removing process. | 07-31-2014 |
| 20140212992 | CENTRIFUGALLY-ENHANCED CAPTURE METHOD AND DEVICE - In a centrifugal microfluidic device for conducting capture assays, a microfluidic platform rotates in a plane of rotation and has at least one capture surface for immobilizing a target particle of interest in the device. The capture surface oriented so that it is not parallel to the plane of rotation of the device and is positionally fixed in the device during operation of the device. The centrifugal force arising from rotation of the device forces the target particles against the capture surface. Capture efficiency is independent of the rate of flow of the fluid and independent of the rate of rotation of the microfluidic platform. | 07-31-2014 |
| 20140220703 | HIGH-FLUX CHEMICAL SENSORS - The present invention relates to the field of chemical detection. Specifically, the invention provides devices that respond quickly to various target chemical analytes present in the environment. Responses are based on a change in an electrical property (such as impedance or resistance) caused by adsorption or absorption of the target analyte(s) to or in a substrate-free chemical sensing element. The chemical sensing element is composed of a thin, electrically conductive polymer material (due to doping of structural polymer material(s) with electrically conductive particles and/or the use of electrically conductive polymer material(s)), which can allow vapors to pass through with little pressure drop. The chemical sensing material is either suspended in the environment, or emplaced adjacent to one or between two porous membranes, resulting in a sensing patch capable of high gas or vapor flux through the chemical sensing element. | 08-07-2014 |
| 20140220704 | ARTICLES COMPRISING TEMPLATED CROSSLINKED POLYMER FILMS FOR ELECTRONIC DETECTION OF NITROAROMATIC EXPLOSIVES - The present invention provides devices and articles of manufacture comprising a low-voltage operable, highly sensitive, and selectively responsive polymer for the detection of nitroaromatic compounds, including explosives. Resistive devices were fabricated by simple spin-coating on flexible and transparent substrates as well as silicon substrates, and were stable under ambient temperature and oxygen levels before exposure to the nitroaromatics. After exposure to 2,4,6-trinitrotoluene (TNT), the devices showed increased conductance, even with pg quantities of TNT, accompanied by a confirming color change from colorless to deep red. The relative conductance increase per unit exposure is the highest yet reported for TNT. Aromatic anion salts, on the other hand, did not induce any electronic responses. Methods of making the articles and devices, and their use are also provided. | 08-07-2014 |
| 20140220705 | AUTOMATED ANALYZER AND ANALYZING METHOD - An analyzer provides conditions suitable for a reagent for performing latex immunoassay with a high sensitivity using a method of measuring scattered light. Irradiation light having a wavelength in the range of 0.65 to 0.75 μm is used, and scattered light generated from a reaction solution is received at a light-receiving angle of 15° to 35° with respect to the irradiation direction during the rotational movement of the reaction container. The reagent contains latex particles the average peak particle diameter of which ranges from 0.3 μm to 0.43 μm and to which antibodies are sensitized. The reaction solution contains latex particles at a concentration at which the absorbance to irradiation light having a wavelength of 0.7 μm is 0.25 abs to 1.10 abs, and a change in the amount of scattered light caused by the aggregation of the latex particles through antigens in a sample is measured and quantified. | 08-07-2014 |
| 20140220706 | Molecularly Imprinted Polymer for Detecting Waterborne Target Molecules and Improving Water Quality - This disclosure relates to the field of molecularly imprinted polymers for detecting or removing target molecules. | 08-07-2014 |
| 20140234985 | DEVICE FOR STRETCHING A POLYMER IN A FLUID SAMPLE - The invention provides structures and methods that allow polymers of any length, including nucleic acids, to be stretched into a long, linear conformation for further analysis. | 08-21-2014 |
| 20140234986 | TAGGED LIGANDS FOR ENRICHMENT OF RARE ANALYTES FROM A MIXED SAMPLE - Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed. | 08-21-2014 |
| 20140234987 | METHODS FOR PREDICTING TIME-TO-DELIVERY IN PREGNANT WOMEN - The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane. | 08-21-2014 |
| 20140234988 | Methods for Diagnosing and Treating Medical Conditions Associated With Oxidative Stress - Non-mercaptalbumin-2 is used as a biomarker for diagnosing a medical condition associated with oxidative stress. A method for diagnosing a condition associated with oxidative stress includes determining the redox state of albumin at the cysteine residue at sequence position 34; quantifying the level of non-mercaptalbumin-2 present, non-mercaptalbumin-2 representing the albumin fraction irreversibly oxidized at cysteine 34; and comparing the result to a control level, wherein an elevated level of non-mercaptalbumin-2 as compared to the control level is indicative of the condition associated with oxidative stress. A method for the prevention and/or treatment of a medical condition associated with oxidative stress includes quantifying a level of non-mercaptalbumin-2 that is elevated as compared to a control, wherein such elevated level of non-mercaptalbumin-2 is indicative of the condition associated with oxidative stress; and restoring a control level of albumin by removing excess nonmercaptalbumin-2 and/or exogenously adding albumin. | 08-21-2014 |
| 20140234989 | METHODS FOR DETECTING DIHYDROXYVITAMIN D METABOLITES BY MASS SPECTROMETRY - Provided are methods of detecting the presence or amount of a dihydroxyvitamin D metabolite in a sample using mass spectrometry. The methods generally comprise ionizing a dihydorxyvitamin D metabolite in a sample and detecting the amount of the ion to determine the presence or amount of the vitamin D metabolite in the sample. In certain preferred embodiments the methods include immunopurifying the dihydroxyvitamin D metabolites prior to mass spectrometry. Also provided are methods to detect the presence or amount of two or more dihydroxyvitamin D metabolites in a single assay. | 08-21-2014 |
| 20140242720 | KIT FOR IMMUNO-CHROMATOGRAPHY, REAGENT FOR IMMUNO-CHROMATOGRAPHY, AND METHOD OF DETECTING USING THEM - A kit for immunochromatography, having: a planar test strip having a test area and a reference area, the test area having a test purpose capturing substance, the reference area having a reference purpose capturing substance; fluorescent particulates provided with a binding property to a target substance, the target substance provided with a binding property to the test purpose capturing substance; and light absorbing particulates provided with a binding property to the reference purpose capturing substance. | 08-28-2014 |
| 20140242721 | Microfluidic Disc For Use In With Bead-Based Immunoassays - The invention relates to a microfluidic system for processing biological samples comprising a rotary motor; a means for controlling said motor; a platform coupled to the rotary motor and adapted to provide at least one particle-washing structure and one particle receiving structure for receiving washed particles; and a detection zone for detection of particles of the sample in the particle receiving structure while the platform rotates. The invention provides a sample processing system that is both automated and prone to fewer errors than manual processing. This is accomplished using a centrifugal microfluidic platform that can process raw biological samples (e.g., blood, sputum, urine,) in order to perform high-quality bead-based immunofluorescent assays. The invention uses a simple rotary motor and custom-designed plastic disc to perform the sample preparation steps outlined above. | 08-28-2014 |
| 20140242722 | ARTICLE AND METHOD FOR DETECTION OF A DRUG IN A LIQUID MEDIUM - An article is provided for the detection of a drug in a liquid medium. The article includes a polymer having pores specifically imprinted to provide for capture of a drug in the pores, nanoparticles, and photochromic optical switch molecules. Capture of the drug in the pores of the polymer results in a change in the spatial relation of the nanoparticles in the polymer, causing the photochromic optical switch molecules to undergo a change in energy state which corresponds to a change in spectra of the photochromic optical switch molecules, thereby providing for detection of the drug. | 08-28-2014 |
| 20140242723 | Methods for Detecting Symmetrical Dimethylarginine - Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases. | 08-28-2014 |
| 20140242724 | Methods and Compositions for the Efficient Reuse of Multiply Dyed Particles - Provided herein are compositions and methods for reuse and/or recycling of internally dyed particles useful for multiplex assays of target analytes. | 08-28-2014 |
| 20140242726 | LUNG CANCER MARKER COMPLEMENT C3dg MOLECULE, AND METHOD FOR ANALYZING LUNG CANCER MARKER | 08-28-2014 |
| 20140242727 | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE (AD) - Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein Aβ-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with Aβ-aggregates or with particles having Aβ-aggregate like surfaces and allowing the Aβ-specific antibodies to bind to the Aβ-aggregates, and —detecting the Aβ-specific antibodies bound to the Aβ-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of Aβ-specific antibodies detected is compared with the amount in a sample of known AD status. | 08-28-2014 |
| 20140248709 | METHODS DEVICES AND SYSTEMS FOR OPTICAL PROBING OF MOLECULAR STRUCTURE AND INTERACTIONS - Non-linear spectroscopic devices, systems, and methods for probing molecules. A non-linear spectroscopic method for probing molecules can include providing a plurality of molecules in an aqueous solution, the providing being effective for permitting the molecules to be free in said aqueous solution and without the molecules being bound to another material such that second harmonic or sum frequency coherent light would result from the illumination of the molecules changes in their conformation. The method can also include probing the molecules by directing light at one or more selected frequencies to generate second harmonic or sum frequency incoherent light resulting from predefined interactions between the first and second molecules and capturing the incoherent light and detecting the same. | 09-04-2014 |
| 20140248710 | THREE-COMPONENT BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 09-04-2014 |
| 20140248711 | APPARATUS AND METHOD FOR ELECTRICAL DETECTION OF OLIGONUCLEOTIDES THROUGH PORE BLOCKADES - Systems and methods for specific nucleic acid (NA) sequence detection that do not rely on polymerase chain reaction (PCR) for target sequence amplification and do not require any special reagents other than a complementary sequence capture probe conjugated to spherical beads. | 09-04-2014 |
| 20140248712 | Magnetic Particles Based Separation and Assaying Method - A magnetic particle based separation and assaying method uses at least two sets of magnetic particles placed in solution within a container and characterized respectively by a coercive field e | 09-04-2014 |
| 20140248713 | Method for Observing at Least One Object, Such as a Biological Entity, and Imaging System Associated Therewith - This method for observing at least one object is applied by means of an imaging system. It includes the following steps:
| 09-04-2014 |
| 20140248714 | METHODS AND SYSTEMS FOR PROCESSING SAMPLES ON POROUS SUBSTRATES - Methods and systems for processing samples fixed to a porous substrate generally comprising, a compressor defining one or more fluid isolation areas, a support, for the porous substrate, having an opening corresponding to one or more of the fluid isolation areas of the compressor, an actuator that causes at least a portion of the compressor to press against the porous substrate, a fluid inlet having access to the fluid isolation area at least when the compressor is pressed against the porous substrate, and a fluid outlet to receive fluid, through the opening in the support corresponding to the fluid isolation area of the compressor, at least when the compressor is pressed against the porous substrate. | 09-04-2014 |
| 20140248715 | METHOD FOR DETECTING BIOMOLECULES - A method of detecting biomolecules present in a complex biological sample includes a) separating the biological sample into fractions according to at least one physical property of the biomolecules; and b) specifically detecting biomolecules present in the fractions using at least one solid-phase-based, immunological detection method including immobilizing the biomolecules from the individual fractions on microsphere populations specific for each fraction and distinguishable from one another. | 09-04-2014 |
| 20140248716 | BIOCHEMICAL DETECTION UNIT AND BIOCHEMICAL DEVICE HAVING THE SAME - A biochemical detection unit for detecting a sample and a biochemical device having the biochemical detection unit and a releasing unit are provided. The biochemical detection unit includes a photoconductor plate, a receptor, and a resistance sensing component. The receptor specifically binds to the sample so that the illumination projected on the photoconductor plate will change to vary the resistance value of the photoconductor of the photoconductor plate. | 09-04-2014 |
| 20140256059 | MULTICOLOR MICROWAVE-ACCELERATED METAL-ENHANCED FLUORESCENCE (M-MAMEF) - The present invention relates to the use of multiple different light emitting molecules that emit different and detectable emission signals to provide systems and methods to detect different target products in a single assay sample, wherein the different light emitting molecules are positioned an optimal distance from metallic particles thereby enhancing emissions. Preferably, the systems and methods further comprise use of either microwave or sonic energy to increase binding reactions, timing of such reactions within the assay sample and reduce background non-specific biological absorption. | 09-11-2014 |
| 20140256060 | pH-INSENSITIVE GLUCOSE INDICATOR PROTEIN - The present invention encompasses a glucose indicator protein, a biosensor comprising one or more glucose indicator proteins, and methods of use thereof. | 09-11-2014 |
| 20140273269 | RAPID TEST FOR URINE ALBUMIN AND URINE CREATININE - Disclosed herein is an immunochromatographic system for measuring albumin and creatinine in a urine sample and a reader that detects signals from the test cassette, calculates, and displays the results for albumin concentration, creatinine concentration, and albumin-creatinine ratio. | 09-18-2014 |
| 20140273270 | DIRECT TEMPERATURE MEASUREMENT OF A TEST STRIP - An optical lateral flow fluid analyte testing device includes a test strip having at least one zone for measuring the concentration of a target analyte in a fluid sample. Devices and methods for facilitating a reliable reading are disclosed. | 09-18-2014 |
| 20140273271 | FLUORESCENCE IMMUNO-CHROMATOGRAPHY, KIT AND TEST STRIP FOR THE SAME - An immunochromatography carried out by illuminating a fluorescent substance in a membrane with excitation light and detecting fluorescence emitted from the fluorescent substance, the immunochromatography comprising the steps of:
| 09-18-2014 |
| 20140273272 | ASSAY WITH INTERNAL CALIBRATION - Provided herein are kits and methods for assays with internal calibration. | 09-18-2014 |
| 20140273273 | BIOMARKERS TO IMPROVE PREDICTION OF HEART FAILURE RISK - The present disclosure relates to the field of laboratory diagnostics. Specifically, methods are disclosed for determining a patient's risk of suffering from heart failure (HF) based on the detection of NT-proBNP, troponin T, and/or a natriuretic peptide. Also disclosed are methods for improving both the accuracy and speed of HF risk models by incorporating biomarker data from patient samples. | 09-18-2014 |
| 20140273274 | METHODS FOR THE SELECTIVE DETECTION OF ALKYNE-PRESENTING MOLECULES AND RELATED COMPOSITIONS AND SYSTEMS - Provided herein are methods for selectively detecting an alkyne-presenting molecule in a sample and related detection reagents, compositions, methods and systems. | 09-18-2014 |
| 20140273275 | BIOMARKERS FOR LIVER FIBROSIS - Methods and systems for diagnosing or prognosing liver fibrosis in a subject are provided. In some examples, such methods and systems can include detecting liver fibrosis-related molecules in a sample obtained from the subject, comparing expression of the molecules in the sample to controls representing expression values expected in a subject who does not have liver fibrosis or who has non-progressing fibrosis, and diagnosing or prognosing liver fibrosis in the subject when differential expression of the molecules between the sample and the controls is detected. Kits for the diagnosis or prognosis of liver fibrosis in a subject are also provided which include reagents for detecting liver fibrosis related molecules. | 09-18-2014 |
| 20140273276 | SYSTEM AND METHOD FOR A MICROFLUIDIC CALORIMETER - Systems and methods are disclosed herein for a microfluidic calorimeter apparatus. A microfluidic calorimeter system includes a calorimetry apparatus and a processor in connection with the apparatus. The apparatus includes a microfluidic laminar flow channel connected to two inlets for flowing fluid into the laminar flow channel. Below the laminar flow channel is a plurality of microscale temperature sensors at known positions in the channel. The processor is in connection with the discrete temperature sensors and determines a calorimetry measurement based on local temperatures derived from data output by the microscale temperature sensors and the respective positions of the sensors in the channel. | 09-18-2014 |
| 20140273277 | DEVICE AND ASSOCIATED METHODS FOR PERFORMING LUMINESCENCE AND FLUORESCENCE MEASUREMENTS OF A SAMPLE - An apparatus for measuring the luminescence and the fluorescence of a sample, comprising: a light tight optics box capable of receiving a pipette tip containing a sample; an optical sensor located within the optics box and capable of being disposed in both a luminescence reading position and a fluorescence reading position; an excitation light fiber optic bundle and a sample transmission fiber optic bundle; an excitation light assembly that projects excitation light onto a first terminus end of the excitation light fiber optic bundle; and an in-line filter located along the sample transmission fiber optic bundle. | 09-18-2014 |
| 20140273278 | G-QUADRUPLEX BINDING ASSAYS AND COMPOUNDS THEREFOR - The present invention provides methods for assaying binding of compounds to G-quadruplex structures. Also provided are methods for screening candidate compounds for use as modulators of G-quadruplex activity, and methods for screening candidate compounds for telomerase inhibitory activity. The invention further provides novel compounds useful in the assays of the invention. | 09-18-2014 |
| 20140273279 | METHOD FOR DETERMINING THE BINDING CONSTANT OF HIGH AFFINITY COMPOUNDS - The invention relates to a method for determining the binding constant of a compound of interest to proteins comprising the following steps: a) adding the high affinity compound to a two-chamber system, wherein the two chambers are separated by a semipermeable membrane, which is permeable for the compound of interest, and determining the amount of the high affinity compound of interest in one of the chambers after the distribution equilibrium has been reached, b) adding a sink compound to one of the chambers whereby the sink compound can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the sink compound after the distribution equilibrium has been reached, c) adding an unspecific protein to the other chamber, whereby the unspecific protein can not permeate the membrane, and determining the distribution coefficient of the compound of interest to the unspecific protein in presence of a sink compound after the distribution equilibrium has been reached, and d) determining the binding constant of the test compound with the distribution coefficient of steps b) and c). | 09-18-2014 |
| 20140273280 | METHOD FOR DIAGNOSING CHRONIC SINUSITIS - The present invention provides a method for detecting chronic sinusitis, which comprises measuring the concentration of a periostin protein in blood or nasal secretion collected from a test subject. Thereby, a method for detecting chronic sinusitis, which is capable of detecting chronic sinusitis more simply, more promptly and less invasively, is provided. | 09-18-2014 |
| 20140287526 | Nanotube Based Lateral Flow Device for Biomarker Detection - Nanotube based lateral flow test device described herein is a lateral flow based diagnostic device, which uses arrays of fragments of single wall carbon nanotubes as sensor to detect the biomarkers at ultralow concentration (below picogram per milliliter). The device is consisted of the following components: (1). an lateral flow strip which typically is consisted of a backing film laminated with conjugate/sample pads, nitrocellulose membrane, wicking pad, (2). the arrays of single wall carbon nanotube conjugate with antibody which is immobilized on the membrane of the lateral flow device as the test line, (3). pairs of micro-electrode are installed on top part of the cassette, (4). a cassette which holds the lateral flow strip. The device can be used in clinical environments for biomarker detection. | 09-25-2014 |
| 20140287527 | METHOD AND APPARATUS FOR TIME-RESOLVED FLUORESCENCE IMMUNOASSAY TESTING - A method and apparatus for assaying to detect the presence or quantity of an analyte in a test sample, comprising: forming an unbounded aqueous mixture of a first test sample with a defined amount of a nanosphere probe which is conjugate of an analyte capturing member and a long emission fluorescent label, contacting a contacting zone of a test strip with the aqueous mixture, the test area having bound thereat a test binding moiety that for a competition assay binds any sample in competition with the analyte capturing member; or for a sandwich assay binds any sample analyte non-competitively with the analyte capturing member, the control area having bound a control binding moiety to nanosphere probe, selectively measuring long emission fluorescence at the test and control areas, and for a given test strip, determining a test zone value normalized with the total of test and control area signals. | 09-25-2014 |
| 20140287528 | INCORPORATION OF METHYL LYSINE INTO POLYPEPTIDES - The invention relates to A method of making a polypeptide comprising at least one N | 09-25-2014 |
| 20140287529 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR POTENTIAL NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN - Methods for monitoring subject compliance with a prescribed treatment regimen are disclosed. In an embodiment, the method comprises measuring a drug level in fluid of a subject and normalizing the measured drug level as a function of one or more parameters associated with the subject. The drug level can be normalized using second order quantile regression. Embodiments of the methods can use both primary and secondary metabolites in the normalization; allow changing variance by dose; allow asymmetry in variance above and below the estimated median values; and/or use analytic variables with stable estimates, such as, for example, variables associated with the percentile for −1 standard deviation, the percentile for 0 standard deviation, and the percentile for +1 standard deviation. | 09-25-2014 |
| 20140287530 | LIPOPROTEIN ANALYSIS BY DIFFERENTIAL CHARGED-PARTICLE MOBILITY - The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention. | 09-25-2014 |
| 20140287531 | G-QUADRUPLEX BINDING ASSAYS AND COMPOUNDS THEREFOR - The present invention provides methods for assaying binding of compounds to G-quadruplex structures. Also provided are methods for screening candidate compounds for use as modulators of G-quadruplex activity, and methods for screening candidate compounds for telomerase inhibitory activity. The invention further provides novel compounds useful in the assays of the invention. | 09-25-2014 |
| 20140287532 | IMMUNOASSAY METHOD FOR PRO-GASTRIN-RELEASING PEPTIDE - To provide a more convenient and more accurate method of assaying ProGRP by improving the stability of ProGRP which is known to be unstable in a biological sample. | 09-25-2014 |
| 20140287533 | DETECTION OF SURFACE-BOUND MAGNETIC PARTICLES - The invention relates to a method and a sensor device ( | 09-25-2014 |
| 20140295573 | BIOSENSOR WITH DUAL GATE STRUCTURE AND METHOD FOR DETECTING CONCENTRATION OF TARGET PROTEIN IN A PROTEIN SOLUTION - A biosensor with a dual gate structure is disclosed herein. The biosensor comprises: a transistor, a sensing pad, and a plurality of nanostructures. The sensing pad has a conductive area working as another gate and neighboring to the channel layer of the transistor, and a sensing area extended outward from the conductive area to be far away from the channel layer of the transistor, wherein the gate and the conductive area of the sensing pad are separated from each other by the channel layer. The plurality of nanostructures are utilized to bind a first protein to generate a drain current value, when the first protein is combined with the target protein and another drain current value is generated, whereby a variation between the two drain current values is calculated to obtain the concentration of the target protein in the protein solution. | 10-02-2014 |
| 20140295574 | Method of Fabricating Testing Reagent Carrier through Ionizing Radiation - A method is provided for modifying a radioactive carbon nanotube (CNT) carrier. Magnetic molecules are used. The modified CNT is highly specified to disease. Surface of the CNT has functional grafts for catching antigen/antibody. Antigen/antibody thus caught on the surface is increased in number. Thus, the present invention improves sensitivity and accuracy of disease detection and greatly saves cost. The present invention can be applied for sample purification or massive disease detection. | 10-02-2014 |
| 20140295575 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS - Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity. | 10-02-2014 |
| 20140295576 | INSOLUBLE CARRIER FOR USE IN ANTI-PHOSPHOLIPID ANTIBODY MEASUREMENT REAGENT, ANTI-PHOSPHOLIPID ANTIBODY MEASUREMENT REAGENT, AND METHOD FOR MEASURING ANTI-PHOSPHOLIPID ANTIBODY - The present invention has an object to provide an insoluble carrier for an antiphospholipid antibody detection reagent having a high reactivity. The present invention also has an object to provide an antiphospholipid antibody detection reagent, and a method of detecting an antiphospholipid antibody. The present invention directs to an insoluble carrier for an antiphospholipid antibody detection reagent, having a zeta potential of lower than −45 mV in the case that the insoluble carrier is suspended in a 20 mmol/L aqueous sodium phosphate solution with a pH of 7.4 so that the resulting suspension has a solids concentration of 0.1%. | 10-02-2014 |
| 20140295577 | CHEMICAL SENSOR, CHEMICAL SENSOR MODULE, BIOMOLECULE DETECTION APPARATUS, AND BIOMOLECULE DETECTION METHOD - [Object] To provide a chemical sensor capable of detecting a biomolecule with high accuracy, a chemical sensor module, a biomolecule detection apparatus, and a biomolecule detection method. | 10-02-2014 |
| 20140302618 | Clozapine Immunoassay - Novel conjugates and immunogens derived from clozapine and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of clozapine in biological fluids. | 10-09-2014 |
| 20140302619 | APPARATUS FOR CLUSTER DETECTION - The invention relates to a sensor apparatus ( | 10-09-2014 |
| 20140308751 | Assays for Analyte Homologs - Methods include adjusting a contribution of one of two analyte homologs to an amount of signal obtained in an assay for determining a total amount of the two analyte homologs in a sample. A non-assay receptor is employed that has a greater binding affinity for whichever of the two analyte homologs whose contribution to the amount of signal is to be adjusted. An amount of the non-assay receptor is sufficient to achieve an adjustment of the contribution of the analyte homolog to the signal. The assay for determining the total amount of the two analyte homologs is conducted where the assay utilizes at least one assay antibody. | 10-16-2014 |
| 20140308752 | BIOSENSING WELL ARRAY BY SELF-ALIGNMENT AND SELECTIVE ETCHING - The present disclosure provides a biological field effect transistor (BioFET) and a method of fabricating a BioFET device. The method includes forming a BioFET using one or more process steps compatible with or typical to a complementary metal-oxide-semiconductor (CMOS) process. The BioFET device includes a plurality of microwells having a bio-sensing layer and a number of stacked well portions over a multi-layer interconnect (MLI). A bottom surface area of a well portion is different from a top surface area of a well portion directly below. The microwells are formed by removing a top metal plate on a topmost level of the MLI. | 10-16-2014 |
| 20140308753 | METHODS OF DETERMINING LEVELS OF FREE AMINO ACIDS AND DIPEPTIDES AND DIAGNOSING ALZHEIMER'S DISEASE - Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual. | 10-16-2014 |
| 20140308754 | FLOW-VALVE DIAGNOSTIC MICROFLUIDIC SYSTEM - A system for detecting concentration of a target in a solution where sample fluid is passed into a microchannel with wall coated with the receptor that reacts and crosslinks with the target to constrict the channel and slow or stop sample flow through the microchannel. Concentration of the target is determined by measuring length of the sample filled channel. | 10-16-2014 |
| 20140308755 | HMGB1 AND ANTI-HMGB1 ANTIBODIES FOR THE PROGNOSTIC OF NEUROLOGICAL DISORDERS - The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient. | 10-16-2014 |
| 20140308756 | METAL/SILICA CORE/SHELL NANOPARTICLES, MANUFACTURING PROCESS AND IMMUNOCHROMATOGRAPHIC TEST DEVICE COMPRISING SUCH NANOPARTICLES - A core/shell nanoparticle includes at least one core made from at least one first metallic material based on at least one metal exhibiting plasmon resonance in a domain chosen from ultraviolet, visible and near-infrared, and a silica shell, the silica including functional groups, and on its surface, covalently bonded agents for stabilizing the nanoparticle. A core/shell nanoparticle includes a core made from at least the first material and a metallic shell made from a second different material based on at least one metal exhibiting plasmon resonance in a domain chosen from ultraviolet, visible and near-infrared, the metallic shell being stabilized by a halogen-free surfactant. An immunochromatographic test device for detecting at least one analyte, including binders specific to the analyte, the binders being marked by nanoparticles which include at least one core, made from at least the first material, and a silica shell, the silica including functional groups. | 10-16-2014 |
| 20140315326 | Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes - A method is taught for the accurate determination of the premature rupture of membranes (PROM), defined as spontaneous rupture of membranes before the onset of uterine contractions. More specifically, a lateral flow assay strip tests for at least two antigens to greatly limit or eliminate the possibility of false negatives. A built in timer in the cassette holding the lateral flow assay further increases the accuracy of the test. A collection buffer vial with self-contained shipping and dropper caps and built in stand is also taught. | 10-23-2014 |
| 20140315327 | Methods for Measuring Concentrations of Biomolecules - The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention. | 10-23-2014 |
| 20140315328 | SYSTEM AND METHOD FOR THE DETECTION OF ANALYTES BY CONTROLLED AGGREGATION NANOPARTICLES - A method for detecting an analyte in a sample, the method comprising contacting the analyte in a sample with nanoparticles comprising a capture probe for capturing said analyte, the capture probe being configured to act as a centre for controlled aggregation of nanoparticles with said analyte to form an aggregate of predefined form, detecting the analyte by detecting the shape and/or size of the aggregate is provided. Also provided are nanoparticles comprising a capture probe for capturing an analyte, wherein the capture probe is configured to act as a centre for controlled aggregation of nanoparticles with the analyte to form an aggregate of particular detectable size and/or shape, and an assay. | 10-23-2014 |
| 20140322818 | Nanocrystal Based Biomolecule Detection - A new signal amplification method exploiting the dense atom packing in metallic nanocrystals has been developed for detecting target substances. By dissolving nanocrystals to individual ions that are stoichiometrically converted to chromophores and quantified photometrically, extremely high signal amplification can be achieved. Signal amplification is fully determined by the total number of atoms in the nanocrystals bound to a single target molecule. The disclosed nanocrystal amplification method can be implemented with a rich selection of metal/metal oxide nanocrystals and metal-reactive chromogenic substrates. The chromogenic reactions can be either solution-based or surface-based and performed in aqueous or organic phase, supporting a variety of assay formats | 10-30-2014 |
| 20140322819 | DETECTION AND/OR QUANTITATION OF ENDOTOXIN - Detection and/or quantitation of endotoxin using biolayer interferometry is disclosed. | 10-30-2014 |
| 20140322820 | MATERIALS AND METHODS FOR ISOLATING PHOSPHOPEPTIDES - Protein phosphorylation is a major post-translational modification and it plays a pivotal role in numerous cellular functions. We present a composition that includes a soluble nanopolymer core functionalized with groups having an affinity for either metal ion or metal oxides which can be used for phosphopeptide enrichment. Exemplary compounds including PolyMAC-Zr, PolyMAC-Fe and PolyMAC-Ti demonstrate outstanding reproducibility, exceptional sensitivity, fast chelation time, and high phosphopeptide recovery from standard mixtures that include phosphorylated peptides. The composition can be used for phosphoproteome isolation from samples of medicinal, diagnostic or biological interest such as malignant breast cancer cells. Such compositions were used for the quantitative analysis of the changes in the tyrosine phosphoproteome in highly invasive breast cancer cells after induction of Syk kinase, a potent suppressor of tumor growth and metastasis. The composition and method disclosed herein offers an efficient and widely applicable tool for phosphoproteomics. | 10-30-2014 |
| 20140322821 | MOLECULE CAPABLE OF BINDING TO ADRENOCORTICOTROPIC HORMONE, AND USE THEREOF - The present invention relates to a molecule capable of binding to adrenocorticotropic hormone (ACTH) with high affinity. The present invention also relates to use of the molecule for detection and/or purification of ACTH. | 10-30-2014 |
| 20140322822 | Determination of a Midregional Proadrenomedullin Partial Peptide in Biological Fluids for Diagnostic Purposes, and Immunoassays for Carrying out Such a Determination - Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proAM; SEQ ID NO:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proAM. | 10-30-2014 |
| 20140322823 | Metallic Nanoparticle Synthesis with Carbohydrate Capping Agent - The disclosure relates to metal nanoparticle compositions and their methods of formation and use, in particular gold nanoparticles (AuNP) and gold-coated magnetic nanoparticles. Compositions according to the disclosure include aqueous suspensions of metal nanoparticles that are stabilized with one or more carbohydrate capping agents and/or that are functionalized with one or more binding pair members for capture/detection of a target analyte. The nanoparticle suspensions are stable for extended periods and can be functionalized as desired at a later point in time, typically prior to use in an assay for the detection of a target biological analyte. The stable nanoparticle suspension can be formed by the aqueous reduction of oxidized metal precursors at non-acidic pH values in the presence of a carbohydrate-based capping agent such as dextrin or other oligosaccharides. | 10-30-2014 |
| 20140322824 | ADRENOMEDULLIN ASSAYS AND METHODS FOR DETERMINING MATURE ADRENOMEDULLIN - Subject of the present invention is an in vitro method for therapy follow-up in septic patients wherein the concentration of mature ADM 1-52 and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined using an assay comprising two binders that bind to two different regions within the region of mature adrenomedullin and/or adrenomedullin-Gly that is aminoacid 21-52-amid SEQ ID No. 1 or aminoacid 21-52-Gly SEQ ID No. 2 wherein each of said regions comprises at least 4 or 5 amino acids. | 10-30-2014 |
| 20140322825 | LAMBODIES WITH HIGH AFFINITY AND SELECTIVITY FOR GLYCANS AND USES THEREFOR - The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging. | 10-30-2014 |
| 20140322826 | METHOD FOR DETECTION OF BINDING - The present invention relates to a method for detection of binding or interaction events between a binding agent and its corresponding analyte (such as an antibody and an antigen) in which a signal is detected which is substantially more amplified and thus easier to detect than in prior art systems. The method comprises simultaneous but separate addition of a first enhancement reagent having affinity for said analyte and a second enhancement reagent having affinity for the first enhancement reagent wherein the first enhancement reagent binds to the analyte and the second enhancement reagent binds to the first enhancement reagent, and, wherein the first and second enhancement reagents have more than one binding site so that they are able to bind to each other to thereby amplify a detectable signal from the binding event. | 10-30-2014 |
| 20140329334 | METHOD FOR MONITORING, DIAGNOSIS AND/OR PROGNOSIS OF ACUTE KIDNEY INJURY IN EARLY STAGE - The present invention relates to a method and a kit for monitoring, diagnosis, prognosis of acute kidney injury in early stage and determination of treatment in subjects suffering thereof. The method comprises the steps of a) providing a urine sample; b) enriching the urine sample in exosomes present in the urine sample using at least one step of immunopurification; c) detecting an acute kidney injury (AKI) marker in the exosome. The invention also relates to a kit for determining the presence and/or level of a specific kidney injury marker, for simple and early determination of the onset of AKI in a subject, the kit comprising means for enriching the urine sample in exosomes using at least one step of immunopurification, and means for detecting a predetermined kidney injury marker of a condition. | 11-06-2014 |
| 20140329335 | MAGNETIC PARTICLE DETECTION WITH INCUBATION PERIOD - The invention relates to a method and a device for the detection of magnetic particles ( | 11-06-2014 |
| 20140329336 | CHEMICAL SENSOR, CHEMICAL SENSOR MODULE, CHEMICAL SUBSTANCE DETECTION APPARATUS, AND CHEMICAL SUBSTANCE DETECTION METHOD - [Object] To provide a chemical sensor provided with a spectral filter excellent in spectral characteristic, a chemical sensor module, a chemical substance detection apparatus, and a chemical substance detection method. | 11-06-2014 |
| 20140335628 | METHOD OF OBTAINING A BINDER TO PREPRO-VASOPRESSIN OR FRAGMENTS THEREOF - Method of obtaining and/or verifying a binder to prepro-Vasopressin (SEQ ID NO. 1) or fragments thereof of at least 6 amino acids in length, including Copeptin (SEQ ID NO. 2), comprising at least one of the steps of: a) generating the binder using a developer comprising an amino acid sequence of at least 6 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); b) determining whether the binder is capable of binding to an amino acid sequence of at least 4 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); c) selecting and optionally isolating the binder from a plurality of binders which is capable of binding to an amino acid sequence contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); d) carrying out binding assays with the binder in order to determine the ex vivo stability of prepro-Vasopressin or fragments thereof of at least 6 amino acids in length, including Copeptin, in a biological sample; e) carrying out binding assays with the binder and another binder for comparison purposes in order to determine the concentration of prepro-Vasopressin or fragments thereof of at least 6 amino acids in length, including Copeptin, in a biological sample; wherein the C-terminal part consists of amino acids 138 to 164 of prepro-Vasopressin (SEQ ID NO. 1), in order to obtain a binder or a mixture of binders capable of binding to an epitope contained in an amino acid sequence corresponding to amino acids 138 to 163 but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1). | 11-13-2014 |
| 20140335629 | GLYCATED PROTEIN MEASUREMENT SENSOR AND PORTABLE GLYCATED PROTEIN MEASUREMENT APPARATUS INCLUDING SAME - Disclosed are a glycated protein measurement sensor and a portable glycated protein measurement apparatus. The glycated protein measurement sensor includes: a sensing film ( | 11-13-2014 |
| 20140335630 | Methods and Devices for Detection and Measurement of Analytes - Sensors for target entities having functionalized thereon, at least one aptamer specific to the target entity, and methods of making and using the same are described for use in glycated protein monitoring and/or biomarkers. | 11-13-2014 |
| 20140342467 | APPARATUS AND METHOD FOR CONTINUOUSLY MONITORING SUBAQUEOUS TARGET HARMFUL SUBSTANCES - The present invention relates to an apparatus and method for continuously monitoring subaqueous target harmful substances. More particularly, it relates to an apparatus and method for continuously monitoring subaqueous target harmful substances by continuously measuring the concentration of the subaqueous target harmful substances. The present invention provides an apparatus and method for continuously monitoring subaqueous target harmful substances, which can continuously measure the concentration of subaqueous target harmful substances using a receptor that can selectively recognize the target harmful substances, a porous membrane fixed with the receptor, and a sensing unit that continuously measures the intensity of fluorescent signals of the target harmful substance reacting with the receptor, and can be utilized as various apparatuses and methods for continuously sensing various harmful substances necessary to continuously monitor for the management of the water quality. | 11-20-2014 |
| 20140342468 | Single Molecule Assays - The present invention provides single molecule analyses of species of use in analytical, diagnostic or prognostic assays. In exemplary embodiments, the assays utilize samples prepared by novel methods, affording assays of unexpected sensitivity and robustness. The method is described in a non-limiting manner by reference to cytokine assays. | 11-20-2014 |
| 20140342469 | METHOD FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - A method for measuring a specific physiologically active substance of biological origin includes preparing a mixed solution of an AL reagent and a sample containing the physiologically active substance and detecting the aggregation or gelatinization of a protein in the mixed solution while agitating the mixed solution, thereby detecting the physiologically active substance or measuring the concentration of the physiologically active substance in the sample. A predetermined fluorescence emission is imparted to a substance involved in the aggregation or gelatinization in the sample to be measured and/or the AL reagent, and the fluorescence emitted from the substance involved in the aggregation or gelatinization is measured or observed in the mixed solution. In this manner, the aggregation or gelatinization in the mixed solution can be detected. | 11-20-2014 |
| 20140342470 | DEVICE AND METHOD FOR PARTICLE COMPLEX HANDLING - An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte. | 11-20-2014 |
| 20140349411 | METHOD AND SYSTEM FOR DETECTION OF AFLATOXIN - The present invention relates to an aflatoxin-detection device. The aflatoxin-detection device includes a flow path for a test solution and a plurality of nanocompo site strips disposed within the flow path. Each nanocomposite strip of the plurality of nanocomposite strips is arranged in a spaced parallel relationship with a successive nanocomposite strip of the plurality of nanocomposite strips. The plurality of nanocomposite strips exhibit high affinity for aflatoxin. Absorption of aflatoxin induces fluorescence of the plurality of nanocomposite strips. Responsive to a fluorescence intensity of each nanocomposite strip of the plurality of nanocomposite strips, a concentration of aflatoxin in the test solution is determined. | 11-27-2014 |
| 20140349412 | BIOSENSOR SYSTEM FOR SINGLE PARTICLE DETECTION - A biosensor system for the detection of particles includes a biosensor cartridge having a sensor surface. A biosensor magnet assembly is disposed on one side of the cartridge for generating a magnetic field effective at the cartridge and the sensor surface. The biosensor magnet assembly includes at least two magnetic sub-units separated by a gap. A first optical detection system detects the particles arranged at the same side of the cartridge as the magnet assembly. The magnet assembly and the first optical sensor are disposed such that the optical detection is accomplished through the gap of the magnet assembly. | 11-27-2014 |
| 20140356977 | Method and Apparatus for Performing Automated Affinity Based Assays - A method for performing automated affinity based assays for determining an analyte content of samples of a process medium, wherein individual samples are fed in time intervals sequentially to a measuring system, and wherein the measuring system, in each case, registers a measured value of a measured variable dependent on the analyte content of the samples, characterized in that at least one of the samples is diluted before it is fed to the measuring system, wherein a dilution factor to be applied for dilution of a sample is ascertained from a measured value registered based on a sample supplied earlier to the measuring system. | 12-04-2014 |
| 20140356978 | Extraction of Mycotoxins - A method and composition for extracting an analyte from a test sample such as grain, so as to determine whether the test sample is contaminated with a toxin. The method is particularly useful for detecting the presence in a batch of grain of a mycotoxin, such as for example aflatoxin, ochratoxin, T2, zearalanone, vomitoxin (deoxynivalenol a/k/a DON), patulin and fumonisin. Extraction is performed with use of a composition that includes a proteinaceous material, such as albumin, as an extraction agent. | 12-04-2014 |
| 20140363898 | METHOD FOR THE IDENTIFICATION OF BETA-SHEET AGGREGATED PROTEIN LIGANDS - The present invention provides an assay for the identification of beta-sheet aggregated protein ligands using Thiazine Red R. | 12-11-2014 |
| 20140363899 | METHOD FOR AVOIDING INFLUENCE OF ENDOGENOUS LIPOPROTEIN AND REAGENT - To identify the aforementioned interference component present in serum or plasma, to thereby provide means for avoiding any interference effect caused by the component. | 12-11-2014 |
| 20140363900 | Giant Porphyrin-Phospholipid Vesicles - There is provided herein vesicles comprising a bilayer comprising porphyrin-phospholipid conjugate, wherein the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipids, wherein the vesicle is 1-100 microns in diameter. | 12-11-2014 |
| 20140363901 | Device for Use in the Detection of Binding Affinities - A device for use in the detection of binding affinities comprises a planar waveguide ( | 12-11-2014 |
| 20140370616 | LATERAL FLOW IMMUNOASSAY FOR DETECTING VITAMINS - The invention is directed to a method for detecting analytes, particularly vitamins, using a lateral flow immunoassay. The method may be used to detect vitamin D, particularly 25-hydroxy vitamin D | 12-18-2014 |
| 20140370617 | APPARATUS AND METHODS FOR DETECTING ANALYTES - The present invention provides an apparatus for retaining solid state reagents and/or for processing sample for a diagnostic test, where the apparatus avoids liquid “hang-up” that would otherwise result in loss of sample or fluid volume during sample transfer. The invention further provides diagnostic methods that employ the apparatus, so as to provide sensitive and accurate analyte detection. | 12-18-2014 |
| 20140370618 | NUCLEIC ACID MOLECULE HAVING BINDING AFFINITY TO RODENT-DERIVED IGG ANTIBODY, BINDER, DETECTION REAGENT, AND DETECTION KIT - The present invention is to provide a nucleic acid molecule having a binding affinity to a rodent-derived IgG antibody, which can be prepared easier than an antibody and has a binding affinity equivalent or superior to that of an antibody, a binder using the nucleic acid molecule, a detection reagent, and a detection kit. The nucleic acid molecule of the present invention has a binding affinity to a rodent-derived IgG antibody and has a dissociation constant of 1 μM or less. The binder for a rodent-derived IgG antibody of the present invention includes the nucleic acid molecule of the present invention. The detection reagent for detecting a rodent-derived IgG antibody of the present invention includes the binder for a rodent-derived IgG antibody of the present invention. The detection kit for detecting a rodent-derived IgG antibody of the present invention includes the detection reagent for detecting a rodent-derived IgG antibody of the present invention. | 12-18-2014 |
| 20140370619 | METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE - The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for Aβ amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided. | 12-18-2014 |
| 20140370620 | MULTIMER TYPE DISCRIMINATION AND DETECTION METHOD FOR MULTIMER-FORMING POLYPEPTIDE - The present invention relates to a method for selectively detecting a multimer type multimer-forming polypeptide in a biological sample, the method comprising: (a) bringing the biological sample into contact with an agglutination reaction inducing agent to induce the formation of an aggregate in an analysis target, the agglutination reaction inducing agent being a particle in which a specific antibody is surface-bonded with the multimer-forming polypeptide; (b) obtaining an image with respect to the aggregate of step (a); and (c) analyzing a size or a shape of the aggregate by using the image. Step (a), step (b), or steps (a) and (b) are performed on a microchip having a microchannel. The image analysis is performed using a coefficient according to the size of the aggregate in a predetermined volume provided by the microchannel. In the case where the multimer type of multimer-forming polypeptide is present in the biological sample, the size of the aggregate is larger than the size of an aggregate of a monomer type control group. According to the present invention, unlike in a detection method using chemiluminescence immunoanalysis of the related art, an image with respect to an agglutination reaction target is obtained and then a size or a shape of an aggregate is analyzed so as to determine whether or not an analysis target is present in a biological sample and to determine the quantity of the analysis target. Also, it is possible to detect a multimer type multimer-forming polypeptide by just analyzing an image acquired from the sample so that the detection process is made more convenient and quick. | 12-18-2014 |
| 20140377881 | LATEX PARTICLES FOR MEASURING PARTICLE AGGLUTINATION - Latex particles for a particle agglutination assay, with which it is possible to carry out high-sensitivity assay while highly suppressing a non-specific reaction are disclosed. The latex particles being obtained by emulsion polymerization with a polymerizable monomer having a phenyl group, and a polymerizable monomer having a phenyl group and a sulfonate in an aqueous medium including a nonionic surfactant at a concentration of 0.005 to 0.02 wt % based on the aqueous medium, the latex particles having an average particle size of 0.005 to 1.0 μm. | 12-25-2014 |
| 20140377882 | MAGNETIC MATERIAL FOR COLLECTING MAGNETIC PARTICLES AND UTILIZATION THEREOF - For collecting magnetic particles, there is used a magnetic material including a plurality of magnets that are arranged in contact one with another in parallel to a direction of magnetization in such a manner that south and north poles of adjacent magnets are reversed alternately or a magnetic material having at least one peak of a magnetic force in a magnetic pole surface, and the peak magnetic force is 600 gausses or more. | 12-25-2014 |
| 20140377883 | PERIPHERIN-SPECIFIC AUTOANTIBODIES AS A MARKER FOR NEUROLOGICAL AND ENDOCRINOLOGICAL DISEASE - The present invention provides for methods and materials for detecting a peripherin-specific autoantibody, which can be associated with neurological and endocrinological disease. | 12-25-2014 |
| 20150011014 | Method Of Manufacturing And Applications Of Biofunctionalized Amorphous Metal Colloidal Suspensions - Disclosed is a process for enhancing the sensitivity of magnetic detection of molecules of interest. The process comprises creating amorphous magnetic metal nanoparticles from a bulk target material comprising at least one magnetic transition metal selected from the group consisting of Ni, Co, and Fe and at least one glass former selected from the group consisting of P, B and Si through the use of a pulsed laser ablation method. The produced amorphous magnetic metal nanoparticles have a large magnetic moment and a large magnetic permeability especially compared to crystalline nanoparticles. One use of the present nanoparticles is in a magnetic immunoassay method. | 01-08-2015 |
| 20150011015 | SENSOR CHIP FOR SPFS MEASUREMENT, SPFS MEASUREMENT METHOD USING SENSOR CHIP FOR SPFS MEASUREMENT, AND SPFS MEASUREMENT DEVICE EQUIPPED WITH SENSOR CHIP FOR SPFS MEASUREMENT - [Problem] To provide a sensor chip for SPFS measurement, by which, irrespective of environmental conditions, fluctuations are low in characteristics such as signal, noise, or detection sensitivity, quantitative property can be ensured, and a highly precise and accurate SPFS measurement can be carried out. [Solution] A sensor chip for SPFS measurement which has a dielectric member having been produced by carrying out injection molding of a resin, when viewing from the metal thin film-formed surface side of the dielectric member and taking as b the distance of the side end surface position of the resin inlet to the position on the metal thin film-formed surface that is farthest from the side end surface position of the resin inlet, the center of a ligand immobilization part is located in the area between the 3b/8 position and the 6b/8 position from the side end surface position of the resin inlet. | 01-08-2015 |
| 20150011016 | Dispersive Pipette Extraction Tip and Methods for Use - A pipette tip device for use in dispersive SPE. The device includes a pipette tip having a lower barrier, loose sorbent that is freely moveable during the extraction process, and a baffle system that is shaped to disrupt the flow of liquid sample that is aspirated into the pipette tip. The baffle system includes an insert that may be separate from or monolithic with the interior of the pipette tip. | 01-08-2015 |
| 20150011017 | DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. | 01-08-2015 |
| 20150011018 | DEVICE AND METHODS FOR THE IMMUNOLOGICAL IDENTIFICATION OF CEREBROSPINAL FLUID - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability. | 01-08-2015 |
| 20150011019 | EARLY BIOMARKERS OF AGE-RELATED LOW-GRADE INFLAMMATION - The present invention relates to a method for predicting the risk of acquiring an age-related low-grade inflammation for a subject, said method comprising a) providing a biological sample from a subject, b) determining in said sample the level of at least one biomarker selected from the group consisting of a compound of molecular weight between 859-863 g/mol and which is an alkylacylphosphatidylcholine, a compound of molecular weight between 861-865 g/mol and which is a diacylphosphatidylcholine, a compound of molecular weight between 791-794 g/mol and which is an alkylacylphosphatidylcholine, a compound of molecular weight between 522-525 g/mol and which is a monoacylphosphatidylcholine, octadecanoylcarnitine (C18), and tryptophan, c) comparing the level of the at least one biomarker to a reference level, and d) determining whether said subject is likely to be at risk of acquiring an age-related low-grade inflammation, when the level of biomarker(s) deviate significantly from the respective reference level. | 01-08-2015 |
| 20150011020 | SYSTEM AND METHOD FOR DETECTION OF TARGET SUBSTANCES - A system and method for detecting harmful substances within a consumable sample comprising: receiving a consumable sample at a first chamber of a test container; transforming the consumable sample into a homogenized sample upon processing of the consumable sample; delivering the homogenized sample to a second chamber of the test container, wherein the second chamber is configured to receive the homogenized sample comprises an outlet port; mixing the homogenized sample with a process reagent within the second chamber, thereby producing a dispersion; transmitting a volume of the dispersion to an analysis chamber, of the test container, configured to position a detection substrate proximal the port of the second chamber and comprising a detection window that enables detection of presence of the allergen; and detecting presence of the allergen within the consumable sample by way of an optical sensor configured to detect signals indicative of the allergen through the detection window. | 01-08-2015 |
| 20150017739 | CONFORMATIONAL-SWITCHING FLUORESCENT PROTEIN PROBE FOR DETECTION OF ALPHA SYNUCLEIN OLIGOMERS - A conformation-switching fluorescent protein probe for detection of alpha synuclein oligomers. The use of intrinsically disordered proteins as conformation-switching biosensors. The use of an alpha synuclein (αS) variant, PG65, together with conformation-sensitive fluorescence to create a molecular probe for rapid, specific and quantitative detection of αS oligomers. | 01-15-2015 |
| 20150017740 | MOLECULAR SENSOR BASED ON VIRTUAL BURIED NANOWIRE - The present invention provides a method and a system based on a multi-gate field effect transistor for sensing molecules in a gas or liquid sample. The said FET transistor comprises dual gate lateral electrodes (and optionally a back gate electrode) located on the two sides of an active region, and a sensing surface on top of the said active region. Applying voltages to the lateral gate electrodes, creates a conductive channel in the active region, wherein the width and the lateral position of the said channel can be controlled. Enhanced sensing sensitivity is achieved by measuring the channels conductivity at a plurality of positions in the lateral direction. The use of an array of the said FTE for electronic nose is also disclosed. | 01-15-2015 |
| 20150024512 | METHOD FOR SELECTIVELY QUANTIFYING A-BETA AGGREGATES - The invention relates to methods for selectively quantifying A-beta aggregates, comprising the immobilization of anti-A-beta antibodies on a substrate, application of the sample to be tested onto the substrate, addition of probes labeled for detection, which mark these by specific binding to A-beta aggregates and detection of the marked aggregates. | 01-22-2015 |
| 20150024513 | NOVEL METHOD FOR DETECTING ANTIGEN, AND APPARATUS USING SAME - The present invention provides a method for detecting an antigen in an analysis sample, the method including: (a) contacting an analysis sample with a detection antibody with which a marker generating a detectable signal is combined and which specifically binds to the antigen; (b) contacting a capture antibody with the resultant product of step (a), the capture antibody specifically binding to an antigen to be detected; (c) contacting the detection antibody, with which the marker generating a detectable signal is combined, with a reference substance which is bound to a surface of a solid substrate and which includes an epitope to which the detection antibody specifically binds; (d) measuring signals generated from the markers of the resultant product of step (b) and the resultant product of step (c); and (e) analyzing the measured signals to determine the presence or absence and amount of the antigen in the analysis sample. The method for detecting an antigen of the present invention can control the flow and the reaction time of an analysis sample, thereby improving sensitivity and minimizing the influences by the concentration of the analysis sample or the temperature of the detection reaction, and thus improving stability, reliability, and reproducibility of data, when compared with the conventional method for detecting an antigen. Accordingly, the method and apparatus for detecting an antigen of the present invention can be easily operated without specialized skills, thereby instantly obtaining the presence or absence and amount of detection antigen in the analysis sample through on-site diagnosis. | 01-22-2015 |
| 20150024514 | METHOD AND DEVICE FOR DETECTING ANALYTES - The present invention relates to a method for determining analytes and to a device suitable for this purpose. | 01-22-2015 |
| 20150037905 | RISK MARKERS FOR CARDIOVASCULAR DISEASE - Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy. | 02-05-2015 |
| 20150037906 | ODOR ADSORBENT MATERIAL, ODOR DETECTION KIT, AND METHOD FOR USING SAME - An odor adsorbent material, an odor detection kit, and a method for using the same for rapidly identifying a facility where binding of an odor component had occurred among facilities used in a distribution route of a commodity. The odor detection kit includes at least two pieces of an odor adsorbent material, a package section that includes at least two storage sections and is configured to store the odor adsorbent material, and a sheet section. The odor detection kit is installed in a facility. At least one of the pieces of the odor adsorbent material is exposed to open space in the facility, recovered therefrom, and sealed and stored. At the time of testing, occurrence of odor emission in the facility is determined by comparing odor components adsorbed by each of the pieces of the odor adsorbent material. | 02-05-2015 |
| 20150037907 | METHODS AND KITS FOR DETECTION OF ACTIVE MALIGNANY - Various embodiments of methods and kits are disclosed for detection and/or diagnosis of cancer (e.g., active malignancy) in a subject patient by analyzing a first sample of the subject patient's albumin-containing extracellular fluid (e.g., blood serum). Some embodiments comprise analyzing a second sample of the subject patient's albumin-containing extracellular fluid obtained between 2 and 90 days (e.g., between 5 and 30 days) after the first sample. | 02-05-2015 |
| 20150037908 | NEW METHOD FOR RAPID DETECTION OF HEPATOCYTE GROWTH FACTOR IN BIOLOGICAL FLUIDS - The present invention relates to a method for determining the presence, absence or amount of biologically active HGF in a sample, comprising the steps (i) bringing the sample in contact with a first porous solid phase comprising a HGF binding component of the extracellular matrix or cell membrane, and an indicator composition comprising bromothymol blue and a quaternary ammonium compound; and (ii) correlating the colour of the porous solid phase with the presence, absence or amount of biologically active HGF in the sample. It further relates to a device comprising a first porous solid phase comprising at least one HGF-binding component of the extracellular matrix or cell membrane, and an indicator composition comprising bromothymol blue and a quaternary ammonium compound. | 02-05-2015 |
| 20150037909 | Electronic Nose or Tongue Sensors - The present invention relates to a sensor for an electronic tongue or nose for analysing a sample or detecting a target. The sensor comprises a support, on one surface of which a plurality of sensitive areas are located, each sensitive area comprising at least one receptor and being capable of transmitting a measurable signal generated by the interaction of at least one constituent of the sample or one target with at least one receptor. The sensor is characterised in that it comprises at least three sensitive areas that differ from one another in terms of their respective receptor compositions, at least one of the sensitive areas comprising a mixture of at least two different receptors, while the two other sensitive areas each comprise at least one of the two receptors. | 02-05-2015 |
| 20150044778 | EXTERNAL FIELD -FREE MAGNETIC BIOSENSOR - A biosensor includes a magnetic structure having grooved surface to biologically bond magnetic labels to a biological substance within the grooves. The grooves are positioned within the magnetic structure so that stray magnetic fields from the magnetic structure magnetize magnetic labels within the groove. The magnetic labels may be magnetic nanoparticles or magnetic microbeads. The techniques may reduce or eliminate the usage of any external magnetic field generator, e.g., electromagnets or current lines. | 02-12-2015 |
| 20150044779 | STABILIZED LOW AFFINITY CONFORMATION OF INTEGRINS FOR DRUG DISCOVERY - The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation. | 02-12-2015 |
| 20150044780 | MULTI-APPLICATION APPROACH FOR PHOTOMETRIC DETERMINATION OF AN ANALYTE IN A FLUID SAMPLE ON AN AUTOMATED ANALYZER - A method for determining the amount of specific analyte of a sample which may show interferences by photometric assays, wherein the analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific reagents. Multiple calibration curves are generated for multiple wavelengths for the specific analyte. An interference test is performed simultaneously to the determination of the specific analyte, for quantifying the amount of interfering substances present in the sample. The amount of each interfering substances is compared to predetermined cut-off values. The optical signal for the specific analyte is measured in the reaction mixture at multiple wavelengths over the complete reaction time, and a calibration curve is selected depending on the interfering substances. The amount of specific analyte is quantified by comparison with the selected calibration curve for the chosen wavelengths. | 02-12-2015 |
| 20150050747 | DIRECTED DNA CO-POLYMER MASS AMPLIFICATION FOR ssDNA DETECTION - The disclosure generally relates to the use of a bio-barcode (BBC) method for capture and demonstrates hybridization co-polymerization amplification readout of the BBC as a method of rapid detection of single stranded DNA output with an increased sensitivity for the initial target input to the BBC assay. The BBC assay reporter ssDNA can be modified for rapid readout. Two ssDNA molecules are designed to co-polymerize and then continually hybridize into double stranded DNA. The double stranded DNA can be optically and/or electrically detected. Kits related to the two ssDNA molecules and the BBC assay also are disclosed. | 02-19-2015 |
| 20150050748 | TEST DEVICE, REACTION APPARATUS AND REACTIVE TEST METHOD - A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times. | 02-19-2015 |
| 20150056719 | Universal Rapid Diagnostic Test Reader with Trans-Visual Sensitivity - A universal rapid diagnostics test reader is disclosed and described herein that includes a set of control electronics, a digital camera component, an illumination component, a housing component, and a rapid diagnostics test tray, wherein the tray can hold at least one rapid diagnostics test having a shape and a size in a fixed position relative to the digital camera component and the illumination component, and wherein the reader can accommodate more than one different rapid diagnostics test. Methods are also disclosed that include: providing at least one first rapid diagnostics test having a first physical size, first feature and first format; providing at least one second rapid diagnostics test having a second physical size, second feature and second format; inserting the first rapid diagnostics test in a universal rapid diagnostics test reader; analyzing the first rapid diagnostics test using the universal rapid diagnostics test reader; removing the first rapid diagnostics test from the reader; inserting the second rapid diagnostics test in a universal rapid diagnostics test reader without any mechanical adjustments of the reader or without the use of any additional parts or additional inserts; and analyzing the second rapid diagnostics test using the universal rapid diagnostics test reader. | 02-26-2015 |
| 20150056720 | DEVICE AND METHOD FOR ANALYZING TARGET - The present invention provides a novel sensor for detecting a target. The nucleic acid sensor of the present invention includes a nucleic acid element that includes a catalyst nucleic acid molecule (D) that exerts a catalytic function and a binding nucleic acid molecule (A) that binds to a target. The nucleic acid element is a double-stranded nucleic acid element including a first strand and a second strand. The first strand (ss1) includes the binding nucleic acid molecule (A), a loop-forming sequence (L1), and the catalyst nucleic acid molecule (D) linked in this order. The second strand (ss2) includes a stem-forming sequence (S | 02-26-2015 |
| 20150056721 | SNTF IS A BLOOD BIOMARKER FOR THE DIAGNOSIS AND PROGNOSIS OF SPORTS-RELATED CONCUSSION - The invention relates to methods for providing prognosis, diagnosis, monitoring and treatment of a mild traumatic brain injury (mTBI) in a subject, including a sports-related concussion. The invention further relates to assessing the severity of brain damage resulting from mTBI in a subject, including in a subject who has not undergone a CT scan following the injury. For example, the methods of the invention can be used to determine the suitability for someone who has suffered a sports-related injury to return to play that sport. This invention also relates to methods of predicting risk for developing brain damage and long-term dysfunction in a subject having suffered mTBI. | 02-26-2015 |
| 20150064800 | DIAGNOSTIC DEVICES, METHODS AND SYSTEMS FOR DETECTING PLATELET FACTOR 4 (PF4)/HEPARIN ANTIBODIES - The present invention provides a novel assay for detecting human antibodies specific for a platelet factor 4 (PF4)/heparin complex in a fluid sample. The assay utilizes an immobilized PF4/polyanion complex and an anti-human antibody conjugated to a non-particulate fluorescent dye to capture and detect human PF4/heparin antibodies. Various devices, methods and systems based on the disclosed PF4/heparin assay are also provided. | 03-05-2015 |
| 20150064801 | METHOD FOR PRODUCING REAGENT FOR ANTIBODY DETECTION AND USE THEREOF - The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection produced by the production method; and a use of the antibody. In a step for solubilizing an antigen protein, it is possible to efficiently solubilize and recover the antigen protein by using a cationizing agent; therefore, when compared to conventional methods, it is possible to efficiently produce a reagent for detecting an antibody that has bound to multiple antigen protein molecules in a carrier. | 03-05-2015 |
| 20150064802 | MODULE TRANSPORT SYSTEM THAT CAN BE COMBINED INTO AN AUTOMATION SYSTEM - An integrated automation system for use in transporting samples between modules, the system can include a plurality of modules configured to be connected to one another for processing samples, each of the plurality of modules having an internal transport system. Each internal transport system includes one or more periphery track portions integrated within a respective module, each of the periphery track portions having two ends and one or more transverse track portions integrated within the respective module, the one or more transverse track portions intersecting at least one of the one or more periphery track portions. The internal transport systems can be configured to connect to one another via one end of the two ends connecting to one end of the two ends of adjacent periphery track portions, thereby forming a continuous periphery track running through and connecting the plurality of modules. Samples are transported along the continuous periphery track and the one or more transverse track portions. The continuous periphery track and the one or more transverse track portions form a plurality of paths along which the samples are transported. | 03-05-2015 |
| 20150064803 | TEST MASS COMPENSATION OF MASS MEASUREMENT DRIFT IN A MICROCANTILEVER RESONATOR - The present disclosure provides methods and mechanisms for measuring small masses attached to a substrate within a microcantilever. Specifically, the disclosure describes the measurement of small particles accumulated at a substrate that cannot be flowed through a microchannel within a microcantilever. A resonance measurement is acquired at a first time. A pair resonance measurements is then acquired at a second point in time one with the test mass at a first position off or along the microcantilever, the second with the test mass at a second position along the microcantilever. Comparing the resonance frequencies determined for the two test mass positions allows for disambiguation of changes in the mass of the particles from changes in the resonant behavior of the microcantilever itself. | 03-05-2015 |
| 20150072438 | COMPOUNDS AND METHODS FOR PREPARATION OF CONJUGATE REAGENTS - Compositions are disclosed that include a support having on a surface thereof at least an inner polysaccharide layer and an outer polysaccharide layer. The outer polysaccharide layer has pendant moieties each comprising a terminal amine functionality. The point of linkage of the pendant moiety to the outer polysaccharide layer does not comprise an amide bond. The composition may be employed in a method of conjugating a member of a specific binding pair to a particle. The method comprises reacting the terminal amine functionality of the composition with the member of the specific binding pair, which comprises an amine-reactive functionality. | 03-12-2015 |
| 20150079695 | METHOD FOR PROCESSING PRIORITY SAMPLES THAT PRESERVES A FIFO PROCESSING QUEUE - Methods and systems for processing samples in an analyzer utilizes a track system with a plurality of track portions. A queue of samples for processing can be handled on a first portion, while priority samples may be handled on another portion. An instrument in a module may process samples in queues and priority samples. The instrument may process priority samples while a queue of samples remains on the first portion and resumes processing the queue of samples along the first portion upon completion of processing the priority sample. | 03-19-2015 |
| 20150079696 | PROGNOSIS OF ADVERSE EVENTS IN PATIENTS WITH SUSPECTED CHRONIC HEART FAILURE - The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT). | 03-19-2015 |
| 20150079697 | Devices For Detecting Airborne Contaminants, And Associated Methods - A device for detecting an airborne contaminant includes (a) a reactive polymer film having affinity for binding with the airborne contaminant, (b) an electrically conductive polymer film in contact with the reactive polymer film and having electrical property sensitive to binding of the airborne contaminant to the reactive polymer film, and (c) two electrodes in electrical contact with the electrically conductive polymer film for measuring the electrical property to detect the binding of the airborne contaminant to the reactive polymer film. Another device for detecting an airborne contaminant includes (a) a polymer film molecularly imprinted with the airborne contaminant, and (b) color reporting molecules having color sensitive to binding of the airborne contaminant to the polymer film. A method for manufacturing a device for detecting an airborne contaminant includes depositing, using one or more inkjet print heads, a polymer film and at least two electrodes onto a substrate. | 03-19-2015 |
| 20150087079 | MICROFLUIDIC DEVICE, SYSTEM AND METHOD - A combination of capillary forces and gas pressure is used to control the movement of liquid samples within a microfluidic device. A liquid sample introduced to a proximal portion of a capillary channel of a microfluidic device moves by capillary action partway along the capillary channel. As the liquid sample moves, a pressure of a gas acting upon a distal gas-liquid interface of the liquid sample increases by an amount sufficient to stop further movement of the liquid sample. To initiate further movement of the liquid sample, a pump connected to a distal portion of the capillary channel decreases the pressure of the gas acting upon the distal gas-liquid interface of the liquid sample by an amount sufficient to permit the liquid sample to move by capillary action further along the capillary channel of the microfluidic device. | 03-26-2015 |
| 20150093839 | METHODS AND SYSTEMS FOR DETECTION OF TARGET AND APPLICATIONS THEREOF - A method of recovering a target from a sample is provided. The method of recovering the target follows different steps. The steps include providing a binding element, wherein the binding elements are immobilized on a solid support, adding the sample comprising the target to the binding element to form a binding element-target complex; washing the binding element-target complex; and eluting the target from the binding element-target complex. The system for reversible detection of target in a range from 2 to 1,000,000 bind/release cycles is also provided. | 04-02-2015 |
| 20150093840 | ENZYME-FREE COLORIMETRIC IMMUNOASSAY - A colorimetric immunoassay of the present invention uses nanostructured material with high absorption and high scattering ability as a label material for biosensors. Subject matters to be measured may be characterized or quantified by determining the changes in optical properties of the nanostructured material. The biosensor of the present invention may be operated in broad light wavelength range and detected by direct observation with naked eye. The biosensor of the present invention may be also provided with advantages such as higher sensitivity and lower cost. | 04-02-2015 |
| 20150099311 | Systems and Methods for Conducting Animal Studies - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. | 04-09-2015 |
| 20150099312 | PROCESS FOR NORMALIZING THE CONCENTRATION OF ANALYTES IN A URINE SAMPLE - Process for normalizing the concentration of at least one analyte in a urine sample, comprising the following steps:
| 04-09-2015 |
| 20150104877 | USE OF DISULFIDE BONDS TO FORM A REVERSIBLE AND REUSABLE COATING FOR NANOFLUIDIC DEVICES - A reusable coating for a nanopore structure is disclosed herein. A nanopore structure includes a substrate comprising a nanochannel and a monolayer of a chemical compound disposed onto at least a portion of a surface of the nanochannel. The chemical compound forms a reversible bond with at least one analyte binding compound introduced into the nanochannel. Methods for making and using the reusable coating are also disclosed. | 04-16-2015 |
| 20150104878 | METHODS OF TRIGGERING ACTIVATION OF ENCAPSULATED SIGNAL-GENERATING SUBSTANCES AND APPARATUS UTILISING ACTIVATED SIGNAL-GENERATING SUBSTANCES - Methods are disclosed for performing a bioassay, comprising activating capsules containing a signal precursor that is hydrolysable from a latent form in which substantially no signal is generated to a form in which it is able to generate a detectable signal, said activating comprising treating said capsules with heat and with an acid or a base catalysing solution, the combination of said heat and the pH of the catalysing solution being such as to hydrolyse said precursor to the form in which it is able to generate a detectable signal. | 04-16-2015 |
| 20150104879 | COMPOSITION FOR DIAGNOSING LIVER CANCER AND METHODS OF DIAGNOSING LIVER CANCER AND OBTAINING INFORMATION FOR DIAGNOSING LIVER CANCER - Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions. | 04-16-2015 |
| 20150104880 | ANALYTE DETECTION METHOD, FLUORESCENCE DETECTION METHOD, AND FLUORESCENCE DETECTION APPARATUS USING SAME - Disclosed is an analyte detection method for detecting an analyte contained in a biological sample, constituted by irradiating a light of a first peak wavelength on a complex containing an analyte and fluorescent substance which gives off light of a second peak wavelength of 450 nm or higher but not exceeding 900 nm when irradiated with light of the first wavelength of 190 nm or higher but not exceeding 350 nm, detecting the light of the second peak wavelength given off by the fluorescent substance when irradiated by light of the first peak wavelength, by a photodetector, wherein the photodetector has a quantum efficiency in the second peak wavelength that is two or more times the quantum efficiency in the first peak wavelength. | 04-16-2015 |
| 20150104881 | SGLT2 AS BIOMARKER FOR DIAGNOSING CHRONIC KIDNEY DISEASE AND MONITORING THE DISEASE STATUS AFTER TREATMENT - The present invention relates to a method for diagnosis of a chronic kidney disease in a subject by detecting the expression level of a sodium-glucose linked transporter 2 (SGLT2) protein in urine samples. A method for monitoring progression of a chronic kidney disease in a patient is also provided. | 04-16-2015 |
| 20150111306 | HEMOGLOBIN A1c-SPECIFIC APTAMER, HEMOGLOBIN-SPECIFIC APTAMER, AND APPLICATIONS THEREOF - The present invention provides a Hemoglobin A1c-specific aptamer and a Hemoglobin-specific aptamer. The aptamers were selected in vitro using SELEX and a microfluidic chip system. The aptamers established low free energy, thus were more stable than conventional antibodies. The high specificity of the aptamers to Hemoglobin A1c or Hemoglobin allows them to be effectively used in diagnosis of diabetes and/or anemia. | 04-23-2015 |
| 20150111307 | Organic Colored Microparticles, Diagnostic Reagent Kit Containing the Same, and In Vitro Diagnosis Method - Provided are an immunochromatography kit that is highly sensitive and capable of multicoloration, and organic colored microparticles that are ideal as an element of the immunochromatography kit. Organic colored microparticles having an average grain size between 10 and 1,000 nm and a color intensity between 1.0 and 5.0 are prepared using cellulose as the starting material. When the organic colored microparticles are used as a label in an immunochromatography kit, the immunochromatography kit is of a high sensitivity than conventional technology. The immunochromatography kit is also capable of multicoloration and is useful for rapid diagnosis. | 04-23-2015 |
| 20150111308 | COMPOSITIONS COMPRISING MODIFIED COLLAGEN AND USES THEREFOR - The invention provides modified collagen and related therapeutic and diagnostic methods. | 04-23-2015 |
| 20150118763 | DETECTION OF SYNTHETIC CANNABINOIDS - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits. | 04-30-2015 |
| 20150125964 | Detection of Diagnostic Peptides - An assay for citrullinated fragments of SOCS-2, Alpha 1 anti tyrpsin, versican, biglycan, laminin, or other protein having a terminal antibody binding site comprising citrulline in a blood derived sample shows diagnostic relevance in relation to rheumatoid arthritis or fibrotic disease. | 05-07-2015 |
| 20150125965 | BIOSENSOR UTILIZING A RESONATOR HAVING A FUNCTIONALIZED SURFACE - Systems and methods for detecting the presence of biomolecules in a sample using biosensors that incorporate resonators which have functionalized surfaces for reacting with target biomolecules. In one embodiment, a device includes a piezoelectric resonator having a functionalized surface configured to react with target molecules, thereby changing the mass and/or charge of the resonator which consequently changes the frequency response of the resonator. The resonator's frequency response after exposure to a sample is compared to a reference, such as the frequency response before exposure to the sample, a stored baseline frequency response or a control resonator's frequency response. | 05-07-2015 |
| 20150132859 | VIBRIO CHOLERAE LIPOPROTEIN 15 (Lp15) VARIANTS AS ANTI-INTERFERENCE ADDITIVE IN TpN17-BASED IMMUNOASSAYS FOR DETECTION OF ANTI-TREPONEMA ANTIBODIES - The invention relates to a method for detecting antibodies against the TpN17 antigen of | 05-14-2015 |
| 20150132860 | CLINICAL DIAGNOSTIC SYSTEM INCLUDING INSTRUMENT AND CARTRIDGE - In embodiments disclosed herein, a diagnostic system is provided having a cartridge comprising at least one needle; at least one reservoir; at least one fluidic seal; and at least one fluidic channel of a fluidic pathway, wherein the cartridge is configured to store at least one reagent and at least one waste material on the cartridge. The diagnostic system is provided also having a diagnostic instrument comprising the fluidic pathway; an electrochemiluminescence (ECL) detection system; and a pump, wherein the fluidic pathway begins and ends in the cartridge and has a substantially single direction of flow in a pathway fluidically connecting the diagnostic instrument and the cartridge. | 05-14-2015 |
| 20150132861 | CLINICAL DIAGNOSTIC SYSTEMS - A diagnostic system is provided herein that includes an instrument comprising an electrochemiluminescence (ECL) detector, and a cartridge configured to fit within a portion of the instrument, wherein the cartridge includes at least one reagent including an ECL label and a blood collection holder. Also provided herein is a system that includes a diagnostic instrument, which includes a pump, an ECL detector, an incubator, a magnet, and an output device, and a cartridge configured to fit within a portion of the diagnostic instrument, a sample holder configured to fit within the cartridge, and a closed fluidic loop between the diagnostic instrument and the cartridge when the cartridge is fit within a portion of the diagnostic instrument, wherein the cartridge is configured to accept a sample from the sample holder and place the sample in fluidic communication with the diagnostic instrument via the closed fluidic loop. | 05-14-2015 |
| 20150140679 | COMPOSITIONS AND METHODS FOR LIQUID MIXING ASSESSMENT - Compositions include an aqueous solution of an organic dye of molecular weight in the range of about 300 to about 1,000 and a density-enhancing material. An amount of the density-enhancing material in the aqueous solution is sufficient to achieve a density of about 1.0 to about 1.3 g/mL. The composition has a viscosity of about 3.5 to about 5.0 centipoise. The compositions are useful in assessing the adequacy of a liquid handling mixing device to mix a reaction mixture. | 05-21-2015 |
| 20150140680 | INTEGRAL LABEL-FREE BIOSENSOR AND ANALYSIS METHOD USING THE SAME - Disclosed is an integral label-free biosensor capable of analyzing a biomolecule with high sensitivity by integrating a light source, a photodetector, an optical waveguide, and a microcantilever on a substrate, and a method of detecting a bio-antigen by using the same. The integral label-free biosensor according to the present invention may be manufactured with low cost, be easily integrated with a silicon electron device, and detect a biomolecule with high sensitivity by using a label-free method. | 05-21-2015 |
| 20150140681 | Liquid specimen cup including movable caddy and translucent adulteration panel - A fluid specimen collection, storage, transport, and testing cup contains a chromatographic strip-carrying caddy which moves between an initial position allowing a deposited liquid specimen to contact the test strips, and a second, sealed position where the strips are hermetically isolated from a remainder portion of the specimen stored for later confirmatory testing. The caddy is moved between the two positions by screwing a threaded lid onto the top opening of the cup. The axial range of the screw is limited by a removable obstruction collar. The caddy can include a liquid specimen containing chamber having a lower opening sealed by a frangible barrier. The strips can be loaded in a cartridge mountable to the caddy. An adulteration panel having a transparent adhesive backed fronting can secure adulteration patches to the caddy. | 05-21-2015 |
| 20150140682 | IRIDIUM-BASED COMPLEXES FOR ECL - The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte. | 05-21-2015 |
| 20150140683 | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF - Herein is a fusion polypeptide with the formula R1-FC-R2, wherein R1 denotes a first Fc-receptor, R2 denotes a second Fc-receptor, and FC denotes a heavy chain Fc-region polypeptide, wherein R1 or R2 or both are present, wherein FC does not substantially bind to R1 and/or R2 and uses thereof. | 05-21-2015 |
| 20150147821 | SYSTEMS AND METHODS FOR DETECTING MOLECULAR INTERACTIONS USING MAGNETIC BEADS - Systems and methods are provided for detecting or measuring binding affinity between different compositions. The methods include contacting one or more magnetic beads having a surface including a first composition with a substrate having a surface including a second composition; applying a rotating magnetic field to the one or more magnetic beads effective to cause the one or more magnetic beads to move across the surface of the substrate; measuring the movement of the one or more magnetic beads across the substrate surface to determine a translational velocity; and determining a binding affinity between the first and second compositions from the translational velocity. | 05-28-2015 |
| 20150147822 | ASSAYS - The invention provides an assay for assessing the conformational stability of a membrane protein, comprising: (a) providing a sample comprising a first population and a second population of a membrane protein; wherein the membrane protein in the first population is labelled with a donor label and the membrane protein in the second population is labelled with an acceptor label, or the membrane protein in the first population is labelled with an acceptor label and the membrane protein in the second population is labelled with a donor label, (b) exposing the first and second populations of the membrane protein to a stability modulating agent and/or condition, (c) and assessing aggregation between membrane proteins of the first and second populations by activating the donor label to permit a distance-dependent interaction with the acceptor label, which interaction produces a detectable signal. | 05-28-2015 |
| 20150147823 | METHODS AND COMPOSITIONS FOR PERSONALIZED MEDICINE BY POINT-OF-CARE DEVICES FOR BRAIN NATRIURETIC PEPTIDE - Methods, devices, reagent, systems and kits for the detection, diagnosis of ovarian cancer as well as for the monitoring of ovarian cancer progression and for monitoring the progress of ovarian cancer treatments using BNP as a biomarker. | 05-28-2015 |
| 20150293081 | ANALYTE-MEASURING SENSOR - An object of the present invention is to provide an analyte-measuring sensor using a thermoresponsive polymer, which is a novel analyte-measuring sensor capable of quantitatively measuring a target analyte with higher sensitivity. The analyte-measuring sensor of the present invention comprises a labeled particle capable of specifically reacting with a measurement target analyte, a thermoresponsive polymer, a charged substance exhibiting a positive or negative zeta potential in a solution, and a metal particle, and said metal particle is coated with a copolymer of said labeled particle, said charged substance and said thermoresponsive polymer. | 10-15-2015 |
| 20150301038 | CONJUGATE FOR USE IN IMMUNOASSAY METHOD - To adjust detection sensitivity and expand a measurement range depending on objects to be detected by a simple procedure in an immunoassay method involving using a colloidal metal having immobilized thereon an antibody or an antigen. Blocking treatment for a surface of a colloidal metal particle having immobilized thereon an antibody or an antigen with both components, i.e., a component of biological origin and a component of non-biological origin enables adjustment of measurement sensitivity with, for example, kinds and concentrations of both the components, and enables use of the component of non-biological origin, which has not been usable alone because of aggregation of a colloidal metal. | 10-22-2015 |
| 20150301072 | MULTIPLE CARRIER AND SLEEVE TRAY - An automation system for use with in-vitro diagnostics that includes a track configured to provide one or more paths and a plurality of sleeves. Each sleeve is configured to hold one of a plurality of fluid containers. The system also includes a plurality of carriers configured to travel along the track. Each carrier is separable from each sleeve and configured to hold one of the plurality of sleeves. The system further includes a tray having a plurality of rows. Each row is configured to hold at least one of: (i) one or more of the plurality of sleeves; and (ii) one or more of the plurality of carriers. The tray is configured to at least one of: (i) unload the plurality of sleeves or the plurality of carriers from the tray; and (ii) load the plurality of sleeves or the plurality of carriers to the tray. | 10-22-2015 |
| 20150308977 | BIOMOLECULE DETECTION METHOD, BIOMOLECULE DETECTION DEVICE AND ANALYSIS DEVICE - The present invention is intended to provide a method and a device for detecting a biomolecule with high sensitivity and high throughput over a wide dynamic range without requiring concentration adjustments of a sample in advance. The present invention specifically binds charge carriers to a detection target biomolecule, and detects the detection target biomolecule one by one by measuring a current change that occurs as the conjugate of the biomolecule and the charge carriers passes through a micropore. High-throughput detection of a biomolecule sample is possible with an array of detectors. | 10-29-2015 |
| 20150309019 | METHOD FOR SUPPRESSING NONSPECIFIC SIGNALS FROM CONTAMINANTS IN AN IMMUNOASSAY USING SURFACE PLASMON-FIELD ENHANCED FLUORESCENCE SPECTROSCOPY (SPFS) - An object of the present invention is to provide a method of suppressing, in an immunoassay using surface plasmon-field enhanced fluorescence spectroscopy (SPFS), nonspecific signals generated by nonspecific adsorption of contaminants contained in a sample to an SPFS sensor section (e.g., a primary antibody, a solid-phase layer and a metal thin film). | 10-29-2015 |
| 20150309020 | SURFACE AND METHOD FOR SENSING PROTEIN-LIGAND BINDING - Method for sensing the binding of an analyte to a surface using a pH-sensitive fluorescent agent having a first fluorescence emission intensity at a first pH and a second fluorescence emission intensity at a second pH, and surfaces for sensing the binding of an analyte to a surface using the pH-sensitive fluorescent agent. | 10-29-2015 |
| 20150314288 | CARTRIDGE FOR UPTAKE AND PROCESSING OF A SAMPLE - The invention relates to a cartridge ( | 11-05-2015 |
| 20150316461 | APPARATUS AND METHOD FOR MONITORING A SEDIMENTATION PARAMETER IN A FLUID MEDIUM SAMPLE - There is provided a method of measuring a sedimentation parameter of suspensions or precipitants in a fluid medium sample, said method compromising providing at least one micro-cantilever sensor, said micro-cantilever sensor comprising at least two materials having different coefficients of thermal expansion, and having a heater and piezo-resistive sensor integrated therein, pulsing the heater with one or more electrical pulses to induce heat generation in the micro-cantilever, sampling the output of the integrated piezo-resistive sensor to characterise a response of the micro-cantilever during sedimentation in the fluid medium sample, and determining a value of the sedimentation parameter from the characterised response. There is also provided an apparatus arranged to carry out the method. | 11-05-2015 |
| 20150316540 | REDUCING/OXIDIZING ACTIVITY OF MATERNAL URINE AS INDICATOR OF FETAL GENDER RELATED CHARACTERISTICS - The present invention provides a method for determining the gender of an unborn child by assaying the overall reducing/oxidizing or redox activity of the maternal urine or other body fluid. The method can be used to determine fetal gender at any time point during the entire pregnancy, the earliest being the first day of a missed menstruation. The body fluid may be processed before assaying. Processing may involve aging the body fluid, or purification of various fractions. The methods of the present invention also provide for a means for pre-conception baby gender planning by assaying the overall redox activity of a non-pregnant female's urine or other body fluid. The overall redox activity of a urine sample correlates with the gender specific compatibility of the ovum being released during a particular menstrual cycle. Therefore, assaying the overall redox activity of a non-pregnant female's urine will help a couple conceive a baby having a desired gender. | 11-05-2015 |
| 20150316542 | Reference and Normalisation Method for Use With Bead-Based Immunoassays in a Microfluidic Disc - The invention relates to a microfluidic system and method of processing biological samples in microfluidic system comprising the steps of the steps of positioning at least one detection chamber adapted for receiving particles, said particles comprising a reference label and reporter label, wherein the labels exhibit different wavelength properties when irradiated with light; and normalising the particle reporter label by using any detected magnitude in the measured properties of the reference label. | 11-05-2015 |
| 20150322489 | SILICA-BASED BIOLOGICAL MATERIAL ISOLATION - An apparatus for isolating nucleic acids includes an elongated body. The elongated body includes a silica surface positioned and configured to bind the nucleic acids when the elongated body is dipped into a biological material sample. | 11-12-2015 |
| 20150323552 | Methods and Devices for Rapid Assessment of Severity of Injury - Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | 11-12-2015 |
| 20150330986 | COMPOSITIONS FOR ENHANCING CHEMILUMINESCENCE AND METHODS OF USING THE SAME - Disclosed herein is a composition for enhancing chemiluminescence and a method of using the composition to improve analyte detection. | 11-19-2015 |
| 20150338395 | METHOD OF PRODUCING LABELED ANTIBODY - A method of producing a labeled antibody, including the steps of:
| 11-26-2015 |
| 20150338400 | OPTICAL SENSOR, DETECTION METHOD USING OPTICAL SENSOR, METHOD FOR AFFIXING CAPTURE BODY, AND INSPECTION UNIT - The optical sensor includes a first metal layer having top and a bottom faces, a second metal layer having top and bottom faces, and a hollow area sandwiched by the first metal layer and the second metal layer. A capturing body for capturing a target substance to be detected can be disposed in the hollow area. Thicknesses of the first metal layer and the second metal layer are both not less than 5 nm and not greater than 50 nm. The hollow area includes a determining part for determining the presence of the target substance contained in a specimen. The second metal layer can transmit an electromagnetic wave from the bottom face to the top face. The first metal layer can transmit the electromagnetic wave from the bottom face to the top face. | 11-26-2015 |
| 20150338423 | METHODS FOR DETERMINING RELATIVE BINDING ENERGY OF MONOMERS AND METHODS OF USING THE SAME - Disclosed herein are monomers that exhibit reduced estradiol related receptor binding activity, and methods for identifying monomers that exhibit reduced estradiol related receptor binding activity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 11-26-2015 |
| 20150346104 | SENSING DEVICE, AND SENSING SYSTEM AND SENSING METHOD USING THE SAME - A sensing device applied to an analyte molecule of a liquid sample and a buffer flow has at least one first inlet, at least one second inlet, a micro-flow channel, and at least one immobilization element. The first inlet is for inputting the liquid sample. The second inlet is for inputting the buffer flow. The micro-flow channel communicates with the first inlet and the second inlet. The immobilization element is for immobilizing sensing molecules for the analyte molecules. The analyte sample flow and the buffer flow, in the reverse direction, in the micro-flow channel enable the association and disassociation kinetics to be obtained. The present invention further provides a sensing system and a sensing method using the sensing device. | 12-03-2015 |
| 20150346141 | DNA-Decorated Graphene Chemical Sensors - The present invention provides a broad response single-stranded DNA-graphene chemical sensor device. The present invention also provides methods for improving the ability of graphene to work as a chemical sensor by using single-stranded DNA as a sensitizing agent. | 12-03-2015 |
| 20150355093 | SURFACE ENHANCED FLUORESCENCE SPECTROSCOPY APPARATUS - According to an example, methods for forming three-dimensional (3-D) nano-particle assemblies may include depositing surface-enhanced spectroscopy (SES) elements onto respective tips of nano-fingers, in which the nano-fingers are arranged in sufficiently close proximities to each other to enable the tips of groups of adjacent ones of the nano-fingers to come into sufficiently close proximities to each other to enable the SES elements on the tips to be bonded together when the nano-fingers are partially collapsed. The methods also include causing the nano-fingers to partially collapse toward adjacent ones of the nano-fingers to cause a plurality of SES elements on respective groups of the nano-fingers to be in relatively close proximities to each other and form respective clusters of SES elements, introducing additional particles that are to attach onto the clusters of SES elements, and causing the clusters of SES elements to detach from the nano-fingers. | 12-10-2015 |
| 20150355175 | TEST SUBSTANCE MEASUREMENT KIT AND TEST SUBSTANCE MEASUREMENT METHOD - To provide a test substance measurement method and a test substance measurement kit adapted to improve the accuracy of the measurement of a test substance. A test substance measurement kit includes: fluorescent particles which are modified with a first binding substance having specific bindability to a test substance; non-fluorescent particles which are modified with a second binding substance having no specific bindability to the test substance; and a substrate on which a first metal film to which a third binding substance having specific bindability to the test substance is fixed, and a second metal film to which a fourth binding substance having no bindability to the test substance, but having bindability to the first binding substance is fixed, and which has a smaller thickness than the first metal film are formed. | 12-10-2015 |
| 20150355207 | TEST MENU EXPANSION SYSTEM AND METHOD - An automation system for use with an in vitro diagnostics environment includes a track and a plurality of carriers configured to move along the track and hold one or more of a plurality of samples and one or more of a plurality of reagents having reagent types. The system also includes one or more testing stations, one or more local reagent storage areas located at or proximate to the one or more testing stations and one or more central reagent storage areas. The system further includes a control system configured to direct the one or more reagents from the one or more local reagent storage areas to the one or more testing stations based on received reagent information and direct the one or more reagents from the one or more central reagent storage areas to the one or more testing stations based on the received reagent information. | 12-10-2015 |
| 20150355208 | AUTOMATION TUBE POSITIONING METHODOLOGY - Methods and systems allow characterization of sample vessels and carriers in an automation system to determine any physical deviation from nominal positions. In response, an offset can be calculated and applied when positioning a carrier relative to a station, such as a testing or processing stations (or vice-versa). This may allow for precise operation of an instrument with a sample vessel on an automation track, while compensating for deviation in manufacturing and other tolerances. | 12-10-2015 |
| 20150362485 | BIOSENSOR HAVING DECOUPLED CAPTURE CHAMBER AND DETECTION CHAMBER, USING PARTICLE AGGREGATION AND SIZE-SEPARATION - A biosensor using a decoupled microfluidic device, which has a capture chamber and a detection chamber separate from and in fluid communication with each other. The sensing method is based on particle aggregation via homogeneous reactions, by employing microparticles having antibodies on their surfaces which can form aggregates through antigen mediation. Either size-separation or magnetic based separation is used to separate aggregates from single microparticles; the aggregates are later dissociated and the resulting single microparticles are counted to measure the amount of the antigen. Another biosensor uses a decoupled microfluidic device with a capture chamber and a detection chamber, and a 3-D structure in the capture camber to increase immobilized antibody concentration. Immunoreaction efficiency is improved by increasing the number of antibody per reaction volume in the capture chamber. | 12-17-2015 |
| 20150367149 | COBINAMIDE-BASED MATERIALS FOR OPTICAL SENSING AND GAS REMOVAL - This disclosure concerns materials for detecting and removing gaseous chemical agents (e.g., cyanide, cyanogen, sulfide, nitrite, nitric oxide, and combinations thereof), devices including the materials, and methods of making and using the disclosed materials. Embodiments of the disclosed materials include a support material impregnated with cobinamide and/or a cobinamide derivative. | 12-24-2015 |
| 20150367339 | DISPOSABLE, FLUID ACTUATED, MECHANICALLY DRIVEN POINT-OF-CARE INVITRO-DIAGNOSTIC APPARATUS AND METHOD OF PERFORMING A POINT-OF-CARE INVITRO-DIAGNOSTIC TEST - A portable, disposable in-vitro diagnostic apparatus and method of performing a point-of-care invitro-diagnostic test is provided. The apparatus has a body with at least one chamber containing an actuator member. The chamber is in fluid communication with an upstream first fluid channel and a downstream second fluid channel. The actuator member has a compressed, deactivated state and an expanded, activated state. The actuator member transitions from the compressed, deactivated state to the expanded, activated state upon contact with fluid flowing through the first fluid channel. The actuator member pumps fluid outwardly from the first chamber through the second fluid channel during the transition from its compressed, deactivated state to its expanded, activated state. The pumped fluid can be channeled to other chambers within the body and/or to an analysis chamber within the body for study. | 12-24-2015 |
| 20150369830 | ARTICLES AND METHODS FOR RAPID THC DETECTION - This disclosure describes articles for detecting THC in a saliva sample and methods of using the articles. Generally, the articles include a detection zone that generates a detectable signal that allows one to determine whether the sample contains Δ-9-tetrahydrocannabinol. The methods can produce a test result in rapid fashion, suitable for on-site testing. | 12-24-2015 |
| 20150376411 | NOVEL DYES AND COMPOSITIONS, AND PROCESSES FOR USING SAME IN ANALYSIS OF PROTEIN AGGREGATION AND OTHER APPLICATIONS - Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, protein thermal stability shift assay and analysis of molecular chaperone activity. These dyes and compositions are also useful as probes in nucleic acid and protein detection. | 12-31-2015 |
| 20150377760 | SYSTEMS AND METHODS FOR COLLECTING TEAR FILM AND MEASURING TEAR FILM OSMOLARITY - A sample receiving chip comprising a substrate that receives an aliquot volume of a sample fluid and a sample region of the substrate, sized such that the volume of the sample fluid is sufficient to operatively cover a portion of the sample region. The energy imparted into the sample fluid is transduced by the sample region to produce an output signal that indicates energy properties of the sample fluid. The sample receiving chip also includes a channel formed in the substrate, the channel configured to collect the aliquot volume of a sample fluid and transfer the aliquot volume of sample fluid to the sample region. | 12-31-2015 |
| 20150377873 | CHARACTERIZATION OF REACTION VARIABLES - A microscale method for the characterization of one or more reaction variables that influence the formation or dissociation of an affinity complex comprising a ligand and a binder, which have mutual affinity for each other. The method is characterized in comprising the steps of: (i) providing a microfluidic device comprising a microchannel structures that are under a common flow control, each microchannel structure comprising a reaction microactivity; (ii) performing essentially in parallel an experiment in each of two or more of the plurality of microchannel structures, the experiment in these two or more microchannel structures comprising either a) formation of an immobilized form of the complex and retaining under flow conditions said form within the reaction microactivity, or b) dissociating, preferably under flow condition, an immobilized form of the complex which has been included in the microfluidic device provided in step (i), at least one reaction variable varies or is uncharacterized for said two or more microchannel structures while the remaining reaction variables are kept essentially constant; (iii) measuring the presentation of the complex in said reaction microactivity in said two or more microchannel structures; and (iv) characterizing said one or more reaction variables based on the values for presentation obtained in step (iii). | 12-31-2015 |
| 20160011156 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | 01-14-2016 |
| 20160011182 | METHOD AND SYSTEM FOR SUBSTANCE DETECTION WITH A MAGNETIC SENSOR | 01-14-2016 |
| 20160011184 | QUANTIFICATION OF A FUNCTIONALIZED SURFACE | 01-14-2016 |
| 20160011187 | SIMPLE MEASUREMENT TOOL | 01-14-2016 |
| 20160011216 | BIOSENSORS INCLUDING SURFACE RESONANCE SPECTROSCOPY AND SEMICONDUCTOR DEVICES | 01-14-2016 |
| 20160018303 | Magnetic Particles Based Separation and Assaying Method - A magnetic particle based separation and assaying method uses at least two sets of magnetic particles placed in solution within a container and characterized respectively by a coercive field e | 01-21-2016 |
| 20160018405 | METHODS AND SYSTEMS FOR ANALYSIS USING POLYMER DOTS - Methods, systems, compositions and kits are provided for the analysis of target molecules using chromophoric polymer dots conjugated to biomolecules. The use of chromophoric polymer dots improves detection sensitivity and stability when compared with existing techniques. In some aspects, methods, systems, and kits are provided for detecting a target protein using chromophoric polymer dots conjugated to biomolecules in a Western blot analysis. Related methods, systems, compositions and kits are also provided. | 01-21-2016 |
| 20160025631 | FABRICATION OF A FLUORESCENT MATERIAL FOR SENSING AN ANALYTE - An analyte indicator may include a porous base and may be included in an analyte sensor. The analyte indicator may retain its physical, chemical, and optical properties in the presence of compression. The porous base may not vary in opacity. The analyte indicator may include (i) a polymer unit attached or polymerized onto or out of the porous base and (ii) an analyte sensing element attached to the polymer unit or copolymerized with the polymer unit. The analyte sensing element may include one or more indicator molecule. The analyte sensing element may include one or more indicator polymer chains. The analyte indicator may include (i) an indicator polymer chain attached or polymerized onto or out of the porous base and (ii) indicator molecules attached to the indicator polymer chain. | 01-28-2016 |
| 20160025748 | NON-OXIDIZED, BIOLOGICAL ACTIVE PARATHYROID HORMONE DETERMINES MORTALITY IN HEMODIALYSIS PATIENTS - A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. | 01-28-2016 |
| 20160025752 | DEVICES AND METHODS FOR DETECTING AND/OR QUANTIFYING ANALYTES IN FLUIDS - The present disclosure relates to devices and methods for determining a target analyte in a sample (e.g., a bodily fluid sample such as sweat, blood, urine, lavage, plasma, saliva, tears) using an analysis device (e.g., a bodily fluid analysis device). The device may include a lateral flow assay in some embodiments. Certain embodiments involve determining a concentration of a target analyte in a sample by generating a volumetric calculation of the sample and/or by use of a non-target analyte. The devices and methods can be used for obtaining and processing a sample to determine the presence and/or concentration of such analytes. In some cases, the methods and/or devices can be used to determine impairment (e.g., drug impairment) in a subject. | 01-28-2016 |
| 20160025826 | NUCLEAR MAGNETIC RESONANCE APPARATUS AND METHODS - A nuclear magnetic resonance (NMR) apparatus includes at least one magnet arranged to induce a static magnetic field in a sample chamber. The static magnetic field has a known amplitude distribution. At least one radio frequency antenna is configured to induce a radio frequency magnetic field in the sample chamber at a predetermined frequency and a predetermines bandwidth. The static magnetic field amplitude at a sample chamber boundary has substantially at most two values. | 01-28-2016 |
| 20160025827 | NUCLEAR MAGNETIC RESONANCE APPARATUS AND METHODS - A nuclear magnetic resonance (NMR) apparatus includes at least one solenoid configured to induce a radio frequency magnetic field in a sample. The sample is located inside the solenoid. At least one cylindrical magnet is arranged to induce a static magnetic field in the sample, wherein the magnet is located inside the sample. | 01-28-2016 |
| 20160033376 | Apparatus and Process for Producing Patterned, Micron and Nanometer Size Reaction and Mixing Zones for Fluids Deposited on Smooth, Rough and Porous Surfaces and Applications of that Process - Process for producing patterned, micron and nanometer scale features by reacting or mixing in the small volumes at the intersections of coalescing drops, at the fronts of colliding thin films in front of spreading drops, or in the pore space of a porous medium under the drop. The process can be implemented on smooth, rough or porous surfaces and embodiments include multiplexed, single drop chemical or biochemical sensors and encryption of information of a printed page. | 02-04-2016 |
| 20160033411 | METHODS AND COMPOSITIONS RELATING TO STORM-BASED PATTERNING - This disclosure provides methods for generating super-resolution patterns of molecules on substrates. | 02-04-2016 |
| 20160033496 | Analyte Detection Enhancement by Targeted Immobilization, Surface Amplification, and Pixelated Reading and Analysis - This disclosure provides, among other things, a method of sample analysis, that comprises: (a) binding target analytes to capture agents that are attached to a surface of a plate, wherein the plate comprises (i) a sensing amplification layer comprises nanostructures that enhance signals and (ii) the capture agents are attached to said sensing amplification layer; (b) reading the plate with a reading device to produce an image of signals that represent individual binding events; and (c) identifying and counting individual binding events in an area of the image, thereby providing an estimate of the amount of one or more analytes in the sample. A system for performing the method is also provided. | 02-04-2016 |
| 20160033500 | DEVICE, NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM, AND METHOD FOR DETERMING TYPE OF TARGET PEPTIDE - Disclosed is a device for determining a type of target peptide includes: an acquisition unit that obtains first to third information on a target peptide contained in a test sample; a storage unit that stores first to third information on a known peptide obtained using a standard sample containing the known peptide; and a controller programmed to perform operations including: comparing the first to third information on the target peptide obtained from the test sample with the first to third information on the known peptide stored in the storage unit; and determining whether or not the target peptide is the known peptide, wherein the first information is a dissociation rate constant when the target peptide dissociates from a protein, in a solid phase carrier in which the target peptide is immobilized on a support through the protein binding to a peptide, the second information is a maximum value of a layer thickness change amount on the support, and the third information is information indicating that a dissociation mode of a peptide and the protein is either a single dissociation mode or a multiple dissociation mode. | 02-04-2016 |
| 20160033505 | Mobile Phase Test Strip Components, Conjugate Pad Pre-treatment Solutions, And Related Methods Thereof - A mobile phase test strip component is described herein including a conjugate pad. The conjugate pad includes a gold solution antibody having an antibody loading concentration of approximately 4 μg/OD and a gold OD of 5 to 6. The gold solution antibody is conjugated with a TRIS buffer solution and re-suspended with a dispensing buffer. The conjugate pad can include a high density polyester fiber pad material. A conjugate pad pre-treatment solution is also described, including at least one protein, at least one surfactant, at least one metal cation, and at least one polymer. A method for pre-treating a conjugate pad is also described. | 02-04-2016 |
| 20160033531 | METHOD AND COMPOSITIONS FOR DETECTING BINDING TO THE PREGNANE X RECEPTOR - In one aspect, the invention relates to compounds useful as fluorescence assay probes, methods of making same, and methods of using same to assay ligand binding interactions with PXR. In various aspects, the invention pertains to compositions comprising a polypeptide comprising a pregnane X receptor polypeptide, or a ligand binding fragment polypeptide thereof; and a molecule comprising a BODIPY residue and a vinca alkaloid residue. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 02-04-2016 |
| 20160033539 | SYSTEM AND METHOD OF COMPONENT ANALYSIS AND AUTOMATIC ANALYSIS DEVICE USING SAME - A component analysis method of an automatic analysis device is provided. The automatic analysis device includes an incubation unit that holds at least one reaction container and a plurality of executing stations set around the incubation unit to correspondingly perform a plurality of analysis operations to the reaction container. The component analysis method sets a transport period of the incubation and a chronological sequence of the analysis operations, controls the incubation unit to transport the reaction container a first transport distance during the regular transport sub-period and transport the reaction container a second transport in the self-adaptive transport sub-period, and performs at least one regular operation to the reaction container in the regular transport sub-period and at least one self-adaptive operation to reaction container in the | 02-04-2016 |
| 20160033542 | BIOSAMPLE PLATE WITH DATA STORAGE AND WIRELESS COMMUNICATIONS - Embodiments of the disclosure relate to a biosample plate that includes a memory component for storing biosample identification and analysis data, and a wireless communication interface for transferring the data to and from the biosample plate. In one embodiment, the biosample plate comprises a base for receiving a biosample, a memory component coupled to the base for storing identification and analysis information related to the biosample, and a wireless communication interface coupled to the memory component for transferring the information to and from the memory component. The wireless communication interface may include an electromagnetic device. | 02-04-2016 |
| 20160038668 | Therapeutic Retrieval of Targets in Biological Fluids - Method and apparatus for removing high density particles from a biological fluid such as blood using aphaeresis. The particles are preferably sub-micron in size and denser than normally occurring components of the fluid and can be removed by a modified reverse-flow gradient density centrifuge without damaging the fluid. The particles can be provided to a patient in vivo or added to the fluid after it is removed from the patient. Some particles can carry and deliver oxygen and scavenge carbon dioxide. Other particles are conjugated to capture molecules for attaching to targets such as cancer cells, viruses, pathogens, toxins, or excess concentrations of a drug or element in the fluid. The targets are then removed from the fluid along with the particles by the aphaeresis instrument. | 02-11-2016 |
| 20160041160 | SPECIMEN MEASUREMENT APPARATUS AND SPECIMEN MEASUREMENT METHOD - According to one embodiment, a specimen measurement apparatus includes a detector and a control circuit, and is configured to perform a plurality of steps to measure the properties of a test substance retained in a reaction container. The detector outputs electromagnetic waves to the reaction container and detects the electromagnetic waves that vary according to the state in the reaction container. The control circuit controls transition timing between steps of the plurality of steps based on the detection result of the electromagnetic waves obtained by the detector. | 02-11-2016 |
| 20160041163 | LATERAL FLOW ASSAY DEVICE - A lateral flow assay device includes a substrate having a top surface, as well as a sample receiving area disposed upon the top surface. At least one fluid flow path extends along the substrate from the sample receiving area, wherein the sample receiving area can be placed in contact with a peripheral reservoir formed at a sample addition area to draw sample therefrom in a controlled manner. The device can further include a reagent area that is designed to promote uniform dissolution of a deposited detection material by a sample moved through the device along the fluid flow path as well, as a flow channel configure to promote mixing of sample and reagent and an absorbing or wicking zone configured to affect various flow characteristics. | 02-11-2016 |
| 20160041190 | Method for Detecting and Monitoring Bone Loss - Methods for identifying subjects having bone loss by detecting bone microparticles in a sample of their bodily fluid are disclosed. Methods for monitoring bone loss and assessing efficacy of bone loss therapies by detecting bone microparticles in bodily fluid samples are also disclosed. Compounds for use as a negative control in the disclosed methods are provided as well as kits comprising such compounds. | 02-11-2016 |
| 20160060631 | DNA APTAMERS BINDING THE HISTIDINE TAG AND THEIR APPLICATION - A DNA aptamer was obtained which has an affinity for His-tag, and contains a nucleotide sequence selected from SEQ ID No. 1 and SEQ ID No. 2, which has clear applications. | 03-03-2016 |
| 20160061824 | METHODS FOR DETECTING INFLAMMATORY DISORDERS - The present invention relates to methods for detecting inflammatory disorders and more particularly to methods for detecting inflammatory disorders by detecting cell-free nucleosomes in a serum sample isolated from a subject. | 03-03-2016 |
| 20160061827 | Analyte Detection - The present disclosure provides methods and/or kits for detecting an analyte in a sample. Some embodiments provide a method for detecting a non-nucleic acid analyte in a sample using a solid substrate comprising a bound immobilisation agent and an antibody capture agent and a detectable agent, which can bind to the analyte. The antibody capture agent comprises, at a plurality of sites, a ligand for the immobilisation agent. A complex between the analyte, the antibody capture agent and a detectable agent is formed and immobilised on the solid substrate by binding between the immobilisation agent and the ligand. In some embodiments, the ligand and the immobilisation agent are a binding pair comprising a peptide tag and an anti-peptide tag antibody. | 03-03-2016 |
| 20160069811 | GOLD NANOROD/POLYMER NANOCOMPOSITES AND SENSORS BASED THEREON - A nanocomposite structure includes:
| 03-10-2016 |
| 20160069870 | SOLID-PHASE SUPPORT, LIGAND-BINDING SOLID-PHASE SUPPORT, METHOD FOR DETECTING OR SEPARATING TARGET SUBSTANCE, AND METHOD FOR PRODUCING THE SOLID-PHASE SUPPORT - A solid-phase support, formed by binding a chain polymer at least to the surface, wherein the chain polymer is a block polymer comprising a first block constituted from repetitions of a hydrophilic structural unit and a second block constituted from repetitions of a structural unit having a reactive functional group, a content ratio of the number of moles “a” of the reactive functional group contained in the chain polymer and the number of moles “b” of the whole structural unit contained in the chain polymer, (a/b), is from 0.03 to 0.25, and a density of the chain polymer occupying the surface of the solid-phase support is 0.1 polymers/nm | 03-10-2016 |
| 20160069909 | REAGENT KIT, MEASUREMENT KIT, AND METHOD OF MEASURING TEST SUBSTANCE - The present invention provides a reagent kit which is used for measuring a test substance in a biological sample and can improve measurement sensitivity of the test substance; measurement kit; and a method of measuring the test substance. Provided is a reagent kit which is used for measuring the above-described test substance in the biological sample and contains first particles which are modified by a first binding substance having specific binding properties with respect to the test substance and have a label, and a compound which has at least one amino group having a positive charge. | 03-10-2016 |
| 20160077091 | PORTABLE TESTING SYSTEM FOR DETECTING SELECTED DRUGS OR COMPOUNDS IN NONCONTROLLED ENVIRONMENTS - Devices, methods, and systems are provided for testing for or detecting the presence of illegal or prohibited drugs, compounds or metabolites in non-controlled environments for testing using lateral flow drug test strips and a smart phone with digital imaging, data processing, data storage and wireless electronic transmission of resulting data, the system or method to test dry buffer conditioned oral fluids using lateral flow test strips for determination of the presence or absence, or other quantitative or qualitative measurement, of specific and/or selected drugs, compounds or metabolites thereof. | 03-17-2016 |
| 20160084768 | DEVICE FOR DETECTING ANALYZED OBJECT IN SPECIMEN AND METHOD THEREFOR - A device for detecting analytes in a sample includes (a) n light source units generating light; (b) a reaction strip including (i) a test area illuminated with light from the light source unit and including a material reacting to the analytes, (ii) a control area illuminated with the light from the light source unit and including a control material, and (iii) a background area illuminated with the light from the light source unit; and (c) at least n+1 light receiving units detecting light emitted from the test area, the control area, and the background area of the reaction strip, respectively. | 03-24-2016 |
| 20160084804 | CATION EXCHANGER FOR LIQUID CHROMATOGRAPHY, PROCESS FOR PRODUCING SAME, AND USE THEREOF - To provide a cation exchanger for liquid chromatography having a high retention for an object to be separated or analyzed, a sufficient binding capacity for the object, a high resolution and mechanical strength, and a low operation pressure. | 03-24-2016 |
| 20160084810 | SYSTEMS FOR DETECTING TARGET CHEMICALS AND METHODS FOR THEIR PREPARATION AND USE - Systems and methods for detecting target chemicals are disclosed. A system includes a chemical sensor configured to filter light. The chemical sensor includes a referencing arm configured to output light at a first intensity level and a sensing arm sensitive to a target chemical. The sensing arm is configured to output light at a second intensity level. A difference between the first intensity level and the second intensity level indicates a presence of the target chemical. | 03-24-2016 |
| 20160084829 | SELF-ASSEMBLED PEPTIDE NANOSTRUCTURES BY EXPLOITING CONFORMATIONAL CHANGE, BIOSENSOR USING THE SAME AND DETECTION METHOD OF BIOMOLECULES USING THE SAME - The present disclosure relates to a self-assembled peptide nanostructure including at least one amphiphilic peptide and a biosensor using the same. The amphiphilic peptide is a hairpin-shaped amphiphilic peptide including a hydrophilic domain having an α-helical structure and a hydrophobic domain. The N-terminal of the hydrophobic domain is a pyrene group. Since the self-assembled peptide nanostructure is derived from an RNA, DNA or amino acid sequence capable of recognizing a specific target substance, it does not recognize other substances but exhibits high selectivity for the target substance. Specifically, since the self-assembled peptide nanostructure has an excimer fluorescence peak at 480 nm through binding with the target substance, it can be usefully used in medical applications such as diagnosis of diseases. | 03-24-2016 |
| 20160084848 | ASSAY FOR DETERMINING ENDOGENOUS LEVELS OF ANALYTE IN VIVO - The present invention relates to an assay for determining endogenous levels of analyte in vivo. In particular, the present invention is directed to an assay for determining endogenous levels of stromal cell-derived factor (SDF-1) isoforms in vivo. | 03-24-2016 |
| 20160084861 | CALIBRATION FOR MULTI-COMPONENT ASSAYS - A method of analyzing a biological sample using an analyzer and an assay. The method comprises providing the assay for producing the signal. The assay has two or more predetermined number of components. Each of the predetermined components has a distinct relation between the intensive property and the signal. The method further comprises providing calibration samples with known values for the intensive property and measuring a calibration signal for each of the calibration samples. The method further comprises determining a calibration by fitting a calibration function to the calibration signal for each of the calibration samples and the known values for the intensive property. The calibration function is equivalent to a constant plus an exponential decay term for each of the predetermined number of components. The method further comprises measuring the signal of the sample using the analyzer and the assay, and calculating the intensive property using the calibration. | 03-24-2016 |
| 20160089670 | FLUID MANIPULATOR HAVING FLEXIBLE BLISTER - A system for fluid manipulation includes a composite wafer and a movable compression device. The composite wafer includes a flexible layer and a substantially rigid layer adhered to the flexible layer. The flexible layer defines one or more recesses that are covered by the substantially rigid layer to form one or more reservoirs and one or more fluid channels among the one or more reservoirs. The movable compression device contacts the flexible layer and is configured to progressively compress the flexible layer such that when the movable compression device traverses the flexible layer, fluid is forced through the one or more fluid channels and the one or more reservoirs in a sequence determined by the layout of the one or more fluid channels and the one or more reservoirs. Certain reservoirs may be pre-loaded with fluids and reagents for performing a specified medical test. | 03-31-2016 |
| 20160091505 | Molecular Template and Manufacturing Method Therefor - Molecular-template polymer particles for a steroid hormone, said molecular-template polymer particles comprising a polymer that interacts with said steroid hormone. The polymerization unit of said polymer preferably contains at least two functional groups that interact with the aforementioned steroid hormone. | 03-31-2016 |
| 20160097724 | METHOD FOR AUTOMATED EVALUATION OF INCUBATED IMMUNOBLOT STRIPS - The invention relates to a device and a method for automated evaluation of incubated immunoblot strips ( | 04-07-2016 |
| 20160097765 | ELECTROCHEMILUMINESCENCE METHOD OF DETECTING AN ANALYTE IN A LIQUID SAMPLE AND ANALYSIS SYSTEM - An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred. | 04-07-2016 |
| 20160097781 | METHOD FOR STRATIFYING A FEMALE SUBJECT FOR HORMONE REPLACEMENT THERAPY - Subject matter of the present invention is a method for stratifying a female subject for hormone replacement therapy wherein the level of Pro-Neurotensin or fragments thereof is determined and the level of Pro-Enkephalin or fragments thereof is determined. | 04-07-2016 |
| 20160097782 | CSF DIAGNOSTIC IN VITRO METHOD FOR DIAGNOSIS OF DEMENTIAS AND NEUROINFLAMMATORY DISEASES - CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (C SF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals. | 04-07-2016 |
| 20160097783 | IMMUNOASSAY FOR PYRROLIDINOPHENONES - The current invention provides an improved immunoassay for the detection and determination of pyrrolidinophenone based designer drugs in hair and biological fluids (urine, blood, and oral fluid). The generic immunoassay is underpinned by novel, sub-family-specific antibodies, which display surprising sensitivity. The invention further describes substrates comprising an antibody that is specific to compounds of the pyrrolidinophenone family. Also described are the novel immunogens from which the antibodies are derived and kits incorporating the antibodies of the current invention. | 04-07-2016 |
| 20160103043 | FLUID-TIGHTLY SEALABLE SAMPLING DEVICE - A fluid-tightly sealable sampling device for analysis of one or more substances in a fluid flow intended to pass through the sampling device is disclosed, wherein it comprises an adsorption device ( | 04-14-2016 |
| 20160103108 | NOVEL PEPTIDE SELECTIVELY BINDING TO VOLATILE ORGANIC COMPOUNDS - Provided is a peptide selectively binding to a volatile organic compound, in which the peptide has excellent selectivity for the volatile organic compound and has stability at room temperature so as to effectively collect and detect or eliminate the volatile organic compound. | 04-14-2016 |
| 20160103124 | APPARATUS AND METHOD FOR PRECONCENTRATING AND TRANSFERRING ANALYTES FROM SURFACES AND MEASUREMENT THEREOF USING SPECTROSCOPY - A system and method for capturing a target analyte in advance of performing spectroscopic analysis to determine the existence of the target analyte from a source contacted with a collection substrate. The collection substrate is fabricated of a material selected to have an affinity for the target analyte, sufficiently transparent in a spectral region of interest and capable of immobilizing the target analyte thereon in a manner that limits scattering sufficient to obscure spectral analysis. The collection substrate may be coated with a material selected to react with, bind to, or absorb the target analyte. The method optionally includes the step of transferring the captured target analyte to a second substrate, which may be an optical substrate. The target analyte may be captured to the collection substrate by one or more of wiping, dabbing or swabbing a target analyte carrier with the collection substrate. | 04-14-2016 |
| 20160103125 | RESONATOR SENSOR MODULE SYSTEM AND METHOD - A resonator sensor module is disclosed. The resonator sensor module includes one or more sensing resonators that includes binding sites for an analyte material; one or more reference resonators that lacks any binding sites for the analyte material; a module interface; and one or more switches each including a first position that operatively couples at least one of the one or more sensing resonators and the module interface and a second position that operatively couples at least one of the one or more reference resonators and the module interface. | 04-14-2016 |
| 20160108471 | A KIT FOR DETECTING MICRO-RNA EXTRACTED FROM A SAMPLE OF BODY FLUID AS WELL AND A METHOD FOR THE DETECTION THEREOF - A kit for detecting a micro-RNA of interest in at least one sample (C) extracted from a body fluid, including: at least one device ( | 04-21-2016 |
| 20160109440 | DISPOSABLE SENSOR ELEMENTS, SYSTEMS, AND RELATED METHODS - Embodiments include disposable sensor elements, systems including the same and related methods. In an embodiment, a disposable sensor element is included having a substrate and a first measurement zone comprising a plurality of discrete binding detectors. The first measurement zone can define a portion of a first gas flow path. In some embodiments the disposable sensor element can further include a second measurement zone, separate from the first measurement zone. The second measurement zone can include a plurality of discrete binding detectors. The second measurement zone can be disposed outside of the first gas flow path. Other embodiments are also included herein. | 04-21-2016 |
| 20160109469 | METHOD OF MEASURING LIPOPROTEIN'S CAPACITY TO ACCEPT CHOLESTEROL - Provided is a method of measuring a lipoprotein's capacity to accept cholesterol including the steps of:
| 04-21-2016 |
| 20160116467 | LATERAL FLOW ASSAY DEVICE - The present invention provides a diagnostic kit for detecting the presence or quantity of one or more test analytes within a test sample taken from a body surface of a mammal, the diagnostic kit comprising: a separate insert for a lateral flow device ( | 04-28-2016 |
| 20160116487 | IN VITRO DETECTION OF PRIONS IN BLOOD - A method of screening a blood sample for the presence of prions. The method includes the steps of collecting the blood sample in heparin, contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT), and measuring the resulting ThT fluorescence in the sample. The method can further include the step of freezing and thawing the sample prior to contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT). The method can also include the step of precipitating the prions in sodium phosphotungstic acid (NaPTA) prior to contacting the sample with a solution comprising recombinant prion protein (rPrP) and Thioflavin T (ThT). | 04-28-2016 |
| 20160121322 | MULTI-STAGE ORAL-FLUID TESTING DEVICE - In an embodiment, the claimed invention includes an oral-fluid collection and testing device that. is simple to operate. The device includes a body assembly and a cap assembly that are easy to handle by a user. A collection sponge projects from an end of the body assembly for absorbing the oral fluid of a donor, A cap assembly is easily aligned with the body assembly by way of visual alignment indicators on both the body and the cap. Once the cap is aligned with the body, a user simply pushes the cap onto the 'body, which causes a first stage fluid, flow. More specifically, a buffer fluid is released from the cap and mixes with the oral fluid collected on the sponge—After waiting a short time* the cap is rotated, then pushed again, causing a second-stage fluid flow in which the sponge is compressed such that the buffer fluid/oral fluid exits the sponge and flows toward a. pair of test strips. A user can then easily view the test results by observing a visual indication, such as a color change of the test strips through a viewing window. | 05-05-2016 |
| 20160123930 | POROUS RESONANT SENSORS - In a general aspect, an apparatus can include a porous, monolithic resonator having nanoscale pores defined therein. The apparatus can also include an adsorbent selective to a given analyte disposed on an exterior of the porous, monolithic resonator, the exterior of the porous, monolithic resonator including surfaces defining the nanoscale pores. | 05-05-2016 |
| 20160123971 | NUCLEAR MAGNETIC RESONANCE APPARATUS AND METHODS - A nuclear magnetic resonance (NMR) apparatus includes at least one magnet configured to induce a static magnetic field in a sample of material to be analyzed. At least one radio frequency antenna is configured to induce a radio frequency magnetic field in the sample of material to be analyzed. The sample chamber is disposed in a substantially longitudinally continuous sample holder separated into discrete sample chambers. Each sample chamber has an internal opening dimension such that substantially all of each sample is affected by surface contact phenomena with an internal wall of each sample chamber. | 05-05-2016 |
| 20160123972 | FLUORESCENCE IMMUNOASSAY SENSOR CHIP AND FLUORESCENCE IMMUNOASSAY METHOD - Provided is a fluorescence immunoassay sensor chip and a fluorescence immunoassay method, which are capable of measuring, at the same time, a marker requiring high sensitivity due to its low content in a sample solution and a marker not requiring high sensitivity due to its high content in a sample solution. The fluorescence immunoassay sensor chip for use in fluorescence immunoassay for detecting and measuring markers contained in a sample solution includes: a dielectric member; a metal thin film formed on part of a main surface of the dielectric member; a first sensor part formed in a predetermined position on the metal thin film; and a second sensor part directly formed in a predetermined position on the dielectric member, wherein a ligand immobilized in the first sensor part and a ligand immobilized in the second sensor part capture different types of markers. | 05-05-2016 |
| 20160131580 | OPTICAL ANALYTE SENSOR - A waveguide sensor capable of direct, real-time detection and monitoring of analytes in the vicinity of the waveguide surface without requiring the tagging or labeling of the analyte, is described. Analytic and numerical calculations have predicted that by locally detecting either changes in the evanescent field or changes in the light coupled out of the waveguide as a result of the presence of the analyte, high detection sensitivity will be able to be achieved. | 05-12-2016 |
| 20160131588 | DEGRADABLE CATIONIC SURFACTANTS AND USE THEREOF IN ENHANCING CHEMILUMINESCENCE - The present invention relates to methods of enhancing chemiluminescence from a chemiluminescent label comprising contacting a chemiluminescent label with an acid in the presence of a degradable cationic surfactant and hydrogen peroxide followed by the addition of a base. Related kits containing such degradable cationic surfactant are also provided. The degradable cationic surfactant can compress light emission time of the chemiluminescent label to an extent that is comparable to or shorter than conventional surfactants. The degradable cationic surfactant can also increase chemiluminescence of the chemiluminescent label, providing increased light emission output that is comparable to conventional surfactants. | 05-12-2016 |
| 20160131644 | METHOD FOR DETECTION OF PROTEIN COMPRISING HISTIDINE-TAG USING IMMUNOCHROMATOGRAPHY - The present invention relates to a method for the detection of a protein including a histidine-tag using immunochromatography. The detection method of the present invention uses immunochromatography using the polymer particle fixed with the histidine-tag, wherein a histidine-tag specific antibody alone is used to detect a histidine-tag conjugated protein (recombinant protein) quickly without using a target protein specific antibody. This method is also efficient in detecting and quantifying the histidine-tagged protein included in the sample without using an additional apparatus but quickly and accurately. | 05-12-2016 |
| 20160131664 | METHOD FOR RISK STRATIFICATION IN STABLE CORONARY ARTERY DISEASE - An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations. | 05-12-2016 |
| 20160131668 | MATERIALS AND METHODS FOR RAPID AND SPECIFIC DETECTION OF COCAINE - The invention pertains to a rapid and specific aptamer-based method for one-step cocaine detection with minimal reagent requirements based on an aptamer sensor that reports the presence of cocaine via the displacement and unquenching of a bound fluorophore molecule. In certain embodiments, the invention provides novel aptamers, which have reduced background fluorescence, bind a fluorophore molecule tightly, and show an increased signal gain in the presence of cocaine. | 05-12-2016 |
| 20160137725 | Methylation and Acetylation Sites - The disclosure features over 5000 methylation and acetylation sites identified in human cell line, human serum and mouse tissues, peptides (including AQUA peptides) comprising a methylation or acetylation site of the disclosure, antibodies specifically bind to a methylation or acetylation site of the disclosure, and diagnostic and therapeutic uses of the above. | 05-19-2016 |
| 20160139054 | System and Method for Detecting Pathogens on Treated and Untreated Substrates Using Liquid Crystal Chromonic Azo Dye - Chromonic azo dyes are particular types of chromonic molecules that are alignable homeotropically (aggregated molecules stack perpendicularly to the surface) on different types of substrates, often without the need of any special surface treatment. This feature enables the optimization of a detection device with increased sensitivity based of the alignment distortion created by a biological immune complex. | 05-19-2016 |
| 20160139164 | CARTRIDGE FOR DISPENSING A FLUID, AUTOMATIC ANALYZER AND METHOD OF ANALYZING A BIOLOGICAL SAMPLE - A cartridge for dispensing a fluid is presented. The cartridge comprises a reservoir chamber for receiving the fluid. The reservoir chamber has a fluid outlet. The cartridge further comprises a controllable dispenser component for dispensing a dispensing volume of the fluid from the reservoir chamber. The dispenser component is connected to the fluid outlet of the reservoir. The cartridge further comprises a single compressible fluid pump with a single elastic pumping element and a conduit extending from the fluid pump towards the fluid outlet. The fluid pump discharges a mixing volume of the fluid from the conduit into the reservoir chamber upon compression of the elastic pumping element. The mixing volume depends on the degree of compression of the elastic pumping element. The fluid pump sucks in the mixing volume from the reservoir into the conduit upon decompression of the elastic pumping element. | 05-19-2016 |
| 20160144364 | REAGENT DISPENSERS, DISPENSING APPARATUS, AND METHODS - Disclosed is a reagent dispenser apparatus. The reagent dispenser apparatus has a reagent container having a dispense port operable to open and close to dispense reagent. Dispense port may include a valve operable to dispense reagent from a bottom of the reagent container. Reagent dispensing apparatus, immunoassay apparatus and methods of operating the reagent dispenser apparatus are provided, as are other aspects. | 05-26-2016 |
| 20160145679 | OLIGONUCLEOTIDE FUNCTIONALIZED QUANTUM DOTS - The present invention provides a DNA-functionalized conjugate comprising single-stranded DNA (ssDNA) strands conjugated to a semi-conductor nanoparticle, wherein the nanoparticle provides fluorescent emissions. The present invention also provides a method to efficiently conjugate DNA strands to a wide variety of quantum dots having fluorescent emissions | 05-26-2016 |
| 20160146761 | GRADED STRUCTURE FILMS - Devices, films, and methods for the detection of target molecules are provided. The devices, films and methods can include sensitive films and a vibration detecting unit. The vibration detecting unit can be a convex or an inverse mesa vibration detecting unit. | 05-26-2016 |
| 20160146772 | FLUORESCENSE SENSOR FOR TARGET ANALYSIS, KIT FOR TARGET ANALYSIS, AND TARGET ANALYSIS METHOD USING SAME - The present invention is intended to provide a novel fluorescence sensor for target analysis, a kit for target analysis, and a target analysis method using the same. | 05-26-2016 |
| 20160146838 | SYSTEM AND METHOD FOR EBOLA DETECTION - A system and method for determining the level of bilirubin in bodily fluids based on the use protein that binds with bilirubin and measuring the level of bioluminescence produced and the use of measurements over time as a means of predicting potential infection and in particular possible Ebola infection. | 05-26-2016 |
| 20160153910 | SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS DEVICE AND SURFACE PLASMON RESONANCE FLUORESCENCE ANALYSIS METHOD | 06-02-2016 |
| 20160153977 | NOVEL GOLD NANOPARTICLE AGGREGATES AND THEIR APPLICATIONS | 06-02-2016 |
| 20160153981 | SILICA PARTICLES HAVING REACTIVE FUNCTIONAL GROUP ON SURFACE, AND METHOD OF PRODUCING THE SAME | 06-02-2016 |
| 20160161406 | CARTRIDGE FOR ANALYZING SPECIMEN BY MEANS OF LOCAL SURFACE PLASMON RESONANCE AND METHOD USING SAME - Present invention describes a cartridge for analyzing target analytes in biological compound, low molecular weight compound, or other samples and an analysis method using the cartridge. In more detail, the present invention describes a fabrication method of a cartridge to measure, based on localized surface plasmon resonance (LSPR) phenomenon, changes in absorbance values or maximum absorption wavelength values, which are caused by changes in effective refractive index due to the reactivity difference between biological compounds or low molecular weight compounds on the metal nanoparticle immobilized surface, and a sample analysis method. | 06-09-2016 |
| 20160161477 | Device for use in the detection of binding affinities | 06-09-2016 |
| 20160161505 | DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1 - The invention relates to a method for the diagnosis and/or risk stratification of cardiac diseases and diseases of the respiratory tract and lungs. According to said method, the free fragment N-terminal proEndothelin (NT-proET-1; amino acids 18-52 of the preproET according to FIG. | 06-09-2016 |
| 20160169780 | SELECTIVE CAPTURE AND RELEASE OF ANALYTES | 06-16-2016 |
| 20160169881 | SYSTEMS, DEVICES AND METHODS FOR A HYDROSCOPIC BASED LATERAL FLOW ASSAY | 06-16-2016 |
| 20160169887 | SYSTEMS, DEVICES AND METHODS FOR A LATERAL FLOW ASSAY WITH SOLUTION ENHANCEMENT | 06-16-2016 |
| 20160169916 | METHOD FOR DETECTING AMYLOID BETA AMYLOIDOSIS | 06-16-2016 |
| 20160169920 | ION SENSOR | 06-16-2016 |
| 20160178597 | Systems and Methods Related to Optical Nanosensors Comprising Photoluminescent Nanostructures | 06-23-2016 |
| 20160178632 | USE OF MARKERS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | 06-23-2016 |
| 20160178638 | Glucose Sensor Molecule | 06-23-2016 |
| 20160187274 | DYNAMIC CHEMICAL SENSORS - Provided herein are embodiments relating to chemical sensors. The sensors include one or more molecules that can transition between the cis and trans configurations thereby altering the degree of hydrophobicity of the system and providing for a sensor whose sensitivity and/or selectivity in regard to hydrophobicity can be altered as desired. | 06-30-2016 |
| 20160187331 | METHOD FOR ACTIVE DETECTION BIO MOLECULES - Provided is a method of detecting biomolecules. The method of detecting biomolecules includes accommodating a plurality of metal particles to which a first molecule specifically binding to target biomolecules is attached, a plurality of magnetic particles to which a second molecule specifically binding to target biomolecules is attached, and the biomolecules; applying a magnetic field to exert an attractive force on magnetic particles; filtering one or more among metal particles, biomolecules and metal particle-binding biomolecules, on which an attractive force is not exerted; and exerting an attractive force on the metal particles of a first assembly in which both of the metal particles and the magnetic particles are bound to the biomolecules by applying an electric field and detecting the metal particles. | 06-30-2016 |
| 20160187342 | DNA Aptamer Specifically Binding to EN2 (Engrailed-2) and Use Thereof - The present invention relates to a DNA aptamer specifically binding to EN2 (Engrailed-2), a biosensor for diagnosing prostate cancer having the same, and a method of diagnosing prostate cancer. A strong binding force and excellent specificity of the DNA aptamer of the present invention and the biosensor using the same with respect to EN2 proteins were identified. A detection specificity problem of a prostate-specific antigen (PSA) test used for prostate cancer diagnosis of the related art was addressed. Therefore, the present invention is expected to be beneficially used for early diagnosis of prostate cancer more effectively and increase diagnostic accuracy. | 06-30-2016 |
| 20160187344 | METHOD OF MEASURING CANCER RELATED SUBSTANCES BY RAMAN SPECTROSCOPY - A method for measuring cancer related substances including cancer cell-derived free DNA by Raman spectroscopy, involving steps for preparing a biochip having a meso-crystal region of silver oxides containing a silver peroxide, adding a blood serum or a biological sample solution dropwise onto the meso-crystal region of said biochip, selectively trapping the cancer-related substances having a positive charge in the sample, irradiating the trapped cancer-related substance with an exciting laser light and detecting a surface enhanced Raman scattering therefrom, wherein cancer diseases are evaluated on the basis of the intensity of the Surface Enhance Raman Scattering (SERS). In the carbon-specific D band and G band in the Raman scattering spectrum, a characteristic peak spectrum of the cancer-related substance can be detected in the proximity of the methyl group characteristic of 2900 cm | 06-30-2016 |
| 20160187349 | Proteomic Biomarkers of Sepsis in Elderly Patients - A proteomic expression platform to identify age-related sepsis risk is disclosed using patients with community-acquired pneumonia. A semi-quantitative plasma proteomics workflow was applied which incorporated tandem immuno affinity depletion, iTRAQ labeling, strong cation exchange fractionation, and nanoflow-liquid chromatography coupled to high resolution mass spectrometry. A protein profile was determined that exhibit statistically significant differences in expression levels amongst patients with severe sepsis as a function of age. Representative pathways that are differentially-expressed include, but are not limited to, acute phase response, coagulation signaling, atherosclerosis signaling, lipid metabolism, and production of nitric oxide/reactive oxygen species. | 06-30-2016 |
| 20160193608 | BIOCHIP SUPPORT MEMBER, METHOD FOR MANUFACTURING BIOCHIP SUPPORT MEMBER, BIOCHIP PACKAGE, SCREENING DEVICE, AND SCREENING METHOD | 07-07-2016 |
| 20160195498 | SPECIMEN SENSOR AND SPECIMEN SENSING METHOD | 07-07-2016 |
| 20160195518 | EXPERIMENTAL METHODS FOR CONDUCTING COMPETITIVE BINDING ASSAYS | 07-07-2016 |
| 20160201118 | NUCLEIC ACID CALIBRATION STANDARDS | 07-14-2016 |
| 20160202154 | METHOD FOR PRODUCING SAMPLE AND METHOD FOR ANALYZING TARGET | 07-14-2016 |
| 20160202255 | GLASS BEAD FLOW RATES TO FACILITATE IMMUNODIAGNOSTIC TEST ELEMENT MANUFACTURE | 07-14-2016 |
| 20160202270 | Highly Sensitive System and Method for Analysis of Troponin | 07-14-2016 |
| 20160202271 | TEST PAPER FOR DETECTION OF DIABETIC NEPHROPATHY | 07-14-2016 |
| 20160202272 | WELLNESS PANEL FOR COMPANION ANIMALS | 07-14-2016 |
| 20160251660 | NUCLEIC ACID APTAMER CAPABLE OF SPECIFICALLY BINDING TO TEBUCONAZOLE, MEFENACET AND INABENFIDE, AND USE THEROF | 09-01-2016 |
| 20160252488 | NOVEL LIGAND FOR DETECTION OF CHROMIUM (III) AND A PROCESS FOR THE PREPARATION THEREOF | 09-01-2016 |
| 20160252499 | METHOD FOR DETERMINING THE RESULT OF AN AGGLUTINATION REACTION AND MICROPLATE FOR DETERMINING PRODUCTS OF AGGLUTINATION REACTIONS | 09-01-2016 |
| 20160252505 | VOLUME RESPONSE SENSORS HAVING ANALYTE CONTROLLED REVERSIBLE CROSSLINKING | 09-01-2016 |
| 20160252520 | COMPETITIVE LIGAND BINDING ASSAY FOR DETECTING NEUTRALIZING ANTIBODIES | 09-01-2016 |
| 20160252526 | A METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT | 09-01-2016 |
| 20160376640 | DETERMINATION OF EXOSOME PURITY METHODS AND APPARATUS - Methods and apparatuses for determining exosome purity are disclosed. In an example embodiment, a laboratory instrument apparatus includes an analytical centrifuge configured to rotate a solution causing a plurality of particles to separate. The analytical centrifuge is also configured to perform an interference measurement on the solution and/or three absorbance measurements on the solution. A computer processor communicatively coupled to the analytical centrifuge is configured to determine an exosome purity of the solution based on the three absorbance measurements and/or the interference measurement. | 12-29-2016 |
| 20160377628 | METHOD FOR QUANTITATIVE DETERMINATION OF MICRO MOLAR CONCENTRATION LEVEL OF D-GLUCOSE USING SURFACE ENHANCED RAMAN SPECTROSCOPY (SERS) WITH 2-THIENYLBORONIC ACID AS LINKER MOLECULE ON SILVER NANO-CLUSTER SUBSTRATES - A method of determining micro-molar concentration of glucose in a body fluid using Surface Enhanced Raman Spectroscopy (SERS), comprising an analyte solution prepared by mixing body fluid and linker molecule solution, allowing the analyte solution to dry on the detection film of the glass substrate; recording and analyzing the glucose specific strong SERS signal in the Raman Spectra; and determining the presence of glucose at micro-molar level by measuring the strong SERS signal. | 12-29-2016 |
| 20170234860 | SEQUENCE AND CHIRAL SELECTIVITY OF DNA-DRUG INTERACTIONS REVEALED BY FORCE SPECTROSCOPY | 08-17-2017 |
| 20170234889 | hGH Determination for Use to Guide Prevention of a Major Adverse Cardiac Event or a Cardiovascular Disease in a Subject | 08-17-2017 |
| 20170234890 | METHOD FOR QUANTITATIVE CHARACTERIZATION OF SUBSTANCES WITH REGARD TO THEIR PROPERTIES OF BINDING TO AMYLOID- (A ) CONFORMERS | 08-17-2017 |
| 20170234893 | Weak Affinity Chromatography | 08-17-2017 |
| 20170234896 | LATERAL FLOW IMMUNOASSAYS FOR THE DETECTION OF ANTIBODIES AGAINST BIOLOGICAL DRUGS | 08-17-2017 |
| 20190145965 | IMMUNOASSAY EMPLOYING SULFATED POLYSACCHARIDE | 05-16-2019 |
| 20220137034 | DETECTION AND QUANTIFICATION OF SMALL MOLECULES - The present invention relates to an in vitro method for determining the presence, absence and/or concentration of an analyte in a sample. The method uses an optically based competition assay comprising a labelled analyte binding protein and a labelled analyte analogue. The concentration/presence of the analyte is determined by inhibitory binding of the analyte to the analyte binding protein thereby impeding binding of the analyte analogue to the analyte binding protein. The invention further relates to kits, solid supports, cartridges, detection chips and uses thereof. | 05-05-2022 |
